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Adoptive Cellular Therapy
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prolong anti-tumor capacity of human natural killer cells
Andreas Lundqvist1, Vincent van Hoef1, Xiaonan Zhang1, Erik
Wennerberg2, Julie Lorent1, Kristina Witt1, Laia Masvidal Sanz1, Shuo
Liang1, Shannon Murray3, Ola Larsson1, Rolf Kiessling1, Yumeng Mao1
1Karolinska Institutet, Stockholm, Stockholms Lan, Sweden; 2Weill Cornell
Medical College, New York, NY, USA; 3Nova Southeastern University, Cell
Therapy Institute, Fort Lauderdale, FL, USA
Correspondence: Andreas Lundqvist (andreas.lundqvist@ki.se)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):O1
Background
NK cell-based immunotherapy is a potential therapeutic modality in
patients with advanced cancers as transfer of haploidentical NK cells
induces beneficial responses in patients with hematological malig-
nancies; and leukemia clearance correlates with persistence and
in vivo expansion of NK cells after infusion. Thus, sustained NK cell
activity in vivo likely represents a therapy performance-limiting
factor.
Methods
We performed genome-wide analysis of cytosolic and polysome-
associated mRNA from interleukin (IL)-2 and IL-15 activated NK
cells. Furthermore, the ability of IL-2 and IL-15 to sustain human
NK cell activity following cytokine withdrawal as well as their ef-
fect on NK cells to resist tumor-induced immunosuppression was
compared.
Results
After cytokine withdrawal, IL-15-treated NK cells maintained a
higher level of cytotoxicity (p < 0.05) and showed lower levels of
apoptosis (p < 0.05) compared with cells treated with IL-2. IL-15
augmented mTOR signaling, which correlated with increased ex-
pression of genes related to cell metabolism and respiration. Con-
sistently, mTOR inhibition abrogated IL-15-induced cell function
advantages. Moreover, mTOR-independent STAT-5 signaling con-
tributed to improved NK cell function during cytokine activation
but not following cytokine withdrawal. Upon co-culture with tumor
cells or exposure to tumor cell supernatant, IL-15 activated NK cell
maintained a significantly higher level of proliferation and cytotoxic
activity (p < 0.05). Mechanistically, tumor-derived prostaglandin-E2
suppressed IL-2 cultured NK cells while IL-15 cultured NK cells
remained activated. The superior performance of IL-15 stimulated
NK cells was also observed using a clinically applicable protocol for
NK cell expansion in vitro and in vivo.
Conclusions
This study adds to our understanding about establishment and
maintenance of tumor-reactive NK cells and supports clinical im-
plementation of IL-15 for adoptive NK cell therapy. More broadly,
our studies suggest that a large aspect of cytokine-mediated
gene expression programs and downstream cellular functions, in-
cluding anti-tumor capacity, are overlooked if post-activation con-
ditions are omitted. This is likely not limited to NK cells and
should hence be considered in similar studies of other immune
cells.
Biomarkers and Immune Monitoring
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Background
There has been a dramatic increase in T cell receptor (TCR) se-
quencing spurred, in part, by the widespread adoption of this
technology across academic medical centers and by the rapid
commercialization of TCR sequencing. While the raw TCR sequen-
cing data has increased, there has been little in the way of ap-
proaches to parse the data in a biologically meaningful fashion.
The ability to parse this new type of ‘big data’ quickly and effi-
ciently to understand the T cell repertoire in a structurally rele-
vant manner has the potential to open the way to new
discoveries about how the immune system is able to respond to
insults such as cancer and infectious diseases.
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Methods
Here we describe a novel method utilizing phylogenetic and
sequencing analysis to visualize and quantify TCR repertoire
diversity. To demonstrate the utility of the approach, we have
applied it to understanding the shaping of the CD8 T Cell
response to self (Kb-TRP2) and foreign (Kb-SIY) antigens in naïve
and tumor bearing B6 mice. Additionally, this method was
applied to tumor infiltrating lymphocytes (TIL’s) from patients
undergoing Nivolumab (anti-PD-1) therapy in a clinical trial for
metastatic melanoma to understand TCR repertoire characteris-
tics between responders and non-responders.
Results
Analysis of the naïve CD8 response to SIY showed a lower clonal-
ity yet more closely structurally related response whereas CD8 re-
sponses to TRP2 were highly clonal yet less structurally related.
Presence of tumor exhibited interesting differential effects on SIY
vs. TRP2. We believe that differences in TCR repertoire suggest
effects from central and peripheral tolerance on self vs. foreign
antigens. In clinical trial data, the phylogenetic analysis revealed
unique TCR repertoire signatures that differentiated responders
from non-responders to anti-PD-1 therapy, including some that
could be detected prior to initiation of therapy. Additionally, this
analysis revealed that patients whose CD8 response had a larger
contribution from novel and unique structural clones responded
better to therapy.
Conclusions
In summary, we have developed and demonstrated a novel method
to meaningfully parse and interpret TCR repertoire data and have
applied it to yield a novel understanding of CD8 T Cell responses to
different types of antigens as well as key characteristics in those who
respond to anti-PD-1 therapy.
Fig. 1 (Abstract O2). a Weighted Phylogenetic Trees Comparing
Kb-SIY vs Kb-TRP2 TCR Repertoire. Size of circles proportional to
frequency of sequence. Color of circle corresponds to V-Beta Usage.
b Dominant Motifs gathered from phylogenetic trees determined
by homologous sequences and their contribution to the response
c V-Beta Usage of Kb-SIY vs Kb-TRP2 Response
Fig. 2 (Abstract O2). a Weighted Phylogenetic Trees comparing
Naive to Tumor-Bearing TCR Repertoire from spleen. Size of Circles
proportional to frequency of sequence. Blue Circles = Naive Reper-
toire. Red Circles = Tumor-Bearing Repertoire. b V-Segment Usage of
Kb-SIY vs Kb-TRP2 Responses for Naive vs Tumor-Bearing Response
Fig. 3 (Abstract O2). Examples of weighted phylogenetic trees from
four cohorts of responders on anti-PD-1 therapy. Size of circles pro-
portional to frequency of sequence. Blue = TCR repertoire prior to
therapy. Red = TCR repertoire on therapy
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Background
Antibody-mediated blockade of the inhibitory receptor PD-1 on T
cells has shown clinical efficacy in the treatment of various malig-
nancies. However, biomarkers of response and mechanisms of re-
sistance remain largely unidentified. To address this gap, we
sought to identify the role(s) of regulatory T cells (Tregs) in meta-
static melanoma patients treated with the PD-1 antibody
nivolumab.
Methods
Pre and post-treatment Tregs were isolated from the peripheral
blood of surgically resected stage III/IV metastatic melanoma
patients treated with adjuvant nivolumab. Suppressive capacity
was assessed in an allogeneic mixed lymphocyte reaction.
Paired (pre vs. post-treatment) Tregs were assessed by flow cy-
tometry for phosphorylated STAT3 (pSTAT3) expression. Finally,
paired Treg samples were assessed for gene expression by RNA-
sequencing.
Results
Tregs from non-relapsing patients demonstrated a significant
decrease in suppressive capacity post-treatment (p < 0.05).
However, suppressive capacity in relapsing patients did not
decrease and their Tregs were significantly more suppressive
post-treatment relative to non-relapsers (p < 0.01). Significantly
increased levels of pSTAT3 post treatment were observed in
non-relapsers (p < 0.05) but not in relapsers (p < 0.40). Signifi-
cantly increased pSTAT3 was not seen in conventional T cells
after nivolumab therapy. Culturing treatment-naïve T cells with
PD-1 blocking antibodies in vitro resulted in increased levels of
pSTAT3 in Tregs compared to IgG controls (p < 0.01). In vitro
PD-1 blockade also significantly increased the number of Tregs
(p < 0.01), and significant increases were seen in paired patient
samples (p < 0.05). Paired analysis of Treg RNA-seq data using
Panther and GeneGo. Metacore showed several significantly in-
creased pathways associated with proliferation in non-relapsers.
Changes in these pathways were absent in relapsers. Gene Set
Enrichment Analysis of non-relapser Tregs showed significant
(q=8.2e-18) overlap with known STAT3 target genes. Conversely,
Enrichr analysis of relapsers showed significant upregulation of
STAT1 and STAT2 target genes. No overlap of significantly chan-
ged gene expression or pathways in Tregs vs. conventional CD4
+ T cells were observed.
Conclusions
These results highlight the potential importance of Tregs in medi-
ating benefit with PD-1 blockade, demonstrating pSTAT3 induc-
tion and reduced suppressive capacity as biomarkers of clinical
benefit. PD-1 blockade also increased the percentages of Tregs,
consistent with the known roles of STAT3 in promoting cell sur-
vival and proliferation. RNA-seq data demonstrated increased
STAT3 and proliferation associated gene expression. Intriguingly,
Tregs from relapsing patients had increased expression of genes
associated with STAT1/2 signaling, warranting further investiga-
tion of these pathways. In addition to highlighting STAT signaling
as a biomarker of relapse, these results demonstrate distinct dif-
ferences in the impact of PD-1 blockade in Treg vs. conventional
T cells.
O4
Analysis of pharmacodynamic biomarkers in the first in-human
trial of GITR co-stimulation with the agonist antibody TRX-518 in
advanced solid cancer patients
Roberta Zappasodi1, Yanyun Li1, Jingjing Qi2, Philip Wong2, Cynthia
Sirard3, Michael Postow4, Walter Newman3, Henry Koon5, Vamsidhar
Velcheti6, Margaret K Callahan7, Jedd D Wolchok4, Taha Merghoub1
1Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer
Center, New York, NY, USA; 2Immune Monitoring Core Facility, Memorial
Sloan Kettering Cancer Center, New York, NY, USA; 3Leap Therapeutics,
Cambridge, MA, USA; 4Department of Medicine, Memorial Sloan
Kettering Cancer Center, New York, NY, USA; 5Case Western Reserve
University, Cleveland, OH, USA; 6Cleveland Clinic Main Campus,
Cleveland, OH, USA; 7Memorial Sloan Kettering Cancer Center, New York,
NY, USA
Correspondence: Roberta Zappasodi (zappasor@mskcc.org)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):O4
Background
GITR is a tumor necrosis factor receptor expressed at high levels on
regulatory T cells (Tregs) and up-regulated on T cells upon activation.
GITR stimulation abrogates Treg suppression and enhances T cell ef-
fector function. These observations suggest that GITR could be an at-
tractive target for immunotherapy with agonist antibodies. GITR
stimulation in tumor-bearing mice has shown therapeutic activity as-
sociated with both Treg reduction and modulation. Here we report
results of pharmacodynamic analyses in the first in-human phase I
trial with the fully humanized agonist anti-GITR antibody TRX518 as
monotherapy in patients with advanced refractory solid tumors.
Methods
Patients were accrued to 9 cohorts (up to 6 patients/cohort) to re-
ceive a single dose of TRX518 (dose range: 0.0001-8 mg/kg). Pharma-
codynamic analyses included flow cytometric evaluation of
frequency and phenotype of circulating T cells and cytokine quantifi-
cation in serum samples at different time points up to 12 weeks after
treatment. Relevant changes observed with these analyses were
monitored in pre- and post-treatment tumor biopsies by immuno-
fluorescence staining.
Results
Here we report results obtained in 37 patients treated with ≥0.005
mg/kg TRX518 (cohorts 3-9), including 6 melanoma, 7 non-small cell
lung cancer (NSCLC) and 7 colorectal cancer (CRC) patients and 17
patients with 11 other solid tumors. Among the T cell parameters an-
alyzed, we found frequent reduction in circulating Tregs after treat-
ment with TRX518 across all cohorts, with some exceptions.
Importantly, this effect could be maintained over the 12-week obser-
vation period. When the analysis was performed by disease type, it
revealed a pronounced TRX518 dose-dependent down-regulation of
peripheral Tregs in both melanoma and CRC patients. Interestingly,
in NSCLC cancer patients, Tregs did not always decrease after treat-
ment. In a subset of patients (n=6; 2 melanoma, 2 CRC, 2 lung), for
whom we had pre- and post-treatment tumor biopsies in addition to
PBMCs, we tested whether intra-tumor Tregs were consistently af-
fected. In melanoma and CRC patients, intra-tumor Foxp3+ Tregs
were significantly reduced after treatment, in agreement with the
peripheral Treg down-modulation observed in the same patients. In
lung cancer patients, lack of circulating Treg reduction was consist-
ently associated with stable or increased intra-tumor Treg infiltration
after TRX518.
Conclusions
Circulating Treg reduction is a potential pharmacodynamic biomarker
of TRX518 biological activity. This parameter may allow predictive
correlation with changes in intratumoral Treg infiltration. We plan to
further investigate this effect and its relevance for the association
with clinical responses in our recently opened TRX518 multi-dose
study.
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Trial Registration
ClinicalTrials.gov identifier NCT01239134.
Consent
Written informed consent was obtained from the patient for publica-
tion of this abstract and any accompanying images. A copy of the
written consent is available for review by the Editor of this journal.
Bispecific Antibodies
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Background
Conventional chemotherapy (chemo) for locally advanced pancreatic
cancer (LAPC) and metastatic pancreatic cancer (PC) is associated
with dismal responses and poor survival rates. Arming activated T
cells (ATC) with anti-CD3 x anti-EGFR bispecific antibody (EGFRBi)
turns every ATC into a non-MHC restricted EGFR-specific cytotoxic T
lymphocyte [1]. Engagement of CD3 on T cells and EGFR on Mia
PACA-2 leads to cytokine secretion, proliferation, cytotoxicity by ATC
and inhibition of tumor growth [2]. An earlier study using Infusions
of anti-CD3 x anti-HER2 (HER2Bi) armed ATC in metastatic breast can-
cer provided encouraging survival (OS = 36 months) and evidence of
anti-breast cancer immunity [3].
Methods
In this study, we used anti-CD3 x anti-EGFR bispecific antibody
(EGFRBi)-armed T cells (EGFR BATs) to target EGFR in 5 metastatic PC
patients and 6 colorectal cancer patients treated at Karmanos Cancer
Institute on Protocol #2014-025 in a phase I dose escalation involving
3 weekly infusions of 10, 20, and 40 x 109 BATs/infusion followed by
a booster infusion 3 months later.
Results
In the 5 PC patients, we report 1 patient was stable for 6.5 months
and 2 patients in whom infusions of EGFR BATs may have “sensi-
tized” the tumor to subsequent chemotherapy. The patient with
stable disease had a near partial response. The median overall sur-
vival in 5 patients is 23.5 months with the median time to progres-
sion (TTP) of 7.0 months. Patient IT20102 received BATs and was
stable (decreased marker lesion by 27%) at 6.5 mos. IT20091 had a
remarkable clinical response to chemotherapy after progressing after
immunotherapy at 4.6 months. After 3 BATs infusions, patient IT2010
had a “flare” or progression and subsequently had a complete re-
sponse to Xeloda and remains in remission. This phase I study shows:
1) long-term stabilization in one patient; 2) a persistent complete re-
sponder after BATs "progression" followed by chemotherapy; 3) im-
proved chemotherapy responsiveness after EGFRBi-BATs therapy; and
4) two patients with slow progressive disease who survived beyond
400 days. Survival for the 5 patients was 13.6, 14.5, 23.3 (alive in CR),
24.9 (alive, stable), and 31.0 months after enrollment, respectively (as
of 7-20-16).
Conclusions
Targeting PC with EGFR BATs resulted in improved survival and re-
markable post-immunotherapy chemotherapy responses in a small
series of patients. The series provides evidence for anti-tumor activity
of EGFR BATs as well as evidence that BATs infusions can sensitize tu-
mors to subsequent chemotherapy.
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Background
While checkpoint inhibitor (CPI) therapy has transformed metastatic
melanoma (MM) treatment, many patients remain refractory. We rea-
soned that combining CPI with an agent that activates antigen pre-
senting cells and improves T cell priming may result in improved
response. Our approach is to modulate the tumor microenvironment
through intratumoral (i.t.) injection of the TLR9 agonist, IMO-2125, in
combination with ipilimumab (ipi). We hypothesize that this will re-
sult in dendritic cell (DC) activation and induction of tumor-specific
CD8+T cells which will synergize with ipilimumab to overcome
immune-escape. Based on this rationale we initiated a phase I/II clin-
ical trial.
Methods
Adults with refractory MM despite up to 2 lines of CPI including
PD-1 blockade therapy (with or without a BRAF inhibitor) are
eligible. IMO-2125, in doses escalating from 4mg to 32mg, is
Table 1 (Abstract O5). Clinical data
Pt Age Disease Prior Tx BATS
(x 109)
TTP
(mo)
OS
(mo)
Comments
IT20087 58 Mets to
liver
Folfirinox 47 6
mo
Died
13.6 mo
Progressed after
Immunotherapy
IT20091 63 T3 N1Mets
to liver.
S/P
Whipple
5FU,
Leu/5FU
Folfirinox
9 79 4.8
mo
Died
31 mo
Folfirinox induced
CR after IT and
responded a 2nd
time to Folfirinox
IT20092 64 T2b Abd
Nodes,
S/P
Whipple
Gemzar,
5FU,
radiation
36 7
mo
Died
14.5 mo
Slowly progress
with chronic
diarrhea
IT20102 56 T4, Mets
to liver,
lungs
Folfirinox 74 6.5
mo
Alive
24.9 mo
Progressed after
6.5 mo
IT20104 51 T4, Abd
Node
FOLFOX,
X eloda
72 2.2
mo
Alive
23.3 mo
Chemo Induced
CR after IT; On
Xeloda
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given i.t. weeks 1, 2, 3, 5, 8, and 11 along with ipilimumab i.v.
3 mg/kg weeks 2, 5, 8, and 11. Dose-limiting toxicity (DLT) is
evaluated using a modified Toxicity Probability Interval design.
Primary endpoints are safety, tumor response, and PK. Blood
and injected and distal tumor biopsies are obtained pre- and
on-treatment. Immune analyses include DC subsets and their ac-
tivation status as well as T cell activation, function and prolifer-
ation. T cell repertoire diversity will be evaluated by high
throughput CDR3 sequencing.
Results
As of August 2, 2016, 11 pts have been enrolled. DLT has not
been observed. Grade 3 hypophysitis (2 subjects) is the only
immune-related AE observed to date. No other drug-related
grade 3-5 AEs were documented and only 1 subject experi-
enced a grade 2 fever. Five patients are evaluable for response
- 2 PR, 2SD, 1PD per investigator assessment. Fresh tumor biop-
sies show maturation (upregulation of HLA-DR) of the myeloid
DC1 subset (CD1c+CD303-) in the IMO-2125 injected tumor le-
sion 24 hrs post-treatment compared to pre-treatment biopsy.
On-treatment biopsy results are consistent with a higher rate of
proliferative (Ki67) effector CD4+ and CD8+ T cells in re-
sponders. Cytokine analysis shows a 2-3 fold increase in circu-
lating IFNγ levels compared to pretreatment in responders.
Conclusions
Though preliminary, these results demonstrate that the combination
of ipi and IMO-2125 is well tolerated with encouraging preliminary
activity in a PD-1 refractory population. Dose escalation is ongoing
and a phase II expansion will include IMO-2125 in combination with
both ipi and anti-PD-1. Updated safety, antitumor activity, and
biomarker data will be presented.
Trial Registration
ClinicalTrials.gov identifier NCT02644967.
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Background
Urelumab is a fully human CD137 agonistic monoclonal antibody
(mAb) that enhances T cell and natural killer (NK) cell antitumor activity
in preclinical models. Nivolumab, a fully human programmed death-1
(PD-1) mAb that blocks the inhibitory function of the PD-1 receptor on
T cells, has shown single-agent activity in many advanced malignancies.
We hypothesized that the distinct, non-redundant mechanisms of these
two mAbs could enhance antitumor activity without compromising
safety. Here we report safety/tolerability, pharmacodynamics, and pre-
liminary efficacy of urelumab and urelumab plus nivolumab combin-
ation therapy in patients with advanced malignancies.
Methods
The monotherapy study evaluated urelumab in patients with advanced
malignancies (0.1 or 0.3 mg/kg Q3W) or advanced non-Hodgkin lymph-
oma (8 mg Q3W or Q6W). The combination study evaluated urelumab
(3 or 8 mg Q4W) plus nivolumab (3 mg/kg or 240 mg Q2W) in patients
with advanced solid tumors or B cell lymphoma (dose escalation) or pa-
tients with diffuse large B cell lymphoma (DLBCL), melanoma, non-
small cell lung cancer (NSCLC), or squamous cell carcinoma of the head
and neck (SCCHN; cohort expansion). Based on preliminary safety/toler-
ability/pharmacokinetic assessments of urelumab, cohort expansion fo-
cused on flat doses of 8 mg.
Results
Overall, patients who received urelumab monotherapy (N=123) experi-
enced infrequent treatment-related serious AEs (7%) and treatment-
related AEs (TRAEs) leading to discontinuation (5%; Table 2). In 104 pa-
tients treated with urelumab plus nivolumab (melanoma, n=40; NSCLC,
n=20; SCCHN, n=22; DLBCL, n=22), the most frequent TRAE was fatigue
(26%); grade 3/4 ALT/AST elevations (3%/3%) and TRAEs leading to dis-
continuation (7%) were infrequent. No treatment-related deaths were
reported. Urelumab stimulated peripheral IFN-γ–induced cytokine pro-
duction; induction was greater with urelumab plus nivolumab. In most
melanoma tumors evaluated, a trend toward increased T and NK cell
number and expression of IFN-γ and CXCL9 was observed upon treat-
ment with the combination. Six patients with lymphoma treated with
urelumab monotherapy had a partial (n=3) or complete (n=3) remis-
sion. Nine of 86 evaluable patients treated with the combination had
partial responses (melanoma, n=8; SCCHN, n=1); no patients with
NSCLC or DLBCL had confirmed responses at the interim analysis. Of 71
patients treated with urelumab plus nivolumab with RECIST/IWG assess-
ments, 33 had reductions in tumor burden (Fig. 4).
Conclusions
Urelumab with or without nivolumab is safe/tolerable at flat and
weight-based doses of 8 mg and 0.1 mg/kg. Although urelumab has
demonstrated single-agent pharmacodynamic and antitumor activity in
lymphoma, combination with nivolumab did not appear to provide sig-
nificant additive/synergistic clinical benefit at the doses evaluated.
Trial Registration
ClinicalTrials.gov identifier NCT01471210 and NCT02253992.
Table 2 (Abstract O7). Treatment-related safety events
Patients, n (%) Urelumab
monotherapy
N=23
Urelumab +
nivolumab
N=104
Treatment-related AEs 65 (53) 65 (53)
Most frequent treatment-related AEsa
Fatigue 18 (15) 27 (26)
AST increased 16 (13) 9 (9)
ALT increased 12 (10) 13 (13)
Treatment-related grade ¾ AST elevation 4 (3) 3 (3)
Treatment-related ¾ ALT elevation 3 (2) 3 (3)
Treatment-related serious AEs 9 (7) 10 (10)
Treatment-related AEs leading to discontinuation 6 (5) 7 (7)
Treatment-related deaths 0 0
AE, adverse event; AKT, alanine aminotransferase; AST,
aspartate aminotransferase.
aTreatment-related AEs occurring in ≥10% of all patients
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Background
In response to oncogenic insult, human cells were induced to
express a family of MHC I-chain related molecules A and B
(MICA and MICB, generally termed MIC) on the surface which
serve as the ligands for the activating immune receptor NKG2D
expressed by all human NK, CD8 T, NKT, and subsets of
gamma-delta T cells. Theoretically, engagement of NKG2D by
tumor cell surface MIC is thought to signal and provoke the im-
mune system to eliminate transformed cells. Clinically, almost
all advanced tumors in cancer patients produce soluble MIC
through proteolytic shedding mediated by metalloproteases, or
by release in exosomes derived from the cell membrane.
Tumor-derived sMIC is known to be highly immune suppressive
and profoundly insults the immune system by downregulating
receptor NKG2D expression on effector NK and T cells, driving
the expansion of tumor-favoring myeloid suppressor cells, skew-
ing macrophages into alternatively activated phenotypes, and
perturbing NK cell peripheral maintenance. High levels of serum
sMIC significantly correlate with advanced diseases of many
types of cancer. These observations clearly endorse sMIC to be
a cancer immune therapeutic target. However, due to mice lack-
ing homologues to human MIC, this concept was not proven
until our recent studies.
Methods
Using a “humanized” MIC-transgenic spontaneous mouse model
which recapitulates the NKG2D-mediated onco-immune dynamics of
human cancer patients, we addressed whether sMIC is a cancer im-
munotherapeutic target and whether antibody targeting sMIC syner-
gizes with immune checkpoint blockade or adoptive T or NK cell
therapy.
Results
We show that therapy with a first-in-field non-blocking antibody B10
that does not block the interaction of MIC with NKG2D revamps en-
dogenous innate and antigen-specific CD8+ T cell responses and re-
models immune reactive tumor microenvironment, by restoring NK
cell hemostatic maintenance and function, enhancing CD8+ T cell in-
filtration to tumors and TCR clonality/diversity, modulating CD8+ T
cells metabolic preferences, eliminating MDSCs and TAMS. Anti-sMIC
stand-alone therapy resulted in effective debulking of primary tu-
mors and eliminated metastasis. Using multiple pre-clinical animal
models, we further demonstrate that antibody B10 neutralizing sMIC
synergizes with CTLA-4 and PD-1/PD-L1 checkpoint blockade therapy
and adoptive cell based therapy with no observed toxicity.
Conclusions
Our study has launched a new avenue of cancer immunotherapy
which can be readily translated into clinical trials.
Fig. 4 (Abstract O7). Best percent reduction in target lesion tumor
burden with urelumab plus nivolumab
Fig. 5 (Abstract O8). These are the examples in human cancer
patients, prostate cancer, Oral cancer, and HBV-induced Liver cancer,
where high levels of circulating sMIC correlates with advanced dis-
ease stages and poor survival.
Fig. 6 (Abstract O8). a. Therapy of the clinically relevant
spontaneous prostate tumor TRAMP/MICB model (Liu et al, 2013,
JCI 123 (10) 4410 ) with CuraB10 (also called B10G5) or control
IgG (placebo) at advanced stage via I.P. injection at the dose of
3.8 mg/KG body weight twice weekly for 8 weeks (b). Mice with
CuraB-1o therapy all enjoyed longtime survived whereas mice in
placebo group are succumbed to cancer (c). Prostate weight.
Comparisons made between Placebo group and CuraB-10
group and between before and after treatment of CuraB-10.
(d). Representative images of the prostate. Top showing large
tumor burden. Bottom showing normal prostate size. (e). All
mice in the control group developed metastasis whereas no
metastasis was detected in animals received CuraB-10 therapy.
In summary, the data demonstrate that CuraB-10 stand-alone
therapy can effectively induce regression of primary tumors and
eliminate metastasis
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Background
Recent work from our laboratory has shown that anti-tumor immun-
ity is suppressed in mice housed at standard temperatures (ST; 22°C)
which could be reversed by housing mice at warmer, thermoneutral
temperatures (TT; 30°C) [1]. However, the mechanisms causing this
impairment at ST remain unclear. Cold stress is mediated specifically
by activation of the sympathetic nervous system and the release of
norepinephrine (NE), which is highly suppressive when signaling
through β-adrenergic receptors (β-ARs) on immune cells. We found
that NE levels are significantly elevated in tumor-bearing mice
housed at ST compared to TT, which led us to hypothesize that
chronic stress induced by cool housing temperatures increases β-AR
signaling that dampens the anti-tumor immune response and the
efficacy of immune modulating therapies.
Methods
We used both physiologic (housing temperature; ST and TT) and
pharmacologic blockade (β-blockers) to modulate β-AR signaling
levels in immune-competent and SCID mice bearing 4T1 or B16-OVA
tumors. Flow cytometry was used for immune cell analysis. Anti-PD-1
checkpoint blockade was given in 6, 200μg doses (Days 0, 2, 4, 6, 9,
and 12) starting the day after tumors became detectable.
Results
We found that the addition of β-blockade significantly delayed 4T1
and B16-OVA tumor growth in mice housed at ST, recapitulating the
slower tumor growth observed in mice housed at TT. However, β-
blockade had no impact on tumor growth in SCID mice at ST or TT
indicating dependence on the adaptive immune system. Analysis of
4T1 and B16-OVA tumors from immune-competent mice showed in-
creased IFN-γ expression in both CD4+ and CD8+ T cells in mice
treated with β-blockade indicating a more robust anti-tumor immune
response. Lastly, we investigated the impact of β-AR signaling on
anti-PD-1 checkpoint blockade efficacy and found that reducing β-AR
signaling by both physiologic (TT) and pharmacologic (β-blockade)
strategies improved responses in both tumor models. Further ana-
lysis of 4T1 tumors from mice treated with β-blockade and anti-PD-1
showed an increase in IFN-γ, producing CD8+ T cells compared to ei-
ther β-blockade or anti-PD-1 alone.
Conclusions
Taken together, these data indicate that elevated β-AR stress signal-
ing caused by cool housing temperatures impairs anti-tumor immun-
ity and the response of tumors to anti-PD-1 checkpoint blockade.
Acknowledgements
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Background
Th17 cells hold promise for immunotherapy of cancer [1]. While the
anti-tumor potential of Th17 cells primarily depends upon IFN-γ se-
cretion and persistence [1], a long-term tumor control has still
remained elusive. Given that both the “effector” and “stemness like”
features are prerequisites for T cells to mount durable anti-tumor re-
sponses, we hypothesized that combining the culture conditions of
Th1 (effector) and Th17 (stemness like) cells could generate hybrid
Th1/17 cells with improved anti-tumor properties.
Fig. 7 (Abstract O8). We further addressed the synergistic effect of
CuraB-10 therapy with FDA approved checkpoint blockade therapy
using the clinically relevant TRAMP/MIC spontaneous prostate tumor
mouse model. Two points: 1) a percentage of TRAMP/MIC mice do
not respond to checkpoint (CTLA4 or PD-1) blockade therapy,
whereas all TRAMP/MIC mice are responsive to CuraB-10 therapy;
also, a population of TRAMP/MICB animals died at 3-4 weeks of
CTLA4 Rx alone. 2) CuraB-10 synergizes with checkpoint blockade
(CTLA4 or PD-1) therapy when used in combination
Fig. 8 (Abstract O8). Because rodents do not express MIC, we
engineered mouse melanoma B16 tumor cells to express sMIC
(B16-sMIC). We implanted B16-sMIC into syngeneic host. When
tumors grew to 50-100mm3 in size, treatment starts. Four treatments
were given: Adoptive transfer of melanoma antigen-specific Pmel
CD8 T cells once, B10G5 (CuraB-10) twice 2 week Adoptive transfer
of melanoma antigen-specific Pmel CD8 T cells once, control IgG
(cIgG) twice 2 week B10G5 alone 4) cIgG alone Tumor growth curve
demonstrating that treatment with B10G5 (CuraB-10) effectuates
the effect of Pmel CD8 T therapy Survival curve. Tumor volume of
1000mm3 was defined as survival end point. In one experiment,
2/7 animals received B10G5 and Pmel therapy had complete tumor
regression. Note: currently Adoptive T cell transfer (ACT) requires
prior-depletion of patient’s immune cells with chemotherapy to
be effective. With B10G5 therapy, not only lymph depletion is not
required prior to ACT, but also ACT is more effective
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Methods
Melanoma epitope tyrosinase reactive CD4+ T cells obtained from
h3T TCR transgenic mice were differentiated ex vivo to Th1, Th17,
and Th1/17 cells before adoptive transfer (0.25×106 cells/animal i.v.)
to C57BL/6 recipient animals with subcutaneously established B16
melanoma. Quantitative PCR (q-PCR), flow cytometry, and metabolo-
mic analyses were used to evaluate the expression of various metab-
olism and stemness associated genes as well as protein expression in
the T cells. To compare the metabolic commitment between differ-
ent subsets (Th1, Th17 and Th1/17), real time metabolic flux analyzer
(Seahorse Biosciences, USA) and radioactive tracer studies were used.
Results
The combined culture conditions of Th1 and Th17 generates hybrid Th1/
17 cells with a IFN-γhi, IL17hi, GM-CSFhi, CD107ahi, T-bethi, Granzyme Bhi,
IL23Rhi, IL22hi, Bcl6hi, Tcf7hi signature. These hybrid Th1/17 cells exhibit
enhanced tumor control in subcutaneous and lung metastasis models of
murine melanoma. A hypothesis generating transcriptional, metabolic,
and proteomic profiling, followed by confirmatory experiments estab-
lished that the enhanced anti-tumor properties were attributed to
increased NAD+ mediated activity of histone deacetylase Sirt1 in hybrid
Th1/17 cells. Inhibition of NAD+ and Sirt1 activity either pharmacologic-
ally or by genetic ablation (Sirt1-KO T cells) led to loss of stable anti-
tumor control. Importantly, anti-tumor T cells or tumor infiltrating lym-
phocytes programmed in the presence of exogenous NAD+ also led to
the similar metabolic phenotype and improved anti-tumor control.
Conclusions
The present study discloses that metabolic status plays an important
role in dictating the anti-tumor response of the T cells. Combining
the culture conditions of Th1 and Th17 cells renders hybrid Th1/17
cells with a unique immune-metabolic feature that enables them to
orchestrate distinct transcriptional programs leading to highly
effector and stem-like T cells.
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Background
Despite recent advances, many cancers remain refractory to available im-
munotherapies by developing various strategies to evade the immune
system. Emerging evidence indicates that the tolerization of local den-
dritic cells (DCs) within the tumor microenvironment plays a critical role
in immune evasion. The role of metabolic re-programming in DC toleriza-
tion remains poorly characterized and the mechanisms by which cancers
may utilize these pathways to promote the establishment of an immuno-
tolerant microenvironment have not been described.
Methods
We investigated the role of the Wnt-beta-catenin pathway in the
metabolic reprogramming of melanoma-derived DCs using real-time
metabolic flux analysis. The impact of DC metabolic re-programming
on the enzymatic activity of indoleamine 2,3-dioxygenase (IDO) was
analyzed by HPLC while protoporphyrin IX(PpIX) levels were quanti-
fied by flow cytometry. The role of DC fatty acid oxidation (FAO) on
regulatory T cell (Treg) generation was investigated using pharmaco-
logic and genetic approaches. The impact of FAO inhibition on anti-
tumor immune responses to anti-PD-1 antibody therapy were investi-
gated in a transgenic melanoma model.
Results
We show that the Wnt5a-beta-catenin-PPARg pathway shifts DCs
from glycolysis to FAO in the melanoma microenvironment in a man-
ner dependent upon induction of the mitochondrial fatty acid trans-
porter, CPT1A (Fig. 9). This metabolic shift promotes DC tolerization
by 1) elevating DC levels of the PpIX prosthetic group of IDO, result-
ing in the enhanced activity of this enzyme (Fig. 10) and 2) potently
suppressing DC-expression of IL-6 and IL-12, both culminating in the
generation of Tregs both in vitro and in vivo (Fig. 11). Genetic silen-
cing and the pharmacologic inhibition of CPT1A potently enhances
the ability of DCs to stimulate effector T cell responses. Indeed, gen-
etic silencing of melanoma-expressed Wnt5a significantly promotes T
cell tumor infiltration and augments PD-L1 expression in this melan-
oma model. Consistent with these findings, we further show FAO in-
hibition to enhance the efficacy of anti-PD-1 therapy while
augmenting melanoma antigen-specific T cell responses (Fig. 12).
Conclusions
Our findings implicate the Wnt5a-beta-catenin-PPARg-CPT1A paracrine
signaling axis as a driver of DC FAO and functional DC tolerization in
the melanoma microenvironment and connect this pathway with the
promotion of a “non-inflamed” phenotype in melanoma. This work de-
scribes a novel association between DC metabolism and the regulation
of IDO enzymatic activity and suggests that this pathway may be a po-
tent pharmacological target for increasing the responsiveness of “non-
inflamed” tumors to anti-PD-1 antibody immunotherapy.
Fig. 9 (Abstract O11). Wnt5a Promotes DC FAO in the Melanoma
Microenvironment. A. Schematic of tumor-infiltrating DC (TIDC)
metabolic analysis. B. Melanoma-derived Wnt5a promotes TIDC
OXPHOS. C. Wnt5a promotes DC FAO
Fig. 10 (Abstract O11). Wnt5a-induced FAO Promotes DC Synthesis
of PpIX and Enhances IDO Enzyme Activity. A. Wnt5a stimulates
DC PpIX synthesis. B,C. Wnt5a promotes DC IDO activity in a FAO-
dependent manner both in vitro and in vivo
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Background
CD8+ tumor-infiltrating T lymphocytes (CD8+ TIL) in the tumor
microenvironment (TME) are unable to effectively control their
tumor targets due to a variety of immunosuppressive mecha-
nisms, including direct tumor cell-T cell inhibition and soluble
immunosuppressive factors. This allows cancer to progress un-
checked as T cells are rendered functionally inert. Recently, poor
metabolite availability in the TME has been identified as an add-
itional suppressive mechanism exploited by bioenergetically-
dysregulated tumors. Because T cell activation also has robust
metabolic demands, we hypothesized that CD8+ TIL dysfunction
was a result of metabolic insufficiency.
Methods
Metabolic capacity was measured at the single cell level by 2NBDG
and MitoTracker FM. Metabolic output was measured by Seahorse
extracellular flux analysis. T cell reprogramming was performed by
retroviral transduction on OVA-specific transgenic T cells in vitro
before adoptive transfer into B16OVA bearing mice.
Results
We found CD8+ TIL are characterized by dramatic loss of mito-
chondrial mass in B16, MC38, and LLC implantable mouse tumors
and human CD8+ TIL, which correlates with upregulation of co-
inhibitory checkpoint molecules PD-1 and Tim-3. CD8+ TIL mito-
chondrial mass loss is caused by decreased mitochondrial biogen-
esis, due in part to repression of the transcriptional co-activator
PGC1α resulting from chronic Akt signaling. Surprisingly, anti-PD-1
therapy had no effect on increasing PGC1α or mitochondrial mass
in CD8+ TIL. We then asked whether improving CD8+ TIL
metabolism genetically might result in enhanced effector func-
tion, so we reprogrammed tumor-specific CD8+ T cells to upregu-
late mitochondrial biogenesis prior to adoptive cell therapy. We
found increased mitochondrial mass, restored cytotoxic function-
ality, and dramatically improved tumor regression in mice with
reprogrammed CD8+ TIL. To better understand why mitochondrial
loss causes T cell dysfunction, we are exploring the importance
of mitochondria for T cell functionality, including ATP and nucleo-
tide production, calcium buffering, and ROS production.
Conclusions
Our data support a model in which chronically-activated CD8+ TIL
are unable to metabolically support their effector functions. By un-
derstanding these metabolic insufficiencies, we can both better
understand T cell dysfunction and design metabolic modulation
strategies to improve cancer immunotherapy.
Inflammation, Innate Immunity, and
the Microbiome
O13
Intestinal microbiota and relapse after hematopoietic-cell
transplantation
Jonathan Peled, Sean Devlin, Anna Staffas, Melissa Lumish, Kori
Porosnicu Rodriguez, Katya Ahr, Miguel Perales, Sergio Giralt, Ying Taur,
Eric Pamer, Marcel R. M. van den Brink, Robert Jenq
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Correspondence: Jonathan Peled (peledj@mskcc.org)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):O13
Background
The major causes of mortality after allogeneic hematopoietic-cell
transplantation (allo-HCT) are relapse, graft-versus-host disease
(GVHD), and infection. We have previously reported that alterations
in the intestinal flora are associated with GVHD, bacteremia, and re-
duced overall survival after allo-HCT. As intestinal bacteria are potent
modulators of systemic immune responses including antitumor ef-
fects triggered by checkpoint blockade, we hypothesized that com-
ponents of the intestinal flora could be associated with relapse after
allo-HCT.
Methods
The intestinal microbiota of 541 patients admitted for allo-HCT was
profiled by means of 16S ribosomal sequencing of prospectively col-
lected stool samples. We hypothesized that evolutionarily related
species exhibit functional similarities, and we therefore defined clus-
ters of related operational taxonomic units (crOTUs) to evaluate for
associations with clinical outcomes. To group OTUs by evolutionary
distances, a phylogenetic tree was empirically constructed from a se-
quence alignment of all OTUs identified in the whole cohort (Fig. 13).
We examined the relationship between abundance of microbiota
species or groups of related species and relapse/progression of dis-
ease during two years of follow-up after allo-HCT using cause-specific
Cox proportional hazards in a retrospective discovery-validation
study (Fig. 14).
Results
The intestinal presence of a group comprised mostly of Eubacter-
ium limosum in the validation set was associated with less re-
lapse/progression of disease (HR 0.52, CI 0.31–0.87, p = 0.01,
Fig. 15). The two-year cumulative incidence of relapse/progression
among patients with and without this group of bacteria was
33.8% and 19.8%, respectively. The relative abundance of this
group was also associated with less relapse/progression of dis-
ease (HR 0.82, CI 0.71–0.95, p = 0.009). These associations
remained significant in multivariate models and were strongest
among recipients of T cell-replete allografts.
Conclusions
We found associations between the abundance of a group of
bacteria in the intestinal flora and relapse/progression of disease
after allo-HCT. These might serve as potential biomarkers or
therapeutic targets to prevent relapse and improve survival after
allo-HCT.
Fig. 11 (Abstract O11). Wnt5a-induced DC OXPHOS Promotes Treg
Generation in the Melanoma Microenvironment. Melanoma-derived
Wnt5a conditions DCs to promote Treg generation in vivo
Fig. 12 (Abstract O11). Inhibition Wnt5a-DC FAO Enhances
Melanoma PD-L1 Expression and Augments anti-PD-1 antibody
Efficacy. A. Schematic of Wnt5a paracrine signaling pathway.
B,C. Genetic silencing of Wnt5a in melanoma promotes T cell
infiltration and PD-L1 upregulation. D. Inhibition of CPT1A/FAO
synergizes with anti-PD-1 antibody therapy in melanoma
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Oncolytic Viruses
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Background
As a clinical setting in which local live biological therapy is already
well established, non-muscle invasive bladder cancer (NMIBC) pre-
sents intriguing opportunities for oncolytic virotherapy. Coxsackie-
virus A21 (CVA21, CAVATAKTM) is a novel intercellular adhesion
molecule-1 (ICAM-1)-targeted immunotherapeutic virus which exerts
potent oncolytic activity against NMIBC cell lines and ex-vivo human
bladder tumour. CVA21 in combination with low doses of Mitomycin
C enhances CVA21 viral replication and oncolysis by increasing sur-
face expression levels of ICAM-1.
Methods
A two stage Phase I/II study (CANON) was initiated to study the toler-
ance of escalating intravesicular (IV) doses of CVA21 administered
alone or in combination with MitomycinC (10mg) in 16 first-line
NMIBC cancer patients prior to TURBT surgery. Cystoscopy photog-
raphy was performed before and after treatment. Tissues were ana-
lysed for CVA21 replication, apoptosis, changes in immune cell
infiltrates (multi-spectral imaging) and immune-checkpoint
molecules.
Results
IV administration of CAVATAK was well tolerated with no adverse
events. Anti-cancer activity including viral induced tumour inflamma-
tion was demonstrated by serial cystoscopy including a complete re-
sponse observed in one of 3 patients in the highest dose
monotherapy cohort. Tumour targeting by CVA21 was shown by de-
tection of secondary viral load peaks in the urine and by immunohis-
tochemical analysis of TURBT tissue displaying tumour-specific viral
replication and apoptotic cell death. Nanostring analysis revealed an
upregulation of interferon-response and immune checkpoint inhibi-
tory genes in CVA21-treated tissues compared to untreated historical
controls. Notable changes in immune cell infiltrates and expression
of PD-L1 within the CVA21-treated NMIBC tissue were also observed.
Increased urinary levels of the chemokine, HMGB1, was observed in
six of eleven patients following exposure to CVA21.
Fig. 15 (Abstract O13). crOTU 1614, which includes members of
family Eubacteriaceae is associated with decreased relapse after
allo-HCT.Cumulative incidence of relapse/POD in the discovery
(n = 271) and validation (n = 270) sets stratified by presence or
absence of crOTU 1614
Fig. 13 (Abstract O13). Phylogenetic tree of OTUs and clusters of
related operational taxonomic units (crOTUs). Each black point is a
crOTU. Phylum is color coded along the circumference. Members of
the same phyla were largely grouped together, indicating that the
tree was broadly concordant with standard taxonomy
Fig. 14 (Abstract O13). Multivariate screening of microbial features
for association with relapse. Volcano plot of multivariate p values of
crOTUs against the multivariate hazard ratios for relapse/progression
of disease in the discovery set. crOTUs are color coded by p value.
Multivariate adjustment was performed for Disease Risk Index score,
graft source, and conditioning intensity. The most abundant species
in each of the labeled crOTUs are 1614: Eubacterium limosum.
2022-3: Streptococcus sinensis. 1638: Eubacterium limosum. 1630-1:
Eubacterium limosum. 1790: Parvimonas micra. 0951-3: Leptotrichia
hongkongensis 2986: Flavonifractor plautii. 1439: Actinomyces
odontolyticus
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Conclusions
The utility of CVA21 as a potent immunotherapeutic agent has been
demonstrated by the observed tumour targeting and viral replica-
tion. Upregulation of checkpoint molecules following CVA21 expos-
ure may also allow potential sequential combination therapies with
checkpoint targeting.
Trial Registration
ClinicalTrials.gov identifier NCT02316171.
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Background
Despite the significant promise of oncolytic viral (OV) therapy in
preclinical models, clinical efficacy of systemically-administered vi-
ruses has proven to be modest. One major limitation of the sys-
temic OV therapy is neutralization of the virus by pre-existing
immunity, or development of neutralizing antibodies shortly after
therapy initiation, which limit viral delivery to tumor sites. Re-
cently, we and others have demonstrated that intratumoral ther-
apy with OV can lead to systemic anti-tumor immunity and
abscopal effects, and several clinical trials are currently exploring
intratumorally administered OVs in patients. The effect of pre-
existing anti-viral immunity or the development of new anti-viral
immunity on the anti-tumor efficacy, however, is not well
defined.
Methods
Using oncolytic Newcastle Disease Virus (NDV) as a model, we
explored the effect of pre-existing immunity to the virus on its thera-
peutic efficacy using syngeneic B16-F10 melanoma and MB49 blad-
der carcinoma models.
Results
BL6 mice were immunized with NDV and subsequently im-
planted with B16 or MB49 murine cancer cells. Immunized and
naïve tumor-bearing mice were treated intratumorally with NDV.
As expected, pre-immunized animals demonstrated decreased
levels of NDV replication. Surprisingly, pre-existing immunity to
the virus did not decrease the antitumor efficacy and led to su-
perior tumor clearance and long-term animal survival. Analysis
of tumor-infiltrating lymphocytes from the treated animals dem-
onstrated marked increase in infiltration with CD8+ and CD4
+FOXP3- cells, and significant decrease in CD4+FOXP3+ cells, an
effect that was significantly more pronounced in the pre-
immunized animals. This was observed in both virus-injected
and contralateral flank tumors, in absence of viral spread to dis-
tant tumor sites. Concurrent adoptive transfer of luciferase-
tagged tumor-specific Trp-1 lymphocytes demonstrated in-
creased intratumoral accumulation of Trp-1 cells in pre-
immunized mice. Furthermore, lymphocytes isolated from tu-
mors of NDV-treated pre-immunized mice produced more IFNg
than those of NDV-treated naïve mice when cultured with
tumor cells in vitro, suggestive of antigen spreading. Finally, in
an animal model of recurrent cancer after “cure” with NDV, re-
treatment with NDV resulted in regression of tumors and long-
term animal survival, an effect accompanied by significant in-
crease in tumor-infiltrating immune cells.
Conclusions
Our findings demonstrate that pre-existing immunity to OVs
might not deter, and even augment the efficacy of intratumoral
OV therapy, which is likely mediated by enhanced tumor-specific
immune response. This is a clinically-relevant question, which
suggests that prior anti-viral immunity should not be a deterrent
to OV therapy with locoregional administration, though it remains
to be demonstrated whether such findings would translate to
other oncolytic viruses.
Promoting and Measuring Anti-Tumor
Immunity
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Background
The Immunoscore® was validated as a powerful prognostic marker in
colon cancer in a study conducted by the Immunoscore® worldwide
consortium, led by the Society for Immunotherapy of Cancer (SITC)
involving 23 pathology centers from 17 countries, and including
more than 3800 patients. HalioDx has developed a standardized ver-
sion of the test that was used in this study. Here we show the con-
cordance with the research version and present the main analytical
performances of the system.
Methods
For each colon tumor block, 2 slides are stained using an auto-
mated IHC staining instrument: one with CD3 and one with CD8.
Digital images of stained slides are obtained using a whole slide
scanner, and analyzed by a software program (Immunoscore®
Analyzer, HalioDx). The Immunoscore® Analyzer automatically pro-
cesses images for tissue detection (core of the tumor, CT and in-
vasive margin, IM). Densities of positive lymphocytes in the CT
and IM are reported. For each marker and each zone, densities
distributions have been established in the SITC study training set.
The Immunoscore® is reported in 5 categories from 0 to 4, or as
IS High (IS3 and IS4), Low (IS0 and IS1) & intermediate (IS2). Pre-
cision of HalioDx Immunoscore® Colon assay in terms of repeat-
ability and reproducibility was evaluated using commercial FFPE
colon cancer blocks, with 152 independent stainings from 4 sam-
ples, corresponding to 62 CD3 and CD8 pairs. Intra-block and
inter-block variability were assessed from 8 additional blocks. Ac-
curacy based on inter-laboratory concordance was determined
using 119 samples. The European Hospital Georges Pompidou
(HEGP - center of reference for the SITC study) workflow was
used as reference.
Results
The inter-instrument, inter-lot and inter-operator/-reader precision
in terms of cell density (cells/mm2) CV were below 12%, 22% and
18%, respectively. Only 1 change in Immunoscore® category (out
of 62 IS assessments) was observed, from IS1 to IS0. The equiva-
lency between HalioDx and HEGP workflows was assessed in
terms of cell densities. Deeming regression slopes were not sig-
nificantly different from 1 for both CD3 and CD8 antibodies. Pear-
son correlation coefficients were above 0.89. The concordance
table is provided in Fig. 16, corresponding to a weighted Cohen’s
kappa coefficient of 0.88.
Conclusions
The Immunoscore® Colon is a robust, easy-to-use and accurate assay.
It is the first standardized immune-based assay for the classification
of cancer.
References
1. Galon J, et al: J Pathol 2014, 232(2):199-209.
2. Galon J, et al: JCO 2016, 34(15_suppl):3500.
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82 Page 11 of 221
O17
Mechanisms of chitosan/IL-12 immunotherapy for the treatment of
bladder cancer
Sean G. Smith1, Khue Nguyen2, Sruthi Ravindranathan3, Bhanu Koppolu1,
David Zaharoff1
1Joint Department of Biomedical Engineering, North Carolina State
University and the University of North Carolina, Raleigh, NC, Cary, NC,
USA; 2Cell and Molecular Biology, University of Arkansas, Fayetteville, AR,
USA; 3Biomedical Engineering, University of Arkansas, Fayetteville, AR,
USA
Correspondence: Sean G. Smith (sgseangr@ncsu.edu)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):O17
Background
Bladder cancer afflicts 430,000 people every year globally and is
plagued by recurrence rates as high as 50%. One way to miti-
gate the risk of recurrence is by engaging adaptive immunity.
Our group has been able to direct adaptive immunity via intra-
vesical treatment with CS/IL-12, a coformulation of interleuki-
n(IL)-12 and the biopolymer chitosan. Four twice-weekly
administrations of CS/IL-12 routinely eliminate more than 90%
of orthotopic bladder tumors in mice while providing systemic
protection from recurrence and rechallenge for the duration of
the lifespan of treated mice. The purpose of this study is to
gain insights into the mechanisms underlying both the initial
elimination and later rejection of bladder tumors by exploring
the importance of the number of administrations, lymphocyte
subtypes, and the immune cell infiltration throughout and fol-
lowing treatment.
Methods
Female C57BL/6J mice were implanted orthotopically with 75,000
MB49 bladder cancer cells. Beginning 7 days after implantation,
mice were treated intravesically 2x/week for two weeks with CS/
IL-12 (1 μg). The importance of the number of treatments was in-
vestigated by monitoring survival while varying the treatment
number. The role of lymphocyte subtypes was investigated by
monitoring survival after depleting CD4+, CD8+, or NK1.1+ cells
prior to and throughout treatment or rechallenge. Cellular re-
sponses 24 hours after each treatment were measured in the
bladder, bladder draining lymph nodes (BDLNs), and the spleen
via flow cytometry.
Results
Varying the number of treatments revealed that a single admin-
istration significantly extended survival beyond saline with 4/10,
2/8, 6/9, and 7/8 mice surviving long term after 1, 2, 3, or 4 ap-
plications respectively. Depletion studies showed a dependence
on CD8+ T cells for tumor elimination (Fig. 17a) and on CD4+ T
cells for rejection of subsequent tumor rechallenge (Fig. 17b).
Flow cytometry revealed fluctuations in the immune-cell popula-
tions over the course of treatment (Fig. 18). The first treatment
was characterized by a 54% increase of macrophages in the
bladder and a 56% increase in the CD8:Regulatory T cell ratio in
the BDLNs. By the third treatment there was an influx of CD4+
and CD8+ T cells in the bladder as well as increased CD8+ T
cells in the BDLNs.
Conclusions
Even a single administration of CS/IL-12 eliminates established tu-
mors, though higher rates of survival were possible with 3 or 4 treat-
ments. The initial response is inflammatory and driven by
macrophage infiltration and CD8+ T cells while the memory re-
sponses is directed by CD4+ T cells.
Fig. 17 (Abstract O17). Depletion studies reveal role of T cell
subtypes. Mice were depleted of NK1.1+, CD4+, or CD8+ cells either
throughout treatment with CS/IL-12 (a) or rechallenge at a distant
site (b). Significant differences (P<0.05) in median survival by the
Log-Rank test are indicated by *
Fig. 16 (Abstract O16).
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Survivorship Issues Related to
Immunotherapy
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Background
Central nervous system (CNS) metastasis are common in patients
with metastatic melanoma (MM) and represent a frequent site of
treatment failure with current therapies. However, little is known
about the incidence, characteristics and outcomes of CNS metastasis
in MM patients treated with anti-programmed death-1 (PD-1) and in
conjunction with more intensive local CNS treatment strategies.
Methods
Under an IRB-approved protocol, outcomes of MM patients
treated with anti-PD-1 at The University of Texas MD Anderson
Cancer Center from January 2012 to February 2016 were
reviewed. The association between development of CNS metasta-
sis and overall survival (OS) was assessed using Cox regression
analysis with time to CNS metastasis treated as a time-varying
covariate.
Results
We identified 264 MM patients who received anti-PD-1 treat-
ment, including 74 (28%) who had CNS metastasis prior to the
first dose of anti-PD-1. With a median follow-up of 10.4 months
(range 0-51.6) from the start of this therapy, 37 (19% of pa-
tients without prior CNS metastasis) developed CNS metastasis
after the initiation of anti-PD-1. Of those, 27 patients were diag-
nosed with CNS metastasis during anti-PD-1 or within 90 days
of treatment discontinuation, and 10 patients were diagnosed
with CNS mets >90 days after last anti-PD-1 dose. The majority
of these patients were male (62%), their mean age at new CNS
metastasis was 62 years (range 31-86), and most patients had a
history of cutaneous primary (59%). Of the 26 patients who
were tested for mutations, BRAF was identified in 8 (22%,
V600E in 6 patients, V600K in 2 patients), NRAS in 5 (14%) and
KIT in 6 (16%). 86% received at least one CNS directed treat-
ment approach. 62% were treated with stereotactic radiosur-
gery, 11% received whole-brain radiation and 30% underwent
surgery. Median OS from start of anti-PD-1 was 34 months
(range 0-51.6 months) for the whole anti-PD-1 treatment cohort.
Development of CNS metastasis while on anti-PD-1 therapy was
strongly significantly associated with death (HR 3.39, 95% CI
2.06, 5.59, p < .0001).
Conclusions
To our knowledge, this is the first report describing the incidence of
CNS metastasis as an initial site of disease progression in MM pa-
tients treated with anti-PD-1 and associated with worse OS, despite
additional CNS directed therapy.
Tumor Microenvironment
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Background
Batf3-lineage CD8α+ and CD103+ dendritic cells (DCs) are required
for the spontaneous priming of CD8+ T cells against solid tumors. In
contrast, the APCs that regulate immune responses against
hematological malignancies have not been characterized. Syngeneic
transplantable and genetically-engineered acute myeloid leukemia
(AML) models associated with a dense CD8+ T cell tolerant state were
employed to identify the APCs responsible for inducing T cell toler-
ance in vivo.
Methods
Transplantable C1498 and genetically-engineered Mx1-Cre x LSLAML1-
ETO/+ x FLT3ITD/ITD x R26-LSLSIY/+ (MAFFS) AML models were employed
to characterize APCs involved in generating leukemia-specific CD8+ T
cell tolerance.
Results
Following systemic introduction of viable, CellTrace violet-labeled
AML cells, leukemia cell-derived fluorescence was observed exclu-
sively within splenic CD8α+ DCs, whereas uptake of proteins from
dead AML cells was mediated by CD11b+ macrophages. CD8α+
DCs were also uniquely capable of cross-presenting leukemia an-
tigens to CD8+ T cells directly ex vivo. Interestingly, antigen
Fig. 18 (Abstract O17). Immune infiltrates after each treatment.
Bladder tumor tissues and bladder draining lymph nodes (BDLNs)
were disassociated and analyzed via flow cytometry 24 hours after
intravesical treatment with either PBS or CS/IL-12. Regulatory T cells
were defined as CD3+CD4+CD25+FoxP3+. Each symbol represents
an individual mouse. Significant differences (P<0.05) by T-tests are in-
dicated by *
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encounter by leukemia-specific CD8+ T cells was severly reduced
in Batf3-/- mice, indicating that CD8α+ DCs mediate T cell recogni-
tion of leukemia antigens, and that their absence is associated
with immunological ignorance of AML antigens. Moreover,
leukemia-specific CD8+ T cells in wildtype AML-bearing mice
failed to respond following vaccination with the tolerizing anti-
gen, while those in leukemia-bearing Batf3-/- mice expanded vig-
orously, demonstrating that CD8α+ DCs induce leukemia-specific
tolerance in vivo. Activation of CD8α+ DCs with the TLR-3 agonist,
poly(I:C) restored functional anti-leukemia T cell responses and
protected mice from disease progression in a Batf3-dependent
manner. RNA-seq analysis of "tolerogenic" versus "naive" CD8α+
DCs from leukemia-bearing mice revealed ~200 differentially
expressed genes in the former, suggesting that tolerance induc-
tion by CD8α+ DCs is an active process.
Conclusions
Our data support a growing body of evidence that has defined a
prominent role for Batf3-dependent DCs in regulating anti-cancer
immune responses. Batf3-lineage DCs generate functional CD8+ T
cell responses against solid tumors, but actively and exclusively
induce CD8+ T cell tolerance to systemic leukemia, indicating that
the same DC lineage can imprint disparate T cell fates in mice
with solid verses hematopoietic malignancies, and suggesting
that environmental cues perceived by CD8α+ DCs may dictate
their ability to activate or tolerize cancer-specific CD8+ T cells.
These results highlight stark differences in the regulation of anti-
cancer immunity in hosts with solid versus hematological
malignancies.
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Background
Regulatory T cells (Tregs) play an integral role in maintaining im-
mune homeostasis; however, they are detrimental in cancer
through suppression of the anti-tumor immune response. There-
fore, identifying Treg targets that are specifically required in the
tumor microenvironment is warranted. We have previously shown
that the Neuropilin-1 (Nrp1) pathway is required for functional
stability of intratumoral Tregs, but remains disposable in maintain-
ing peripheral immune homeostasis. However, 1) the mechanisms
that drive Treg functional instability, 2) the fate and impact of
functionally unstable Nrp1-deficient (Nrp1–/–) Tregs on the tumor
microenvironment and 3) how NRP1 affects function in human
Tregs remain unknown.
Methods
In order to further understand the role of Nrp1–/– Tregs in cancer, we
injected B16.F10 melanoma into Nrp1L/LFoxp3Cre-YFP/DTR-GFP cellular
heterozygous mice comprised of 50% WT Tregs and 50% Nrp1
–/– Tregs.
Using these mice, we performed whole transcriptome sequencing to
determine global transcriptomic changes. Once identified, differen-
tially regulated pathways were tested both ex vivo through functional
assays and in vivo with Treg transfers into Foxp3
–/– mice. Lastly, we
obtained head and neck squamous cell carcinoma and metastatic
melanoma samples to determine the abundance and function of
NRP1 on human Tregs.
Results
Using Nrp1L/LFoxp3Cre-YFP/DTR-GFP mice, we found that intratumoral
Nrp1–/– Tregs produce interferon-γ (IFNγ), driving the functional
destabilization of surrounding WT Tregs, which in turn boosts anti-
tumor immunity and facilitates tumor clearance. Furthermore, we
have shown that NRP1 is expressed on a proportion of TIL Tregs
in head and neck cancer as well as metastatic melanoma and
that the IFNγ pathway is likely conserved in human Tregs. In
addition, human TIL Tregs pre-treated with IFNγ show significantly
reduced suppressive function in comparison to those without
pre-treatment.
Conclusions
Overall, we have shown that Nrp1 is required for functional sta-
bility of intratumoral Tregs, and in its absence, there is an alter-
ation in the tumor microenvironment, leading to an enhanced
anti-tumor immune response. These studies uncover a novel po-
tential target for cancer immunotherapies that preserves periph-
eral immune health. This is of clinical interest, given that NRP1 is
expressed on select Tregs in human melanoma and head and
neck cancer and that NRP1+ Tregs show a suppressive advantage
over NRP1– Tregs.
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Background
To overcome tumor-mediated inhibition of chimeric antigen re-
ceptor (CAR) T cells, we herein investigated the impact of tumor
PD-L1 upregulation on CAR T cell exhaustion and anti-tumor effi-
cacy, and further developed clinically translatable T cell-extrinsic
as well as -intrinsic strategies to overcome PD-L1 inhibition in
models of lung cancer (LC) and malignant pleural mesothelioma
(MPM).
Methods
Human T cells were transduced with MSLN-specific CAR with CD28
and CD3zeta domains (M28z) were tested in vitro and in clinically-
relevant LC and MPM mouse models by bioluminescence imaging
(BLI) of tumor burden progression. To counteract PD-1/PD-L1 inhib-
ition in vivo, we evaluated the efficacy of PD-1 blocking antibody or
cell-intrinsic genetic-engineering strategies by cotransducing M28z
CAR T cells with a PD-1 dominant negative receptor (PD1-DNR) or
with PD-1/4-1BB fusion protein.
Results
A single, low-dose ofM28z CAR T cells is able to resist the pro-
gression of established tumor for 40 days, but mice eventually
died with progressing tumor. Tumor harvest analysis demon-
strated the PD-1 and PD-L1 upregulation on CAR T cells and
tumor cells (Figure Panel A). We then confirmed in vitro that PD-
L1 inhibits M28z T cell effector functions (proliferation, cytotox-
icity and cytokine secretion). The addition of PD-1 blocking po-
tentiates CAR T cell therapy in vivo but its efficacy requires
multiple injections (Panel B). In contrast, a single dose of M28z T
cells coexpressing PD-1-DNR restore effector functions, enhance
tumor burden control (Panel C) and prolong median survival (56
vs 82 days, p=0.001). Converting PD-L1 inhibition into a positive
costimulatory signal by PD-1/4-1BB construct cotransduction into
M28z CAR T cells enhanced cytokine secretion and T cell accumu-
lation (Panel D).
Conclusions
Our results demonstrate the therapeutic benefit of providing optimal
costimulation and coinhibitory blockade to counteract PD-L1/PD-1
immunosuppression, thus potentiate CAR T cell therapy for lung can-
cer and mesothelioma.
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Background
Moesin is a member of the ezrin-radixin-moesin (ERM) protein
family that are crucial for organizing membrane domains [1].
However, the role of ERM proteins in regulating signal transduc-
tion activities is still less clear and identifying new target proteins
regulated by the ERMs for drug targeting remains an important
area within the field due to their increased levels in multiple can-
cers. Whether ERM proteins play any role during the differenti-
ation of naïve CD4+ T cells to TGF-β-induced Tregs is completely
unknown.
Methods
We utilized a combination of knockout (MsnKO) mice, polyribo-
some profiling, RT-PCR and immunoblotting to demonstrate that
a lack of moesin promotes efficient adoptive T cell therapy in
mice by controling translational upregulation of moesin by TGF-β
in T cells.
Results
The lack of moesin led to poorer development and function of both
peripherally-inducible Tregs and in vitro-induced Treg cells (Fig. 20).
We found that the loss of moesin significantly delayed tumor recur-
rence in a mouse model of melanoma and supported the rapid ex-
pansion of adoptively transferred CD8 + T cells against cancer-
associated antigens (Fig. 21). Of note, moesin knockout CD4+ T cells
exhibited no defects in T cell receptor activation, proliferation or
cytokine production, suggesting no alternations in T cell activation in
these mice. Instead, our data indicate that moesin interacts with TGF-
β receptor II and controls its surface abundance and stability (Fig. 22).
Indeed, the lack of moesin significantly impaired optimal TGF-β sig-
naling (Fig. 23) and improved adoptive T cell therapy under cancer
setting (Fig. 24).
Conclusions
This finding is important and suggests that modulation of moesin
(via inhibitors or agonists), such as developed recently for ezrin [2],
could serve as a potential candidates for use in immunotherapy com-
binations for the treatment of cancer as well as advance our
knowledge.
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Fig. 20 (Abstract P2). a Immunoblot of moesin knockout (KO or
MsnKO) in multiple organs of mice. b Representative enlarged
spleen size and increased cell number as observed in MsnKO mice.
Data are reported as the mean ± SEM; ***P <0.001 by Student’s t-
test. n = 6 per group. c and d Flow cytometry of inflammatory cyto-
kines, TNF-α and IL-4 (c), and IFN-γ and IL-17A (d) produced by CD4
+ T cells from spleens of WT and MsnKO mice after PMA-Ionomycin
stimulation for 4 h. Data are reported as the mean ± SEM; *P <0.05
and ***P <0.001 by Student’s t-test. WT n = 3, MsnKO n = 4. e and
f Flow cytometry analysis and absolute number of pTregs (Foxp3
+Heliolo) in the small intestine lamina propria (sLP) (e) and colon
lamina propria (cLP) (f) of 10-12 weeks old mice. Data are reported
as the mean ± SEM; *P <0.05, **P<0.01 and ***P <0.001 by Student’s
t-test. n = 4 per group, MsnKO sLP n = 3. g and h Flow cytometry
analysis and absolute number of pTregs (Foxp3+Helioslo) in the
spleen (g) and peripheral blood (h) of 10-12 weeks old mice. Data
are reported as the mean ± SEM; ns, not significant; *P <0.05 and
**P <0.01 by Student’s t-test. n = 4 per group
Fig. 19 (Abstract P1).
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Fig. 22 (Abstract P2). a Immunoprecipitation (IP), with anti-TβRII and
control immunoglobulin G antibodies of EL4 cell lysates, followed by im-
munoblot of pulldown and input samples with the indicated antibodies.
b Confocal microscopy images of EL4 cells stimulated with TGF-β (5 ng/
ml for 1 h) and stained with anti-TβRII and anti-moesin antibodies. c and
d HEK293FT cells co-transfected with plasmids encoding wild-type
moesin-tagged with CFP at the carboxy terminus (Msn-WT-CFP) and
TβRII-tagged with haemagglutinin at the carboxy terminus (TβRII-HA). Im-
munoprecipitation of solubilised proteins using anti-GFP and anti-HA anti-
bodies and immunoblot of the pull-down samples. Input - whole cell
lysate immunoblotting (throughout). e-g Immunoprecipitation and im-
munoblot (as in c) of HEK293FT cells co-transfected with CFP-tagged
wild-type or phosphomimetic moesin mutants and TβRII-HA constructs.
Data are representative of at least three (a-c) or four (d-f) independent ex-
periments. h and i Primary CD4+ T cells (h) and B220+ B cells (i) from the
spleen of WT and MsnKO mice were treated with cyclohexamide at the
indicated times and surface TβRII analyzed by flow cytometry. Data repre-
sents the mean ± SD of at least three independent experiments. ***P
<0.001 by two-way analysis of variance (ANOVA). j Flow cytometry ana-
lysis of primary CD4+ T cells isolated from the spleen of WT and MsnKO
mice, and treated with brefeldin A (BFA), 20 μg/ml for up to 5 h and then
washed. Cell surface TβRII was left to recover for up to 12 h prior to ana-
lysis. Data represents the mean ± SD of at least three independent experi-
ments. ***P <0.001 by two-way analysis of variance (ANOVA)
Fig. 21 (Abstract P2). a Treatment scheme for B6 mice injected
subcutaneously with B16-F1 melanoma tumor cells (2.5 x105) 7 days
prior to lympho- 31 depletion with 6Gy total body irradiation and
adoptive transfer (ACT) of 2 x106 Pmel-1 T cells (i.v.) at day 8. b
Tumor growth kinetics in individual mice treated as indicated in A,
(each line represents one mouse); WT (n=6), MsnKO (n=4). c Fre-
quency of donor Pmel-1 CD8+ T cells circulating in the blood of WT
and MsnKO mice from B at 8 weeks. d Survival analysis of WT and
MsnKO mice upon B16 melanoma tumor injection and adoptive cell
transfer. *P = 0.05 by Log-rank test (B and D), *P < 0.05 by Student’s
t-test (C). Data are reported as the mean ± SEM
Fig. 23 (Abstract P2). a-c EL4 LAF (EL4) cells transduced with
lentiviral scrambled vector (Scram) or moesin shRNA (MsnKD),
stimulated with TGF-β (5 ng/ml) and analyzed for intracellular
pSmad2/3 by flow cytometry at the times indicated. Data are
representative of the mean ± SD of at least three independent
experiments. *P <0.05 and **P <0.01 by Student’s t-test. (d and e)
Analyses of phospho-Smad2/3 (pSmad2/3) by flow cytometry after
3-day cultures (d) and pSmad3 and total Smad3 by immunoblotting
(e) stimulated at the indicated times in WT and MsnKO iTregs.
Data are representative of at least two independent experiments.
Fig. 24 (Abstract P2). (i, ii) Under pathological conditions such as
cancer, TGF-β production by tumor cells binds to cognate receptors
on T cell surfaces and triggers signaling events that lead to Foxp3
expression and induced Treg cell development. (iii-iv) Signaling
via the TGF-β non-canonical Akt-hnRNP E1-axis leads to post-
transcriptional moesin expression. The TGF-β signaling pathway,
Rho kinase and/or Phosphatidylinositol 4,5-bisphosphate[Pt-
dIns(4,5)P2] pathways, lead to phosphorylation/activation of
moesin and aids moesin binding to the F-actin. (v-viii) Moesin-
F-acting binding may promote internalization of TGF-β receptors
possibly via early endosomes which feeds forward to promote
optimal TGF-β signaling leading to efficient Foxp3 induction and
iTreg cell differentiation. (ix) Moesin may also promote efficient
recycling of TGF-β receptors to maintain the abundance of
TβRII on the cell surface. (x) Differentiated induced Treg cells
then suppress the proliferation of other immune cells such as
cytotoxic T lymphocytes and effector T (Teff) cells to limit
anti-tumor responses and promote tumor progression
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Background
Adoptive immunotherapy employing optimal affinity T cell receptor
(TCR) engineered T cells is a highly attractive treatment modality for
multiple cancer indications. In order to ensure the safety of novel T
cell receptor therapies, it is important both that expression of the tar-
get antigen is tightly restricted to tumor, and that the TCR does not
display off-target activity. Here we describe development of an
optimal-affinity MAGE-A4 TCR for adoptive T cell therapy.
Methods
Expression profiling of the cancer-germline antigen MAGE-A4 was
performed in tumor and normal tissues, determined by analyzing
public RNAseq datasets and by in-house qPCR. We then generated
an enhanced affinity TCR that recognizes a validated MAGE-A4 HLA-
A*02 peptide, selected based on potency and specificity in in vitro
testing from panels of engineered TCRs originating from multiple
parental TCRs. The selected TCR was subject to full preclinical
characterization using Adaptimmune’s extensive preclinical testing
process. This process involves potency testing against both tumor
cell lines and primary tumor tissue in 2D and 3D, and safety testing
consisting of extensive screening of TCR-transduced T cell responses
to a wide range of tumor lines, normal human primary cells and in-
duced pluripotent stem cell-derived cells. In addition, the fine specifi-
city of the TCR was characterized to allow the generation of a
binding motif and the identification of putative mimotype peptides
within the human proteome.
Results
The MAGE-A4 antigen was found to be highly over-expressed in sev-
eral clinically important solid tumor indications, such as lung squa-
mous cell cancer (60%), head and neck cancer (42%), bladder cancer
(34%) and esophageal cancer (33%), while expression in non-tumor
material was limited to expression in the testes and placenta, both
immune-privileged tissues. We generated an enhanced-affinity TCR
that demonstrated enhanced potency against MAGE-A4-expressing
tumor cell lines and fresh tumor tissue, whilst retaining absence of
relevant response against MAGE-A4-negative cells and non-MAGE
peptide mimotypes.
Conclusions
MAGE-A4 is an attractive target antigen for adoptive T cell therapy
using enhanced affinity TCRs. We have generated and characterized
an optimal enhanced-affinity TCR, which shows enhanced potency
against MAGE-A4-positive tumor targets whilst maintaining specifi-
city. These data will be used to support an IND for the use of this
TCR for investigatory clinical trials.
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Background
SPEAR® T cells reactive against the NY-ESO-1 specific HLA-A02:01 re-
stricted peptide (SLLMWITQC) have demonstrated clinical activity
(ORR 50%) in patients (n=12) with advanced synovial sarcoma (SS).
The mechanisms underlying tumor relapse in the presence of persist-
ing SPEAR® T cells remain unclear. Here, we report on phenotypic
and functional studies on both engineered T cells and tumor biopsies
from a patient with a NY-ESO-1+ SS treated with NY-ESO-1C259
SPEAR® T cells.
Methods
Engineered T cell persistence was determined by qPCR for the vector
backbone and flow cytometry for HLA-A2:01-SLLMWITQC reactive
pentamer+ T cells in post-infusion PBMC samples. Multi-parameter
flow cytometric analyses were performed on pre-infusion manufac-
tured product and post-infusion PBMCs to assess memory subsets
using CD45RA and CCR7, exhaustion using CD28 and PD-1, and func-
tionality by IFN-ɣ and Gzmb. Tumor and NY-ESO-1C259 T cells from
patient PBMCs were isolated at 28 months post-infusion to deter-
mine their ex vivo killing capacity against a NY-ESO-1+ cell line, A375
. Antigen expression and immunomodulatory milieu (e.g. PD-L1) in
baseline and post-treatment biopsies were assessed by immunohis-
tochemistry. Serum cytokines were measured by a Luminex based
immunoassay. Tumor response was determined by RECIST v1.1.
Results
The patient achieved a partial response to NY-ESO-1C259 SPEAR® T
cells with progression at 9 months post-infusion. Persistence at 28
months with NY-ESO-1C259 T cells was observed by qPCR and flow
cytometry. Over the course of treatment, the phenotype of the engi-
neered cells changed from a mix of TEMRA (CD45RA
+CCR7-), TEM
(CD45RA-CCR7-), and TSCM (CD45RA
+CCR7+) populations at the time
of infusion to a predominately TSCM (~98.7%) within five months.
PBMC derived NY-ESO-1C259 SPEAR® T cells 28 months post-infusion
exhibited substantial ex vivo killing of NY-ESO-1+ A375 cells without
additional ex vivo re-stimulation. Pre- and post-infusion biopsies
showed NY-ESO-1 expression and exhibited minimal to moderate
leukocytic (CD45+) infiltration accompanied by minimal lymphocytic
infiltration post-infusion. Of note, PD-L1 expression was exclusive to
CD45+ cells.
Conclusions
Despite an initial response to NY-ESO-1C259 SPEAR® T cells, this pa-
tient eventually relapsed despite the persistence of functional
SPEAR® T cells and antigen positive tumor . The basis for tumor pro-
gression following response remains unclear, but does not appear to
result from T cell exhaustion. Other possibilities include loss of anti-
gen expression and/or diminished tumor infiltration, which could re-
sult from the large peripheral TSCM population, known to traffic to
lymphoid tissue rather than tumor.
Trial Registration
ClinicalTrials.gov identifier NCT01343043.
Consent
Written informed consent was obtained from patient for publication.
A copy is available for editor review.
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Background
Adoptive cell therapy (ACT) with NY-ESO SPEAR® T cells, is showing
promising initial clinical responses in phase I/II trials for both solid
and liquid tumors including synovial sarcoma and multiple myeloma.
However, the depth and durability of response may be affected by
the inhibitory tumor microenvironment. Tumors utilize many differ-
ent methods to inhibit anti-tumor immunity including secretion of in-
hibitory cytokines, such as transforming growth factor-β (TGF-β) and
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induction/recruitment of other inhibitory cells including regulatory T
cells and myeloid-derived suppressor cells. These inhibitory cells also
secrete cytokines such as IL-10 and TGF-β that potentially reduce the
efficacy of T cells. TGF-β is expressed at high levels in a range of can-
cer indications.
Methods
We investigated whether SPEAR® T cells can be engineered to ex-
press additional proteins, allowing them to overcome such immune
resistance mechanisms, potentially improving clinical responses. TGF-
β inhibits T cells by binding to a dimer of TGFβRII, which then re-
cruits a dimer of TGFβRI forming a heterotetrameric complex that ac-
tivates inhibitory intracellular SMAD signaling pathways. Truncating
the intracellular signaling domain produces a dominant negative
TGF-β receptor (dnTGFβRII) that, although capable of binding TGF-β,
is unable to signal. We therefore generated SPEAR® T cells co-
expressing enhanced affinity T cell receptors (TCR) that recognize a
peptide from NY-ESO/LAGE-1A in the context of HLA-A2, together
with dnTGFβRII and tested their function in vitro.
Results
Firstly we showed that the function of NY-ESO SPEAR® T cells is
inhibited with physiologically-relevant concentrations of TGF-β. We
further show that dnTGFbRII can be co-expressed with enhanced af-
finity NY-ESO TCR in SPEAR® T cells. T cells expressing dnTGFβRII had
reduced SMAD phosphorylation in response to TGF-β compared with
cells expressing TCR alone, indicating that inhibitory signaling in re-
sponse to TGF-β was reduced. Subsequently we showed that T cells
expressing dnTGFβRII were partially or completely resistant to the ef-
fects of TGF-β, using assays for T cell proliferation, cytotoxicity (in 2D
and with 3D microtissue models) and Th1 cytokine release (IFN-γ and
IL-2) in response to antigen positive tumor cells.
Conclusions
Together these data indicate that co-expression of dnTGFβRII may be
a viable approach to improve the efficacy of SPEAR® T cells in treat-
ing cancer.
P6
Inducible MyD88/CD40 (iMC) costimulation drives ligand-
dependent tumor eradication by CD123-specific chimeric antigen
receptor T cells
MyLinh Duong1, An Lu1, Peter Chang1, Aruna Mahendravada1, Nicholas
Shinners1, Kevin Slawin1, David M Spencer2, Aaron E Foster1, J Henri
Bayle1
1Bellicum Pharmaceuticals, Houston, TX, USA; 2Bellicum Pharmaceuticals
and Baylor College of Medicine, Houston, TX, USA
Correspondence: J. Henri Bayle (jhbayle@bellicum.com)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P6
Background
CD123/IL-3Rα is a promising chimeric antigen receptor (CAR)-T cell
target due to its high expression on both acute myeloid leukemia
(AML) blasts and leukemic stem cells (AML-LSCs). However, the anti-
gen is also expressed at lower levels on normal stem cell progenitors,
presenting a major toxicity concern should CD123-specific CAR-T
cells show long-term persistence. Here, we describe a CAR platform,
“GoCAR-T”, that uses a proliferation-deficient, first generation, CD123-
specific CAR together with a ligand-dependent costimulatory switch
(inducible MyD88/CD40 (iMC)) to provide physician-controlled eradi-
cation of CD123 + tumor cells and regulate long-term CAR-T cell
engraftment.
Methods
T cells were activated and transduced with a bicistronic retro-
virus encoding iMC (MyD88 and CD40 cytoplasmic signaling do-
mains fused with tandem copies of FKBPv36 (binding domain
for the dimerizing ligand rimiducid (Rim)) and a first generation
CAR targeting CD123 (SFG–iMC-CD123.ζ). Ligand dependence
for costimulation with iMC was assessed in coculture assays
with CD123+ AML cell lines (KG1, THP-1 and MOLM-13) by
examination of cytokine production and observation by
IncuCyte-based live cell imaging. In vivo efficacy was assessed
by i.v. injection of 106 EGFPluc-expressing CD123+ THP-1 tumor
cells into immunodeficient NSG mice. After seven days 2.5x106
non-transduced or iMC-CD123.ζ-modified T cells were injected
and Rim (1 mg/kg) or vehicle only administered i.p. on days 0
and 15 post-T cell injection. Animals were evaluated for tumor
burden using IVIS bioluminescent imaging (BLI) and for T cell
persistence by flow cytometry and qPCR at day 30 post-T cell
injection.
Results
In coculture assays, both CD123 antigen recognition and Rim-
dependent iMC costimulation were required for IL-2 production
(285±41 versus 2,541±255 pg/ml for control and 1 nM Rim, re-
spectively), robust CAR-T cell proliferation (87-fold increase with
Rim stimulation) and enhanced KG1 cell killing. In NSG mice
engrafted with CD123+ THP-1-EGFPluc tumor cells, only animals
treated with iMC-CD123.ζ-modified T cells and Rim controlled
tumor growth, showing a 2-log reduction in tumor burden with
Rim treatment. Two weeks after the second Rim injection, CAR-T
cells were infrequent (<1.0%) in the spleen and bone marrow of
both CAR groups, suggesting that active costimulation is required
for CAR-T persistence.
Conclusions
GoCAR-T, a platform comprising a ligand-dependent activation
switch and a proliferation-deficient first generation CAR, efficiently
eradicates CD123+ leukemic cells when costimulation is provided by
systemic rimiducid administration. Deprivation of iMC costimulation
results in reduction of CAR-T levels, providing a user-controlled sys-
tem for managing persistence and safety of CD123-specific CAR-T
cells.
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Background
Adoptive cell transfer (ACT) is a promising immunotherapeutic
approach for cancer. Host lymphodepletion is associated with fa-
vorable ACT therapy outcomes, but it may cause detrimental ef-
fects in humans. Among the benefits provided by
lymphodepletion, ablation of cells forming a cytokine “sink” re-
sults in high levels of homeostatic cytokines that support prolifer-
ation and survival of the transferred lymphocytes. Interleukin-15
(IL-15) is a lymphocyte growth and activation factor presently in
clinical trials for immunotherapy of metastatic cancers. We previ-
ously showed that bioactive IL-15 in vivo comprises a stable com-
plex of the IL-15 chain with the IL-15 receptor alpha chain (IL-
15Rα), termed heterodimeric IL-15 (hetIL-15). In this study, we
tested the hypothesis that hetIL-15 administration enhances ACT
in the absence of lymphodepletion.
Fig. 25 (Abstract P6). Rimiducid-dependent MyD88/CD40
costimulation enhances antitumor activity of a first-generation
CD123-specific CAR
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Methods
We evaluated the effects of the combination regimen ACT
+hetIL-15 in the absence of lymphodepletion by transferring
melanoma-specific Pmel-1 T cells into B16 melanoma-bearing
mice. Tumors were analyzed by both flow cytometry and multi-
parameter immunohistochemistry. Tumor-infiltrating transferred
Pmel-1 were analyzed for their persistence, proliferation and ef-
fector functions.
Results
hetIL-15 treatment delayed tumor growth by promoting infiltra-
tion and persistence of both adoptively transferred Pmel-1 cells
and endogenous CD8+ T cells into the tumor. In contrast, persist-
ence of Pmel-1 cells was severely reduced following irradiation in
comparison to hetIL-15 treatment. Importantly, we found that
hetIL-15 led to the preferential enrichment of Pmel-1 cells in B16
tumor sites in an antigen-dependent manner. Upon hetIL-15 ad-
ministration, tumor-infiltrating Pmel-1 cells showed a “non-
exhausted” effector phenotype, characterized by increased IFN-g
secretion, proliferation and cytotoxic potential and low level of
PD-1. hetIL-15 treatment also resulted in an improved Pmel-1 to
Treg ratio in the tumor.
Conclusions
This study shows that hetIL-15 administration improves the out-
come of ACT in immunocompetent hosts and is able to replace
the need for lymphodepletion prior ACT for cancer therapy. Ap-
plications of heterodimeric IL-15 to ACT will provide new tools
and techniques for cancer immunotherapy protocols. Elimination
of the need for lymphodepletion will make more patients eligible
for cell transfer protocols. In addition, IL-15 could be a general
method to place T cells into tumors, increasing the success rate
of other immunotherapy interventions.
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Background
Infusion of highly heterogeneous populations of autologous tumor-
infiltrating lymphocytes (TILs) can result in tumor regression of ex-
ceptional duration. Initial tumor regression has been associated with
persistence of tumor-specific TILs one month after infusion, but
mechanisms leading to long-lived memory responses are currently
unknown. Here, we studied the dynamics of bulk tumor-reactive CD8+
T cell populations in patients with metastatic melanoma following
treatment with TILs.
Methods
We analyzed the function and phenotype of tumor-reactive CD8+ T
cells contained in serial blood samples of sixteen patients treated
with TILs.
Results
Polyfunctional tumor-reactive CD8+ T cells accumulated over time in
the peripheral lymphocyte pool. Combinatorial analysis of multiple
surface markers (CD57, CD27, CD45RO, PD-1 and LAG-3) showed a
unique differentiation pattern of polyfunctional tumor-reactive CD8+
T cells. This subpopulation acquired simultaneously expression of the
early differentiation marker CD27, alongside typical features of late
effector cells such as loss of CD45RO and up-regulation of PD-1 and
CD57. The differentiation and functional status appeared very similar
from 1 month to 1 year after infusion. Despite some degree of clonal
diversification occuring in vivo within the bulk tumor-reactive CD8+ T
cells, further analyses showed that CD8+ T cells specific for defined
tumor-antigens had similar differentiation status.
Conclusions
We demonstrated that tumor-reactive CD8+ T cell subsets that persist
after TIL therapy are mostly polyfunctional,and display a stable par-
tially differentiated phenotype. These atypical CD27+ incompletely
differentiated polyfunctional TILs may have a high capacity for per-
sistence and be crucial in keeping patients tumor free.
Trial Registration
ClinicalTrials.gov identifier NCT00937625.
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Background
Adoptive cell therapy (ACT) has shown promise in tumor eradication in
cancer, but current methods require harmful and toxic adjunct proce-
dures. Our laboratory has developed a potent peptide vaccination strat-
egy called TriVax that bypasses the necessity of these adjunct
procedures. Previous studies show that retrovirally (RV)-transduced T
cells are effective in ACT against various cancers. The present study
aimed to determine whether RV-transduced T cells could respond to
TriVax specific for melanosomal tumor antigen gp100, and to see if the
responses could be enhanced when transduced with a constitutively
active form of STAT5 (CA-STAT5), which has been shown to increase
survival of CD8 effector/effector memory T cell populations.
Methods
CD8 T cells were purified from B6 mouse splenocytes and RV-
transduced with a gene encoding the clonal T cell receptor (TCRs) for
mouse gp100. In some experiments, cells were also co-transduced
with a gene encoding for CA-STAT5 (co-expressing Thy1.1). Transduc-
tion efficiency was assessed using flow cytometry with gp100 tetra-
mer and Thy1.1 antibody. Functional activity was measured using
flow cytometry and EliSpot (IFNγ) assays. These cells were then adop-
tively transferred (1.0x105 tetramer+ cells) into naïve and tumor bear-
ing congenic CD45.1 B6 mice, which were then vaccinated with
TriVax. Tumor growth was assessed 3 times per week, and immune
status was assessed in blood using flow cytometry every 7 days.
Results
TriVax administration selectively expanded the ACT cell population
expressing gp100-TCR. Cell numbers in spleen indicate a 14-fold ex-
pansion 25 days after vaccination from what was initially transferred.
When co-transduced with CA-STAT5, an even higher fold expansion
(55-fold) was observed. CA-STAT5+ cells also expanded more ro-
bustly than CA-STAT5- cells when stimulated with a subsequent vac-
cine boost, demonstrating a 5000-fold increase in cell numbers with
85% of CD8+ T cells also being positive for gp100 tetramer. ACT of
these cell populations into tumor bearing mice also yielded a dra-
matic increase in cell numbers, which greatly enhanced the survival
of mice in treatment groups.
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Conclusions
CD8 T cells RV-transduced to express a gp100 TCR and CA-STAT5
are capable of expansion in response to TriVax, bypassing the ne-
cessity of adjunct procedures. Co-expression of CA-STAT5 greatly
enhances the boost effect of TriVax, leading to a dramatic anti-
tumor effect.
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Background
Lion Biotechnologies focuses on the development and
commercialization of cancer immunotherapies based on tumor-
infiltrating lymphocytes (TIL). Cryopreservation is a beneficial process
which allows the final cell product to be shipped in a safe manner
with less time constraints [1]. Clinical studies using cryopreserved TIL
have not been conducted so far. Freezing and thawing of the cells
may cause phenotypic changes such as loss of cell surface receptors
[2]. Here, we tested fresh versus frozen/thawed TIL samples and eval-
uated the expression of phenotypic markers.
Methods
Briefly, PreREP TILs were obtained by culturing melanoma tumor
fragments in IL-2 (6000 IU/ml). Rapid expansion protocol (REP) cells
were initiated using allogeneic PBMC feeder cells with OKT3 and IL-2
in a Grex-100 flask. When the desired confluency was reached, the
cells were cryopreserved in a 5% DMSO solution. We used flow cy-
tometry to phenotype the fresh and thaw/rested TIL at 0h, 24h and
7d following reREP TIL. Flow cytometric analysis was performed using
fluorescent antibodies specific for TCRa/b, CD4, CD8, CD27, CD28,
CD56, CCR7, CD45RA, CD95, PD-1, and CD25.
Results
No significant differences in CD4, CD8 and TCRa/b expression or
memory markers comparing fresh TIL versus thaw/rested TIL at
24h was noted. CD27 expression on TIL was reduced by 50% on
thawed TIL, however after a 24h resting period the expression re-
covered. All other surface antigens that we tested were within
10% difference in their expression levels as compared to
baseline.
Conclusions
Cryopreservation did not affect the measured phenotypic characteris-
tics of TIL. We are further investigating the possibility of using cryo-
preserved TIL in a clinical setting.
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Background
Adoptive transfer of tumor infiltrating lymphocytes (TIL) can ef-
fect long-term durable regression in patients with metastatic
melanoma but has not been widely tested in common epithelial
cancers. When examining the TIL of successfully treated patients
with melanoma, a heterogeneous T cell population can be iden-
tified with reactivity against melanoma differentiation antigens,
cancer germline antigens, and personalized non-synonymous
somatic mutations. Common epithelial cancers, including breast
cancer, express far fewer somatic mutations than melanoma,
however, in a study of metastatic gastrointestinal cancer, lym-
phocytes targeting neoantigens were identified in the majority
of specimens. This pilot study investigates the ability to grow
TIL from breast cancer metastases, to identify personalized non-
synonymous somatic mutations and potential neoantigens, and
to adoptively transfer TIL into patients with breast cancer.
Methods
Eligible patients were evaluated and treated under IRB-approved
protocols for tissue procurement, genomic testing, and adoptive
cell transfer. Portions of resected tumors were placed in culture
under standard TIL conditions. DNA was extracted from tumor
and matched normal peripheral blood samples for whole exome
sequencing (WES). Non-synonymous somatic mutations were
identified and tested for potential immunogenicity using previ-
ously described tandem mini-gene and long (25mer) peptide
techniques. Recognition was assessed by IFNγ release on ELI-
SPOT and/or CD137 (4-1BB) upregulation with appropriate
controls.
Results
Nine patients underwent surgical resection in this ongoing pilot
study, and TIL were successfully grown from the tumors of all pa-
tients. All were primarily CD3+ (median 79%) with a small popu-
lation of natural killer cells. Of the CD3+ cells, 7 of 9 patients
had a predominantly CD4+ population (median CD4:CD8 ratio
2.2, range 0.4-5.8). For eight tumors, WES was performed, and
non-synonymous somatic mutations were identified as potential
neoantigens (median count 96.5, range 71-148). Autologous T cell
reactivity has been identified against tumor-specific mutations in
6 of 8 patients.
Conclusions
Tumor-infiltrating lymphocytes derived from metastatic breast cancer
can react to tumor-specific non-synonymous somatic mutations
in vitro. TIL grown from breast cancers are predominantly CD4+ and
can form the basis of an adoptive cell transfer experimental
approach to patients with metastatic breast cancer.
Trial Registration
ClinicalTrials.gov identifier NCT01174121.
P13
Comparison of RECIST 1.0 to RECIST 1.1 in the evaluation of
adoptive cell transfer
Kasia Trebska-McGowan1, Isaac Kriley1, Parisa Malekzadeh1, Eden
Payabyab1, Richard Sherry2, Steven Rosenberg1, Stephanie L. Goff1
1Surgery Branch, National Cancer Institute, National Institutes of Health,
Bethesda, MD, USA; 2National Cancer Institute, Bethesda, MD, USA
Correspondence: Stephanie L. Goff (stephanie.goff@nih.gov)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P13
Background
Adoptive transfer of tumor infiltrating lymphocytes (TIL) can effect
long-term durable regression in patients with metastatic melanoma.
The earliest studies utilized WHO criteria for evaluation of response,
but more recent studies replaced the bidimensional analysis with
simplified unidimensional criteria of RECIST 1.0. With improved cross-
sectional imaging, there became concern that the pathophysiology
of lymph node response required distinct evaluation criteria, as
tumor clearance may not completely eradicate normal structures.
RECIST 1.1 was developed and validated in a variety of histologies
with various treatments, but has not been evaluated for adoptive cell
transfer.
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Methods
Eligible patients were enrolled on an IRB-approved protocol of adop-
tive cell transfer, randomizing patients to receive one of two lympho-
depleting regimens prior to transfer of TIL. This study was reported
using RECIST 1.0 criteria, with 24 complete responders and 30 partial
responders among 99 treated patients [1]. The official tumor mea-
surements of target lesions and notations of non-target lesions were
re-evaluated using RECIST 1.1 criteria, which limits the total number
of target lesions, the number of target lesions/organ, and uses short-
axis measurements for lymph node disease.
Results
By design, the number of target lesions/patient was decreased, from
4 (range 1-10) to 3 (range 0-5). Thirty-eight lymph nodes did not
meet short-diameter criteria for target lesions (10-14mm), and an
additional 12 measured <10mm were reclassified as “non-patho-
logic”. With retrospective application of RECIST 1.1, three patients
would not have met eligibility criteria for lack of evaluable disease. In
assessing overall response to treatment, 25 patients met CR criteria,
with an additional 27 with PR. While there were five patients who
achieved CR at an earlier time point, overall time to response was
not significantly different (median 16.0 v 19.8 months p=0.19). One
patient with lymph node disease did not achieve CR by original cri-
teria, was an early CR in this analysis, but recurred three months
later.
Conclusions
Adoption of RECIST 1.1 demonstrated comparable response rates for
this trial. A hallmark of our modern studies is the durability of
complete responses with RECIST 1.0, and only by further application
of the new criteria will we be able to confirm the validity of lymph
node response criteria in adoptive cell transfer.
Trial Registration
ClinicalTrials.gov identifier NCT01319565.
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Background
Administration of TILs is a promising treatment for patients with
melanoma and other solid tumors. TIL therapy involves culturing
and expanding T cells isolated from a patient’s tumor in vitro and
then reinfusing them back into the patient. TIL antitumor activity
is commonly measured using tumor cells from the patient’s
tumor, when available. However, autologous tumor cell lines are
difficult to grow consistently. In order to test the potency of TILs
that are infused into patients, we developed a surrogate target
cell line that can be used to assess the lytic potential of TILs in a
BRLA.
Methods
Mouse mastocytoma P815 cells expressing endogenous CD16, trans-
duced with eGFP and firefly luciferase were selected as a surrogate
for autologous tumor cells. The CD16 Fc receptor binds anti-CD3
antibodies providing a potent TCR activation signal. The P815 cells
were sorted and cloned and then co-cultured with TILs +/- anti-CD3
antibodies to assess tumor reactivity through TCR activation and
basal non-specific killing. Following 4 hours of incubation, luciferin
was added to the wells for 5 minutes. After the incubation, biolumin-
escence intensity was determined. The % cytotoxicity and survival
were calculated thus: % Survival = (experimental luminescence-
background)/ (maximum luminescence-background)*100; % Cytotox-
icity = 100-(% Survival); and Interferon-γ release in the media of the
co-cultured TILs and P815 cells was analyzed by ELISA and LAMP1
(CD107a) expression analyzed by flow cytometry to evaluate the
cytotoxicity of TILs.
Results
TCR-mediated TIL cytotoxicity can be measured in a highly sensitive
dose-dependent manner. As shown below, this assay is highly sensi-
tive. The following data will be presented: Highly Sensitive Potency
Assay for TILs. A) % cytotoxicity of TIL (from patient M1033T-1) when
co-cultured with P815 Clone G6 (with and without anti-CD3 anti-
body) at different ratios of effector to target cells. B) ELISA data
showing amount of IFN-γ released at different ratios of effector to
target cells. C) % LAMP1 marker expressed by the M1033T-1 when
co-cultured with P815 Clone G6 and anti-CD3 at 1:1 effector to target
cells for 4 and 24hr co-culture.
Conclusions
Our ‘Bioluminescent Redirected Lysis Assay’ (BRLA) using an engi-
neered P815 cell line can be used as an assay to measure TIL po-
tency. It requires no radionuclides and is more efficient than
traditional cytotoxicity assays.
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Background
Ovarian cancer is the number one cause of death due to gynecological
malignancies and the fifth leading cause of death in cancer in women.
75% of patients will have recurrent disease. Recurrent disease is chemo-
therapy refractive that progresses to chemotherapy resistant disease.
Currently there are no definitive second-line treatments for patients.
Patients with ovarian cancer have a 5-year survival rate of 25-30%, mak-
ing it one of the most lethal malignancies.
Methods
One of the limitations of in vitro studies is the use of immortalized
cell lines grown in two-dimensional flasks. To address this issue,
many laboratories have been growing spheroids. We have employed
3-dimensional culturing techniques to create complex spheroids
from ovarian cancer cell lines that have phenotypic structure similar
to metastatic ovarian cancer. To further characterize spheroids we
Fig. 26 (Abstract P14). a % cytotoxicity of TIL (from patient
M1033T-1) when co-cultured with P815 Clone G6 (with and without
anti-CD3 antibody) at different ratios of effector to target cells. b
ELISA data showing amount of IFN-γ released at different ratios of
effector to target cells. c % LAMP1 marker expressed by the M1033T-
1 when co-cultured with P815 Clone G6 and anti-CD3 at 1:1 effector
to target cells for 4 and 24hr co-culture
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have created a system for sorting spheroids based on size. The
spheroids can then be cultured in 2-dimensions for the study of
chemotherapy sensitivities, and the efficacy of monocyte and interferon
therapies for the treatment of ovarian cancer. Further, we have devel-
oped a single-photon confocal microscopy protocol for the multi-
parameter imaging of live spheroids and monocytes with and without
interferons. To create experimental robustness, we have employed a
technique to image multiple conditions (4) over long periods of time
(14-16 hours), allowing for the simultaneous imaging of both control
and experimental conditions. Post-acquisition analysis of the images can
be used to study migration of the individual cells within the spheroids,
loss of cell dye viability, and migration of monocytes into the spheroids.
Results
We have found that the size of the spheroid defines, in part its sensi-
tivity to standard chemotherapy agents. Post-acquisition analysis of
the images have been used to study migration of the individual cells
within the spheroids, loss of cell dye viability, and migration of
monocytes into the spheroids. The addition of interferons with or
without monocytes significantly reduces the movement of the indi-
vidual cells within the spheroids. Furthermore, we have found that
the addition of interferons slows monocyte migration and initiates
monocyte attachment and entry into the spheroids.
Conclusions
The combination of novel cell culturing techniques with modern im-
aging and post-acquisition data analysis will increase our under-
standing of ovarian cancer response to both standard chemotherapy
and novel cell based therapies.
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Background
Chimeric antigen receptor (CAR)-engineered T lymphocytes are dem-
onstrating striking clinical success, yet these treatments can be ac-
companied by severe on- and off-tumor toxicities. The availability of
murine models to study these toxic phenomenon are currently
lacking.
Methods
In our model, human T lymphocytes are engineered with a second-
generation CD28-based CAR, targeted with a designed ankyrin repeat
protein (DARPin) with picomolar affinity against HER2 (anti-HER2
DARPin CAR-T cells), and adoptively transferred into NRG mice at
doses ranging from 6 x 105 – 1.2 x 107 CAR-T cells/mouse.
Results
Toxicity manifested in a drop in core body temperature and
weight and, in some cases, lethality. The onset and severity of
the toxicity varied with the source of the T lymphocytes (i.e.,
donor) used to generate CAR-T cells. We evaluated seven differ-
ent donors and the toxicities associated with each donor’s cell
product was reproducible across multiple experiments and mul-
tiple manufacturing runs. Anti-HER2 DARPin CAR-T cells were
toxic in tumor-free mice, but toxicities were most severe in the
presence of HER-2+ tumors demonstrating both on-tumor and
off-tumor effects. The CAR-T cells did not respond to murine
HER-2 indicating that the toxicity was both off-tumor and off-
target. The toxicity was not due to the DARPin itself, as CAR-T
cells bearing DARPins with other specificities were not toxic in
this model. Further characterization of the model indicated that
severity of toxicity was dose-dependent and could be
exacerbated by the presence of a HER2+ tumor. Moribund mice
were found to have aggregates of T cells in their lungs, liver, and
heart and displayed a cytokine storm in the blood. The toxicity
was triggered by CD4+ T cells in the anti-HER2 DARPin CAR-T cell
product. While anti-HER2 DARPin CAR-T cells generated from donors
demonstrating reduced toxicity were able to mediate anti-tumor effi-
cacy in vivo in a xenograft model of ovarian carcinoma at low doses,
they exhibited a narrow therapeutic window consistent with data
emerging from the clinic where CAR-T therapy is effective.
Conclusions
This model offers a promising avenue to test strategies for the pre-
vention or mitigation of toxicities associated with adoptive CAR-T cell
transfer as well as insights into the contribution of T cell source to
toxicities. Investigations are ongoing.
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Background
Natural killer (NK) cells play a crucial role during the innate immune re-
sponses, and as such form part of the body of immunological defense
against various diseases, including infectious diseases and malignan-
cies. Therefore, adoptive immunotherapy using NK cell is emerging as
promising treatments for intractable malignancies; however, there has
been still developing because of difficulties in culture, shortage of over-
all effector numbers, contamination of considerable numbers of T cells,
and their limited anticancer potencies. We here established the simple
feeder-free method to generate purified (>90%) and highly activated
NK cells from human peripheral blood-derived mononuclear cells
(PBMCs) in accordance with GMP/GCTP for clinical studies.
Methods
Under approval of the institutional ethical committee, PBMCs were
collected from healthy volunteers by using CliniMACS Prodigy® (auto-
matic/closed system). CD3+ cells were depleted by CliniMACS CD3
beads, and CD3-depleted PBMCs were cultured at a concentration of
5 x 105 cells/ml with high concentration of hIL-2 and 5% human AB
serum for 14 days. Fresh medium wad added every 4-5 days
throughout the culture period. Then, we confirmed the expression of
surface markers, CD107a mobilization and cell-mediated cytotoxicity
against various tumor cells and normal cells with or without mono-
clonal antibody drugs in vitro and antitumor effects against K562
in vivo.
Results
Among the several parameters, we found that simply 1) only CD3-
depletion, 2) high dose IL-2, and 3) use of specific culture medium
were sufficient to obtain the highly purified, expanded (~200-fold)
and activated CD3-/CD56+ NK cells from PBMCs. Almost all activated
NK cells expressed lymphocyte-activated marker CD69, and showed
dramatically high expression of NK activation receptors (i.e. NKG2D,
NKp30, NKp46, etc.), interferon-g, perforin and granzyme B. Import-
antly, only 2 hours reaction at effector/target ratio=1:1 was sufficient
to kill almost all K562 cells, and antitumor activity was also represen-
tative on tumor bearing mice in vivo. Cytolysis was specific for vari-
ous tumor cells, but not for normal cells, irrespective of MHC class I
expression.
Conclusions
These findings strongly support that NK cells activated by our
method is purified, expanded, and near fully activated. The cells were
currently under investigation in clinical trial (phase I/IIa).
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Background
Engineering T cells with chimeric antigen receptors (CARs) is proving
to be an effective method for directing T cells to attack tumors in an
MHC-independent manner [1, 2]. Current generation CARs aim to
recapitulate T cell signaling by incorporating modular functional
components of the TCR and co-stimulatory molecules. We sought
to develop an alternate method to re-direct the T cell receptor
which employs the native TCR. To this end, we developed the T
cell Antigen Coupler (TAC) technology, a membrane-anchored re-
ceptor redirects the TCR and co-receptor in the presence of
tumor antigen.
Methods
The utility of the TAC receptor has been assessed using in vitro and
in vivo assays. In vitro assays are based on receptor surface staining,
cytokine release and cytotoxicity assays. In vivo studies examined the
anti-tumor effect of TAC-engineered T cells against established
xenografts.
Results
In vitro testing has demonstrated robust and specific cytokine pro-
duction and cytotoxicity by TAC-engineered human T cells directed
against either HER-2 or CD19. In vivo TAC-engineered T cells revealed
strong activity against HER-2 expressing solid xenograft tumor
models such as MDA-MB-231 and OVCAR-3. Curiously, the TAC-
engineered T cells outperformed a matched CD28-based second
generation CAR in these models, demonstrating both increased anti-
tumor efficacy and reduced toxicity. Whereas, mice treated with CAR
engineered T cells showed serious toxicities that were both donor-
and dose-dependent, we did not observe any toxicities arising from
the TAC-engineered T cell, even at doses that produced complete
tumor regression.
Conclusions
These differences in toxicities and efficacy highlight the biological
differences of TAC and CAR receptors and indicated the potential for
a superior therapeutic index for TAC engineered T cells. Current TAC’s
in development target lymphatic malignancies and have shown great
promise in early in vitro and in vivo assays.
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Background
The human papillomavirus (HPV)-16 E7 oncoprotein is constitutively
expressed by HPV-16-associated cancers and absent from healthy tis-
sues, and it is therefore an attractive therapeutic target for T cell re-
ceptor (TCR) gene engineered T cell therapy. However, E7 displays
manifold mechanisms of immune evasion, and its potential as a tar-
get for TCR-T cell therapy is unknown.
Methods
The nucleotide sequence of a TCR targeting HPV-16 E711-19 was de-
termined by study of cervix-infiltrating T cells from a subject with
HPV-16+ cervical intraepithelial neoplasia. Expression of the TCR was
optimized by hydrophobic substitutions in the alpha chain trans-
membrane region and introduction of an additional inter-chain TCR
constant region disulfide bond. Second-party T cells genetically engi-
neered to express the optimized TCR (E7 TCR T cells) were evaluated
in in vitro immunologic assays and in an in vivo murine model of hu-
man cervical cancer.
Results
E7 TCR T cells displayed binding to HLA-A*02:01-E711-19 tetramers.
HLA-A*02:01 restriction was confirmed with major histocompatibility
complex (MHC) blocking and with testing for recognition of target
cells either expressing or lacking HLA-A*02:01. In functional assays,
E7 TCR T cells recognized and killed a panel of HLA-A*02:01+ HPV-16
+ cervical and oropharyngeal cancer cells lines but not cell lines that
lacked either the restriction element or target antigen. Tumor recog-
nition by CD8 and CD4 T cells that expressed the E7 TCR was ob-
served. They displayed minimal if any cross-reactivity against
peptides from human proteins that were identified by BLAST search
based on protein sequence similarity or the presence of key
shared residues mapped by alanine scanning of E711-19. E7 TCR T
cells recognized E711-19 peptide-pulsed T2 cells at concentrations
as low as 10-11 M indicating relatively high functional avidity.
Direct comparison to a previously described E6-specific TCR re-
vealed greater functional avidity, a slower TCR-pMHC Koff-rate,
and superior tumor cell recognition for the E7 TCR. In a murine
xenograft model, a single intravenous injection of E7 TCR T cells
induced complete regression of tumors from one human cervical
cancer line and controlled tumors from another human cervical
cancer line.
Conclusions
E7 TCR T cells specifically recognized and killed HPV-16+ cancer cells
in vitro and mediated regression of HPV-16+ tumors in vivo. These
findings provide the preclinical basis for a new personalized TCR-T
cell therapy for metastatic HPV-16+ cancers including many cervical,
oropharyngeal, and anal malignancies. A clinical trial for E7 TCR T
cells is now active (NCI-16-C-0138).
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Background
Immune checkpoints have been implicated in the down-
regulation of antitumor immunity. Anti-PD-1/PD-L1 checkpoint in-
hibitory monoclonal antibodies (mAbs) can restore immune func-
tion in the tumor microenvironment, and have demonstrated
clinical benefit in patients with melanoma, Hodgkin’s lymphoma,
lung and bladder carcinomas, and other tumor types. In addition
to its checkpoint inhibitory function, avelumab, a fully human
IgG1 anti-PD-L1 mAb, can mediate antibody-dependent cellular
cytotoxicity (ADCC) to lyse human tumor cells in the presence of
natural killer (NK) cells [1]. NK cells can be used for cancer ther-
apy. However, obtaining sufficient numbers of functionally active
NK cells from patients is technically challenging since only about
10% of the population expresses on NK cells the high-affinity FcR
that provides maximum ADCC. One alternative is to use estab-
lished NK cell lines that have antitumor activity. High affinity NK
cells (haNK), provided by NantKwest, derived from the human NK
cell line NK-92, are genetically engineered to express high-affinity
human CD16 (FcgRIIIA-V158) and transduced with the human IL-2
gene. In addition, haNK cells have little inhibitory killer-cell
immunoglobulin-like receptor (KIR) expression, a unique feature
that may be a factor in their highly cytotoxic activity against a
broad range of malignancies. We report here our investigation of
1) whether haNK cells used in combination with avelumab can
lyse human tumor cells via the ADCC mechanism, and 2) the fac-
tors that may influence this cytotoxic activity.
Methods
Cell lines used in our experiments included human carcinomas of
the head and neck, cervix, bladder, and colon, as well as prostate
and pancreatic cancers. haNK cells irradiated with 10 Gy were
used as effector cells at various effector-to-target-cell ratios in all
experiments. Four- and 18-hour 111In release assays were per-
formed to evaluate ADCC activity.
Results
Our results show that 1) haNK cells can lyse a range of human carcin-
oma cells when avelumab is used to target PD-L1 expression; 2) the
addition of anti-CD16 neutralizing antibody significantly inhibits
ADCC lysis, implicating CD16 ligation as a major mechanism of action
for ADCC lysis mediated by haNK and avelumab; and 3) in combin-
ation with avelumab, haNK cells mediate significantly higher levels of
ADCC lysis than do NK cells isolated from healthy donor peripheral
blood mononuclear cells (PBMC).
Conclusions
These results provide a rationale for using haNK cells in combination
with avelumab or other ADCC-mediating cytotoxic mAbs to treat hu-
man malignancies.
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Background
Adoptive T cell therapy (ACT) has emerged as a potential curative
therapy for patients with advanced solid tumors. However, for
hematologic cancers, identifying and enriching the cancer antigen-
reactive T lymphocytes for ACT remains a challenge. Our lab previ-
ously demonstrated that blockade of the PD-1/PD-L1 pathway (in the
context of non-myeloablative, lymphodepleting whole body irradi-
ation) was capable of eliminating established myeloma in mice [1, 2].
In the current study, we tested whether PD-1 is a marker for
myeloma-reactive T cells.
Methods
C57BL/KaLwRij (KaLwRij) mice were inoculated with 5T33 mye-
loma cells intravenously, and 28 days later, splenic PD-1+ and
PD-1- T cells (CD8+ and CD4+) were isolated by flow cytometric
sorting. The purified T cells were expanded in culture for 7 days
on plate-bound CD3 and soluble CD28 antibodies plus IL-2, IL-7
and IL-15. Some of the expanded T cells were assayed in vitro for
myeloma reactivity. Equal mixtures of expanded CD4+ and CD8+
T cells, or each subset alone, were infused to myeloma-bearing
Rag1-deficient recipients, and the mice were followed for mye-
loma progression.
Results
We found that numbers of cancer antigen-reactive T lympho-
cytes in myeloma-bearing mice were enriched in PD-1+ CD8+
and CD4+ T cell subsets. PD-1+ T cells could be efficiently ex-
panded ex vivo for adoptive transfer, and the expanded cells
maintained their anti-myeloma reactivity. Adoptive transfer of
the ex vivo-expanded PD-1+ T cells effectively eliminated estab-
lished myeloma in Rag1-deficient recipients. In contrast, adop-
tive transfer of expanded PD-1- T cells failed to demonstrate
anti-myeloma efficacy in vivo. Notably, both CD8+ and CD4+
PD-1+ T cell subsets played a role in eradicating myeloma, but
combined administration of the ex vivo-expanded subsets was
most efficacious.
Conclusions
Our results show that PD-1 is a biomarker for myeloma-specific CD8+
and CD4+ T cells in mice. Furthermore, these PD-1-expressing T cells
can be expanded in culture for effective adoptive cell immunother-
apy of myeloma-bearing recipients.
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Background
The goal of this study is to find an alternate therapy for osteosar-
coma (OS) lung metastasis. We previously showed that NK cell
therapy significantly decreased, but did not cure, OS lung metas-
tasis in a mouse model. Other studies have shown that histone
deacetylase inhibitors (HDACi) sensitize tumor cells to NK cell
cytotoxicity, primarily by increasing expression of ligands for NK
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cells on tumor cells; thus, to augment NK cell therapy, we com-
bined it with the HDACi, entinostat.
Methods
Flow cytometry, western blot analysis, and Q-PCR were used to
determine whether entinostat increased expression of NK cell li-
gands on OS cells. Effects of entinostat on NK cell viability, recep-
tor expression, and cytotoxicity were explored using a viability
test, flow cytometry, and calcein release assay, respectively. NK
cells were isolated from blood buffy coats and were expanded
ex vivo using genetically engineered K562 cells and human IL-2.
Q-PCR was used to measure microRNAs expression in OS cells
and a CHIP assay was used to determine increased histone
acetylation at the MICA/B gene promoters. For the in vivo study,
mice were given 10, 5, or 2.5 mg/kg of entinostat orally to deter-
mine the subtherapeutic dose of the drug.
Results
We demonstrated that 2 μM entinostat for 48 h upregulated expression
of NK cell ligands on OS cell lines. Increased expression of ligands on
OS cells resulted in increased susceptibility of OS cell lines to NK cell
cytotoxicity in vitro. NK cell treatment with up to 2 μM entinostat did
not affect NK cell viability or NK cell receptor (NKG2D, NKp30, NKp44,
NKp46, and DNAM-1) expression. NK cells pretreated with entinostat
for 24 h did not decrease cytotoxicity of NK cells to OS cell lines. We
also showed two mechanisms by which entinostat controls MICA/B ex-
pression on OS cells: 1) by increasing H4 acetylation at the MICA/B
genes promoters and 2) by down-regulating mir-20a, mir-93, and mir-
106b expression. We demonstrated that the sub-therapeutic dose of
entinostat that significantly increased MICA/B on OS lung metastasis
was 5 mg/kg three times a week for 5 weeks. Combining 5mg/kg enti-
nostat and NK cell therapy is our ongoing in vivo experiment.
Conclusions
We demonstrated that entinostat immunosensitized OS cells to NK
cell lysis by inducing upregulation of ligands for NK cells on OS cells.
Our results suggest that NK cell therapy combined with entinostat
provides an innovative approach to enhance the immunotherapeutic
effect of NK cells against OS pulmonary metastases.
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Background
Anti-CD19 chimeric antigen receptor (CAR) redirected T cells have
demonstrated profound efficacy in relapsed/refractory B cell malig-
nancies. However, CAR T cells have thus far failed to recapitulate
these results in solid tumors. Accumulating evidence suggests that
macrophages naturally traffic to and persist in solid tumors. The goal
of this study was to evaluate the anti-tumor function of genetically
engineered CAR macrophages (CARMA) and assess their potential for
translation as a novel immunotherapeutic platform for solid tumors.
Methods
To examine the function of CARs in macrophages, first generation
CARs with a CD3ζ intracellular domain were introduced into the THP-
1 macrophage model. In vitro function was assessed via quantitative
phagocytosis and luciferase-based specific killing assays. To assess
the function of the CD3ζ-domain, CD3ζ-null CAR constructs were
compared. Ad5f35 was used to transduce primary human monocyte
derived macrophages with an anti-HER2 CAR construct, and anti-
tumor function was tested in vitro and in vivo. The impact of inhibit-
ing the CD47/SIRPα “do-not-eat-me” signal was tested with blocking
antibodies and CRISPR-Cas9 mediated SIRPα knockout. Macrophage
M1/M2 phenotype was determined by flow cytometry. Immunodefi-
cient mouse xenograft models of a human HER2(+) ovarian cancer
cell-line (SKOV3) were used for in vivo efficacy studies.
Results
CAR19, but not untransduced macrophages, phagocytosed CD19+
(but not CD19-) K562 cells. Deletion of CD3ζ in CAR19 macro-
phages abrogated phagocytosis and significantly reduced specific
killing. Phagocytosis was inhibited by pharmacologic blockade of
phagocytic signaling - suggesting that CAR activation drives pro-
ductive cell-signaling in macrophages. Phagocytosis was also
demonstrated in HER2 and mesothelin CARMA models. Blockade
of the inhibitory CD47/SIRPα “do-not-eat-me” signal enhanced
CARMA phagocytosis of antigen-bearing target cells in a dose-
dependent manner (Fig. 27). We identified Ad5f35 as an efficient
transduction approach for engineering primary human macro-
phages, resulting in >70% CAR transduction efficiency. Primary
human anti-HER2 CARMA demonstrated targeted phagocytosis
and specific killing. Ad5f35 transduction polarized human macro-
phages to the pro-inflammatory M1 phenotype, and rendered
them resistant to downstream M2 subversion by immunosuppres-
sive cytokines and cell lines. Anti-HER2 CARMA was evaluated
in vivo in an ovarian cancer xenograft model. Mice that received
CARMA had a decrease in tumor burden of approximately two or-
ders of magnitude and had a 30-day survival benefit relative to
untreated or control macrophage treated mice (p=0.018, Fig. 28).
Conclusions
Here, we introduce for the first time that human macrophages engi-
neered with a CAR exert antigen-specific tumor phagocytosis and
killing, and propose a novel immunotherapeutic platform for the
treatment of diverse solid tumors.
Fig. 27 (Abstract P23). Timelapse of a CAR19 macrophage (mRFP+)
phagocytosing a CD19+ K562 cells (GFP+) cell (A). CARMA but not Wt
macrophages phagocytosed CD19+ but not CD19- tumor cells (B).
Phagocytosis was confirmed by Imagestream cytometry, gating on
mRFP+GFP+ events (C). Blockade of CD47 and SIRPa led to a dose
dependent increase in CARMA phagocytosis. Non-blocking anti-CD47
clone 2D3 (opsonization control) did not enhance phagocytosis (D)
Fig. 28 (Abstract P23). Anti-HER2 primary human CARMA were tested in
immunodeficient mouse models of human HER2+ ovarian cancer (schema,
a). CARMA but not control untransduced macrophages reduced tumor
burden (b, c) and prolonged survival by 30 days (p=0.018, d)
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Background
Immunotherapies for cancers have made great strides in recent
years, yet new and improved approaches are required to achieve
more durable responses in a greater number of patients. The
in vitro expansion phase of adoptive T cell therapy prior to rein-
fusion into the patient present opportunities to genetically en-
hance T cell subsets to improve in vivo performance. While the
most common genetic modification is the incorporation of engi-
neered antigen-specific TCRs or chimeric antigen receptors, modi-
fication to signaling pathways in T cell memory subsets in order
to enhance T cell sensitivity is an underexplored strategy. This is
mainly because contributions of TCR signaling components that
confer differences in activation sensitivity and functional out-
comes between CD8+ Tcm and Tem are unclear.
Methods
To understand how TCR-proximal signaling differs significantly
between T cell memory subsets, we derived TCM and TEM from
the humanized TCR-transgenic melanoma mouse model (JR209).
We quantified differences in TCR activation and feedback regula-
tion by novel live-cell imaging technologies, phospho-specific
protein assays and used modeling of early TCR signaling to reveal
the physiological significance of these differences.
Results
One of the critical steps of T cell triggering is the coordinated
phosphorylation and binding of CD3 and Zap-70 by Lck following
TCR ligation by pMHC. Here, we show that Tcm and Tem possess
differential constitutive Lck activities. Immediately proximal to Lck
signaling, we observed enhanced Zap-70 phosphorylation in TEM
following TCR ligation compared with TCM. Further, we observed
increased intracellular calcium influx and cytotoxic effector func-
tion in TEM compared with TCM, and provide evidence that this
results from a lower probability of TCM reaching threshold activa-
tion signaling due to the decreased magnitude of TCR-proximal
signaling. We show that the differences in Lck constitutive activ-
ity between CD8+ Tcm and Tem are driven in part by differential
regulation by SH2 domain-containing phosphatase-1 (Shp-1) and
C-terminal Src kinase (Csk). We demonstrate that inhibition of
Shp-1 results in increased constitutive Lck and cytotoxic activity
in TCM to levels similar to that of TEM.
Conclusions
Together, this work demonstrates that differential activities of
TCR-proximal signaling components may contribute to establish-
ing the divergent effector properties of TCM and TEM. Inhibition
of negative regulatory molecules, for example Shp-1 or Csk, or
generalized augmentation of T cell sensitivity with miRNA offer
potential therapeutic approaches in T cell immunotherapy but
must be considered in the context of specificity and optimal
targeting.
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Background
HER2-CAR T cells home to the central nervous system (CNS) and
induce tumor regression in patients with glioblastoma (GBM) [1].
However, most responses are transient, as CAR T cells fail to ex-
pand and have limited persistence. Ex vivo analyses of tumor
infiltrating lymphocytes demonstrate high levels of inhibitory re-
ceptors, including PD-1. Monoclonal antibodies blocking PD-1/
PD-L1 induce responses in some patients with solid tumors and
potentiate anti-tumor T cell activity. However, because antibodies ex-
hibit erratic CNS pharmacokinetics, combining this approach with
CAR T cells is not optimal for CNS tumors. We hypothesize that
co-expression of a synthetic PD-1 fusion protein will convert PD-
L1 into a costimulatory T cell signal, improving expansion, persist-
ence, and anti-tumor activity of adoptively transferred HER2-CAR
T cells.
Methods
We generated an array of bicistronic vectors encoding our clinic-
ally utilized 2nd generation HER2-CAR (CD28ζ-endodomain) and a
PD-1 fusion protein. All PD-1 fusion proteins contained the native
PD-1 ectodomain fused to either the CD28 transmembrane and
endodomain (PD-1/CD28) or CD8α-transmembrane and 4-1BB-
endodomain (PD-1/4-1BB). T cell expansion, persistence, and ex-
haustion (LAG3, TIM3, PD-1) were measured using flow cytometry
following coculture with autologous HER2+/PD-L1+ GBM cells for
2-4 weeks. Cytokine release at 24 hours was measured using
standard ELISA, and the xCELLigence impedance-based system
was used to evaluate cytolytic activity. Using high-resolution im-
munofluorescence imaging, we interrogated differences at the
CAR T cell/GBM contact point, also referred to as the immuno-
logic synapse (IS).
Results
Compared to conventional HER2-CAR T cells, PD-1/CD28 T cells
expanded more quickly with significantly higher IL2/IFNγ-release
at 24 hours (Fig. 29), whereas PD-1/4-1BB T cells demonstrated
enhanced cytolytic ability against autologous GBM cells in pro-
longed killing assays (Fig. 30) and better long-term persistence.
Inhibitory receptor expression following coculture was compar-
able among T cell products, but PD-1/4-1BB T cells maintained a
greater percentage of central memory cells (CCR7+/CD45RA-).
HER2-CAR T cells bearing PD-1 fusion proteins demonstrated in-
creased levels of activated kinases in CD28/4-1BB signaling path-
ways. Three-dimensional reconstitution and quantification of
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confocal images of the CAR T cell/tumor interface revealed in-
creased stability of the IS between the HER2-CAR and the HER2
molecule on GBM.
Conclusions
We conclude that PD-L1 can be converted into a costimulatory
signal using synthetic PD-1 fusion molecules to drive key T cell
activation pathways and enhance stability of the CAR-target anti-
gen interface, leading to improved HER2-CAR T cell functionality
against GBM.
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Background
Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) has
been established as an effective treatment option for metastatic mel-
anoma but is available at only a small number of institutions. We
have developed a TIL program at the Fred Hutchinson Cancer Re-
search Center and present our initial results in melanoma patients.
Methods
Patients with metastatic melanoma were enrolled in a two-step fash-
ion to a nonrandomized, phase II TIL trial: Step 1 for TIL generation
and Step 2 for TIL treatment. TIL are cultured from tumor fragments,
using standard methodologies developed at the NCI. At a time of
future disease progression, patients are given cyclophosphamide
60mg/kg/day x 2 days, fludarabine 25mg/m2/day x 5 days, then TIL
up to 1.5 x 10^11, followed by high-dose IL-2, 600,000 units/kg every
8 hours, up to 14 doses as tolerated. TIL populations are selected for
infusion based on growth, phenotype, and MHC-class-I-dependent
autologous tumor recognition, as assessed by interferon-gamma
release.
Results
Thirty-two patients have been enrolled on Step 1 for TIL gener-
ation. Of these, 23(72%) achieved adequate TIL number of >40
x10^6 by 5 weeks of culture. TIL in 17(53%) patients also dem-
onstrated positive autologous tumor reactivity. To date, 7 pa-
tients have received TIL therapy on Step 2; all had progressed
on prior immunotherapy (Table 3). In these 7 patients, the
RECIST 1.1 responses are: 2 CR, 1 PR, 3 SD, 1PD. All patients ex-
perienced tumor regression of some or all baseline target lesions;
the patient with PD progressed in the brain, but experienced a
partial response of extracranial sites. Two patients were on con-
current BRAF therapy and had reached a plateau in their re-
sponse to BRAF inhibitors prior to start of TIL treatment, and
both experienced further tumor reduction after TIL. Responses
were associated with a higher percent CD8+TIL, a lower percent
Treg(CD4+CD25+CD127-), and TCR oligoclonality, while functional
markers PD-1 and TIM3 did not associate with response.
Conclusions
Our single-institution study validates the utility of TIL therapy in pa-
tients with advanced melanoma, refractory to other immunotherapy.
TIL can induce durable CRs and can also mediate additional tumor
regression in patients on active BRAF inhibition. The replication of TIL
methodology across different institutions, with reproducible clinical
efficacy, supports the feasibility of its widespread application, as well
as further investigation into optimizing elements of this treatment
modality.
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Fig. 30 (Abstract P25). The xCELLigence platform uses
impedance across resistor-coated plates to measure adherant
tumor cell viability. Once 10,000 tumor cells became adherant
and confluent, 1,000 T cells were added that expressed either
a HER2 CAR only (H2) or a HER2 CAR with a truncated PD-1
protein (X), PD-1/CD28 protein (28), or PD-1/4-1BB protein
(BB). Non-transduced T cells and tumor only wells served
as controls
Fig. 29 (Abstract P25). 2nd generation HER2 CAR T cells with
and without PD-1/CD28 fusion proteins were incubated with
autologous GBM cells at a 1:1 ratio. Cytokine concentrations from
culture supernatant collected at 24 hours were measured using
standard ELISA
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Background
Chimeric antigen receptor (CAR) T cells targeting CD19 have shown
dramatic results in patients with refractory B cell malignancies but
the precise mechanisms of how CD19 CAR T cells kill tumor cells are
not all well understood.
Methods
Second generation CD19 CAR T cells were produced from peripheral
blood mononuclear cells (PBMCs) obtained from pediatric patients
with acute lymphoblastic leukemia (ALL) and adult patients with
chronic lymphocytic leukemia (CLL). Here we present the phenotype,
cytokine and cytotoxic profile of CD4+ and CD8+ CD19 CAR T cells
generated from patients and healthy donors (HDs).
Results
T cell frequency in PBMCs from patients (ALL and CLL) was low (<4% of
lymphocytes). In patients with CLL, 90% of lymphocytes were CD19+ B
cells. In patients with CLL, as compared to HDs, the majority of CD8+ T
cells displayed a terminally differentiated phenotype, while CD4+ T cells
were mostly effector memory cells. Retroviral transduction was per-
formed on PBMCs without prior B cell depletion or T cell enrichment
step. CAR T cell cytotoxicity towards CD19+ target cells was mediated
via granzymes, but not perforin, Fas-L or TRAIL. In patients and HDs,
CD4+ and CD8+ CD19 CAR T cells showed a comparable cytokine (IL-2,
IFN-g, TNF) production, CD107a expression in response to stimulation
with K562 CD19+ cells. The majority of CAR T cells were polyfunctional
(≥2 functions). However, patients with CLL, as compared to HDs and
patients with ALL, displayed a higher frequency of IFN-g producing and
polyfunctional CD4+ and CD8+ CD19 CAR T cells. When stimulated
with autologous CD19+ B cells, as compared to K562 CD19+, lower fre-
quencies of CD4+ and CD8+ CD19 CAR T cells produced IL-2, IFN-g and
TNF. The frequency of polyfunctional CD19 CAR T cells was lower when
stimulated with autologous B cells as compared to K562 CD19+ cells.
Stimulation with other CD19+ cell lines induced a different cytokine
production profile of CD19 CAR T cells.
Conclusions
CD4+ and CD8+ CD19 CAR T cells display comparable differentiation
phenotype, cytokine production and cytotoxic capacity. The presence
of a high frequency of CD19+ B cells during the generation of CAR T
cells did not have an impact on CAR T cell phenotype. However CAR
T cells from patients with CLL produced more cytokines when stimu-
lated with CD19+ target cells suggesting that activation of CD19 CAR
T cells by B cells during cell expansion impacts the cytokine profile.
Furthermore, our data show that the level of CD19 cell surface ex-
pression modulates CAR T cells cytokine production.
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Background
Previously, a critical role for chemokines was found in a unique
immune-related gene expression signature (GES) for immune cell re-
cruitment and tertiary lymphoid structure formation in metastatic mel-
anoma [1]. Regarding adoptive cell therapy (ACT) of tumor-infiltrating
lymphocytes (TIL), we hypothesized that expression of chemokine re-
ceptors (CCR)2, CCR5, and CCR7, which bind multiple GES chemokines,
favor TIL re-trafficking to the tumor, thereby bolstering ACT efficacy.
Methods
We utilized a preclinical ACT model in which TIL from syngeneic MC-38
colon carcinomas grown in wild-type (WT) C57BL/6 mice, or gene
knock-out (KO) C57BL/6 mice lacking CCR2, CCR5, or CCR7, were ex-
panded ex vivo, and adoptively transferred into MC-38-bearing C57BL/6
recipient mice bearing congenic CD45.1. After seven days, tumor bur-
den was assessed, and Spanning-tree Progression Analysis of Density-
normalized Events (SPADE) of 18-parameter cytometry data was used
to identify and quantify TIL subsets, and 51Cr-release assays quantified
cytotoxicity among sorted TIL populations.
Results
ACT of WT TIL reduced tumor burden by 50% compared to untreated
mice (p=0.0098). This benefit was lost when transferring CCR5KO or
CCR7KO TIL, and reduced when transferring CCR2KO TIL (all p < 0.05).
MC-38 tumors contained 90%, 85%, and 70% less transferred TIL with
ACT of CCR2KO, CCR5KO, or CCR7KO TIL, respectively, compared to WT
TIL (all p < 0.01) . SPADE identified eight novel subsets in re-trafficked
TIL with unique patterns of activation, memory, and immune check-
point markers (Fig. 31). Nearly all subsets displayed impaired re-
trafficking with CCR2KO, CCR5KO, or CCR7KO TIL ACT (all p < 0.05).
Cytotoxicity assays suggest a range of cytotoxic potential among identi-
fied subsets, with CD8+TIL3 and 4 subsets being most cytotoxic (all p <
0.05). During TIL expansion, IL-2 up-regulated CCR2, CCR5, and CCR7 in
a cell density-dependent fashion (all p < 0.007). ACT of TIL with up-
regulated CCRs increased tumor re-trafficking three-fold (p < 0.05), and
decreased tumor burden by an additional 25% (p < 0.05) versus WT TIL
without up-regulated CCRs.
Conclusions
CCR2, CCR5, and CCR7 are vital for TIL re-trafficking to MC-38 tumors
following ACT, including cytotoxic subsets among eight novel TIL
phenotypes. Fostering CCR expression during TIL expansion aug-
ments ACT efficacy in murine MC-38 colon carcinoma. Translational
studies to human TIL ACT are currently underway.
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Table 3 (Abstract P26). Characteristics and responses of treated
patients
Age/
Gender
Prior Treatments M Classification
and Metastatic
Sites
Response Response
Duration
(months)
1 54 F Anti-CLA-4,
interferon (IFN)
M1c: Mesentery,
small bowel,
lymph nodes (LN)
PR 8
2 34 F Anti-PD1, anti-
CLA-4, IFN, IL-2 +
radiation (XRT),
temozolomide
M1c: Brain,
kidneys, adrenals,
bone, liver, LN,
subcutaneous (SC)
SD 3
3 61 M IL-2, BRAF
inhibitor
M1c: Brain, liver,
lungs, SC,
mesentery, chest
wall
PD
(Progression in
brain, but PR
in extracranial
sites)
8, for
extracranial
response
4 27 F IL-2, anti-CTLA-4
+IL-21, anti-CTLA-
4 + XRT, recom-
binant IL-15
M1c: Brain, SC, LN,
pleura, kidneys,
peritoneum
SD 3
5 63 M Anti-CTLA-4 M1a:
Intramuscular, LN
CR 17,
ongoing
6 52 M Anti-CTLA-4 M1a: SC, LN CR 20,
ongoing
7 31 F Anti-PD1, anti-
CTLA-4, decarba-
zine, BRAF/MEK
inhibitor
M1c: Brain, lungs,
liver, SC
SD 5
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Background
Although adoptive immunotherapy using T cells expressing chimeric
antigen receptors (CAR) is successful in refractory hematological ma-
lignancies, limited clinical responses have been observed in solid tu-
mors. We reasoned that introducing an inducible co-stimulation
(iCO-STIM) gene into T cells would allow for improved activation of
CAR T cells, resulting in enhanced antitumor activity. Due to the co-
stimulatory properties of MyD88 and CD40 in T cells, we explored
whether CAR T cells expressing an iCO-STIM molecule consisting of a
myristoylation-targeting sequence, two FKBP dimerizing domains,
MyD88ΔTIR, and the intracellular domain of CD40, have superior ef-
fector function relative to standard CAR T cells in vitro and in vivo.
Methods
T cells expressing a HER2-CAR and iCO-STIM (HER2-CAR/iCO-STIM
T cells) were generated by transduction with a retroviral vector
encoding FRP5.ζ (HER2-CAR), a 2A peptide, and iCO-STIM. HER2-
CAR/iCO-STIM T cell effector function was then evaluated in vitro
and in murine xenograft models.
Results
In the presence of CID (AP20187), HER2-CAR/iCO-STIM T cells pro-
duced significantly higher levels of IL2 (p < 0.05) compared to HER2-
CAR/iCO-STIM T cells in the absence of CID or HER2-CAR.CD28.ζ T
cells in co-culture assays with HER2+ tumor cells (MDA-HER2, LM7,
A549). In contrast, HER2-negative tumor cells (MDA) did not induce
IL2 production by HER2-CAR/iCO-STIM T cells +/- CID or HER2-
CAR.CD28.ζ T cells. In repeat stimulation assays, HER2-CAR/iCO-STIM
T cells showed robust antigen-dependent expansion in the presence
of CID and were able to lyse HER2-positive LM7 cells after 4 re-
stimulations compared to HER2-CAR.CD28.ζ T cells (p < 0.0001). In
vivo, a low dose of HER2-CAR/iCO-STIM T cells (3x105) + CID had su-
perior antitumor activity in the metastatic LM7 osteosarcoma murine
xenograft model compared to HER2-CAR/iCO-STIM T cells without
CID or HER2-CAR.CD28.ζ T cells, resulting in a significant survival ad-
vantage (p < 0.001). In 3 mice that developed late recurrences after
HER2-CAR/iCO-STIM T cell + CID therapy, a second dose of CID, given
100 days post T cell injection, eliminated 2/3 tumors. Superior antitu-
mor activity of HER2-CAR/iCO-STIM T cell + CID therapy was con-
firmed in the HER2+ A549 lung cancer murine xenograft model.
Conclusions
CID-mediated activation of MyD88 and CD40 co-stimulatory signals in
HER2-CAR T cells results in superior effector function compared to
standard HER2-CAR T cells. Thus, expressing iCO-STIM molecules in CAR
T cells has the potential to improve the efficacy of CAR T cell therapy
approaches for solid tumors. In addition, our results indicate that the
CID/iCO-STIM system will enable the ‘remote control’ of infused T cells.
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Background
T cell reactivity against mutated antigens, derived from cancer genomic
alterations, is a key mediator of immunotherapy efficacy. Adoptive cell
transfer (ACT) of mutation-reactive tumor-infiltrating T lymphocytes
(TILs) however has been only effective in a minority of patients with
metastatic gastrointestinal cancers. We hypothesize that the low fre-
quency of mutation-reactive TILs and their exhaustion features may
contribute to the lack of efficacy of TIL ACT, and that these factors can
be overcome by in vivo administration of blocking antibodies against
CTLA-4 or PD-1 prior to tumor harvest and TIL expansion.
Methods
We selected the mouse MC-38 colorectal cancer model to study CD8+
TIL reactive to 2 mutated, 2 self, and 1 retroviral antigens using co-
cultures with peptide-pulsed splenocytes followed by IFN-γ intracellular
staining. MC-38 cancer cells were inoculated subcutaneously and
allowed to grow until 20mm2. Then anti-CTLA-4 (9H10) and/or anti-PD-
1 (RPM1-14) antibodies were administered twice (4 days interval). Three
days following the last antibody injection, tumors were harvested and
analyzed for immune cell infiltration, phenotype and functionality. TILs
were also expanded in vitro and characterized regarding the specificity
and the functionality against the known antigens.
Results
The administration of anti-CTLA-4 prior to tumor harvest increased
immune cell infiltration, decreased the proportion of myeloid derived
suppressor cells and regulatory T cells in the tumors and enhanced
CD8+ T cell IFN-γ and TNF-α production. Administration of both anti-
CTLA-4 and anti-PD-1 was more effective to eliminate the tumor
burden and recapitulated the effects observed following anti-CTLA-4
injection alone. Anti-CTLA-4 and/or anti-PD-1 alone did not appear to
change the relative frequency of TIL reactive to mutated, self, or viral
antigens but increased their polyfunctionality.
Conclusions
In vivo pre-conditioning of MC-38-bearing mice with immune check-
point blocking antibodies may generate TILs more fit for ACT im-
munotherapy. Experiments are underway to compare the efficacy of
this approach to conventional TIL ACT in this mouse model.
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Fig. 31 (Abstract P28).
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Background
Infusion of T cells genetically engineered to express a chimeric anti-
gen receptor (CAR) is a promising approach for the treatment of cer-
tain cancers. Though CAR T cells are highly efficacious against CD19+
hematological malignancies, limitations exist in broadening their use.
Conventional CAR T cells target a single tumor associated antigen
(TAA), limiting their effectiveness against tumors with heterogeneous
TAA expression as well as emerging antigen loss variants, as ob-
served in CD19 CAR trials. Additionally, stably engineered CAR T cells
may continually proliferate and activate in the presence of antigen,
potentially causing fatal toxicity, without a method of elimination. To
overcome these issues, we and others have developed a variety of
universal immune receptors (UIRs) that allow for targeting of multiple
TAAs with a single receptor-expressing T cell. Although these UIRs
are a promising new technology, their reliance on noncovalent inter-
actions between receptor and targeting ligand can lead to potential
issues of affinity, specificity and activity.
Methods
Our UIR platform employs the use of the SpyCatcher and SpyTag
proteins that, when combined, can form a covalent bond with high
efficiency both in vitro and in vivo. Our SpyCatcher immune receptor
is composed of an extracellular SpyCatcher domain attached to
intracellular T cell signaling motifs in a lentiviral expression vector.
Anti-TAA antibodies conjugated to SpyTag are used to confer redir-
ected specificity to SpyCatcher expressing T cells. Measurements of T
cell effector function include T cell cytokine secretion, activation, and
targeted tumor cell lysis in vitro.
Results
In this study, we demonstrate the first universal immune receptor
platform that allows for the endowment of function through post-
translational covalent attachment of targeting ligands, securing their
loading on the T cell surface while expanding recognition specificity.
We demonstrate that the SpyCatcher immune receptor is expressed
in primary human T cells and allows for specific T cell activation and
cytokine secretion against plate bound SpyTag. Notably, in the
presence of SpyTag-labeled targeting antibody, SpyCatcher T cells
recognize and lyse antigen-expressing human tumor cells in a target-
specific and dose-dependent fashion.
Conclusions
The SpyCatcher immune receptor is the first universal immune recep-
tor designed for its capacity to covalently bind targeting ligands and
redirect T cells against a diverse array of antigens, addressing current
limitations of conventional CAR T cell therapy.
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Background
Adoptive immunotherapy using gene-modified T cells redirected
against cancer has proven clinical efficacy and tremendous potential
in several medical fields. However, such personalized medicine faces
several challenges in the complexity associated with the current clin-
ical manufacturing methods. The processes are mostly suboptimal re-
quiring cell manufacturers to deal with open steps, liquid handlings
between devices used, manual interventions, removal of activation
beads and often the use of reagents for which commercial availabil-
ity is not in line with the high and increasing demand. GMP compli-
ant human AB serum is one of such reagents. Therefore, developing
improved methods to generate gene-engineered T cells suitable for
clinical use that do not require serum are essential for the commer-
cial scalability of such therapies.
Methods
We have developed a robust and reproducible automated manufac-
turing process for the lentiviral gene-modification and expansion of
selected T cells. The CliniMACS Prodigy TCT (for T Cell Transduction)
process software allows automated purification and polyclonal T cell
stimulation followed by gene-modification and expansion of T cells
in a single-use closed tubing set.
Results
Here we show that the TCT process enables the manufacturing of
gene-modified T cells without the need for serum supplementation
(human AB serum) when using TexMACS GMP Medium. Furthermore,
implementation of a humanized recombinant activation reagent
TransAct allows for a simplification of the process whereby the “bead
removal” step is unnecessary. Comparable results from healthy donor
or patients starting cells are demonstrated.
Conclusions
Taken together the TCT process in combination with the CliniMACS
Prodigy and minimal user interactions enables the preparation of
gene-modified T cells in serum free conditions. Process risks, due to
use of different devices, unnecessary manipulations, or potential
shortage of human AB serum availability can be minimized by auto-
mation of the entire process as developed and shown here. Overall,
these improvements are meant to fully support commercial treat-
ment of a large number of patients.
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Background
Adoptive Cell Transfer (ACT) using Tumor Infiltrating Lymphocytes
(TIL) for unresectable metastatic melanoma results in a median over-
all survival of 52 months at our institution. This stands in contrast to
the median overall survival for metastatic soft tissue sarcoma (mSTS)
which is 12 months. The purpose of this report is to describe the
phenotype and function of TIL from fresh surgical sarcoma speci-
mens as a rationale for applying ACT to mSTS.
Methods
Fresh surgical sarcoma specimens were acquired under an IRB-
approved protocol. Half of the specimen was digested and pheno-
typed by flow cytometry. The remaining half was plated as fragments
for the isolation of TIL, which were expanded in vitro with conditions
validated for melanoma-derived TIL. Cultured TIL were phenotyped
by flow cytometry and propagated further with a rapid expansion
protocol (REP). Tumor-specific reactivity was assessed by co-culture
of TIL with autologous tumor or HLA-matched cell lines with meas-
urement of IFN-gamma using ELISA.
Results
Sixteen patient-derived sarcoma specimens were collected. Hist-
ology of primary tumor included dedifferentiated liposarcoma (9),
well-differentiated liposarcoma (2), undifferentiated pleomorphic
sarcoma (2), and one each of gastrointestinal stromal tumor, myxo-
fibrosarcoma and synovial sarcoma. Analysis of tumor digests indi-
cated an average of 48% of cells from the lymphocyte gate were
CD3+ (range 3.6%-76%). TIL were grown from all specimens, with
TIL observed in 152 out of 192 (79%) fragments. The phenotype of
the CD3+ subpopulations from TIL cultures included a median of
90.8% (range 2-99.9%) CD8+ and 2.3% (range 0-96.4%) CD4+ T
cells. TIL were expanded in a REP to clinically meaningful numbers
(mean 1385-fold) with no change in the CD8+ T cell proportion.
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Tumor-specific function of TIL generated from fragments was mea-
sured in two patients. There was tumor-specific IFN-gamma release
(mean 148.8±13.5 pg/ml) in TIL co-cultured with HLA-matched cell
lines and also in TIL co-cultured with autologous tumor digest
(mean 259.9±14.7 pg/ml). The degree of IFN-gamma release was
significantly greater when TIL were co-cultured with autologous di-
gest compared to an HLA-mismatched cell line (p=0.0295).
Conclusions
CD3+CD8+ TIL can be isolated from human sarcoma tumors in vitro,
expanded to meaningful numbers for therapeutic use, and demon-
strate reactivity to the tumor from which they were cultured. These
data form the basis for efforts to develop a clinical trial using ACT for
patients with advanced sarcoma.
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Background
ACT based on infusion of autologous TILs has the ability to induce
complete and durable response in some patients with advanced malig-
nant melanoma [1]. We believe that this approach could also be effective
in sarcoma. In this preclinical study we are investigating feasibility of
expanding TILs from sarcoma, as well as performing functional in vitro
analyses on these TILs. This abstract is an update on our results so far.
Methods
A portion (>1 cm3) of the excised sarcoma tumor tissue is cut into frag-
ments and placed in a growth medium containing IL-2 for initial TIL ex-
pansion. Afterwards, TIL cultures undergo a rapid expansion protocol
(REP) expansion by adding OKT-3 and feeder cells. Phenotype and
functional analyses are performed using flow cytometry and Elispot.
Results
To this date we were able to expand TILs from 18 of 20 tumor
samples. TILs were harvested and frozen when an estimated
number of 100x106 to 200x106 cells were reached. Mean expan-
sion time was 32 days (16 - 61). 87.7% (36.4 – 99.1) of these cells
were CD3+, and of these 66.7% (16.3 – 99.1) were CD4+, and
21.8 % (0.1 – 50.6) were CD8+. Most of the expanded TILs were
effector memory subtype, while a smaller fraction was the more
differentiated effector T cells. REP expansion rates ranged from
630 fold to 2.300 fold, and followed expansion pattern similar to
TILs from malignant melanoma. TILs from 6 of 10 tested tumor
samples with 4 different sarcoma subtypes (undifferentiated pleo-
morphic sarcoma, myxofibrosarcoma, myxoid liposarcoma and
osteosarcoma) demonstrated reactivity against autologous tumor
cells using Elispot. Further assessment is ongoing.
Conclusions
We were able to expand TILs from 90% of the included tumor samples
to numbers needed for possible future clinical implementation. TILs
were a mix of CD4+ and CD8+ with CD4+ being predominant. As of
yet we have demonstrated TIL reactivity against autologous tumor cells
from 6 of 10 tested patients. Thus, we conclude that it is feasible to
translate TIL based ACT into clinical testing in sarcoma patients.
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Background
The suppressive microenvironment of solid tumors inhibits the
anti-tumor activity of endogenous and chimeric antigen receptor
(CAR)-bearing T cells, thereby limiting the efficacy of adoptive T cell
therapies. Myeloid-derived suppressor cells (MDSCs; CD33+ CD11b+
HLA-DRlow) and regulatory T cells (Tregs; CD4+ CD25high FoxP3+
Helios+) contribute to the inhibitory tumor microenvironment
(TME) through secretion of suppressive cytokines, expression of in-
hibitory ligands, and by promoting tumor neo-vascularization.
NKG2D is an activating surface receptor expressed on natural killer
(NK) cells, whose ligands are highly expressed by human Tregs and
MDSCs. We genetically modified primary human NK cells to express
a chimeric NKG2D molecule (ectodomain of endogenous NKG2D
fused to the cytotoxic CD3-zeta chain; called NKG2D.z) in order to
promote NK cell activation against Tregs and MDSCs. We hypothe-
sized that NKG2D.z NK cells would exhibit enhanced cytolytic activ-
ity against suppressive autologous Tregs and MDSCs via the
chimeric NKG2D, as well as secrete chemokines and cytokines that
recruit and activate tumor-specific T cells. The objective of the
current study was to compare the activity of NKG2D.z NK cells vs.
non-transduced (NT)-NK cells on Tregs, MDSCs, or the combination.
Methods
We isolated MDSCs and Tregs from normal donors and patients
with solid tumors, confirmed their phenotype by flow cytometry
and their suppressive activity in T and NK cell proliferation as-
says, and used them as targets in NK cell cytotoxicity and co-
culture assays.
Results
NT (endogenous) and mock-engineered (empty vector control) NK
cells were unable to mediate cytotoxicity or release pro-inflammatory
cytokines in response to autologous MDSCs or Tregs, either alone or
in combination. In contrast, NKG2D.z NK cells exhibited enhanced cy-
tolysis and secreted T cell-recruiting and -activating cytokines in re-
sponse to both suppressive cell types alone. Further, when NKG2D.z
NK cells were co-cultured in a highly suppressive environment con-
taining both MDSCs and Tregs, their cytolytic and cytokine-secreting
activities against either cell type were unimpaired. We have estab-
lished an in vivo TME model comprising tumor cells with MDSCs and
Tregs, and experiments testing the ability of NKG2D.z NK cells to
eliminate suppressive cells and recruit endogenous or CAR-T cells
in vivo are underway.
Conclusions
Our results suggest that our modified NK cells may reverse immune
suppression by the TME and improve T cell-based immune therapies
for solid tumors.
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Background
Acute lymphoblastic leukemia (ALL) is the most common childhood
malignancy. The cure rate has reached up 90% with modern therapy,
outcomes are still very poor for patients who relapse. Immunother-
apy with donor lymphocyte infusions for ALL has not demonstrated
the success seen in other hematologic malignancies, suggesting
there are characteristics inherent to ALL that make it less amenable
to detection and elimination by the immune system. T cell dysfunc-
tion in the setting of leukemia has been well described, but the
mechanisms have not been fully elucidated. It is also unclear if this T
cell dysfunction underlies some of the treatment failures seen in pa-
tients receiving adoptive therapy with chimeric antigen receptor
(CAR) expressing T cells. Immune checkpoint blockade has led to ad-
vances in the treatment of many solid tumors, but it has yet to dem-
onstrate similar success in ALL.
Methods
Using two preclinical models of pre-B cell ALL, we studied the
negative impact of ALL progression on T cell function and the ef-
ficacy of CAR T cell therapy and immune checkpoint blockade.
We also dissected the mechanism underlying the observed T cell
dysfunction.
Results
Prophylactic vaccination protects mice against the murine pre-B
ALL in a T cell-dependent manner. However, therapeutic vaccin-
ation is ineffective, even in the setting of low disease burden.
Adoptive transfer of primed T cells from immunized donors can
completely eradicate established leukemia; however, this efficacy
is not seen with the adoptive transfer of T cells from leukemia-
bearing mice. Expression of a CD19 CAR in T cells from leukemic
mice fails to eradicate ALL, while the CAR T cells derived from
naïve mice can. T cells from leukemic mice express markers of T
cell dysfunction. The expression of these molecules was associ-
ated with elevated levels of IL6, TNFa and IL10 in the serum of
leukemia-bearing mice. Incubation of naïve T cells in these cyto-
kines ex vivo recapitulated the upregulation of exhaustion
markers seen in vivo, suggesting these cytokines play a role in
the observed T cell dysfunction. Blockade of PD-1, its ligand, PD-
L1, or Tim3 were ineffective at reversing T cell dysfunction and
preventing leukemia progressions in vivo, suggesting other mech-
anisms must be targeted to restore immune function in leukemia
bearing hosts.
Conclusions
Cytokines induced by Pre-B Leukemia progression mediates irre-
versible T cell dysfunction. These findings underscore the need to
elucidate the mechanisms of leukemia-induced immune suppres-
sion to fully optimize the use of CAR-expressing T cells in the
treatment of ALL.
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Background
T cells are trained to differentiate between cell-surface MHC-
displayed peptide sequences from self- and non-self proteins and act
on the latter. The numerous mutations often associated with cancers
can occur in coding regions of the genome and modify the sequence
of wild-type proteins, potentially creating targets for immunother-
apies. We have developed an analysis pipeline ProTECT (Prediction of
T cell Epitopes for Cancer Therapy) to identify and rank neo-epitopes
in terms of immunogenicity. Running ProTECT on a set of recurrent
neuroblastomas showed that recurrent tumors share neo-epitopes
with their corresponding primary tumors suggesting that immuno-
therapies could provide long-term protection.
Methods
ProTECT accepts paired tumor and normal DNA sequencing fastq
files, and tumor RNA sequencing fastqs. Mutations are called using a
panel of callers, and are annotated to identify coding mutations. Pre-
diction of self-MHC:mutated-peptides is carried out and the final
binding predictions are ranked using an in-house algorithm. We sup-
port both MHCI and MHCII predictions.
Results
Running ProTECT on 6 recurrent neuroblastoma samples (NBL)
from the TARGET (Therapeutically Applicable Research To Generate
Effective Treatments) project revealed that the relapsed tumor in-
herits neo-epitopes predicted in the primary tumor. We also pre-
dicted neo-epitopes from 2 well-known hotspot mutations in NBL
(NRAS Q61K and ALK R1275Q) that bind to common MHC alleles
(HLA-A*01:01, HLA-A*03:01 and HLA-B*15:01). We carried out
in vitro refolding and crystallization assays [1] for the five highest-
ranking mutant NRAS and ALK predictions. Properly conformed
MHC trimers were verified by a single, monodisperse peak after
anion exchange chromatography and validated by SDS gel electro-
phoresis. Mass spec confirmed bound peptide for 4/5 tested pre-
dictions and 3 of these were used to set up hanging-drop
crystallization trials in various conditions. Positive hits were ob-
tained for one (MAQDIYRASY::HLA-B*15:01). ProTECT has also been
run on a large subset of The Cancer Genome Atlas (TCGA). We
aim to reveal clinically relevant hotspot-mutation:MHC pairs.
Conclusions
We have described a pipeline for identification and ranking of thera-
peutically relevant neo-epitopes. We have predicted potentially
therapeutic targets for NBL that have been validated in vitro.
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Background
As many potential targets of chimeric antigen receptor (CAR) T cell
immunotherapy are self-antigens that are over-expressed in tumors
but also present at lower levels on some normal tissue, understand-
ing the nature of on-target off-tumor toxicity and how to overcome
it is important in the development of new CAR T cell therapies. Pre-
clinical modeling of such toxicity is complicated by the fact that
most antigens are not shared between humans and mice, and strat-
egies have largely relied on co-injection of antigen-low tumors or
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introduction of human antigen into mouse tissue by viral gene de-
livery. The GD2 tumor antigen would provide an excellent model in
which to study on-target off-tumor toxicity as the exact glycolipid
antigen is naturally shared between mice and humans. However, as
of yet, GD2-specific CAR T cells have yielded modest efficacy and
little toxicity in preclinical studies. Here we have engineered a
higher potency GD2 CAR by introducing an affinity-enhancing mu-
tation (E101HK), previously described by Horwacik et al., that we
show significantly enhances CAR T cell activity and provides a
model for toxicity.
Methods
Primary human T lymphocytes were transduced with lentivirus en-
coding either wild-type 14G2a-based anti-GD2 CAR, E101K mutant
GD2 CAR, or a negative control CAR. After standard stimulation and
expansion, T cells were analyzed for CAR surface expression by flow
cytometry and for in vitro effector function by chromium release and
IFN gamma ELISA. To evaluate in vivo, NOD-SCID-IL2Rγc-/- (NSG) mice
were injected with the luciferase-expressing GD2-high human neuro-
blastoma cell line SY5Y, and four days later 3,000,000 CAR+ T cells
were injected via tail vein. Tumor burden was measured using in vivo
bioluminescence, and tumor and normal tissues were evaluated his-
tologically by H&E staining and immunohistochemistry.
Results
The higher affinity mutant displayed comparable surface expression
and T cell expansion but significantly enhanced GD2-specific cytotox-
icity and cytokine release in vitro and tumor control in vivo. However,
this enhanced efficacy was associated with severe CNS toxicity caus-
ing neurologic symptoms and death, and post-mortem evaluation of
tissues revealed extensive CAR T cell infiltration into certain brain
structures, particularly cerebellum, known to contain GD2.
Conclusions
The introduction of an affinity-enhancing mutation into the GD2-
specific CAR dramatically increases CAR T cell potency and permits
off-tumor CAR T cell activity in areas of the brain containing GD2.
This scenario provides a new opportunity to investigate the mechan-
ism of this toxicity and test strategies to achieve a therapeutic
window.
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Background
Ovarian cancer is responsible for 5% of cancer-related deaths among
women, and the majority of the cases are diagnosed at a late stage,
accounting for a 5-year survival rate of 27%. Therefore, there is a dire
need for effective therapies. The recent success of adoptive cell ther-
apy using T cells engineered to express anti-CD19 chimeric antigen
receptors (CARs) for the treatment of hematologic malignancies, ra-
tionalizes the development of similar strategies for solid tumors such
as ovarian cancer. The achievement of safe, effective therapy requires
the selection of a target antigen that is overexpressed in malignant
cells but present in few to no normal cells. The Müllerian inhibiting
substance type 2 receptor (MISIIR) is a member of the TGF-β recep-
tors family involved in the regression of the primordial female repro-
ductive tract in male embryos. This action is exerted through its
interaction with soluble Müllerian inhibiting substance (MIS), trigger-
ing a downstream signaling cascade that induces apoptosis. MIS sig-
naling through MISIIR has been shown to cause growth inhibition in
ovarian, breast, prostate and endometrial cancer cell lines in vitro. In
humans, MISIIR is expressed at very low levels in a restricted set of
healthy tissues but is overexpressed in gynecologic cancers, includ-
ing 69% of epithelial ovarian cancers, making it a candidate target
antigen.
Methods
Here, we evaluate for the first time the potential of MISIIR as a target
for CAR T cell therapy. In this work, we generated and functionally
tested 5 distinct CARs comprised of different human MISIIR-specific
single-chain antibody variable fragments (scFv) isolated from a phage
display library coupled to the T cell signaling domains from CD27
and CD3Z.
Results
All the CARs were efficiently expressed primary human T cells trans-
duced using recombinant lentivirus technology and showed specific
binding and reactivity against recombinant MISIIR protein. Interest-
ingly, when co-cultured with target cells engineered to overexpress
MISIIR, just one of the CARs, GM7-27Z, showed specific reactivity in
terms of cytolytic function and proinflammatory cytokines secretion.
The activity of this CAR was further evaluated in vitro and in vivo in a
panel of tumor cells lines expressing different levels of the target
antigen.
Conclusions
Although the assessment of CAR-mediated antitumor activity and
on-target off-tumor toxicity potential in vivo is required, the results
obtained so far support the further exploration of an anti-MISIIR CAR-
based therapy for the effective treatment of ovarian cancer as well
as other gynecologic malignancies.
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Background
The use of interleukin-2 (IL-2) has been a major asset to boost
the therapeutic anti-tumor efficacy of adoptive cell therapy, in-
cluding tumor infiltrating lymphocyte (TIL) therapy in the context
of solid tumors. However, clinical assessments have revealed that
its systemic administration results in poor accumulation at solid
tumor sites. Additionally, the half-life of this recombinant mol-
ecule is short. High dose administration has therefore been used
but this results in severe adverse events, including mortality.
Hence, local production at the tumor is an attractive concept
which might retain or even increase the useful aspects of IL-2,
while reducing systemic side effects.
Methods
We aimed to evaluate the efficacy and safety of, intratumoral deliv-
ered IL-2-armed adenoviruses combined with T cell transfer in ro-
dents. Experiments were set up using the syngeneic CB57BL/6
mouse B16.OVA melanoma tumor model infused with OVA-specific T
cells, and the syngeneic Syrian hamsters Hapt1 pancreatic tumor
model infused with TILs. Both therapeutic schedules involved once-a-
week intratumoral administration of replication deficient serotype 5
(mice) or oncolytic serotype 5/3 chimeric (hamsters) IL-2-armed ade-
noviruses comparing with weekly-continuous systemic administration
of recombinant IL-2.
Results
In both models, local production of IL-2 successfully replaced that
need for systemic IL-2. In fact, efficacy was even higher than with
systemic IL-2. Furthermore, the vectored delivery of IL-2 significantly
potentiated the infiltration of CD8+ T cells and, significantly de-
creased the percentage of regulatory T cells. In animals that received
systemic recombinant IL-2 therapy, significant histological changes
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were observed in the lungs, liver, heart, spleen and kidneys that
should be considered as side-effects of the treatment.
Conclusions
In summary, local production of IL-2 seems appealing from the point
of view of efficacy and safety in the context of adoptive cell therapy.
This preclinical assessment provides the rational for clinical transla-
tion, which is ongoing by TILT Biotherapeutics Ltd.
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Background
Adoptive cell therapy (ACT) has shown promise in comparison to
other methods of cancer immunotherapy that rely on the active de-
velopment of antitumor T cells in vivo to mediate cancer regression
[1]. Administration of autologous TILs in melanoma patients has
shown an overall response rate of 55% at NCI, 38% at Moffitt Cancer
Center, 48% at MD Anderson Cancer Center and 40% in Sheba at the
Ella Cancer Institute, Israel [1]. TILs have been found in a variety of
solid tumors, and their presence has been shown to be a prognostic
indicator of improved survival. Here, we demonstrate the feasibility
of growing TILs and the potential to develop TIL therapies to treat
other solid tumors, such as lung, breast, and bladder cancers.
Methods
Upon receiving surgically resected tumor specimens, samples were
washed in HBSS and cut into small fragments prior to propagating
in vitro in G-REX-10 cell culture flasks with interleukin-2 (commonly
referred to as a pre-rapid expansion protocol [pre-REP]). After culture
initiation, media was exchanged. The media was changed every 3
days subsequently for 2 weeks. TILs were harvested to assess
cell count and viability, followed by immunophenotyping and
cryopreservation.
Results
The average yield of TILs cultured and expanded from bladder, cer-
vical, head & neck, lung, and triple-negative breast tumors is listed in
Table 4. Phenotypic characterization of TILs from bladder, cervical
and lung cancer were >60-70% CD8+ T cells whereas TILs from head
and neck demonstrated variable distribution of CD8+ and CD4+ T
cells. TILs propagated from TNBC were >80% CD4+ T cells. Regard-
less of the tumors, most cultures had < 20% CD56+ NK cells.
Conclusions
We have been successful in culturing and expanding TILs from vari-
ous non-melanoma solid tumors. We will initiate REP from pre-REP
TILs from non-melanoma tumors to enable product development for
subsequent possible clinical trials. Efforts are currently focused on
culturing TILs from smaller tumor specimens/biopsies to assess utility
in promoting expansion of TILs with central and effector memory
phenotypes and selecting for mutanome reactive TILs.
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Background
Strategies that enhance the function of T cells are critical for
immunotherapy. Targeted delivery of T cells through BiTE (bis-
pecific T cell engager) platform to cancerous tissues shows po-
tential in sparing unaffected tissues. However, it has been a
major challenge for cells penetration in solid tumor tissues due
to the complicated tumor microenvironment. Activated T cells
expression integrin, which is the target of peptide RGD. Peptide
iRGD (CRGDK/RGPD/EC) increased vascular and tissue permeabil-
ity in a tumor-specific and neuropilin-1-dependent manner,
allowing co-administered drugs to penetrate into extravascular
tumor tissue. Recombinant protein anti-EGFR-iRGD was purified
and examined.
Methods
Recombinant protein anti-EGFR-iRGD consisting of an anti-EGFR
VHH (the variable domain from the heavy chain of the anti-
body) fused to iRGD, a tumor-specific binding peptide with high
permeability were expressed in E. coli BL21 (DE3) and purified
by nickel-nitrilotriacetic acid affinity chromatography. We use
tumor cell lines and mice to analyze the targeting, penetrating
and antitumor activity of antigen-secific T cells together with re-
combinant protein.
Results
We have successfully constructed a recombinant protein named
anti-EGFR-iRGD, a dual targets of EGFR and integrin and high
permeable protein. It could spread extensively throughout both
the multicellular spheroids and the tumor mass. The recombin-
ant protein anti-EGFR-iRGD could help more T cells infiltrating
into tumor mass and also exhibited antitumor activity in tumor
cell lines and mice.
Conclusions
Our results provide impetus for further studies for potentially
using iRGD based fusion protein anti-EGFR-iRGD with immune
therapy regimens for enhancing therapy of gastric cancer
patients.
Table 4 (Abstract P41).
Tumor Number of
patient tumors
Average yield (and range) or
TILs from pre-REP (106)
Bladder 2 290 (97-600)
Cervical 4 360 (147-800)
H&N 7 539 (132-738)
Lung 8 688 (50-915)
TNBC 13 429 (81-665)
Fig. 32 (Abstract P42). Purification and verification of recombinant
protein
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Background
Immunotherapy has clinical activity in human papillomavirus (HPV)-
induced epithelial cancers, but the tumor antigens targeted by T cells
resulting in cancer regression are poorly defined. The viral proteins
expressed by these malignancies are generally considered the pri-
mary targets of T cell based immune attack. However, HPV+ cancers
also harbor somatic mutations and express cancer-germline antigens
that may be targets of tumor-specific T cells. Here, we aimed to
elucidate the landscape of tumor antigens targeted by T cells in two
patients with metastatic HPV+ cervical cancer who experienced dur-
able complete tumor regression after adoptive transfer of tumor-
infiltrating lymphocytes (TIL).
Methods
To this end, reactivity of therapeutic TIL was assessed in immuno-
logical assays against HPV-derived antigens (L1, L2, E1, E2, E4, E5, E6
and E7), mutated neoantigens and cancer-germline antigens identi-
fied by whole-exome and/or RNA sequencing of patient’s tumors. T
cell receptor (TCR) clonotypes conferring specificity to tumor anti-
gens were elucidated and quantified, and their in vivo persistence
was profiled by TCR deep sequencing.
Results
T cell reactivity against the HPV-E6 and/or -E7 antigens was detected in
both patient’s infused TIL, consistent with previously reported results.
No T cell reactivity was detected against other six HPV-derived anti-
gens. However, our data indicated that these patient’s infused TIL dis-
tinctly recognized mutated neoantigens or a cancer-germline antigen.
Detailed TCR clonotype analysis showed that in one patient multiple
CD8+ clonotypes (35% of infused TIL) recognized somatically mutated
gene products (n=3) unique to patient’s tumor in addition to several
CD8+ and/or CD4+ clonotypes (14% of TIL) targeting HPV-E6 and/or
-E7. In the other patient, one CD8+ clonotype (67% of TIL) recognized
the cancer-germline antigen Kita-kyushu lung cancer antigen 1 in
addition to one CD4+ clonotype (14% of TIL) that targeted HPV-E7. Ad-
ministered viral and non-viral tumor antigen-specific T cells in both pa-
tients remained functional and persisted at elevated levels in the
circulation for months during ongoing remission.
Conclusions
Our data show that both patients who experienced complete tumor
regression received TIL that contained low frequency of HPV-
targeted T cells but a high frequency of mutated neoantigen- or
cancer-germline antigen-targeted T cells. These results reveal a previ-
ously unappreciated role for T cells targeting non-viral antigens in
HPV+ cervical cancer. By expanding the categories of potential tumor
regression antigens for cervical cancer and possibly other HPV-
induced malignancies, our findings provide new targets for personal-
ized cancer vaccines and/or adoptive T cell therapies as well as for
immune-monitoring of various cancer immunotherapies.
Consent
Written informed consent was obtained from patients.
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Background
MCC is an aggressive skin cancer associated with Merkel cell poly-
omavirus (MCPyV). Downregulation of class I major histocompatibility
complex (MHC) expression in >80% of MCC tumors suggests poten-
tial susceptibility to adoptively transferred NK cells. aNK cells are de-
rived from a NK cell line that is highly cytotoxic to a broad range of
tumor cells. Phase I studies suggest that aNK cell therapy is well tol-
erated and has antitumor activity in patients with advanced
hematologic or solid cancers. This study seeks to determine the effi-
cacy of aNK cell therapy in patients with advanced MCC.
Methods
In this open-label phase II study, advanced MCC patients (planned
N=24) receive aNK cells (2 × 109 cells/m2) intravenously on two
consecutive days (1 cycle) every 2 weeks. Key eligibility criteria include
age ≥18 years, unresectable stage III or IV MCC, and ECOG performance
status ≤2. Up to two prior systemic chemotherapies and/or immuno-
therapies are allowed. The study uses a Simon optimal two-stage de-
sign. The primary efficacy endpoint is 4-month progression-free survival
(PFS) rate. Secondary endpoints include objective response rate by
RECIST 1.1, time to progression, overall survival, safety, and qual-
ity of life assessment (FACT-G). Planned correlative studies include
genomic and proteomic tumor profiles, MCPyV status, and immu-
nohistochemical assessment of MHC-1, correlated to treatment
outcome.
Results
As of August 2016, 3 patients have been enrolled. Treatment-related
adverse events have been grade 2 or milder with no serious adverse
events. The efficacy criterion for the first stage of the study has been
met, with a patient with advanced MCC refractory to multiple prior
therapies including PD-1 blockade demonstrating an impressive
partial response (PR) with >70% regression, ongoing at 20 weeks. In-
triguing changes were observed clinically in another patient’s superfi-
cial tumors just a few hours after aNK infusions, although this patient
developed progressive disease at 4 weeks. Correlative studies on
tumor biopsies of the patient with PR are ongoing.
Conclusions
ACT with allogeneic aNK cells has been safe and well tolerated in the
initial three patients with advanced MCC. Encouraging antitumor
activity has been observed with an impressive PR in a patient with
advanced MCC refractory to PD-1 blockade. The pre-specified effi-
cacy criterion for the first stage of the trial has been met and en-
rollment continues on the trial. Updated results will be presented
at the meeting.
Trial Registration
ClinicalTrials.gov identifier NCT02465957.
Fig. 33 (Abstract P42). Penetration of CTL together with
recombinant protein
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Background
Anti-CD19 CAR T cell therapy has shown promising clinical efficacy. Re-
cent evidence points to a critical role for non-myeloablative condition-
ing chemotherapy, influencing the expansion, persistence and activity
of CAR T cells. To diminish toxicities, Kochenderfer, et al. pioneered a
conditioning chemotherapy regimen with low dose cyclophosphamide
(300-500mg/m2) and fludarabine (30mg/m2) administered daily for 3
days [1]. This resulted in a response rate of 73% in patients with ad-
vanced Non-Hodgkin lymphoma, with lower rate of hematologic toxic-
ities. Post CAR T cell-treatment peak levels of cytokines in blood were
associated with T cell expansion, clinical efficacy or neurotoxicity [1].
Methods
We analyzed 41 blood biomarkers in 22 patients treated with anti-
CD19 CAR T cells, preceded by low dose conditioning chemotherapy.
We also measured cytokine levels produced by CAR T cells ex vivo,
upon culture with CD19-expressing target cells. The expansion of
CAR T cells in blood was measured by quantitative PCR.
Results
Conditioning chemotherapy enhanced IL-15 and decreased lymphocytes
and perforin blood levels. Several cytokines peaked sequentially in blood
post CAR T cell infusion: among those, IL-15 and GM-CSF at days 2-3,
followed by IL-10 and Granzyme B, at day 6. CAR T cell expansion in
blood occurred within 7-14 days. IL-15 blood levels associated with T cell
expansion, clinical response and toxicities. In addition, early post-CAR T cell
treatment levels GM-CSF and peak blood levels of IL-10 and Granzyme B,
were associated with clinical efficacy or neurotoxicity. When stimulated
ex vivo with CD19-expressing cells, CAR T cells produced a broad range of
molecules including GM-CSF, IL-10 and Granzyme B, but not IL-15.
Conclusions
In conclusion, these preliminary findings suggest that three immune
programs impact clinical outcome of CAR T cell treatment: a T cell
proliferative program initiated by conditioning chemotherapy, to-
gether with an inflammatory and a cytotoxic program deployed by
CAR T cells. In addition, this analysis highlights the need to carefully
optimize the conditioning chemotherapy regimen.
Acknowledgements
This study was conducted under a CRADA between NCI and Kite Pharma.
Trial Registration
ClinicalTrial.gov identifier NCT00924326.
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Background
For more than a decade, allogeneic peripheral blood mononuclear
cells (PBMC) have been used as accessory feeder cells that provide
“costimulatory signals” necessary for the expansion of tumor-
infiltrating lymphocytes (TILs) in the presence of IL-2 and CD3 stimu-
lation (Rapid Expansion Protocol [REP]) [1]. The intrinsic heterogen-
eity of allogeneic PBMC is an important variable when considering
the expansion and resulting phenotype of post-REP TIL prepared
for transplantation. The procurement of allo-PBMC in large num-
bers is also challenging and expensive. Our objective was to
evaluate artificial antigen presenting cells (aAPC) as a potential
substitute for PBMC. As such, we developed a novel aAPC from
the CD64+ MOLM-14 human leukemia cell line, genetically engi-
neered to express recombinant CD86 (B7-2) and CD137-L (41BBL)
(MOLM14-86/137).
Methods
The MOLM-14-86/137 cell line was generated via transduction of wild
type MOLM-14 with lentiviral virions encoding genomic RNA of CD86
or CD137 downstream of the U3 promoter from MSCV. MOLM-14-86/
137 was ɣ-irradiated at 100Gy and co-cultured with TILs at a 1:100
ratio (TIL:aAPC) in media containing OKT3 (30 ng/ml) and IL-2 (3000
IU/ml) for 14 days. On Day 14, we calculated their expansion and
examined their differentiation (flow cytometry), metabolic rate, and
cytotoxicity.
Results
Compared to TIL co-cultured with PBMC or wild type MOLM-14,
we obtained 95-100% TILs via co-culture with MOLM-14-86/137.
This value was within the expected range using PBMC (Fig. 34).
TIL differentiation, cellular respiration (OXPHOS) and redirected
cytotoxicity were also within the range expected via co-culture
with PBMC.
Conclusions
According to our measurements, co-culture of TIL with MOLM-14-86/
137 aAPC resulted in expansion, metabolic activity and cytotoxicity
that were sufficiently similar to that obtained with PBMC. This data
suggests that investigation of a MOLM-14-86/137 based REP protocol
in a clinical setting is warranted.
References
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Fig. 34 (Abstract P46). Rapid expansion of TILs using irradiated
engineered MOLM-14 or PBMC feeders. TIL were co-cultured with PBMC
Feeders or MOLM14 (CD86/41BBL) at 1:100 ratios plus OKT3(30ng/ml)
and IL-2 (3000 IU/ml). Cells were counted and split on Day 6 and 11.
Each dot represents cell numbers determined on Day 14
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Background
The goal of allogeneic bone marrow transplantation (allo-BMT)
is the elimination of leukemia cells through the graft-versus-
leukemia (GvL) activity of donor cells, while limiting graft-
versus-host disease (GvHD). Immune checkpoint pathways regu-
late GvL and GvHD activities, but blocking these pathways can
cause lethal GVHD. Vasoactive intestinal peptide (VIP) is an
immunosuppressive neuropeptide that regulates co-inhibitory
pathways.
Methods
Murine models of MHC-mismatched allogeneic bone marrow
transplantation were used to evaluate the effect of blocking VIP-
signaling on the graft-versus-leukemia (GvL) and graft-versus host
disease (GvHD) effect of donor T cells. Mice were transplanted
with donor grafts from VIP-KO mice or recipients of wild-type
grafts were treated with seven daily injections of a peptide an-
tagonist to VIP (VIPhyb). Survival, GvHD and the growth of lucifer-
ase+ LBRM, a T cell lymphoblastic leukemia cell line, or C1498, a
myeloid leukemia cell line, were monitored by bio-luminescent
imaging. Expression of chemokine receptors, cytokines and check-
point molecules were measured by flow cytometry. VIP expres-
sion on donor and host cells was visualized using a transgenic
mouse in which GFP expression is driven by the VIP promoter. T
cell repertoire from T cells in mice with GvHD or GvL was ana-
lyzed by deep sequencing.
Results
VIP is expressed transiently in donor NK, NKT, dendritic cells,
and T cells after allo-transplant, as well as in host leukocytes. A
peptide antagonist of VIP signaling (VIPhyb) increased T cell
proliferation in vitro and reduced IL-10 expression in donor T
cells. Treatment of allo-BMT recipients with VIPhyb, or trans-
planting donor grafts lacking VIP (VIP-KO), activated donor T
cells in lymphoid organs, reduced T cell homing to GvHD target
organs, and enhanced GvL without increasing GvHD in multiple
allo-BMT models. Genetic or ex vivo depletion of donor NK cells
or CD8+ T cells from allografts abrogated the VIPhyb-enhanced
GvL activity (Fig. 35A). VIPhyb treatment led to downregulation
of PD-1 and PD-L1 expression on donor immune cells (Fig. 35B),
increased effector molecule expression, and expanded oligoclo-
nal CD8+ T cells that protected secondary allo-transplant recipi-
ents from leukemia (Fig. 35C & D).
Conclusions
VIP production by donor immune cells is dynamically regulated
after allo-BMT, and transplanting VIP-KO cells, or daily treatment
with VIPhyb, significantly enhanced survival of leukemia-bearing
transplant recipients via a CD8+ T cell dependent GvL effect
without increased GvHD in murine models of MHC mis-matched
allo-BMT. Blocking VIP-signaling thus represents a novel
pharmacological approach to separate GvL from GvHD and en-
hance adaptive T cell responses to leukemia-associated antigens
in allo-BMT.
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Background
Cancer stem cells (CSCs) from solid and hematopoietic tumors resist
conventional cytotoxic therapies that target rapidly proliferating cells.
Thus, residual CSCs can hide within the tumor niche and seed re-
lapse and metastasis. Due to their relapse potential there is an ur-
gent need to identify ways to therapeutically target CSCs. We
previously found that cells expressing high amounts of the stem cell
associated protein aldehyde dehydrogenase (ALDH) are effectively
killed by activated natural killer (NK) lymphocytes. NK cells are known
to kill malignant cells though apoptotic processes inherent to the tar-
get cell, such as TRAIL-DR5 or Fas-FasL binding, without prior
immunization. We and others have also found that the FDA
Fig. 35 (Abstract P47). Treatment of allo-BMT recipients with a VIP
antagonist induces a CD8+ donor T cell-dependent GvL response
associated with down-regulation of PD-L1 on donor pDC and expan-
sion of oligoclonal donor CD8+ T cells. A: Survival curves and GVHD
clinical scores for B10.BR–>B6 allo-BMT harboring C1498 leukemia
cells. Donor T cell subsets were depleted of specific populations by
MACS prior to transplantation as shown. B: Expression of PD-L1 on
donor pDC in B6–>B10.BR transplants. C: TCR Vbeta and J gene seg-
ments present in donorCD8+ T cells (left), CD8+ T cells from mice
with GVHD (middle) and Cd8+ T cells from mice with GvL (right). D:
Lack of correspondence between TCR Vbeta and J genes sequenced
in mice with GvHD and mice with GVL
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approved proteasome inhibitor, bortezomib, sensitizes tumor cells to
NK cell killing by upregulating DR5 and intracellular machinery asso-
ciated with apoptosis. Based on this previous work, we investigated
the effects of bortezomib to promote NK cell killing of ALDHbright
CSCs. We evaluated CSCs derived from solid tumors, in vitro and
in vivo, for the induction of receptors associated with NK cell medi-
ated killing, and for their susceptibility to NK killing after treatment.
Methods
In vitro sensitization and cytotoxicity assays were performed using
cultured NK cells isolated from human peripheral blood. The glio-
blastoma and sarcoma cell lines, U87 and A673, respectively, were
first treated with bortezomib, then co-cultured with activated NK
cells at serial effector:target ratios. Target tumor cells were analyzed
using flow cytometry for cell survival, and expression of Fas, DR4,
DR5, and MICA/B on both ALDHbright and ALDHdim cells.
Results
Bortezomib led to a 3-fold increase in the percentage of viable
ALDHbright glioblastoma and sarcoma cells, in vitro, compared to un-
treated controls. Bortezomib enhanced the expression of Fas and
DR5 by 10% and 40%, respectively, in ALDHbright U87 cells. It in-
creased the expression of DR4 by 20% in ALDHbright A673 cells. How-
ever, bortezomib had little effect on ALDHdim cells. Bortezomib
pretreatment lead to a 98% decrease in viable ALDHbright cells follow-
ing NK cytotoxicity assays in vitro. In vivo, bortezomib improved the
efficacy of adoptive NK cell therapy in multiple mouse xenograft
models.
Conclusions
ALDHbright CSCs are resistant to the cytotoxic effects of bortezomib.
Bortezomib resistance is marked by increases in the expression of
Fas, DR4, and DR5 and leads to increased susceptibility to lysis by ac-
tivated NK cells. The combined use of bortezomib with activated nat-
ural killer cells could act as a potential anti-CSC strategy to improve
outcomes for patients with solid tumors.
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Background
Significant progress has been made over the last decade towards
realizing the potential of natural killer (NK) cells for cancer immuno-
therapy. In addition to donor-derived primary NK cells, also continu-
ously expanding cytotoxic cell lines such as NK-92 are being
considered for adoptive cancer immunotherapy. High cytotoxicity of
NK-92 has previously been shown against malignant cells of
hematologic origin in preclinical studies, and general safety of infu-
sion of NK-92 cells has been established in phase I clinical trials. To
enhance their therapeutic utility, here we genetically modified NK-92
cells to express a chimeric antigen receptor (CAR), consisting of an
ErbB2 (HER2)-specific scFv antibody fragment fused via a linker to a
composite CD28-CD3ζ signaling domain. GMP-compliant protocols
for vector production, lentiviral transduction and expansion of a
genetically modified NK-92 single cell clone (NK-92/5.28.z) were
established.
Methods
Functional analysis of NK-92/5.28.z cells revealed high and stable
CAR expression, and selective cytotoxicity against ErbB2-expressing
but otherwise NK-resistant tumor cells of different origins in vitro.
Ongoing work focuses on the development of these cells for adop-
tive immunotherapy of ErbB2-positive glioblastoma (GBM). ErbB2
expression in primary tumors and cell cultures was assessed by im-
munohistochemistry and flow cytometry. Cell killing activity of NK-
92/5.28.z cells was analyzed in in vitro cytotoxicity assays. In vivo anti-
tumor activity was evaluated in NOD-SCID IL2Rγnull (NSG) mice carry-
ing orthotopic human GBM xenografts and C57BL/6 mice carrying
orthotopic ErbB2-expressing murine GBM tumors.
Results
We found elevated ErbB2 protein expression in >40% of primary
GBM samples and in the majority of GBM cell lines investigated. In
in vitro assays, NK-92/5.28.z in contrast to untargeted NK-92 cells
lysed all ErbB2-positive established and primary GBM cells analyzed.
Potent in vivo antitumor activity of NK-92/5.28.z was observed in
orthotopic GBM xenograft models in NSG mice, leading to a marked
extension of symptom-free survival upon repeated stereotactic injec-
tion of CAR NK cells into the tumor area. In immunocompetent mice,
local therapy with NK-92/5.28.z cells resulted in cures of transplanted
syngeneic GBM in the majority of animals, induction of endogenous
antitumor immunity and long-term protection against tumor rechal-
lenge at distant sites.
Conclusions
Our data demonstrate the potential of ErbB2-specific NK-92/5.28.z
cells for adoptive immunotherapy of glioblastoma, justifying evalu-
ation of this approach for the treatment of ErbB2-positive GBM in
clinical studies.
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Background
Adoptive T Cell Therapy (ACT) of in vitro expanded T cell clones or
transduced T cells redirected against defined tumor antigens has
shown therapeutic efficacy in some patients. Ideas to improve upon
this therapy are multifaceted, including combining ACT with check-
point blockade, increasing the number of defined T cell receptors
(TCR) against defined antigens, identifying new tumor-specific som-
atic mutations to target, and engineering TCRs to have increased
avidity. However, even for well characterized antigens such as Melan-
A, the optimal TCR is not known. Some engineered TCRs have shown
off-tumor toxicity, and so selecting TCRs with maximal therapeutic ef-
ficacy but at the same time giving minimal side effects remains an
important goal.
Methods
We reasoned that one strategy for selecting optimal TCRs might be
to identify T cells expanded after active immunization against de-
fined epitopes in patients who experienced clinical benefit but no
apparent side effects. To this end, we performed deep TCR sequen-
cing of HLA-2/Melan-A+ CD8+ T cells from 16 metastatic melanoma
patients vaccinated against a Melan-A epitope.
Results
While changes in overall TCR clonality measured before and after
vaccination did not correlate with clinical benefit, many TCRs showed
a significant increase in representation of the total TCR repertoire
after vaccination. Of the 6 patients that received a clinical benefit we
found 122 public TCRβ and 124 public TCRα sequences. 105 of these
sequences showed expansion after vaccination in 2 or more patients.
Surprisingly, we did not observe the defined Melan-A-specific TCRs
used previously in redirected ACT clinical trials, designated DMF4
and DMF5. Mapping of public sequences by frequency per patient
and aligning TCRα/TCRβ sequences highlighted several potential
TCRα/TCRβ pairings. One patient was of particular interest as he had
participated in two vaccine trials, with a 32-month interim between
trials and clinical benefit each time. By the end of the second
treatment period, the patient’s TCR repertoire contained 55 public
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sequences. Interestingly, 7 of these sequences showed an initial con-
traction at the end of the first trial followed by a significant expan-
sion by the end of the second trial, suggesting a strong clonotypic
response to Melan-A.
Conclusions
Together, these data highlight multiple TCRα and TCRβ sequences
correlating with clinical benefit in the setting of no treatment-related
toxicities. Similar results have been observed in other trials utilizing
CEA peptide or WT1 peptide immunization. These sequences should
enable full-length cloning of TCRs to be used in redirect adoptive cell
therapy.
Trial Registration
ClinicalTrials.gov identifier NCT00515528.
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Background
Targeting the tumor vasculature holds promise to improve the out-
come for patients with refractory solid tumors. Tumor endothelial
marker (TEM) 8 is an attractive target for T cell therapies since it is
expressed at higher levels in malignant cells and the tumor endothe-
lium as judged by studies using monoclonal antibodies (mAbs). How-
ever T cells do not require high expression of the targeted antigen
for activation, because of the higher overall avidity of a multivalent T
cell compared to bivalent mAbs. Thus, the aim of this project was to
determine the safety and antitumor activity of T cells expressing
TEM8/CD3-specifc T cell engagers (TEM8-ENG).
Methods
qPCR and FACS analysis was used to determine the expression of
TEM8 in solid tumor and endothelial cells. TEM8-ENG T cells were
generated by transducing T cells with a retroviral vector encoding a
TEM8-ENG consisting of the TEM8-specific scFv L2 linked to a scFv
recognizing CD3. TEM8-ENG T cell effector function was evaluated
in vitro and in vivo. Appropriate controls were used including ENG T
cells specific for an irrelevant antigen (CD19).
Results
To confirm the specificity of TEM8-ENG T cells we used targets that
did not express TEM8 (BV173) or BV173 cells that were genetically
modified to express human TEM8, murine TEM8, or murine TEM1.
TEM8-ENG T cells recognized TEM8pos targets (BV173.hTEM8,
BV173.mTEM8) as judged by their ability to secrete IFNγ in coculture
assays and kill both targets in cytotoxicity assays; in contrast, TEM8-
neg cells (BV173, BV173.mTEM1) were not recognized. Specificity of
TEM8-ENG T cells was further confirmed with TEM8pos U373 glioma
cells and U373.k/oTEM8 cells. TEM8-ENG T cells recognized a panel
of TEM8pos solid tumor cells (A431, A549, LM7, LAN1, U87), and pri-
mary endothelial cells (HHSEC, HPAEC) in contrast to TEM8neg tumor
cells (KG1a, Daudi). In vivo, intratumoral administration of TEM8-ENG
T cells induced regression of U373 gliomas in an orthoptic xenograft
model. Intravenous administration of 1x107 TEM8-ENG T cells re-
sulted in antigen-dependent expansion and death of 7/10 mice; no
toxicity was observed after the injection of 1x106 TEM8-ENG T cells.
Conclusions
TEM8 is expressed in tumor endothelium, normal endothelial cells
and solid tumor cells as judged by qPCR, FACS, and functional assays.
TEM8-ENG T cells had antitumor activity in vivo, but displayed dose-
dependent toxicity. Our studies highlight that mAbs and T cells may
have different toxicity profiles, most likely due to differences in their
avidity for the targeted antigen. TEM8-ENG T cell xenograft models
represent an ideal model to study genetic approaches to prevent ‘on
target/off cancer toxicities’ of cell therapies.
P52
A pathogen boosted adoptive cell transfer immunotherapy to
treat solid tumors
Gang Xin1, David Schauder1, Aimin Jiang2, Nikhil Joshi3, Weiguo Cui1
1Blood Center of Wisconsin, Milwaukee, WI, USA; 2Department of
Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA; 3Koch
Institute for Integrative Cancer Research and Department of Biology,
Massachusetts Institute of Technology, Cambridge, MA, USA
Correspondence: Gang Xin (Gang.Xin@BCW.edu)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P52
Background
Despite the remarkable success in treating hematological malignan-
cies, adoptive cell transfer (ACT) still faces several challenges in treat-
ing solid tumors. The main stumbling blocks include insufficient
quantity of tumor-specific T cells for transfer, impaired migration of
transferred T cells into the tumor and the immunosuppressive micro-
environment within the tumor.
Methods
To overcome these problems, we designed an innovative approach
that not only overcomes immunosuppression, but also induces ro-
bust anti-tumor T cell responses in the tumor. We first genetically
engineered dual-specific CD8 T cells that can recognize both a tumor
associated antigen and a bacterial antigen in vitro. Then, we treated
tumor-bearing mice with ACT using a small number of the dual-
specific CD8 T cells. This was accompanied by intratumoral injection
of a low dose of the bacteria, which was sufficient to break local
immunosuppression.
Results
The dual-specific CD8 T cells expanded robustly and migrated to the
tumor bed in response to the infection. At the same time, the second
TCR of these effector CD8 T cells recognized tumor antigen and exe-
cuted effector function, causing tumor regression. As a result of this
enhanced anti-tumor effect, 60% of the treated mice successfully
eradicated their solid tumor at the primary site.
Conclusions
Our approach not only overcomes immunosuppression, but also re-
cruits robust anti-tumor T cell responses to the tumor. Overall, our
study harnesses the power of multiple arms of the immune system
with promising translational value, which can be used to target many
types of solid tumors.
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Background
Immunotherapy has emerged as a strategy for the treatment of can-
cer. One of these immunotherapies is adoptive tumor-infiltrating
lymphocyte (TIL) therapy, in which T cells from resected tumors are
expanded in vitro and then given to patients. However adoptive TIL
therapy has little efficacy for many patients, because the tumor
microenvironment creates an extreme environment for T cells. Our
lab has revealed that T cells display metabolic defects, especially a
loss of mitochondria, when they infiltrate the tumor microenvir-
onment. This loss is related to T cell exhaustion. We hypothesize
that these exhausted T cells were the most functional cells as
they responded to tumor earliest and strongest. However their
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loss of mitochondria prevents them from further expansion when
removed and cultured in vitro. Thus, we are utilizing what we
have identified about their metabolic dysfunction to rejuvenate
those T cells during ex vivo expansion. Our goal is to make
exhausted T cells more metabolically active and provide a potent
method for TIL therapy.
Methods
Tumor injection: mice were given either 250,000 B16 or MC38 tumor
cells injected intradermally in the center of the back. T cell activation:
TILs are activated with 3 ug/ml anti-CD3 (plate bound), 2 ug/ml anti-
CD28, 50 units/ml IL-2. Adoptive TIL transfer: treated and non-treated
TIL are given to the mice that bear tumors by intravascular injection.
Results
PD-1hi cells remain mitochondrially deficient and fail to proliferate
ex vivo. Rosiglitazone can rescue mitochondrial mass and prolifera-
tion. PD-1 Tim-3hi cells are over proliferated by PD-1 Tim-3lo cells.
Preliminary data has shown that glitazone compounds to long-term
expansion protocols prevents loss of the previously-exhausted T cells
during expansion.
Conclusions
Cells expressing high levels of PD-1 and Tim-3 have low mitochondrial
mass and fail to proliferate effectively in vitro. Mixing congenically
marked cells from the non-exhausted or exhausted compartment
shows exhausted cells are quickly overtaken by the non-exhausted (less
than 1 week). Adding glitazone compounds to stimulate mitochondrial
biogenesis results in short-term improvement of T cell proliferation
in vitro. Preliminary data has shown that glitazone compounds to long-
term expansion protocols prevents loss of the previously-exhausted T
cells during expansion.
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Background
Both CD28- and 4-1BB-based second-generation CAR T cells elicit
dramatic clinical responses in patients with refractory/relapsed CD19
positive malignancies, especially patients with acute lymphoblastic
leukemia. We recently demonstrated that co-expressing the second-
generation 19-28z CAR with 4-1BBL yields balanced tumoricidal
function and T cell persistence, resulting in the greater therapeutic
efficacy (Turbocharged CAR). However, due in part to their tumor
microenvironment, solid tumors often resist CAR T cell therapy. We
hypothesized that CD28-based second-generation CAR T cells coex-
pressing 4-1BBL would have better therapeutic efficacy against solid
tumors than current second-generation CARs, owning to their unique
intrinsic and immunomodulatory qualities.
Methods
Prostate-specific membrane antigen (PSMA) is a dimeric type II integral
membrane glycoprotein, which is overexpressed in castrate-resistant,
metastatic prostate cancer. We constructed a tricistronic PSMA-targeted
CAR vector encoding the Pd28z CAR, 4-1BBL and a truncated, nonfunc-
tional EGFR as a safety control (Pd28z–4-1BBL–EGFRt). Two second-
generation CARs (Pd28z and PdBBz) served as controls.
Results
In a high tumor burden model of disseminated prostate cancer, we
used the in vivo “stress test” in which the T cell dose is gradually low-
ered lowered to levels where CAR therapy begins to fail, in order to
compare the relative functionality and persistence of these CAR T
cells. CAR T cells coexpressing Pd28z with 4-1BBL exhibited higher
tumor eradication and T cell persistence in NSG mice bearing diffuse
metastatic prostate cancer, compared to both second-generation
CARs Pd28z and PdBBz.
Conclusions
4-1BBL Turbocharged CAR T cells thus seem to possess striking thera-
peutic potential against solid tumors.
Biomarkers and Immune Monitoring
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Background
Dendritic cells (DCs) orchestrate adaptive and innate immune re-
sponses and are therefore key targets for immunotherapy (IT). Of
special interest for IT directed against cancer are DCs with a high
capacity of antigen cross-presentation, potentially resulting in cell-
mediated tumor antigen-specific effects. This study reports an update
on the map of DC subtypes and phenotypical aspects that may be
reached by adjuvant measures in human tonsils and lymph nodes,
both potential sites for “vaccine” deposition.
Methods
From biopsies of tonsils (n=23) and neck lymph nodes (n=16), single
cell suspensions were prepared by enzymatic digestion and DCs were
identified by an 8-color flow cytometry Ab panel. DC subsets frequen-
cies (CD1c+, CD123+, CD141+, CD1c- CD141-), maturity status, and sur-
face receptor profiles, focusing on a variety of C-type lectin receptors.
Toll-like receptor 2 (TLR2) and the chemokine receptor XCR1, were then
described and investigated at protein level via flow cytometry. The re-
sults were then analyzed through two-group comparison tests.
Results
DCs with similar myeloid CD11c+/plasmacytoid CD123+ ratios and
largely similar frequencies among CD45+ leukocytes were observed
in tonsils as well as lymph nodes. However, among the DC subsets
studied, CD141+ DCs showed a higher frequency in tonsils compared
to lymph nodes. No maturity differences were found among the DC
subsets in tonsils and lymph nodes based on expression of CD80
and CD86. DC subsets expressing XCR1, TLR2, CLECSF14, CD206,
DEC205, and Dectin-1 were observed with similar frequencies in ton-
sils (n < 18) and lymph nodes (n < 11).
Conclusions
DCs in tonsils and lymph nodes largely share similar features in terms of
frequency, maturation, and PRR expression. However, a higher frequency
of CD141+ cells in tonsils may be of interest considering this subset’s cap-
ability in antigen cross-presentation. Our work suggests tonsils as well as
lymph nodes as vaccine deposition sites in DC-mediated IT. Furthermore,
specific adjuvant measures directed at C-type lectin receptors, TLR2, and
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XCR1 may be employed to achieve cross-presentation of antigen and
cell-mediated tumor antigen-specific effects.
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Background
Gastric cancer (GC) is often diagnosed at an advanced stage, for
which therapeutic options are largely limited to cytotoxic chemother-
apy and five-year survival is less than 20%. Immune checkpoint
blockade with anti-programmed cell death-1 (PD-1) or anti-
programmed cell death ligand-1 (PD-L1) antibodies is emerging as a
promising therapeutic approach for several cancer types. An import-
ant question is whether the clinical efficacy of PD-1/PD-L1 check-
point blockade can be improved through combination with targeted
agents, such as trastuzumab, for use in human epidermal growth fac-
tor receptor 2 (HER2)-positive disease and olaparib, a poly (ADP-ri-
bose) polymerase (PARP) inhibitor. This study determines the
association of PD-L1 expression and immune cell infiltrates with clin-
ical outcome and investigates the overlap of these with microsatellite
instability (MSI)-high, ATM low and HER2 high segments.
Methods
PD-L1 membrane expression on tumour cells (TC) and infiltrating im-
mune cells (IC), CD3+ T lymphocytes, CD8+ cytotoxic T cells, ATM and
HER2 were assessed by immunohistochemistry (IHC) in a cohort of 380
Korean gastric cancer patients. PD-L1 positivity was assessed by a path-
ologist (positive < 0%). CD3 and CD8 were quantified by HALO® image
analysis (cells/mm2). EBV status was determined using in situ
hybridization and MSI status was performed using PCR and MLH1 IHC.
Results
The ATM-low and HER2-high segments are mutually exclusive and
differ markedly in their immune profile; the ATM-low segment being
enriched for MSI (p < 0.01), PD-L1 TC positivity (p < 0.01) and CD8+
cytotoxic immune infiltrates (p=0.033), while the HER2 segment is
enriched for MSS, with no enrichment for immune markers. The PD-
L1 segment is associated with increased T cell infiltrates: CD3 (p <
0.01) and CD8 (p < 0.01), while the MSI-high segment is enriched for
PD-L1 TC (p < 0.01), PD-L1 IC (p < 0.001), CD3 (p < 0.05) and CD8 (p
< 0.01), and has significant overlap with the ATM-low but not HER2
segments. Multivariate analysis confirmed PD-L1 TC positivity (p <
0.01), high CD3 (overall survival [OS] P < 0.01; disease-free survival
[DFS] p=0.021) and high CD8 (OS p < 0.01; DFS p=0.027) as inde-
pendent prognostic factors for both DFS and OS. Patients with MSI-
high tumours had better overall survival by both univariate (p < 0.01)
and multivariate (p < 0.05) analysis.
Conclusions
Here we present evidence for segmentation of gastric cancers into
four distinct molecular segments, namely ATM-low, HER2-high, PD-L1
positive and MSI-high. This illustrates the potential for subsets of GC
patients to respond differently to immune therapy and the opportun-
ity to employ different strategies for maximising the benefit from im-
mune therapies in these segments.
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Background
ELISPOT assays are a key research tool for enumerating antigen-
specific T and B cells in PBMC. As both T and B cells occur in major
classes, immune monitoring has to be concerned with identifying
these as well. So far, ELISPOT assays have been primarily done single
or double color. In this report, we demonstrate the development of
four color T and B cell ELISPOT assays.
Methods
PBMC were cultured for 4 days with a peptide pool of CMV-, EBV-
and Flu- viruses for T cell assays or polyclonal B cell activators for B
cell assays. On day 4, cells were washed, counted and plated in a low
autofluorescence PVDF plate. Plates were precoated with capture
antibodies for detection of IFN-g, IL-2, GzB, or TNF-α (T cell assays) or
Ig secretion (B cell assays). During a 4h culture, the cytokine or anti-
bodies secreted by the individual T or B cells respectively was cap-
tured on the membrane. The plate-bound “spots” were visualized
using cytokine-specific or IgG subclass- or Ig class-specific detection
reagents, whereby each detection reagent is distinguished from the
other 3 reagents through its unique fluorescence. The four-color as-
says were analyzed using an ImmunoSpot® S6 Analyzer.
Results
We show that the four color assay has the same sensitivity for de-
tecting individual cells secreting analytes as the respective single
color assays, and that the four fluorescent colors can be discerned
unambiguously, without overlap. Cells secreting any of the four ana-
lytes can therefore be identified unambiguously in an automated
fashion, without the need for compensation. Cells co-expressing ana-
lytes can be identified by superimposing the individual colors. Study-
ing B cells and T cells experimentally has permitted us to verify the
accuracy of co-expression measurements. Each B cell secretes only
one type of Ig class/subclass. T cells, in contrast, frequently coexpress
cytokines. Serial dilution experiments showed that for T cells the
numbers of co-expressors linearly decreased with the numbers of
cells plated. For B cells, no coexpressors were found.
Conclusions
The feasibility of four color T and B cell assays have been shown
here. This is particularly important when conserving cell material
thereby allowing researchers the opportunity for comprehensive im-
mune monitoring spanning multiple cytokines.
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Background
Testing of PBMC for immune monitoring purposes requires verifica-
tion of their functionality. This is of particular concern when testing
cryopreserved PBMC or cells that have been shipped, stored for pro-
longed periods of time. The CEF peptide pool has been developed as
a positive control for CD8 cell functionality. A positive control for de-
tecting CD4 memory cell functionality so far is lacking.
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Methods
Protein antigens from infectious/ environmental organisms have
been selected that are ubiquitous. T cell reactivity to these antigens
has been tested in an IFN-g Immunospot® assay from CTL. Cryopre-
served PBMC from 100 Caucasian donors were selected from CTL’s
ePBMC database for testing. Magnetic bead depletion experiments
were performed to verify CD4 or CD8 response.
Results
Of an initial selection of 12 antigenic systems, (Varicella, Influenza,
Parainfluenza, Mumps, Cytomegalovirus, Streptococcus, Mycoplasma,
Lactobacillus, Neisseria, Candida, Rubella, and Measles) 3 were se-
lected as a) eliciting CD4 cells exclusively and b) eliciting recall re-
sponses in the majority of donors. While individually none of the
antigens triggered recall responses in all of the donors, the pool of
these three antigens did. Only 2 of 100 donors did not respond to
the CPI (Cytomegalo-, Epstein Barr-, and Influenza- virus) protein
pool. These two however were impaired functionally non-viable cells
with increased numbers of dead and apoptotic cells and showed in-
creased apoptotic progression. Comparisons with CEF peptide pool,
showed clear cut responses in ~50% of donors, borderline responses
in xx and no responses in 30% of donors.
Conclusions
CPI protein pool is suited as a positive control in Caucasians. Studies
are on the way to establish the suitability of this pool for functional-
ity testing in Asians and Africans.
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Background
It has been a matter of debate to determine the best cutoffs in
ELISPOT assay analysis for the unambiguous identification of a
positive T cell response. At present, the answers to the above
question is largely based on empirical or mixed criteria. To
come up with scientifically validated answers, parametric statis-
tical analysis has to be used, which in turn requires knowledge
about the distributional properties of ELISPOT counts in repli-
cate wells.
Methods
PBMC of HLA-A2-0201 positive human subjects who had been
infected with HCMV were plated with a HCMV peptide antigen
(CEF-7 peptide, pp65 (495-503)) at 100,000 cells per well in IFH-
g ELISPOT assays. However, we selected donors whose PBMC,
when tested at 100,000 cells per well and challenged with the
HLA-A2-0201-restricted HCMV peptide, pp65(495-503) did not
display spot counts over medium background. We tested the
PBMC for pp65 reactivity in 96 replicate wells to establish the
distributional properties of these low frequency ELISPOTs. The
distributional properties of the spot counts in the replicate wells
were analyzed using diagnostic plots (QQ plots) and the
Shapiro-Wilk normality tests.
Results
We observed that increasing the number of PBMC plated per well
resulted in higher positive to negative count ratio, lower relative
experimental error (CV), and higher power for detecting pp65-
induced positive responses without causing false positive results
from HCMV negative subjects. This decrease of CV and increase
in the power of the test was directly proportional to the numbers
PBMC plated. The distributional properties showed that the spot
counts in replicate wells follow Normal distribution. We showed
that parametric statistics, such as Student's t test can be used
and provide higher statistical power detecting weak positive
HCMV responses than nonparametric methods (Wilcoxon or DFR).
We also show that compared to increasing cell numbers per well,
the increase of replicate wells is a more efficacious means of es-
tablishing positivity when statistical analysis is at the limits of
confidence.
Conclusions
The Normal distribution of ELISPOT counts permits us to make
precise predictions regarding the numbers of replicate wells
needed, and cut off values, especially when responses from do-
nors are low.
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Background
High levels of microsatellite instability (MSI-H) can occur in some
patients with colorectal cancer (CRC) due to defects in mismatch
repair (MMR). In the phase II KEYNOTE-016 study, MSI-H CRC pa-
tients were more responsive to PD-1 inhibition with pembrolizu-
mab, as were MSI-H non-CRC patients. Here, we evaluate loss of
MLH1 gene expression across tumor types, and effect of MSI sta-
tus on clinical response to pembrolizumab in the KEYNOTE-012
and KEYNOTE-028 studies in patients with recurrent, metastatic
tumors including breast, gastric, urothelial, and CRC tumors.
Methods
Microarray analysis of loss of MLH1 gene expression was used as a sur-
rogate for MSI-H status to assess prevalence of MSI-H in the proprietary
Moffitt database of approximately 18,000 annotated, archived tumors.
MSI status of tumors from KEYNOTE-012 and KEYNOTE-028 was evalu-
ated using the Promega MSI Analysis system v1.2. Microsatellite
markers were amplified from DNA isolated from tumors and separated
and size analyzed by capillary electrophoresis. MSI-H status was identi-
fied by comparison of formalin-fixed, paraffin-embedded tumor sam-
ples to matched blood DNA. Samples were MSI-H if 2 or more markers
changed or non-MSI-H if 1 or no markers changed relative to blood. Lo-
gistic regression analyses assessed the correlation between MSI status
and overall response rate (ORR, centrally-assessed RECIST v1.1).
Results
In the Moffitt database, loss of MLH1 expression mirrored results from a
clinical MSI immunohistochemistry assay in CRC patients. Loss of MLH1
expression also correlated with mutational load. Inferred MSI-H status
was identified across multiple tumor types (aggregate prevalence 3.2%)
in the Moffitt database (Fig. 36). In KEYNOTE-012 (n=96) and KEYNOTE-
028 (n=265), MSI-H status was identified in 6% and 2% of patients, re-
spectively, (3% overall), similar to the unselected population in the Mof-
fitt database. Gastric cancer had the highest prevalence (n=4 patients),
with estrogen receptor positive breast, biliary, esophageal, triple nega-
tive breast, endometrial, CRC, and bladder tumors also having MSI-H in
at least one patient. For patients with MSI and response data (n=310),
ORR was 70% versus 12% (1-sided p=0.0001) in those with MSI-H and
non-MSI-H status, respectively.
Conclusions
In this retrospective analysis, identification of MSI-H status was associated
with a statistically relevant increase in response to pembrolizumab. This
suggests that determination of MSI-H status may be predictive of re-
sponse to pembrolizumab regardless of histology. The association be-
tween MSI-H status and clinical benefit of anti-PD-1 therapy is being
evaluated in ongoing studies (KEYNOTE-158 [NCT02628067], KEYNOTE-
164 [NCT02460198], and KEYNOTE-177 [NCT02563002]).
Trial Registration
ClinicalTrials.gov identifier NCT01848834 and NCT02054806.
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Background
Tremelimumab is a cytotoxic T lymphocyte-associated antigen-4-
blocking monoclonal antibody. An unmet clinical need exists for blood-
based response-predictive gene signatures to facilitate use of cancer
immunotherapy in the most clinically effective and cost-efficient
manner.
Methods
Pre- and post-treatment (30 days) peripheral blood samples were
taken from 210 treatment-naïve melanoma patients receiving treme-
limumab in a worldwide, multicenter phase III study. Objective
response was determined by an expert panel of radiologists using
RECIST criteria. 169 mRNA transcripts were measured for the n=210
patients using reverse transcription polymerase chain reaction (RT-
PCR) [1]. Pre- and post-treatment response-predictive signatures were
identified in the n=210 training dataset. An independent population
of n=150 refractory/relapsed melanoma patients receiving tremeli-
mumab after chemotherapy enrolled in a worldwide, multicenter
phase II study [2] was the test dataset.
Results
A 16-gene pre-treatment and 8-gene post-treatment mRNA signa-
tures were identified in the n=210 training dataset. These pre- and
post-treatment signatures were tested in the n=150 test dataset first,
for objective response as determined by RECIST criteria, and second
for one-year survival after treatment. The same genes, coefficients
and constant from the training dataset were used in the test cases
with the results in Table 5. Both the 16-gene pre- and 8-gene post-
treatment response-prediction training gene signatures validated
when compared to objective response in the test dataset. The one-
year survival criteria also validated with even higher AUC’s for both
pre- and post-treatment.
Conclusions
This is the first large clinical study of tremelimumab, independently
validated in a second large clinical study, to show both pre- and
post-treatment response-predictive mRNA signatures in blood. The
pre-treatment biological signature may represent expression levels of
particular immune system genes that are needed for a robust im-
mune response against cancer. They may identify patients whose
immune systems are already primed to fight the cancer and are par-
ticularly amenable to a boost in effectiveness provided by immuno-
therapy. The 30-day post-treatment biological signature represents a
timely way to determine whether the patient is responding positively
to the immunotherapy.
Trial Registration
ClinicalTrials.gov identifier NCT00257205.
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Background
Checkpoint inhibitors are becoming widely used for immunotherapy
but methods to monitor dosing and duration for each individual pa-
tient needs to be more fully understood. Immune monitoring by flow
cytometry is a tool that can be utilized for measuring responses to
immunotherapy in patients. In this study we assessed the expression
of PD-1 and CTLA-4 on numerous cell types in healthy volunteers
(HVs) and glioblastoma (GBM) patients enrolled in a dendritic cell
clinical trial.
Methods
Peripheral blood was collected from 20 HV and 20 GBM patients receiv-
ing a DC vaccine in a clinical trial. Whole blood was stained using a
previously established method for the identification of multiple cell popu-
lations by flow cytometry and novel analysis that captures data on over
120 phenotypes [1]. An extended analysis focused on T cell phenotypes
was performed using markers for CD154, CD45RO, CD56, CD3, CD8,
CD28, CD4, and CD45. T cell parent populations were characterized by
SS, FS, CD45+, CD3+, CD4+, CD8+, CD4+/CD8+ sub populations. Non-T cell
populations were assessed by various gating strategies. These popula-
tions were measured for PD-1+, CTLA4+, DP, and DN populations.
Results
We identified 15 parent populations, of which 11 expressed PD-1
and 9 expressed CTLA-4. Within subsets of the parent populations
we found statistically significant differences (p <0.001) in PD-1
between CD8+ memory and CD8+ naïve cells, CD4+ memory and
CD4+ naïve cells, CD8+ NKT and CD8+CD3+ cells, as well as NKT and
NK cells. These statistical differences hold true for both HV and
GBM patients. We also found HVs to have higher levels of CTLA-4
on CD4+CD8+ cells and B cells compared to GBM patients, and
lower levels of PD-1 on CD8+ and naïve CD8+ cells.
Table 5 (Abstract P61).
Pre-Treatment Blood-Based Post-Treatment Blood-Based
16-Gene mRNA Signature 8-Gene mRNA Signature
Melanoma Training Test Test Training Test Test
Cases N=210 N=150 N=150 N=210 N=150 N=150
Biomarker Response Response Survival Response Response Survival
Sensitivity 96.4% 65.0% 74.4% 85.7% 70.0% 69.8%
Specificity 66.5% 59.2% 55.1% 64.3% 60.8% 59.8%
NPV 99.2% 91.7% 84.3% 96.7% 92.9% 83.1%
AUC 0.8634 0.6376 0.6785 0.7853 0.6125 0.6512
Fig. 36 (Abstract P60).
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Conclusions
This panel allows us to measure approximately 60 phenotypes re-
lated to checkpoint proteins. The data presented here identify PD-1
and CTLA-4 phenotypic differences within parent populations, within
subsets of parent populations, and differences in healthy volunteers
compared to GBM patients. These results may help optimize the tar-
geting of checkpoint proteins as well as other immunotherapeutic
approaches in clinical trials.
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Background
Immunostimulatory therapies targeting immune suppressive pathways
produce durable clinical responses in advanced solid tumors. Indoleamine
2, 3-dioxygenase (IDO) is the rate-limiting oxidoreductase that catalyzes
the degradation of tryptophan to kynurenine. IDO induces immune toler-
ance by downregulating CD8+ and effector CD4+ T cell responses. IDO1,
the most active isoform, is expressed in diverse tumor types and can be
targeted using small molecule inhibitors. Here, we used a validated quan-
titative in situ assay to measure the levels of IDO1 protein in a retrospect-
ive collection of hormone receptor-positive breast cancer (BC).
Methods
IDO1 was measured using quantitative immunofluorescence (QIF) in
362 stage I-III hormone-receptor-positive breast carcinomas repre-
sented in tissue microarray format. The levels of IDO1 were deter-
mined in the tumor compartment; and were stratified using the
median as cut-point. The association between IDO1 levels, clinico-
pathological features, CD3+, CD8+ and CD20+ tumor-infiltrating lym-
phocytes (TIL) and survival was studied.
Results
IDO1 protein was detected in 76.2% of hormone receptor-positive BC.
There was no significant association between IDO1 levels and major
clinico-pathological characteristics. Increased IDO1 correlated with de-
creased CD20+ infiltration (P=0.0004) but not with changes in CD3+ or
CD8+ levels. Elevated IDO1 expression was associated with worse 20-year
overall survival (log-rank P=0.02, HR=1.39, 95% C.I.: 1.05-1.82). IDO1 scores
were independently associated with outcome in multivariable analysis.
Conclusions
IDO1 protein is expressed in the majority of hormone receptor-
positive BC and is an independent negative prognostic marker. Add-
itionally, IDO1 expression is negatively associated with tumor B cell
infiltration. Measurement of IDO1 has the potential to identify a
population that might derive benefit from IDO1 blockade.
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Background
Cancer immunotherapies historically, have low success rates. One
way to increase these success rates involves investigating baseline
or early response biomarkers that predict success. Selecting pa-
tients with early biomarkers for success and competent immune
status are essential when choosing the best therapeutic strategy.
CD137 agonists, activators of T and NK cells and a promising newer
immunotherapy, have dramatically reduced tumor size and disease
in murine tumor models [1] and are currently being examined in
clinical trials [2].
Methods
This study investigated the immune response and potential
early immune biomarkers in both solid tumor and hematologic
cancer patients participating in the phase I BMS-663513
NCT01471210 clinical trial of urelumab monotherapy. We used
peripheral blood mononuclear cells to determine the circulating
immune competence of patients (n=8) before treatment (base-
line/C1D1), 24 hours after the first treatment (C1D2), before the
second treatment (C2D1), and up to 30 days after the third
treatment (C3R). Analysis was performed using mass cytometry,
surveying 38 different immune proteins simultaneously.
Results
At all time points, we observed a trend toward higher central mem-
ory and naïve CD8+ T cells in patients with stable disease (n=3) or
partial response (n=1) vs. progressors (n=4), while the opposite was
true in effector and effector memory RA cells. The most striking dif-
ference was seen when considering all CD8+CD27+ T cells, which
were higher in those with stable disease or partial response, at all
time points. CD8+FcεR1α+ T cells showed a similar trend, albeit to
a lesser extent, while CD57+CD8+ T cells showed the opposite
trend. CD8+ T cells in both groups were comparably responsive to
PMA/ionomycin stimulation, producing multiple cytokines. These
trends were not seen in CD4+ T cells or with head and neck solid
tumor patients treated with cetuximab.
Conclusions
The aforementioned trends suggest that CD27+CD8+ T cells, and
possibly other subsets of CD8+ T cells, should be further ex-
plored to determine whether they predict response to anti-CD137
agonist therapy. They also suggest that potential predictive mea-
sures of immune status prior to immunotherapy are detectable in
peripheral blood.
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Background
The therapeutic effects of PD-1/PD-L1 inhibition in multiple can-
cers indicates a critical role for this pathway in immunosuppres-
sion in the tumor microenvironment (TME), but factors regulating
PD-L1 expression on tumor and immune cells are poorly under-
stood. The dichotomous transcription factors STAT1 and STAT3
have both been reported to bind the PD-L1 promoter. The current
study investigates the role of STAT1/3 and other signaling in
cytokine-induced PD-L1 expression on human melanoma (MEL)
cells and monocytes.
Methods
Seventeen cultured MELs or short-term monocyte cultures were
treated with recombinant cytokines including IFN-g, IL-6, IL-10, IL-
32g, or TNF-a. PD-L1 cell surface protein expression was detected by
flow cytometry, and mRNA by quantitative real-time RT-PCR (qRT-
PCR). STAT1 or/and STAT3 were knocked down by small interfering
RNAs (siRNAs). Total and phosphorylated STAT1/3 proteins were
quantified by Western blotting.
Results
While PD-L1 is expressed on 35-40% of MELs in situ, it was not
expressed on 17 cultured MELs. IFN-g significantly enhanced PD-L1
protein expression on MELs (p=0.0003), increasing PD-L1 mRNA ex-
pression (qRT-PCR) in association with PD-L1 cell surface protein ex-
pression (FACS) in all MELs tested (p=0.0004). This suggests that
IFN-g regulates PD-L1 expression primarily at the transcriptional
level and not via translocation of intracellular protein stores. En-
hanced PD-L1 expression in IFN-g-treated MELs correlated with in-
creased STAT1 phosphorylation (p=0.05). Consistent with this,
siRNA knockdown of STAT1 reduced PD-L1 expression by 40-70% in
2 MELs after 24-48hr IFN-g exposure. In contrast, STAT3 knockdown
reduced IFN-g-induced PD-L1 expression by only 12-15%, on one of
two MEL lines. In cultured monocytes from two donors, PD-L1
mRNA expression was induced by IFN-g, IL-10, IL-32-g and TNF-a,
and significantly correlated with PD-L1 cell surface protein expres-
sion, suggesting that these cytokines acted at the transcriptional
level. In monocytes, IFN-g was associated with markedly increased
pSTAT1, and IL-10 with increased pSTAT3. These cytokines were not
associated with increased pp65 or focal adhesion kinase (FAK)
phosphorylation in monocytes.
Conclusions
In addition to IFN-g, other cytokines in the TME may play im-
portant, coordinate and selective roles in promoting PD-L1 ex-
pression on different cell types including tumor and stromal
cells. pSTAT1 and pSTAT3 are associated with PD-L1 protein ex-
pression in response to different cytokine stimuli. Future studies
will further characterize cytokine-triggered transcription factors
and signaling pathways responsible for PD-L1 expression on
tumor cells and immune cells. Understanding mechanisms regu-
lating PD-L1 expression will help guide the development of
more optimal predictive biomarkers and combinatorial therapies
based on anti-PD-1.
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Background
Assays of the abundance of immune cell populations in the tumor
microenvironment promise to inform immune oncology research
and the choice of immunotherapy for individual patients. We
propose to measure the intratumoral abundance of various immune
cells populations with gene expression. In contrast to IHC and flow
cytometry, gene expression assays yield high information content
from a clinically practical workflow. Previous studies of gene expres-
sion in purified immune cells have reported hundreds of genes
showing enrichment in a single cell type, but the utility of these
genes in tumor samples is unknown. We describe a novel statistical
method for using co-expression patterns in large tumor gene expres-
sion datasets to validate previously reported candidate cell type
marker genes.
Methods
We used co-expression patterns in 9986 samples from The Can-
cer Genome Atlas (TCGA) to validate previously reported cell
type marker genes. We compared immune cell scores derived
from these genes to measurements from flow cytometry and
immunohistochemistry. We characterized the reproducibility of
our cell scores in replicate runs of RNA extracted from FFPE
tumor tissue.
Results
We identified a list of 60 marker genes whose expression levels
quantify 14 immune cell populations. Cell type scores calculated
from these genes are concordant with flow cytometry and IHC read-
ings, show high reproducibility in replicate RNA samples from FFPE
tissue and reveal an intricate picture of the immune infiltrate in
TCGA. Most genes previously reported to be enriched in a single cell
type have co-expression patterns inconsistent with cell type
specificity.
Conclusions
Due to their concise gene set, computational simplicity and util-
ity in tumor samples, these cell type gene signatures may be
useful in future discovery research and clinical trials to under-
stand how tumors and therapeutic intervention shape the im-
mune response.
Fig. 37 (Abstract P66). Comparison of gene expression and flow
cytometry cell type measurements in PBMCs
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Background
Breast cancer is a leading cause of cancer-related death among
women worldwide. Although, surgery, radiotherapy, and chemother-
apy have improved the 5-year survival rate, new treatment methods
are needed to combat this disease. To date, significant efforts have
been invested into harnessing the therapeutic potential of the im-
mune system for the treatment of cancer. However, tumor tolerance
and immune suppression can severely limit its therapeutic efficacy.
In fact, natural killer T (NKT) cells play an important role in cancer im-
mune surveillance, but are reduced in cancer patients. In order to
assess which patients will likely benefit from immune cell-based ther-
apies, we have developed a quantitative method to rapidly assess
the baseline function of NKT cells using stimulation with artificial
antigen presenting cells followed by and quantitative real-time PCR
(aAPC-qPCR).
Methods
In this study, we assessed NKT cell number and function in healthy
donors and breast cancer patients by flow cytometry, ELISA, and
qPCR. In addition, we assessed the percentage of tumor-infiltrating
lymphocytes and PD-L1 expression within the tumor microenviron-
ment by immunohistochemistry.
Results
Although % circulating NKT cell were significantly reduced in breast
cancer patients (BCP), compared to healthy donors (HD), we detected
NKT cell function in 82% HD (n=22) and 70% BCP (n=30). We com-
pared high responders (high IFN-γ induction) to low responders and
found that there was no significant difference in NKT cell number be-
tween these two groups. Following further characterization of these
groups, it was found that low responders had a significant reduction
in the induction of TNFα, LAG3, and LIGHT.
Conclusions
In summary, this data we have developed a novel diagnostic platform
using aAPC-qPCR to determine NKT cell function in patients. This tech-
nology is important because NKT cell number did not correlate with
function in our breast cancer patient cohort. Thus, our studies demon-
strate that there is a critical need to assess baseline immune function
prior to the initiation of immunotherapy. Future studies can focus iden-
tifying new breast cancer classifications according to immune gene ex-
pression patterns, and these tumor subtypes may provide a basis for
new therapeutic opportunities.
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Background
Survival and expansion of NK cells depends on interleukin (IL)-15. It
has recently been shown that IL-15 infusions caused NK cell expan-
sions in cancer patients. The objectives of our study were to assess
the effects of IL-15 on functions of CD56dim and CD56bright subpopu-
lations of NK cells in IL-15-treated cancer patients.
Fig. 40 (Abstract P67). a Circulating % NKT cells are reduced in BC
patients. Peripheral blood mononuclear cells (PBMC) were collected
from healthy donors (HD) and breast cancer patients (BC), stained
for NKT TCR and analyzed by flow cytometry. b NKT cell function
correlates total T cell function in BC patients. PBMCs from BC
patients were stimulated with CD1D-Ig aAPC loaded with a-GalCer
to specifically activate NKT cells or anti-CD3/CD28 to activate T cells.
Media serves as a negative control and PMA/ionomycin was the
positive control. After 4 hours, RNA was extracted and qPCR was
performed to assess IFN-g and 18S. Fold induction was calculated
relative to the control
Fig. 39 (Abstract P66). Reproducibility of gene expression
measurements of immune cell types
Fig. 38 (Abstract P66). Comparison of gene expression and IHC cell
type measurements in FFPE
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Methods
We monitored numbers, phenotypic changes, cytokine production
and lytic activities of CD56dim and CD56bright NK cell subpopulations
in the blood of cancer patients that had received daily infusions of 2
μg/kg IL-15 for 10 days.
Results
Ten-day continuous infusion of IL-15 led to expansions of both CD56dim
and CD56bright subpopulations of NK cells. Phenotypic analyses re-
vealed that IL-15 infusions caused the expression of CD56bright–typical
surface proteins on CD56dim NK cells that included Trail, CD62L, NKG2D,
CD94 and the IL-18 receptor, while CD56bright NK cells remained essen-
tially unchanged. CD56bright NK cells retained their superior ability to
produce IFNγ/TNFα in responses to IL-12/IL-18 when compared with
CD56dim NK cells, and IL-15 infusions increased the percentage of
cytokine-producing CD56bright NK cells. The cytotoxic capacity of
CD56dim NK cells remained superior to CD56bright NK cells even after IL-
15 infusions. However, cytotoxic competencies were increased for both
subpopulations after IL-15 infusions that resulted in substantial lytic
activities via natural cytotoxicity receptors, stress receptors, and
antibody-dependent cytotoxicity even among CD56bright NK cells.
Conclusions
These data show that IL-15 infusions increase the functional abilities
of both types of NK cells in cancer patients.
P69
Identification of a novel subset of tumor-resident human CD8+ T
cells, marked by dual expression of CD103 and CD39
Rebekka Duhen1, Thomas Duhen2, Lucas Thompson3, Ryan Montler2,
Andrew Weinberg1
1Earle A. Chiles Research Institute, Providence Cancer Center, Portland,
OR, USA; 2AgonOx, Inc., Portland, OR, USA; 3Juno Therapeutics, Portland,
OR, USA
Correspondence: Rebekka Duhen (rebekka.duhen@providence.org)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P69
Background
Homing and retention of T cells in tissues is mediated by the inter-
action of adhesion molecules with their respective ligands. Among
those, the integrin CD103 interacts with its ligand E-cadherin and al-
lows T cells to home to epithelial tissues. T cells expressing high levels
of CD103 have recently been identified as tissue-resident memory (TRM)
cells and play a crucial role in protecting epithelial tissues against viral
infections. Previous reports have shown that CD103+ CD8+ T cells were
present in some but not all human solid malignancies.
Methods
Cell sorting, gene expression analysis, and TCR sequencing.
Results
Here, while confirming these data, we identify a subset of CD103+
CD8+ T cells that co-express the ectonucleotidase CD39. This subset
is enriched in primary tumors and metastatic lymph nodes but ab-
sent in the blood and normal lymph nodes of cancer patients. We
compared several tumor histologies and found highest frequencies
in head and neck squamous cell carcinomas (HNSCC), ovarian, lung
and rectal cancers (ranging from 20-80% of tumor-infiltrating CD8+ T
cells), whereas those cells were absent or low in primary colon can-
cer and colorectal liver metastasis. Gene expression analysis of
CD103/39 double positive CD8+ T cells revealed a gene signature
reminiscent of TRM cells (CCR7
lo, L-selectinlo, S1PR1lo and CD69hi), and
their activated phenotype (HLA-DRhi, Ki67hi, Granzyme Bhi) implies
strong tumor reactivity. Furthermore, TCR repertoire analysis shows
high clonality and distinct CDR3 sequences in this subset compared
to other CD8+ T cells present in the tumor. Based on this phenotype,
gene signature, circulation pattern and clonality, we believe that
CD103/39 double positive CD8+ T cells are being chronically stimu-
lated within the tumor microenvironment, and may recognize neoan-
tigens. In support of this finding, our in vitro data suggests that
expression of CD39 is upregulated as a result of strong, sustained
TCR stimulation in naïve CD8+ T cells. Finally, to better address the
role of those cells in vivo we examined 9 different solid murine tumor
models. Unexpectedly, CD103/39 double positive CD8+ T cells were
only found in the transgenic MMTV-PyMT breast cancer model. Utiliz-
ing this model, we plan to study their differentiation and function
in vivo and address their antigenic specificity and role in tumor
development.
Conclusions
Taken together our findings suggest that targeting tumor-resident
CD103/39 CD8+ T cells may be a promising approach to enhance
immune-mediated tumor regression.
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Background
Bladder cancer is the 5th most common malignancy in the US, and
the majority of bladder cancer is diagnosed while confined to the
most superficial layer (non-muscle invasive bladder cancer, NMIBC)
[1]. Treatment goals in this minimal residual disease setting are ideal
for immunotherapy: reduce local disease recurrence following surgi-
cal resection and prevent progression to muscle invasive bladder
cancer (MIBC). Bacillus Calmette-Guérin (BCG), an attenuated form of
Mycobacterium bovis, is an intravesical immunotherapy which re-
mains the mainstay of NMIBC treatment since 1976. Despite the
tenure in bladder cancer treatment, full characterization of the im-
munologic mechanism of action of BCG is still lacking [2]. In a pilot
study, we sought to investigate the diversity of T cells infiltrating
bladder tumors and compare the changes in T cell diversity among
patients who were responders and unresponsive to BCG.
Methods
Six patients were selected from the IRB-approved Johns Hopkins
bladder cancer tumor repository. All patients had T1 disease without
concurrent carcinoma in situ (CIS) and received standard of care BCG
induction and maintenance. Three patients were classic “responders”
to BCG, with disease-free intervals of 8, 28, and 34 months. Three pa-
tients were unresponsive to BCG: two patients progressed to MIBC
and ultimately died of metastatic bladder cancer and one had recur-
rent disease requiring cystectomy. Pre-treatment and post-treatment
tumor tissue samples were compiled; genomic DNA was isolated,
amplified, and sequenced using Adaptive Biotechnologies’ Immuno-
Seq assay.
Results
ImmunoSeq technology surveyed the T cells in all 12 samples. Me-
dian fraction of T cells in the samples pre-treatment was 0.16 (95%
CI, -0.419 to 0.731) while post-treatment median was 0.36 (95% CI,
0.184 to 0.532), indicating a trend towards a higher T cell fraction
after treatment. Clonality, an objective measure of T cell diversity,
was low in most patients and unchanged post-treatment: some T
cell clones in the tumor samples expanded or contracted, though
most clones were stable post-treatment, and no clones expanded
to be dominant. Clonality likewise did not appear to correlate with
patient response to BCG.
Conclusions
Tumor infiltrating T cell kinetics do not appear to correlate with re-
sponse to BCG in this pilot sample of patients. These data suggest
that an alternative mechanism involving the innate immune cell
population may be the primary driver of BCG response.
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Background
PD-L1 expression, which predicts response to PD-1-directed therap-
ies such as pembrolizumab in many cancer types, is often associ-
ated with an active T cell infiltrate in the tumor microenvironment,
suggesting that the presence of activated intratumoral T cells may
be a determinant of response to PD-1 checkpoint blockade. This
study describes the stepwise derivation of an immune-related gene
expression profile (GEP) that identifies key biological features of a T
cell inflamed tumor microenvironment and predicts clinical response to
pembrolizumab across a wide variety of solid tumors.
Methods
Associations between clinical response to pembrolizumab and
gene expression signatures of IFN-γ signaling and activated T cell
biology were evaluated using RNA isolated from formalin-fixed
paraffin-embedded baseline samples of patients with multiple
tumor histologies. Gene expression was analyzed on the Nano-
String nCounter system.
Results
Preliminary signatures, comprised of genes associated with IFN-γ and
activated T cell biology, were initially evaluated in a discovery set of 19
patients with melanoma, and subsequently validated in an independ-
ent cohort of 62 melanoma patients [1, 2]. Refined versions of these
signatures were independently tested and shown to predict objective
response and progression free survival (PFS) in 40 patients with head
and neck squamous cell carcinoma (HNSCC) and 33 patients with gas-
tric cancer [3, 4]. Using data combined from 220 pembrolizumab-
treated patients across 9 cancer types, a final 18-gene GEP was derived
that included immune-related genes related to antigen presentation,
chemokine expression, cytotoxic activity, and adaptive immune resist-
ance. The predictive value of the GEP compared favorably with that of
PD-L1 immunochemistry when evaluated in an additional independent
cohort of PD-L1-unselected HNSCC patients (n=96).
Conclusions
The pan-tumor GEP described in this study, typified by indicators of
a T cell inflamed microenvironment, captures hallmark characteristics
of tumors that are responsive to anti-PD-1 therapy. Our data suggest
that these immune-related components are generally necessary, but
not always sufficient, for clinical response to pembrolizumab. The
GEP represents a potential tumor type-agnostic determinant of re-
sponse to PD-1 checkpoint blockade, and has undergone analytical
validation as a potential diagnostic assay with a clinical utility profile
that suggests good performance for maintaining high negative-
predictive value and sensitivity [5].
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Background
Non-synonymous, single-nucleotide variant mutational load (ML) is
associated with response to cancer immunotherapies, including
CTLA-4 and PD-1/L1 blockade, in some tumor types. A presumptive
mechanism is increased tumor antigenicity through generation of
neoepitopes not subject to central immune tolerance. A T cell in-
flamed microenvironment characterized by T cell infiltration, an IFNγ-
centric gene-expression profile (GEP), and PD-L1/PD-L2 upregulation,
likewise associates with response to PD-1/PD-L1-directed therapies.
However, the interaction and independent predictive values of these
two distinct aspects of tumor biology have not been well studied.
This study evaluates the association between ML and outcome, as
well as the independent predictive values of ML and GEP, in
pembrolizumab-treated cancer patients across 21 indications.
Methods
Whole-exome sequencing and gene-expression profiling were per-
formed on FFPE specimens from patients pooled from two multi-
cohort, advanced solid tumor trials (KEYNOTE-028, n=80 and
KEYNOTE-012, n=39). The previously defined GEP score was calcu-
lated as a weighted sum of normalized expression values for 18
genes. ML and neoantigen analytical approaches included public
tools (GATK, MuTect, NetMHC). Statistical testing was pre-specified
and adjusted for multiple-testing. Association of ML and GEP was fur-
ther explored across cancer types using a proprietary database (Mof-
fitt) of tumor gene expression (microarray RNA, n=16,000) and
targeted exome (~1300 genes, n=2500) profiles, and TCGA datasets.
Results
ML and neoantigen load were both significantly associated with ob-
jective response (AUROC=0.76 and 0.78, nominal 1-sided p=0.0036
and 0.0083, respectively). Median numbers of mutations were 180 in
responders and 61 in non-responders. The overall response rate
(ORR) in all patients was 15 %. At a ML cutoff of 102 (associated with
ROC Curve Youden Index), the ORR was 32.3%, with a prevalence of
31.0% and negative-predictive value of 92.8 %. GEP was also signifi-
cantly associated with objective response (AUROC=0.76, nominal 1-
sided p=0.0071). ML and GEP were modestly correlated (r=0.28), con-
sistent with associations observed between ML and GEP in Moffitt
(r=0.11) and TCGA databases (r=0.29). When jointly modeled, ML
showed significant association with response (p=0.0078) after adjust-
ing for GEP (also significant, p=0.0251).
Conclusions
These data validate the utility of ML and GEP across tumor types as
independently predictive, complementary biomarkers of response to
pembrolizumab. Moreover, these data suggest that tumor antigenic-
ity and T cell infiltration have a non-linear, rather than tightly covari-
ant, relationship. As measures of distinct, yet common features of a
PD-1 checkpoint-blockade-responsive tumor, ML and GEP may have
utility in characterizing responses to PD-1 blockade and potentially
other cancer immunotherapies.
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Background
Cancer immunotherapies are changing treatment paradigms and
expanding the therapeutic landscape for cancer patients. The current
success of these therapies is well documented, however not all pa-
tients respond to immunotherapy and those that do can experience
toxicities. There is a growing need to identify predictive and prog-
nostic biomarkers to enhance understanding of the mechanisms
underlying the interactions between the immune system and cancer.
This presentation will discuss emerging biomarker techniques.
Methods
Several new technologies will be showcased in this presentation: (1)
The ability to obtain deep transcriptomic data including both coding
and non-coding transcripts from a single FFPE section - less than 1ng
of RNA and from 50pg of RAN from exosomes; (2) RNA in situ method-
ologies to explore ncRNAs and secreted cytokines/chemokines and
quantify their expression levels in the tumor micro-environment; and
(3) immuno-assays for assessing soluble checkpoint markers from 25ul
of serum/plasma.
Results
Data will be showcased that demonstrates the importance of explor-
ing different isoforms of genes and non-coding RNA when searching
for biomarkers. A new ncRNA discovered through single cell sequen-
cing and microarray work is a surrogate marker for CD8+ T cell infil-
tration in a melanoma cohort and correlates with response to
nivolumab in this initial small dataset (n=13). Additional data will be
available by November. Finally, data will be presented that demon-
strates that it is possible to detect "cleaved" or soluble PD-L2 upregu-
lation in the serum of a glioblastoma patient who has undergone
immunotherapeutic vaccine therapy via a novel multiplexed Luminex
assay.
Conclusions
Biomarkers are critical as we move further into the age of combin-
ation immunotherapies. It is important to cast the net as broadly as
possible and not restrict studies to small subsets of known genes
as the likely next generation of clinically useful biomarkers will be
non-coding elements or endogenous retroviruses. It is also critical
to understand which spliced variant of any given transcript is differ-
entially expressed to fully understand the mechanism that drives
any given cancer or response to treatment. New technologies are
now available to do this cost effectively from clinical samples such
as fine needle aspirates, FFPE tissue sections and blood. This pres-
entation demonstrates the importance of using the latest molecular
tools to advance the field of immunotherapy to facilitate the next
wave of therapeutic advances.
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Background
Major histocompatibility complex (MHC)-encoded glycoproteins bind
peptide antigens through non-covalent interactions to generate
complexes that are displayed on the surface of antigen-presenting
cells for recognition by T cells. Peptide-binding site occupancy is ne-
cessary for stable assembly of newly synthesized MHC proteins and
export from the endoplasmic reticulum. During this stage peptides
produced in the cytosol compete for binding to MHC molecules,
resulting in extensive peptide exchanges.
Methods
We have developed a kit based on the principle of peptide exchange
to generate novel specificity MHC tetramer reagents in a four-hour
assay. While alternate methodologies rely on UV cleavage of exiting
peptide on monomeric MHC complexes and a subsequent lengthy
tetramerization procedure, we have developed a fully formed fluores-
cently labeled MHC tetramer that requires only the addition of the
peptide of interest and a proprietary peptide exchange factor to
complete the reaction.
Results
A human HLA-A*02:01 tetramer made from monomer units folded
with an irrelevant exchangeable peptide, along with peptide ex-
change factor, was used with exogenous peptides to generate new
specificity tetramers. The efficiency of peptide exchange was quanti-
fied using a novel flow cytometry-based sandwich immunoassay
using magnetic beads conjugated with an anti-HLA-A,B,C capture
antibody and a FITC conjugated antibody reacting against the exiting
peptide. Exogenous peptide exchange rates correlated with their the-
oretical binding affinity to HLA-A*02:01. Tetramers generated using
peptides specific for CMV and Influenza demonstrated efficient ex-
change and detected similar percentages of antigen-specific CD8+ T
cells as classically folded MHC tetramers in flow cytometry staining
assays.
Conclusions
The application of this technology to screening and neoantigen cyto-
toxic T lymphocyte (CTL) epitope discovery will be discussed.
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Background
ICOS (inducible co-stimulator of T cells) is a co-stimulatory molecule
expressed primarily on T lymphocytes. Clinical data identified ICOS as
a potentially key molecule in providing optimal anti-tumor benefit
following anti-CTLA-4 therapy, with preclinical data confirming that
engagement of the ICOS pathway plays a significant role in mediat-
ing anti-CTLA-4 driven anti-tumor responses. JTX-2011 is an ICOS
agonist antibody that will be entering early phase clinical develop-
ment for the treatment of advanced solid tumors in the ICONIC trial.
JTX-2011 is designed to generate an anti-tumor immune response
through stimulation of T effector cells and preferential reduction of
intratumoral T regulatory (Treg) cells. Efficacy of an ICOS agonist in
mouse syngeneic tumor models is greatest in tumors with the high-
est levels of intra-tumoral ICOS, suggesting a potential predictive bio-
marker approach for clinical development. In this study we report
assessment of indications for enrollment in the clinic trial using
in silico and IHC analyses across multiple tumor types.
Methods
Integrated analyses of RNA, DNA, and clinical data from the Cancer
Genome Atlas (TCGA) were performed within multiple indications to
understand the context in which ICOS is expressed. Using a propri-
etary ICOS IHC assay, ICOS expression analysis was performed on a
subset of indications based on ranking from in silico analysis. ICOS
expression was also compared to histology and molecularly defined
indication subtypes as well as signatures of immune cell infiltrates to
understand context of ICOS positivity.
Results
We analyzed ICOS mRNA expression in ~10,000 solid tumors samples
across ~30 indications. These data were used to rank indications, and
ICOS expression in key indications was orthogonally confirmed using
IHC. Consistent with previous data showing ICOS protein expression
on Treg cells, ICOS RNA expression significantly correlated with Treg
marker expression across multiple indications in TCGA tumor sam-
ples. Based on frequency of high ICOS expression, we determined
non-small cell lung cancer, head and neck squamous cell carcinoma,
triple negative breast carcinoma, gastric adenocarcinoma, and melan-
oma to be potential indications for JTX-2011 therapy. We further
compared ICOS expression to PD-L1 expression to understand if
there is a distinct population within an indication that is not a candi-
date for PD-1/PD-L1 therapy but could benefit from JTX-2011 ther-
apy. A subset of patients in multiple indications exhibit high ICOS
levels but low PD-L1 expression.
Conclusions
In conclusion, these data support the prioritization of specific tumor
types for treatment with JTX-2011 in the ICONIC trial.
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Background
Anticancer immunotherapies eliminate cancer cells by targeting im-
mune cells to promote immune activation or block immune suppres-
sion. Ipilumumab and nivolumab, targeting CTLA-4 and PD-1
respectively, have demonstrated dramatic responses in melanoma
and lung cancer [1, 2]. However, poor response rates in other types
of cancer underscore the need to better understand immunomodula-
tory mechanisms [3]. In this work, we extend previous methods for
inferring immune cell type proportions from gene expression profiles
[4], applying them to tumor and normal tissue samples from different
tissue types to investigate interactions between tumors and the im-
mune system.
Methods
Proportions of 22 immune cell types were inferred from breast, colo-
rectal, lung, and prostate microarrays representing tumors and
normal tissue using machine learning. Statistical hypothesis testing
was used to investigate immune cell proportion differences (1) be-
tween tumor and normal tissues and (2) between tumor types.
Prostate tumors were further investigated to determine whether par-
ticular cell types (1) were associated with androgen receptor (AR)
signaling or (2) could serve as prognostic markers.
Results
All tumor types showed significantly higher proportions of M1 mac-
rophages than normal tissues of the corresponding type, a charac-
teristic of early-stage tumors and tumors of patients with better
prognosis. Immunosuppressive regulatory T cells (Tregs), were de-
tected more often at higher levels in tumors than normal tissue
(significantly in breast and lung). Tumors of the prostate were most
similar to normal tissue, possibly reflecting low immune infiltrate.
Deeper research into prostate cancer showed (1) tumor AR activity
to be positively correlated with plasma cells and negatively corre-
lated with CD8+ T cells, Tregs, and monocytes and (2) indicated
that more M1 macrophages (and lower M2/M1 ratios) were associ-
ated with better prognosis.
Conclusions
Our results indicate that immune cell infiltration differs greatly be-
tween (1) healthy and cancerous tissues and (2) different tumor
types. With further development, the inference of immune cell type
proportions from gene expression profiles may lead to improved
prognosis, predictive biomarkers for immunotherapy to assist in pa-
tient stratification, and new immunoncology targets by indicating
immunosuppressive mechanisms.
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Background
Here, we report novel correlations between the antibody and T cell
responses that develop to tumor-specific molecular targets following
complex cancer vaccination. Further investigation of these correla-
tions might lead to new methods of monitoring T cell immune re-
sponses via their corresponding antibody responses.
Methods
This study involves a complex autophagosome-enriched vaccine (DRib-
bles) made from 4T1 murine mammary carcinoma cells combined with
poly-IC adjuvant. Animals pre-treated with 4T1 DRibbles and poly-I:C
benefit from a significant delay in 4T1 tumor growth upon tumor chal-
lenge (p < .001), and an increase in CD3+CD8+ tumor infiltrates by
multi-spectral immunohistochemistry (p < .001).
Results
We designed an array of 150 paired mutant neoepitope and wild-
type 4T1 variant site 15mer peptides; this array included all single-
nucleotide polymorphism (SNP) variant sites which were an exact
match between a published 4T1 sequence and variants identified
from sequencing our own 4T1 cell bank. In pooled data from three
independent biological experiments, we observed an increase in
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antibody responses to both the mutant and wild-type variant site
peptides in combination vaccinated animals versus adjuvant alone
(p=.0002). Surprisingly, we found that these antibody response in-
creases strongly correlated with a higher maximum predicted MHCI
binding score from NetMHCpan. To investigate T cell responses, we
performed an ex vivo screen with a selection of predicted MHCI
binding minimal peptides. IL2 expanded splenocytes from vacci-
nated animals were more likely than those from naïve animals to
make an interferon gamma response to the SNP peptides whose
parent proteins we had previously identified in the vaccine by mass
spectrometry (p=.01). A similar trend was seen for mass spectrom-
etry identified wild-type variant site peptides; these results are from
a pool of three independent biological experiments.
Conclusions
This study identifies a previously unknown link between predicted
MHCI binding affinity and the anti-tumor antibody response, a link
which correlates with pooled T cell response data found in screening
assays. We are confirming these data with larger scale T cell studies
of screening assay hits ex vivo.
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Background
Pancreatic ductal adenocarcinoma constitutes the majority of malig-
nant pancreatic tumours. Pancreatic adenocarcinoma is one of the
deadliest cancers for humankind to tackle. More so over, its lethality
has increased in the presence of late presentation. The median sur-
vival in advanced stage is 5-6 months. The present state CA 19.9 is
the most commonly used marker though its sensitivity is question-
able regarding terms of any help in early diagnosis. One of the prom-
ising evolving entities is miRNA, which has recently come to light, as
a possible biomarker and cellular target for pancreatic cancer. The
main aim of this study is to create a potential pool of circulatory
miRNA panel for diagnosis of pancreatic cancer.
Methods
We have evaluated the current literature for various reported miRNA
of diagnostic value in the serum by using MeSH terms: pancreatic
adenocarcinoma, serum miRNA, and urinary miRNA. Six studies re-
lated to miRNA were evaluated in detail and discussed here.
Results
Details analysis of various studies have outlined many promising
miRNA as potential candidates for the biomarker pool. The most not-
able ones are miRNA 143, miRNA 223, miRNA 30e, miRNA 204, miRNA
486, miRNA 145, miRNA 150, miRNA 223, miRNA 200, miRNA 21, miRNA
155 are few notable ones. Details of all potential miRNA are outlined in
the Table 6.
Conclusions
miRNA will be a great potential tool to help in the disease diagnosis
in the very early stage of a disease. Creating the database of these
circulatory miRNAs will be of great potential in creating a panel that
will aid in the development of a screening tool.
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Background
With numerous therapies available for treatment of RCC, there is a need
to evaluate factors predictive of response to enable patient selection.
We are reporting a preliminary analysis evaluating the neutrophil
lymphocyte ratio (NLR) and response to prior vascular endothelial
growth factor (VEGF) inhibitors as factors predictive of response and
clinical outcome in RCC patients treated with nivolumab. We also evalu-
ated factors such as race, smoking status and prognostic scoring by
MSKCC (Memorial Sloan Kettering Cancer Center) and Heng criteria.
Methods
Regulatory approval was obtained. A retrospective chart review of RCC
patients at Karmanos Cancer Institute treated with PD-1/PD-L1 inhibi-
tors was conducted. Data was collected on demographics, smoking sta-
tus, prognostic scoring (MSKCC and Heng), NLR pre and post 4 doses
of nivolumab, response to prior therapies and correlated with clinical
Table 6 (Abstract P78). Table showing pool of potential miRNA with
diagnostic values
Study Body
Fluid
Examined
Sample Size
of
pancreative
cancer
miRNA Remarks
Debernadi
et al. 2016
Urine 59 miRNA 143, miRNA 223,
miRNA 30e, 204
Sensitivity-
83.3%
Specificity-
96.2%
Xu et al.
2016
Plasma 192 miRNA 486 AYC-0.861
Sensitivity-
75%
Specificity-
87%
Schultz
et al. 2014
Blood 409 miRNA 145, miRNA 150,
miRNA 223, miRNA 636
AUC-0.86
Sensitivity-
85%
Specificity-
64%
Liu et al.
2012
Serum 197 miR20a, miRNA 21, miRNA
24, miRNA 25, miRNA 99a,
miRNA 99a, miRNA 185,
miRNA 191
AUC-0.992
Sensitivity-
89%
Specificity-
100%
Bauer et al.
2012
Blood 345 miRNA 320, miRNA 159,
miRNA 225
AUC-0.973
Liu et al.
2012
Plasma 140 miRNA 16, miRNA 21,
miRNA 155, miRNA 181a,
miRNA 181b, miRNA 196a,
miRNA 210, miRNA 199
AUC-95.6
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outcomes on immunotherapy therapies. Univariable and multivariable
analyses were performed to evaluate any association with response
rate (RR), progression free survival (PFS) and overall survival (OS).
Results
Twenty-six patients were evaluated; 25 received nivolumab and 1 re-
ceived nivolumab and ipilumimab. The median age was 61 years (39-
82). 7 patients (27%) were African American (AA) and 12 patients (46%)
were smokers. Pretherapy NLR > 6 months and 2 prior therapies. On
univariable Cox analysis, pretherapy NLR ≥ 4 was not a significant pre-
dictor of response, but approached borderline statistical significance in
the prediction of shorter PFS and OS (PFS: p= 0.06, HR 2.532, OS:
p=0.058, HR 4.926). Median OS was 2.79 months in the group with NLR
≥ 4 and 18.39 months in the group with NLR > 6 months had a nega-
tive impact on PFS and OS (PFS: p= 0.067, HR= 2.98; OS: p=0.028,
HR=10.834). In univariable logistic analysis, AA patients had higher risk
of non-response (OR 10.5, p=.018), and demonstrated shorter OS
(HR15.81, p=0.01) with nivolumab therapy in RCC.
Conclusions
NLR is worthy of future investigation as a predictor of clinical outcomes
with immune checkpoint inhibition therapy in RCC. Prior therapy that
was ≥ 6 months had a negative effect on the PFS and OS with im-
munotherapy. Validation of this preliminary observation is required in a
larger sample size.
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Background
Merkel cell carcinoma (MCC) is an aggressive, neuroendocrine skin can-
cer with currently no effective, durable treatments for advanced dis-
ease. CD47 delivers an anti-phagocytic (“do not eat”) signal by binding
SIRPα on the surface of macrophages. While CD47 has recently
emerged as a promising drug target in oncology, its role in MCC is un-
known. In this study, we evaluated CD47 expression in MCC tumor
samples in conjunction with markers of immune infiltrate, Merkel cell
polyomaviral (MCPyV) status, and survival. In addition, we assessed the
ability of TTI-621 (SIRPαFc), a CD47-blocking decoy receptor, to enhance
macrophage-mediated phagocytosis of MCC tumor lines.
Methods
A formalin-fixed paraffin-embedded (FFPE) tissue microarray (TMA)
from 23 MCC patients (Fig. 41) was simultaneously stained for DAPI,
CD3, CK20, CD47, CD64, CD68, and CD163 and analyzed using multi-
spectral imaging and inForm software (Perkin Elmer). An in vitro
assay was used to determine the effect of TTI-621 on the phagocyt-
osis of the MCC tumor cell line MCC26. Monocyte-derived macro-
phages were primed with IFN-γ and co-cultured with violet
proliferation dye (VPD) labeled MCC26 cells +/- TTI-621 or control Fc
for two hours. Phagocytosis was determined by flow cytometry as
the percentage of VPD+CD14+ macrophages.
Results
Mean membranous CD47 levels on CK20+ tumor cells ranged from
0.55-17.63 (median 4.5) compared to 0.55-9.55 (median 3.33) on CD3
+ cells. Using median CD47 expression on MCC cells, Kaplan-Meier
analysis suggested that patients with lower CD47 expression have
improved survival rates however, this did not reach statistical signifi-
cance (p=0.121) in this small number of patients. There were few
intratumoral T cells (146 ± 434.9 CD3+/mm2) compared to infiltrating
macrophages (519±1781 CD68+/mm2). Spearman correlation analysis
indicated a weak correlation between higher expression of tumor
CD47 and decreased numbers of infiltrating T cells (r=-0.352,
p=0.012). Additionally, MCPyV+ patients (17/23) had slightly higher
mean expression levels of CD47 (6.08), and it was not significantly
higher than the small number of MCPyV negative (6/23) patients
represented on the TMA (mean = 4.17; p = 0.223).Phagocytosis of
MCC26 was increased in the presence of TTI-621, in a dose-
dependent manner.
Conclusions
CD47 is over-expressed in MCC, regardless of MCPyV status, sug-
gesting that blockade of CD47 by TTI-621 may be particularly
beneficial to patients with sparse T cell infiltrate. A phase I dose
escalation clinical trial of TTI-621 in patients with solid tumors,
including MCC, will initiate enrollment this year. This study will
examine changes in the tumor microenvironment in response to
TTI-621.
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Background
Understanding the spatial relationships between immune cells and
tumor cells in the context of cancer tissue is thought to be important for
understanding and predicting therapeutic response. Investigation of sin-
gle immune markers as predictors of clinical response can prove insuffi-
cient, necessitating several markers be evaluated for a single patient,
which can be confounded by heterogeneity within the tissue block.
Multiplex assays that measure two or more analytes in a single tissue
section allow direct investigation of spatial relationships while using a
fraction of the tissue required for multiple monoplex assays. Fluores-
cence immunohistochemistry (IHC) multiplex assays provide this advan-
tage, but fluorescence high-complexity testing requires specialized
instruments, training, and interpretation of results, potentially preventing
their broad adoption by clinical diagnostic laboratories. Chromogenic as-
says, on the other hand, are standard methods that most of these la-
boratories have the equipment, expertise, and training to perform.
Methods
In this study, Flagship Biosciences analytically validated a chromo-
genic duplex IHC assay that quantifies Ki67 and CD8 in formalin-
Fig. 41 (Abstract P80). Patient Demographics
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fixed, paraffin-embedded non–small cell lung cancer tissues. Similar
to analytical validation studies for monoplex IHC assays, this study
utilized an appropriate reference method and multiple days of stain-
ing. Distinct to this assay validation study, however, was the inclusion
of an additional step in the reference standard comparison due to
the potential for false-positive and false-negative results linked to the
dual-staining methodology. Specifically, a reference method was
used to qualify Ki67 and CD8 monoplex IHC assays that were then
used as the reference standard to assess duplex assay performance.
Five performance criteria were evaluated: reportable range, analytical
sensitivity, analytical specificity, accuracy, and precision. These per-
formance criteria were selected based on Clinical Laboratory Stan-
dards Institute guidelines.
Results
To ensure accurate and consistent measurement of chromogenic stain-
ing in the duplex setting, we quantified the percentage of cells positive
for Ki67 nuclear staining and/or CD8 membrane staining, using our
Computational Tissue Analysis (cTATM) technology. Performance of the
Ki67/CD8 chromogenic duplex IHC-cTA assay was considered accept-
able for the performance criteria evaluated.
Conclusions
The multiplex setting requires additional assay performance assess-
ments due to the complexity of the staining interpretation when
multiple IHC stains are present on one tissue section. Flagship’s cTA
technology allows for more consistent quantification of individual
analytes on dual-stained tissue sections.
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Background
Recent triumphs in cancer immunotherapy have benefited many can-
cer patients across multiple malignancies, generating much interest
from all sides. At the same time, there is an urgent need to develop
predictive biomarkers to identify patients who are most likely to benefit
from various immunotherapeutic strategies. While many biomarker
analysis technologies are available, most do not provide spatial and cell
type-specific information critical for assessing the specific immune cell
types with lineage and functional information in the evolving micro-
environment of each tumor . Furthermore, multiplexing capabilities are
highly desirable in order to obtain comprehensive single cell-level co-
expression information and to maximize the use of limited biopsied
sample material.
Methods
In this study, we demonstrate the development of an improved fluor-
escence multiplex in situ hybridization (ISH) method to detect three
RNA biomarkers simultaneously in FFPE and fresh frozen tissues on
the Leica BOND RX automated slide staining system. The presented
method detects RNA biomarkers in a highly specific and sensitive
manner, overcoming the inherent challenge of auto-fluorescence in
FFPE tissues. Individual RNA molecules are visualized as distinct
bright dots using any fluorescence microscopy or multi-spectral fluor-
escence imaging system.
Results
We applied this technique to archived non-small cell lung cancer FFPE
tissues to detect (1) the co-expression of various immune checkpoint
markers (such as PD-1, LAG-3, TIM-3) in PD-L1 positive and negative
tumor environments and (2) immune functional markers such as cyto-
kines and chemokines in combination with cell lineage markers. We
further demonstrate the flexibility of this technique to allow for detec-
tion of both RNA and protein biomarkers, where immune checkpoint
and functional markers are detected by ISH and cell lineage markers
(such as CD3, CD8) by IHC. The data on the co-expression and
localization of multiple combinations of markers derived from serial
sections of FFPE tissues provide comprehensive information regarding
the immune network in each tumor microenvironment.
Conclusions
The newly developed multiplex fluorescence RNAscope assay and its
combination with IHC presents a powerful tool to interrogate the
various cell types and spatial heterogeneity within tumor tissues. In-
formation revealed through simultaneous detection of multiple RNA
and/or protein markers may provide new insights to maximize the
benefits of current therapeutic approaches. This fully automated
assay platform is well suited for developing and validating clinically
relevant biomarkers in FFPE tissue.
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Background
Cholangiocarcinoma is a malignancy arising from the epithelial cells of
the biliary tract with poor prognosis. TILs and PD-L1 have a prognostic
impact in various solid tumors. We aimed to investigate TILs and PD-L1
expression and their clinical relevance in cholangiocarcinoma.
Methods
Formalin-fixed paraffin-embedded tumor samples from 41 patients
with resected and histologically verified cholangiocarcinoma be-
tween 1990 and 2015 were identified and immunohistochemically
(IHC) stained with anti-CD8, anti-CD45RO and the anti-PD-L1 mouse
IgG1 (clone 5H1; Thompson) antibodies. Stained tumor samples were
reviewed and enumerated by a GI pathologist. PD-L1 positivity was
defined ≥5% of tumor cells with a minimum of 100 evaluable tumor
cells. The association between expression of PD-L1, CD8 or CD45RO
and survival was investigated using Kaplan-Meier survival and COX
proportional hazard regression analyses.
Results
The median age of patients was 64 (41-85) with 53% male. 22%, 41%
and 37% were stage I, II and III, respectively. 29 patients, 4 patients and
2 patients had R0 resection (microscopically margin-negative), R1
(microscopic residual tumor) and R2 (macroscopic residual tumor), re-
spectively. 11 patients received post-surgical adjuvant treatment. CD8
was positive in 16 (39%), CD8CD45RO (memory CD8 cells) was positive
in 5 (12%), and PD-L1 was positive in 19 (46%). With a median follow-
up of 21.4 months, tumors with CD8+CD45RO+ TIL has better cancer
specific survival (median: unreached vs 41.2mo, HR=0.27, 95% CI: 0.09-
0.83, P=0.023) and overall survival (median: unreached vs 21.4mo,
HR=0.34, 95%CI: 0.14-0.82, P=0.016) than CD45RO-. The expression of
CD8 alone or PD-L1 in tumor was not associated with prognosis.
Multivariate analysis showed that CD8+CD45RO+ TIL (HR=0.13,
95% CI: 0.02-0.99, P=0.049) as well as stage, adjuvant treatment
and R0 resection were independent predictors of OS.
Conclusions
Presence of CD8 memory T cells (CD8+CD45RO+) in tumor micro-
environment was associated with significant better clinical outcome,
and the expression of PD-L1 on cholangiocarcinoma cells may sug-
gest a potential therapeutic target of anti-PD-L1 antibody therapy in
cholangiocarcinoma.
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Background
The promising advances of immunotherapy in cancer patient suggest a
need of parallel innovative solution to facilitate study and manipulation
of immune cells. The design of cell based assays for studying patient T or
B cells in conventional microtiter plate suffers from key limitations. The
large microwell volume of classical microtiter plate is poorly suited to the
limited amount of primary immune cells available and especially when a
rare subpopulation study is needed. Furthermore, a cell based assay with
multi-step staining procedures and immune cells often leads to signifi-
cant cell loss and require a complex washing process optimization. Here,
we present the use of DropArray wall-less microtiter plate for cell based
assays with immune cells.
Methods
DropArray 384 well plates are designed with hydrophobic/hydrophilic
patterning and hold an array of 2 μl drops in which cell based assays
can be conducted conveniently and where cells and reagent consump-
tion can be minimized by up to 90%. DropArray wall-less plates employ
surface tension to retain suspension cells efficiently on the plate surface
during a wash process with a convenient automatic washing station
with no optimization required. DropArray plates are used in conjunc-
tion with common high content imaging platforms for analysis.
Results
DropArray plates display efficient retention of suspension cells such
as PBMC, plasmacytoid dendritic cells, and B or T cells in a range of
70 to 90% after multiple wash steps. Among few cell based assays
we highlight how the DropArray plate is used to visualize/quantify
events of cytotoxic T cells mediating tumor cell killing and where bi-
specific antibody efficacy is evaluated with high content imaging
platforms in a real time assay.
Conclusions
DropArray wall-less plates constitute the next generation microtiter
plate for running immune cell based assay with suspension cells.
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Background
Luminex® magnetic bead-based assays have contributed to the ex-
pansion of biomarker discovery by providing tools for simultaneous
measurement of multiple analytes. However, high cost and sample
volume requirements limit the use of this technology in drug discov-
ery and research, especially when analyzing cerebrospinal fluid, tears
and limited organic and body fluids. In this poster, we use Curiox’s
DropArray technology to reduce Luminex reagents and sample use
by 80% while generating similar or enhanced data as obtained by
traditional Luminex® methods.
Methods
DropArray 96 (DA-96) plate is a wall-less plate that can accommodate
5 to 20 μl drops in each of its 96 circular imprints. DA-96 plate fol-
lows standard SLAS/ANSI format, compatible with standard microtiter
instruments and follows the same Luminex workflow for magnetic
bead-based assays. Each circular hydrophilic area of the DA-96 plate
can hold 5μl of each Luminex reagent and samples thus effectively
miniaturizing the Luminex assay by at least 80%. DA-96 plate is used
sequentially on vortex/orbital shakers, washed in a fully automated
station and used in Luminex instruments for data acquisition. We use
Millliplex®, Bio-Plex® or Procartaplex™ kits coupled with DA-96 plates
for cytokine analysis.
Results
Using Millliplex®, Procartaplex™ or Bio-Plex® based kits with DropAr-
ray 96 (DA-96) plate and washer, produce interpolated concentration,
which correlates 99% with classic high multiplexing methods. Preci-
sion and accuracy analysis with DA-96 plates equals or excels
conventional Luminex methods with intra assay CV% below 10% and
recovery within acceptable range of 70-130%. Range of concentra-
tion detection conforms conventional methods with 3.5 to 4 logs
range depending on analytes and produce similar sensitivities down
to the pg/ml level. DA-96 plate offers excellent reproducibility well-
to-well and plate to plate. 2μl and 5μl cytokine supernatant analysis
from stimulated immune cells with Milliplex or Bio-Plex based kit DA-
Bead method are presented as a functional example. Analysis of 150
serum samples with DA-96 plates indicate enhanced data detection
of various analytes when compared to a conventional microtiter
plate method.
Conclusions
The DA-96 plate and washer is an effective miniaturization platform
for Luminex assays that provides similar or enhanced performance
reducing costs and sample use by up to 80%. DA-96 plates maximise
sample use by requiring only 1/5 of the sample volume. DA-96 plates
workflow is similar to standard Luminex workflow. DA-96 plates can
be used with Luminex xMAP based kit (Milliplex, Bio-plex, Procarta-
plex) and any Luminex based instrument.
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Background
Recent expansion in biomarker discovery has been possible by the
use of bead-based assays and single molecule detection capabilities
such as the Singulex assay. Minimal volume requirement with the
Singulex methodology requires 50-100μl per well and can be a major
bottleneck with limited clinical samples. Furthermore, requirement of
multiple plate transfers with the Singulex workflow present a signifi-
cant delay and obstacle during the workflow when multiple plates
are processed simultaneously. Here, we combine DropArray 96 plates
(DA-96) and the Singulex assay to achieve similar performance with
80% less volume than the current method.
Methods
DA-96 plate is a wall-less plate with 96 circular hydrophilic imprints
on a hydrophobic/plastic surface displayed in SLAS/ANSI format,
compatible with standard microtiter instruments. Each circular hydro-
philic area can hold conventional Singulex reagents such as magnetic
beads/antibody/sample/standards up to a total of 20μl volume. Fol-
lowing a highly similar Singulex workflow and using conventional
multichannel pipettes, DA-96 plates are used sequentially on vortex
shakers and washed in a fully automated wash station. DA-96 to DA-
96 plate bead transfer is performed conveniently with a Magnet
Transfer Jig™ tool to bypass the need for multiple pipetting steps re-
quired in the conventional method. Finally, Beads on DA-96 plate are
eluted out in a 384 well plate in a highly convenient manner which
avoids centrifugation of beads and laborious plate transfer before ac-
quisition into Singulex reader.
Results
Using Singulex Erenna based kits for cardiac Troponin-I, DA-96 plate
miniaturized workflow displayed precision and accuracy analysis in
line with conventional methods with intra assay CV% below 20% and
recovery within acceptable range of 80-120%. Reliable sensitivity
LLOQ reached 0.35pg/ml. DA-96 plate and washer offer excellent re-
producibility well to well and plate to plate with 20μl of sample vol-
ume per well.
Conclusions
With similar performance as conventional plates, faster and stream-
lined workflow, DA-96 plate is the next generation plate for Singulex
assay providing similar or improved sensitivity and a smaller sample
volume requirement.
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Background
T cell dysfunction in AML remains poorly understood. Therefore, we
aimed to genotypically, phenotypically and functionally characterize
T cells of AML-patients before and after induction-chemotherapy.
Methods
To study transcriptional signatures, FACS-purified peripheral blood
(PB) CD8+T cells from 6 patients [3 responders (R) and 3 non-
responders (NR)] and 4 healthy controls (HCs) were analyzed by
microarray. Significantly differentially expressed genes were selected
based on >2FC between patient and HC, and p < 0.01. We phenotyp-
ically characterized PB T cells from 69 AML-patients before and after
induction-chemotherapy, and from 55 HCs, by flow cytometry (FLC).
To study AML-blast/T cell interactions, we FACS-purified and in vitro
cultured T cells and primary AML-blasts from newly diagnosed pa-
tients for 3 days. T cells were cultured alone or in co-culture with
blasts (1:10) and analyzed by FLC.
Results
The transcriptional profile of CD8+ T cells at AML diagnosis included
significant upregulation of the immune inhibitory receptors genes
2B4, KLRG1, CD160 and TIGIT compared to HCs. In contrast, co-
stimulatory receptor genes were downregulated, including CD40LG,
CD28 and CD30LG. Ingenuity pathway analysis (IPA) revealed that
the co-stimulatory CD28, ICOS and OX40 signaling pathways were
downregulated. We performed confirmatory T cell phenotype
characterization by FLC in a larger patient cohort (n=69). CD8+ T cells
were phenotypically senescent (CD27-CD28-CD57+) and %T cells co-
expressing 2-4 co-inhibitory receptors (2B4/KLRG1/CD160/CD57) was
significantly higher in AML patients compared to HCs. Next, we com-
pared R to NR after induction chemotherapy. R-patients upregulated
immune-stimulatory receptor genes like ICOS, whereas NR-patients
upregulated immune-inhibitory receptor TIM3; LST1 (inhibits lympho-
cyte proliferation); TWEAK-APRIL (T cell apoptosis); and CD39 (termin-
ally exhausted T cells). In accordance with these findings, IPA
showed enrichment of the co-stimulatory ICOS and OX40 signaling
pathways in R-patients. In the confirmatory patient cohort, %senes-
cent T cells and T cells co-expressing 2-4 co-inhibitory receptors was
significantly decreased in R-patients (n=52), but unchanged in NR-
patients (n=17) compared to pretreatment levels. The co-culture
assay showed that the presence of AML blasts also significantly de-
creased the %primary AML T cells expressing co-stimulatory recep-
tors 41BB, ICOS and OX40, while it increased the frequency of HC T
cells expressing 2B4 and CD57.
Conclusions
Our study provides insight into AML-associated phenotypical and
transcriptional changes in T cells. Our data suggest that that the
AML-blasts influence the T cell phenotype and genotype. Response is
associated with reversion to HC pattern, whereas NR patient remain
in an exhausted/senescent state. Identification of their immune sig-
nature will hopefully help to rationally designing future clinical trials
of immune-modulating strategies in AML.
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Background
RNActive® CV9201 is a novel mRNA-based therapeutic vaccine tar-
geting five lung cancer-associated antigens. A phase I/IIa clinical
trial was conducted in 46 patients with stage III or IV non- small
cell lung cancer (NSCLC). We sought to comprehensively analyze
changes in peripheral blood during the vaccination period to
generate hypotheses facilitating the identification of potential
biomarkers correlating with differential clinical outcomes post
mRNA-based immunotherapy.
Methods
Whole-genome expression profiling was performed in peripheral
blood mononuclear cells (PBMCs) derived from a subgroup of 22
stage IV NSCLC patients before and after initiation of treatment with
CV9201. We used a modular approach to gene expression data analysis
based blood transcriptional modules (BTMs), a previously described,
sensitive tool for blood transcriptome data analysis. In addition, pheno-
typic T cell, B cell and NK cell analyses were performed by flow cytome-
try on the same PBMC samples.
Results
Patients segregated into two major clusters based on transcrip-
tional changes post treatment with CV9201. The first group of pa-
tients was characterized by the upregulation of an expression
signature associated with myeloid cells and inflammation, whereas
the other group exhibited an expression signature associated with
T and NK cells. Patients with an enrichment of T and NK cell mod-
ules exhibited significantly longer progression-free and overall sur-
vival compared to patients with an upregulation of myeloid cell
and inflammatory modules. Notably, these gene expression signa-
tures were mutually exclusive and inversely correlated. Further-
more, our findings correlated with phenotypic data derived by flow
cytometry as well as the neutrophil-to-lymphocyte ratio suggesting
changes in the cellular composition of peripheral blood leukocytes
after mRNA immunotherapy.
Conclusions
We demonstrate non-overlapping, distinct transcriptional signa-
tures associated with differential survival outcomes. These results
warrant further validation in controlled, prospective clinical trials
for the development of biomarker candidates for mRNA-based
immunotherapy.
Trial Registration
ClinicalTrials.gov identifier NCT00923312.
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Background
Ipilimumab is a human monoclonal antibody targeting CTLA-4, which is
expressed in activated T cells and involved in negative regulation. 22%
of patients with metastatic melanoma who received ipilimumab mono-
therapy are alive 3 years after treatment and the majority of these pa-
tients have had a durable response lasting ten years or more [1]. It is
important to uncover underlying resistance mechanisms as most pa-
tients still fail to benefit from ipilimumab or other immunotherapies.
Methods
We assessed whether activation and/or proliferation of peripheral
T cells correlated with clinical outcome of patients with meta-
static melanoma treated with ipilimumab. PBMCs from patients at
baseline and 12 weeks following initiation of treatment participat-
ing in a compassionate use trial of ipilimumab [2] were evaluated
for ICOS+ or Ki-67+ frequencies on CD4+ and CD8+ T cells, as
well as regulatory T cells, using flow cytometry. We conducted T
cell receptor (TCR) CDR3 sequencing for sorted bulk CD4+ T cells
from baseline, weeks 7 and 12 of ipilimumab treatment to under-
stand their clonal behaviors in patients with metastatic melanoma
upon treatment.
Results
Ipilimumab treatment significantly increased the frequency of ICOS+ T
cells regardless of clinical outcome as previously reported by others [3].
Increased Ki-67+ CD4+ T cells upon ipilimumab treatment (>1.7 fold)
was associated with prolonged overall survival. Our results suggest that
ipilimumab’s anti-tumor effects may be mediated in part by prolifera-
tion of CD4+ T cells. However, some patients with melanoma progres-
sion showed increased Ki-67 expression in CD4+ T cells after
ipilimumab, implying that CD4+ T cell proliferation alone is not a
predictive biomarker. When we tracked destiny of newly emerging CD4
+ T cell clones upon treatment (present at weeks 7 but not present at
baseline), we found prominent turnover at weeks 12 in patients who
progressed upon treatment. In contrast, a patient who showed
complete response and later survived longer than 3 years showed per-
sistence of new CD4+ T cell clones upon treatment.
Conclusions
Our results suggest that successful treatment with ipilimumab may
be, in part, explained by appearance and persistence of potentially
tumor-specific CD4+ T cell clones. We will be conducting TCR CDR3
sequencing for DNA extracted from tumor FFPE blocks to see
whether clones of interests can be detected in tumor.
Trial Registration
ClinicalTrials.gov identifier NCT00495066.
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Background
The use of antibodies against the negative immune checkpoints, PD-
1 and PD-L1 proteins, is an effective therapy for NSCLC patients. In
this study, we evaluated the levels of PD-1+ and PD-L1+ expressing-
immune cells (ICs) and CTCs, and their association with the clinical
outcome in advanced/metastatic NSCLC.
Methods
Peripheral blood was collected from 37 advanced/metastatic
chemotherapy-naïve NSCLC patients before treatment. Flow cytometry
was performed to enumerate the PD-1 and PD-L1 expressing-ICs with
anti-tumor (CD4+ and CD8+ T cells, B cells, Dendritic cells) and suppres-
sive functions [CD4+ and CD8+ Treg, Bregs, Myeloid-derived Suppressor
cells (MDSC)]. Moreover, PD-1+ and PD-L1+ CTCs were enumerated by
immunofluorescence. Correlation between the levels of PD-1+ and PD-
L1+-expressing ICs and CTCs and their association with overall (OS) and
progression-free survival (PFS) was evaluated; high expression of ICs
was defined as the percentage of the cells above the mean value.
Results
The detection and quantification of all PD-1 and PD-L1-expressing ICs
and CTCs, in NSCLC is presented. PD-1 and PD-L1 expression was de-
tected on all tested effector cells and CTCs. In addition, PD-1 and PD-L1
expression was found on all immunosuppressive cells, except Bregs and
monocytic-MDSCs. Importantly, the increased percentages of PD-1+CD8+
T cells were associated with worse response to treatment (p=0.032) and
shorter PFS (p=0.023), indicating its clinical relevance. In contrast, the
high expression of PD-1 on naive CD4+ Treg was correlated with longer
PFS (p=0.017), implying that PD-L1/PD-1 axis could be a mechanism
leading to Treg apoptosis and hence re-activation of immune system. In
multivariate analysis, high percentage of PD-1+CD8+ T cells was an inde-
pendent predictor for decreased PFS (HR: 4.1, p=0.0007), while the in-
creased percentages of naive PD-1+CD4+ Treg cells were independently
associated with increased PFS (HR: 3.8, p=0.018). Interestingly, high levels
of PDL-1+ CTCs were correlated high levels of PD-1+CD8+T cells (p <
0.04), indicating a likely immune escape mechanism of CTCs. The levels
of all other PD-1 and PD-L1 expressing cells were not associated with
the clinical outcome.
Conclusions
For the first time the current study provides evidence for a possible
interaction between the ICs and CTCs in NSCLC patients via the PD-
1/PD-L1 axis. Moreover, these results indicate that PD-1 expression,
on two distinct ICs with opposite functions, differentially impact
NSCLC patient’s clinical outcome.
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Background
The PD-1/PD-L1 pathway mediates immunosuppression in the tumor
microenvironment. Therapies targeting this pathway have been ap-
proved along with corresponding diagnostic assays for selected indica-
tions. These assays predict patient responses to therapy by measuring
the percentage of tumor cells (Keytruda, Opdivo) or immune cells (dur-
valumab) that stain positive for PD-L1. The AACR-ASCO-FDA Blueprint
Project seeks to facilitate harmonization of PD-L1 tests in order to
enable their practical use, with the goal of building a method for ob-
jective, consistent, proper test interpretation. In response, we have de-
veloped Computational Tissue Analysis (cTA™) approaches that enable
objective, consistent assessments of staining. In addition to evaluating
staining concurrently in multiple cell types (eg, tumor epithelium, im-
mune infiltrate) and ensuring reproducible scoring, these approaches
may help clarify the differences between various PD-L1 assays. The
present study evaluated Flagship’s cTA™ approaches to scoring samples
stained with the Dako PD-L1 pharmDx (28-8) immunohistochemistry
complementary diagnostic assay. The current manual scoring method
considers any patient with at least 1% PD-L1–positive tumor cells a can-
didate for Opdivo treatment. However, a trend toward increased overall
survival was observed in patient groups with greater PD-L1 positivity
(5% and 10%), suggesting the importance of reliably distinguishing be-
tween positivity thresholds.
Methods
We developed a cTA™ approach to test the hypothesis that it could
provide more consistent scoring around these low thresholds, which
are challenging for pathologists. We stained 40 formalin-fixed,
paraffin-embedded nonsquamous non–small cell lung cancer sam-
ples with the aforementioned Dako assay; a subset of these we
stained on consecutive days to evaluate assay and scoring precision.
The cTA strategy digitally identified tumor cells and quantified mem-
brane staining intensity consistent with the manufacturer’s scoring
guidelines. We also evaluated scoring of PD-L1 expression in immune
infiltrate in the same analysis.
Results
The cTA™ membrane scoring approach for tumor cells met Flagship’s
Clinical Laboratory Improvement Amendments (CLIA) validation cri-
teria, with the manually scored assay as the reference standard. This
approach was accurate and provided greater reproducibility of scor-
ing over the dynamic range of PD-L1–positive cell frequencies.
Conclusions
This study demonstrated the utility of cTA™ approaches for consist-
ently and objectively scoring PD-L1 expression in tumor cells within
the CLIA environment. It also highlighted the challenge pathologists
face in differentiating between 1%, 5%, and 10% positivity. cTA™
approaches could be used for consistent scoring of a single assay or
to understand differences between assays in performance or relation-
ship to clinical response.
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Background
MicroRNAs (miRs) are noncoding small RNAs that regulate protein ex-
pression at the post-transcriptional level in all cells, including those
forming the immune system. We previously showed that a single miR,
miR-155, promotes effector CD8+ T cell responses in viral infection,
vaccination and adoptive cell transfer for tumor therapy in mice [1].
However, little is known yet about miR-155 expression regulation in
tumor infiltrating CD8+ T cells.
Methods
Our goal here was to study the dynamics of miR-155 expression, i) in
tumor specific effector CD8+ T cells from mouse spleen and melanoma
tumors expressing high or low affinity antigen ligands, and ii) in ex vivo
sorted human CD8+ T cell subsets from melanoma patient's blood,
non-tumor infiltrated lymph nodes (NLNs), tumor infiltrated lymph
nodes (TILNs) and non-lymphoid tumor masses.
Results
We report that antigen recognition and T cell avidity are major de-
terminants in the regulation of miR-155 expression in tumor anti-
gen specific CD8+ T cells. Moreover tumor specific mouse and
human effector memory (EM) CD8+ T cells from melanoma patients
showed increased miR-155 expression levels in melanoma tumors
and TILNs compared to T cells from tumor-free areas. In addition,
high miR-155 expression levels correlated with increased tumor
specific effector CD8+ T cell infiltrates and tumor control in mice. In
agreement with these observations in mouse model systems, miR-155
expression levels in human EM CD8+ T cells positively correlated with
their frequencies in TILNs and tumor masses in melanoma patients. In
addition, high EM CD8+ T cell frequencies correlated with increased
overall patient survival.
Conclusions
We propose miR-155 expression levels in CD8+ T cells from tumor
infiltrated tissues as a surrogate marker for antigen specific CD8+ T
cell responses in situ and a possible prognostic biomarker in melanoma.
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Background
The molecular basis for response to immune checkpoint therapy in
different cancers is not well understood. In some cases response cor-
relates with high tumor mutation burden, due to environmental ex-
posure to carcinogens (UV exposure/tobacco), or intrinsic DNA repair
defects (mismatch repair defects/POLE mutations) leading to gener-
ation of immunogenic neoantigens. However, some tumors with low
mutation burdens are sensitive to immune checkpoint therapy, sug-
gesting other mechanisms of immune activation.
Methods
Exceptional clinical benefit was observed in a patient with ad-
vanced gastric cancer treated with the PD-L1 inhibitor avelumab. In-
formed consent was obtained and she was enrolled to the Rutgers
Cancer Institute of New Jersey genomic tumor-profiling protocol. Com-
prehensive genomic profiling was performed using the Foundatio-
nOne platform. In situ hybridization was performed to evaluate
expression of Epstein Barr Virus (EBV)-encoded RNA. Data from The
Cancer Genome Atlas (TCGA) dataset of gastric cancer was analyzed
to review associations between EBV status, mutation burden, gene
expression based immune signatures and histologic lymphocytic
infiltration.
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Results
This 57-year-old female presented with chemotherapy refractory
metastatic gastric cancer causing complete esophageal obstruction,
cervical and thoracic lymphadenopathy, and chronic anemia from
tumor blood loss. Avelumab 10 mg/kg every 2 weeks was adminis-
tered in a clinical trial. She experienced tumor reduction after 4 cy-
cles. After 10 cycles, further tumor regression, improved anemia, and
improved ability to ingest solid foods with > 15 lb weight gain was
observed and continues at 20+ cycles. Genomic analysis of a pre-
treatment tumor specimen did not show a high mutation burden or
evidence of mismatch repair defects, but was strongly positive for
EBV-encoded RNA. Approximately 9% of gastric cancers in the TCGA
dataset have evidence of EBV RNA expression. These EBV+ cancers
were micro-satellite stable with relatively low mutation burden, but
high expression of immune checkpoint genes including PD-1 and
PD-L1, and gene expression evidence of immune infiltration.
Conclusions
These data suggest that EBV+ gastric cancers are a subset of micro-
satellite stable gastric cancers with low mutation burden that re-
spond to immune checkpoint therapy. Tumor EBV expression may be
a marker of sensitivity to immune checkpoint therapy that is inde-
pendent of total mutation burden and microsatellite instability. A
phase III trial of avelumab in patients with recurrent gastric cancer is
ongoing.
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Background
Immune checkpoint (ICP) blockade therapies using anti-PD-1 have
elicited positive responses in non-small cell lung cancer (NSCLC) pa-
tients, where non-responders are suspected to arise from the down-
stream expression of additional ICP on effector TIL. In this age of
companion diagnostics, during the expanding of the list of predictive
biomarkers like PD-L1, it will become invaluable to: 1) define which
ICP impact prognosis; 2) determine whether ICP expression is co-
dependent, ordered, and can be used to stratify patients; and 3) de-
velop standardized methods for their use in scoring patients ahead
of ICP blockade therapies.
Methods
An immune-cell-specific biopsy-based tissue microarray (TMA) from
untreated NSCLC patients (n=81) was fabricated to profile TIL-ICP
using multiplex immunofluorescence (MP-IF). ICP distributions and
coexpression were correlated with clinical data, and results were
compared to The Cancer Genome Atlas (TCGA) RNA-Seq lung adeno-
carcinoma (LUAD; n=520) and lung squamous cell carcinoma (LUSC;
n=504) datasets. Using microfluidic qRT-PCR, coexpression of ICP
with numerous effector TIL genes was assessed in CD8+ and CD4+
TIL isolated from freshly resected untreated tumors, normal tissues,
and peripheral blood mononuclear cells (PBMC).
Results
TIL that are proliferating and expressing certain ICP positively correl-
ate with the overall survival (OS) of NSCLC patients. From TMA stain-
ing data, ICP expression is increased (CTLA4) or decreased (PD-1,
CD26, CD57, CD244) relative to patient mortality, and ICP coexpres-
sion (CD57-CD39, CD26-CD39) or TIL-ICP expression (CD3-CTLA4,
CD3-TIM-3, increased; CD3-CD26, CD3-CD73, decreased) enhance
statistical significance. Increased expression of ICP (TIM-3, CD26, LAG-
3) or TIL-ICP (CD3-TIM-3, CD3-BTLA, CD3-LAG-3, CD3-CD26, CD3-
CD39) correlates with improved OS. From both TMA results and
TCGA datasets, ICP subset expression is observed to have heightened
importance relative to OS at earlier time points, suggesting an or-
dered accruing of ICP by TIL. Hierarchical cluster analysis reveals ICP
groupings (CD26, CD39, TIM-3; TIGIT, CTLA4, PDCD1; CD244, CD57)
reflected by qRT-PCR results also revealing ICP distributions on CD8+
and CD4+ TIL and PBMC. TCGA datasets also provide evidence that
overall ICP expression positively correlates with OS, and that
advanced cancer stages have lowered ICP expression. Finally, ICP ex-
pression analysis defines an ordered build of ICP on NSCLC TIL.
Conclusions
This multi-cohort analysis performed using an array of techniques
has resulted in the discovery of TIL ICP expression having the great-
est benefit for different NSCLC subtypes. ICPs are coexpressed, and
their early, stepwise acquisition may be an important determinant of
OS. In this era of personalized medicine, use of ICP MP-IF panels may
better stratify patients for ICP blockade therapies.
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Background
There is growing evidence supporting the association of tumor infil-
trating lymphocytes, inflammatory signaling molecules, and drug
sensitivity to cancer checkpoint blockade therapy. At the same time,
the exact markers that are predictive of response for each thera-
peutic agent are still the subject of active investigations. To address
the need for better understanding of the effect of different T cell
subsets, antigen presentation, and tumor killing, gene expression
profiling presents an attractive means to simultaneously evaluate the
tumor microenvironment and cancer cells. Furthermore, as most of
the samples available for drug sensitivity research studies are derived
from formalin-fixed paraffin-embedded (FFPE) slides with typically
low RNA quality, target sequencing offers a cost-effective solution
that provides significantly higher sensitivity and specificity over
whole transcriptome sequencing or other gene expression profiling
methods.
Methods
Here we report the results of a 395-gene expression panel profiling FFPE
non-small cell lung cancer (NSCLC) and melanoma tumor research sam-
ples. The panel uses Ion AmpliSeqTM technology to measure the expres-
sion of genes involved in T cell activation, markers of different leukocyte
subsets, antigen presentation, and tumor characteristics (proliferation, ad-
herence/migration, epithelial-to-mesenchymal transition, etc).
Results
Gene expression measured by the panel stratified NSCLC samples
into groups that are consistent with histopathology classification and
tumor infiltrating levels provided by pathologists. The panel offers re-
producibility between replicates and high sensitivity of detection for
low expressing genes such as IL-2, IL-10, IL-21, and IFNG, among
others. We further demonstrated excellent concordance between
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fresh frozen and FFPE samples (correlation >0.95) as well as concord-
ance with TaqMan(R) qPCR. With a series of limiting dilution experi-
ments between two cell lines, the assay showed broad dynamic
range and linearity up to 200 fold. This OncomineTM Immune Re-
sponse Research Assay* is accompanied by a Torrent Suite™ software
package that provides run quality metrics, normalized gene expres-
sion, and hierarchical clustering among multiplexed samples.
Conclusions
In summary, the current gene panel offered an accurate and access-
ible tool for evaluating biomarkers that may be relevant to cancer
immunotherapy.*For Research Use Only. Not for use in diagnostic
procedures.
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Background
Immune checkpoint blockade with monoclonal antibodies directed at
the inhibitory immune receptors has emerged as a successful treat-
ment for cancer patients. Evaluation of tumor checkpoint blockade by
IHC is subjective, not reproducible, and importantly not scalable. We
have designed a custom 362 gene RNA-Seq immune profiling panel
that uses a multi-analyte algorithmic analysis (MAAA) to evaluate
checkpoint blockade, tumor infiltrating lymphocytes (TILs), and cyto-
kine/chemokine interactions.
Methods
269 cancer samples of diverse histologies with both frozen and FFPE
samples were evaluated by RNA-Seq with a custom 362-gene Ion
AmpliSeq Immune Response Profiling Assay using the Ion Chef™ and
Proton. RNA-Seq analysis was performed with the Torrent Suite™
followed by normalization. All samples were also included in a cus-
tom TMA and IHC was performed for 61 different markers for various
immunotherapy targets. Custom TaqMan assays were also performed
for each of the 61 different markers.
Results
Correlation of frozen and FFPE samples was directly related to level
of expression at the gene level. High expression genes showed a bet-
ter correlation than low expression genes. RNA-Seq and TaqMan re-
sults were highly correlated for all 61 genes evaluated. As compared
to IHC the results for RNA-Seq were continuous rather than bimodal
and allowed for a much more detailed analysis of the immune reper-
toire. Frequent difficult-to-interpret results for IHC for PD-L1 and
other markers were easily interpreted by RNA-Seq, while subsets of
TILs were identified allowing for a detailed analysis of this important
parameter.
Conclusions
Immune profiling by RNA-Seq allows for the identification of samples
with over-expression of multiple genes involved in checkpoint block-
ade, TILs, and cytokine/chemokine interactions. Subjectivity of inter-
pretation of IHC as well as the lack of scalability will require a more
high-throughput approach such as RNA-Seq. Our results show that
such an approach is feasible with FFPE specimens and is more accur-
ate and reproducible than IHC.
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Background
Immune checkpoint blockade with monoclonal antibodies directed
at the inhibitory immune receptors has emerged as a successful
treatment for cancer patients. Evaluation of tumor checkpoint block-
ade by IHC is subjective, not reproducible, and importantly not scal-
able. We have designed a custom 362 gene RNA-Seq immune
profiling panel that uses a multi-analyte algorithmic analysis (MAAA)
to evaluate checkpoint blockade, tumor infiltrating lymphocytes, and
cytokine/chemokine interactions. Additionally, we have previously
profiled several hundred samples that are used for ranking of expres-
sion of each gene.
Methods
269 FFPE cancer samples of diverse histologies were evaluated by
RNA-Seq with a custom 362-gene Ion AmpliSeq Immune Response
Profiling Assay using the Ion ChefTM and Proton. RNA-Seq analysis
was performed with the Torrent SuiteTM followed by normalization.
Results for each sample were then evaluated with a MAAA to provide
a prediction score for 61 known immunotherapy drugs. Predictions
were reported for a continuous scale of 1-100 and interpreted as
low, neutral, or high. All samples were also included in a custom
TMA and IHC was performed for known targets of various immuno-
therapies when available.
Results
At least one over expressed immunotherapeutic target was identified
in more than 50% of the samples. By evaluating upstream and down-
stream mediators for each overexpressed target at least one high
prediction score was identified in almost one-third of the samples.
Not surprisingly the class of immune recognition, including check-
point blockade, was the most frequently identified group of high
prediction scores. High prediction scores were also identified for im-
mune therapy drugs for the classes of immune inhibition (eg IDO1),
tumor targeting mAbs (eg CD56), and microbe-associated (TLR7).
Conclusions
Profiling by RNA-Seq allows for the identification of samples with
over expression of multiple genes involved in the tumor immune
repertoire. By applying a MAAA to these results in the context of a
known database of results we can provide a prediction score that
guides selection of various immune therapies, including more than
just checkpoint blockade. As immune therapy moves from treatment
of last resort to first and second line treatment an accurate scal-
able interrogation of the total tumor immune microenvironment
will be required.
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Background
The expression of PD-L1 in melanoma metastases limits immune con-
trol of tumor progression. Reliable biomarkers of patient survival, and
response to treatment, are critical for patient care and selection. Yet
the prognostic ability of PD-L1, or highly related PD-L2, remain con-
troversial. We hypothesized that the expression of PD-L1 and PD-L2
by melanoma cells would correlate with both immune cell infiltration
and patient survival, independent of checkpoint blockade therapy.
Methods
Tissue microarrays of metastatic melanoma samples from 147 pa-
tients were evaluated (median follow-up: 19 months). None had been
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82 Page 59 of 221
treated with PD-1/PD-L1 blockade. Cancer vaccines had been admin-
istered to 49 of the patients (33%). Melanoma cells were assessed by
immunohistochemistry for surface and cytoplasmic expression of PD-
L1 (clone 5H1) and PD-L2 (R&D Systems, AF1224). Immune cells were
enumerated with stains for PD-L1, PD-1, CD8, CD45, CD4, CD3,
CD163, CD20, CD138, and FoxP3. Relationships between the propor-
tions of PD-L1 and PD-L2 expressing tumor cells with immune cell
counts were assessed (by Spearman correlation), and with immune
cell distribution (Immunotype, by Wilcoxon rank sum tests). Associa-
tions with patient survival were evaluated using Kaplan-Meier curves
and Log-rank tests. P values less than 0.05 were considered
significant.
Results
Surface expression of either PD-L1 or PD-L2 by melanoma cells corre-
lated significantly with increasing intratumoral densities of immune
cells expressing each of the following: CD45, CD3, CD4, CD8, PD-1
and FoxP3 (p≤0.001). PD-L1 expression was more common in tumors
of patients who had previously participated in melanoma vaccine
trials (p = 0.034). Diffuse infiltration (Immunotype C), as opposed to
infiltration limited to the perivascular spaces (Immunotype B), was
associated with increased PD-L1 (p = 0.058) and PD-L2 (p=0.033)
expression by melanoma cells. Expression of PD-L2 on ≥5% of tumor
cells was associated with improved overall survival (p=0.043), and
the simultaneous positive expression of both PD-1 ligands was
even more strongly associated with improved survival (p=0.005,
Figure).
Conclusions
Both PD-L1 and PD-L2 are markers of immune infiltration. PD-L2
alone, or in combination with PD-L1, is a marker for prognosis in
metastatic melanoma patients. The prognostic associations of the
combination of PD-L1 and PD-L2 support future studies of the pre-
dictive value of these ligands in the setting of combination check-
point blockade therapy.
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Background
PD-L1 expression is induced by IFNγ, providing a feedback mechan-
ism to control inflammation locally. There are conflicting data con-
cerning its prognostic implication in patients with NSCLC. We
hypothesized that PD-L1 is a positive prognostic indicator in NSCLC
and that tumors expressing PD-L1 also express other immune check-
point molecules and are highly infiltrated by T cells.
Methods
Tissue microarrays (TMA) were constructed using two 1 mm cores from
formalin-fixed paraffin embedded surgical specimens of 151 NSCLC (90
adenocarcinomas (AdCA), 58 squamous cell, and 3 mixed histology). Pa-
tients were not treated with PD-1/PD-L1 antibodies, 93% had stage I/II
disease (median follow-up: 27 months). TMAs were evaluated by immu-
nohistochemistry for PD-L1 (clone 5H1, membranous or cytoplasmic
staining), GAL9, CD155, and PD-1 on tumor cells and CD8, FoxP3, PD-1
and LAG3 on immune cells. PD-L1 expression was recorded as the per-
cent of staining tumor cells. GAL9, CD155, and PD-1 were assessed by in-
tensity of staining on tumor cells (scale 0-4). Stained immune cells were
enumerated per core. Overall survival (OS) was assessed as a function of
PD-L1 expression using Cox-proportional hazard. Correlations between
PD-L1 expression and other markers were assessed using Pearson correl-
ation coefficients. The Cancer Genome Atlas (TCGA) data were explored
for validation of co-expression profiles using Fisher exact tests.
Results
Increased percentages of PD-L1+ tumor cells were associated with lon-
ger OS (univariate: p=0.03 and multivariate accounting for stage, age,
histology, CD8 counts and tumor grade: p=0.04). PD-L1 expression also
correlated with increasing CD8(p=0.002), FoxP3(0.013), LAG3(0.007) or
PD-1(p=0.049) expressing lymphocytes and with the expression of PD-
1, GAL9 and CD155 on tumor cells (p≤0.02). Tumors with high PD-L1
and CD8 expression (21%) also highly expressed inhibitory markers
(FoxP3, LAG3, CD155 and GAL9, Figure). Similar significant correlations
with PD-L1 mRNA expression were found in the TCGA cohort of 517
AdCA patients with PD-1 and CD8, and with checkpoint molecules
LAG3 , TIM3, and PD-L2, as well as the TIM3 ligand Gal9 (Fig. 43).
Conclusions
Tumor cell expression of PD-L1 is a favorable prognostic indicator
and correlates with CD8+ T cell infiltration and co-expression of other
inhibitory checkpoint molecules and ligands. The simultaneous pres-
ence of additional tumor protective signals in these tumors may
influence their response to PD-1/PD-L1 blockade. Patterns of co-
expression of checkpoint molecules may guide selection of combin-
ation checkpoint blockade therapy.
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Fig. 42 (Abstract P100). The expression of different immune markers.
Heatmap depicts protein expression intensities as determined by IHC
in the 151 NSCLC tumors
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Background
Currently, the preclinical assessment of immuno-oncology (I-O) agents
relies heavily on murine tumor efficacy models, typically necessitating
surrogate antibodies. Although nonhuman primate studies enable the
use of human clinical candidate antibodies, such studies rely on limited
pharmacodynamic (PD) markers. To more thoroughly evaluate the abil-
ity of I-O therapies to impact T cell immunity, we took advantage of
the limited major histocompatibility complex (MHC) diversity in Maur-
itian cynomolgus macaques (MCMs) and utilized a highly immunogenic
vaccine containing known MCM T cell epitopes. This design enabled
longitudinal tracking of vaccine-elicited responses using antigen-
specific T cell readouts. We then evaluated the effects of ipilimumab
(anti-CTLA-4) in this nonhuman primate PD model.
Methods
Pre-selected MCMs with specific MHC class I alleles that restrict
known CD8+ T cell epitopes were vaccinated intramuscularly with
two non-replicating adenovirus serotype 5 (Ad5) viral constructs, one
encoding simian immunodeficiency virus (SIV) Gag protein and the
second encoding SIV Nef protein. Following vaccination, MCMs re-
ceived intravenous administration of either saline as control or ipili-
mumab (anti-CTLA-4) at 10 mg/kg. Vaccine-induced SIV-specific T cell
responses were longitudinally evaluated via flow cytometry, includ-
ing the use of peptide loaded MHC class I tetramers and IFN-gamma
ELISPOT assays.
Results
All vaccinated MCMs generated detectable levels of Gag- and Nef-
specific T cell responses that typically peaked 2 to 3 weeks post-
vaccination with a consistent immunodominance hierarchy. Addition
of a single dose of ipilimumab resulted in robust augmentation of
vaccine-induced CD8+ T cell responses both at the peak of the vac-
cine response and after the vaccine response waned (>6 weeks post-
vaccination). Enhanced Ki-67 expression was also detected on bulk
CD8+ and CD4+ T cells, signifying increased proliferative capacity
with ipilimumab treatment.
Conclusions
Using this nonhuman primate PD model, we observed that the admin-
istration of ipilimumab enhanced the magnitude of vaccine-induced
Ag-specific T cell responses. The ability to demonstrate such PD effects
in monkeys allows for the testing of human clinical candidate anti-
bodies in pharmacologically relevant models. This vaccine system can
be used to provide early proof-of-concept data as well as aid in lead
candidate selection by comparing antibodies targeting different epi-
topes or expressing different Fc domain formats (e.g., human IgG1 vs
human IgG4). The described findings highlight the feasibility of this ap-
proach to investigate the impact of immunomodulatory antibodies/
therapies on T cell immunity, particularly at an antigen-specific T cell
level, and warrant the study of additional I-O agents.
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Background
In ESBC, TILs by gold-standard H&E Salgado criteria are prognostic for
survival. Salgado criteria employ a single-slide “average” pathologist esti-
mation of stromal TILs and excludes analysis of immune cell “hotspots.”
Alternatively in colorectal cancer, the immunoscore methodology is
prognostic for survival but employs CD8+ assessment of immune cell
“hotspots.” Recently, immune cell hotspots predicted response to anti-
PD-L1 in breast cancer. Therefore, we wished to preliminarily evaluate
both gold-standard and immune hotspot strategies for scoring TILs in
ESBC, and to evaluate the utility of multispectral immunofluorescence
(fluorescent mIHC), which allows for single-slide quantification of numer-
ous immune cell subsets.
Methods
From 8 sequentially diagnosed ESBC specimens, FFPE-preserved
diagnostic core biopsies and subsequent excision specimens were
obtained via an IRB-approved biospecimen protocol. Adjacent
slides were submitted for routine H&E and fluorescent mIHC. H&E
TILs were scored by a trained breast pathologist using Salgado
criteria. Fluorescent mIHC was conducted using the PerkinElmer
Vectra platform using a validated antibody panel (CD3, CD8,
FoxP3, CD163, PD-L1, cytokeratin, and DAPI) [1]. To recapitulate
the Salgado “TIL average” scoring method using fluorescent mIHC,
9 randomly-selected tumor-bearing 20x fields were selected from
a single slide, then stromal TIL scores were averaged across these
fields. To recapitulate the immunoscore “immune hotspot” meth-
odology, CD8+ high-density areas were visually identified at 4x
magnification, then subsequently scored at 20x magnification.
Results
Representative images are shown in Fig. 44; all 16 specimens were high
quality without significant crush artifact or nonspecific staining. Cyto-
keratin staining delineated stroma from tumor, allowing for automated
quantification of both stromal and intratumoral TILs by fluorescent
mIHC. H&E Salgado TIL scores ranged from 0-60%; core biopsy and ex-
cisional H&E TIL scores were highly correlated (r2=0.7, Fig. 45). By the
“TIL average” fluorescent mIHC method, core biopsy and excisional bi-
opsy immune cell counts were highly correlated (Table 7). By the “im-
mune hotspot” fluorescent mIHC method, at least one hotspot was
identified in each of the 16 specimens; however, core biopsy and exci-
sional hotspot immune cell counts were only weakly correlated.
Conclusions
In ESBC, fluorescent mIHC provides complementary data on TIL pheno-
type that may ultimately prove useful in personalizing immunotherapy.
A “TIL average” strategy of assessing TILs by fluorescent mIHC may
more stably characterize individual tumors compared to an “immune
hotspot” approach; however, further evaluation is warranted.
Fig. 43 (Abstract P100). Genes expressed in association with PD-L1
in NSCLC. Gene expression analysis in the 517 adenocarcinoma and
501 squamous cell carcinoma specimens from the TCGA provisional
database
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82 Page 61 of 221
References
1. Feng Z, Puri S, Moudgil T, et al: Multispectral imaging of formalin-fixed
tissue predicts ability to generate tumor-infiltrating lymphocytes from
melanoma. J Immunother Cancer 2015, 3:47.
P103
Changes in uveal melanoma immune infiltrate in response to
checkpoint blockade
Sapna P. Patel, Mariana Petaccia De Macedo, Yong Qin, Alex Reuben,
Christine Spencer, Michele Guindani, Roland Bassett, Jennifer Wargo
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Correspondence: Sapna P. Patel (sppatel@mdanderson.org)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P103
Background
Uveal melanomas are a subset of melanomas that contain few genomic
mutations, thereby generating few neo-epitopes, and making them of
low immunogenic potential. What is unknown is how systemic treatment
for metastatic disease changes the immunogenicity of metastatic uveal
melanomas. Previous work has demonstrated the immune infiltrate in cu-
taneous melanomas changes in response to treatment with checkpoint
blockade. We undertook a pilot study to describe the changes in uveal
melanoma immune infiltrate in response to treatment with systemic
checkpoint blockade.
Methods
Twenty-two uveal melanoma patients who had received checkpoint
blockade for metastatic disease, and who had archival pathologic
tissue, were identified. Formalin-fixed paraffin-embedded tissue sec-
tions were obtained on available cases, and bleaching protocols were
utilized to reduce heavy melanin pigmentation. Immunohistochemis-
try was performed using validated antibodies for CD3, CD8, CD68,
FOXP3, PD-1, and PD-L1.
Results
Eleven uveal melanoma patients had at least one time point of tumor
tissue collected and evaluated, most commonly before treatment initi-
ation. Nine patients had at least two time points collected and evalu-
ated, some while on treatment, others at progression of disease. In a
representative case, a pre-treatment metastatic liver biopsy showed
low level of CD8+ lymphocytes infiltrating the tumor. After 4 doses of
ipilimumab, with best overall clinical response of disease progression,
the patient had another liver biopsy. This tissue sample showed a not-
able increase in CD8+ lymphocyte infiltration via immunohistochemis-
try compared to the pre-treatment sample. This is consistent with
similar data from cutaneous melanoma patients receiving checkpoint
blockade, where CD8+ infiltrates at progression is lower than during
treatment response, but higher than at baseline. Full details of all cases
will be presented at the SITC Annual Meeting.
Conclusions
Immune infiltration does change in metastatic uveal melanoma in re-
sponse to systemic checkpoint blockade. Some patients did experience
an increase in infiltrating CD8+ T lymphocytes while on immunotherapy.
The change in immune infiltrate did not, however, correlate with clinical
response to treatment. Future analysis includes an evaluation for im-
mune suppressive molecules, such as indoleamine 2,3-dioxygenase and
transforming growth factor-beta, and evaluation of immune infiltration
in response to combination checkpoint blockade as well as to targeted
therapy.
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Background
Behavior of various tumor-infiltrating immune cells in the tumor envir-
onment correlates with patient responses to therapies. Particularly, the
localization of CD8+ T cells within and around a tumor mass containing
immune and tumor cells expressing the programmed death-ligand 1
(PD-L1) checkpoint marker is positively correlated with response to im-
munotherapy targeting PD-L1 blockade. Simultaneous detection of
CD8+ T cells and PD-L1+ cells could become a valuable diagnostic tool.
We developed a fully automated duplex immunohistochemistry (IHC)
assay to detect these two biomarkers on a single formalin-fixed,
paraffin-embedded (FFPE) tissue section using VENTANA BenchMark
ULTRA stainers and brightfield microscopy.
Table 7 (Abstract P102). Correlation of IF cell densities, core biopsy
versus excisional specimen
Cell Type “TIL average”
method, r2
“Immune
hotspot”
method, r2
CD3+ 0.67 0.04
CD8+ 0.63 0.06
PD-L1+ .042 0.34
PD-L1+ CD3+ 0.74 0.29
CD163+ 0.61 0.43
Fig. 45 (Abstract P102). Correlation of H&E Salgado score, core
biopsy versus excisional specimen
Fig. 44 (Abstract P102). Representative H&E and IF Images
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Methods
The duplex IHC assay uses anti-PD-L1 (SP263) and anti-CD8 (SP239)
rabbit monoclonal primary antibodies and goat anti-rabbit secondary
antibodies conjugated to either horseradish peroxidase (HRP) or
alkaline phosphatase (AP). The detection and amplification of signal is
achieved upon activation of tyramide- or quinone methide-conjugated
chromogens by the corresponding enzymes and covalent binding of
chromogens. The detection of PD-L1, with a purple chromogen and
CD8 with either yellow or cyan is performed sequentially and fully auto-
mated on the VENTANA BenchMark ULTRA stainers and includes a heat
deactivation (HD) step between the two rounds of detection to prevent
cross-reactivity of same species antibodies. The assay was developed
and tested using normal human tonsil tissue, lung carcinomas, and
multi tissue arrays. The staining was assessed by trained pathologists or
measured using commercially available imaging software.
Results
The PD-L1/CD8 duplex assay showed equivalent staining to the single
PD-L1 or CD8 DAB staining (Fig. 46) on normal tonsil and lung carcin-
omas. The reproducibility test showed 100% agreement between three
lots of reagents and 89% (blue detection) and 100% (yellow and purple
detection) agreement between three testing laboratories. The staining
precision is acceptable as the coefficient of variation of staining inten-
sity was less than 2%. Effectiveness of heat deactivation was validated
for the conditions of the duplex assay as we did not detect cross-
reactivity or adverse effects on the epitopes and the chromogens.
Conclusions
We developed a fully automated and robust dual IHC staining assay for
detection of PD-L1 and CD8 markers on the same slide. The chromo-
gens used in this assay are compatible with regular counterstains and
alcohol dehydration. The dual IHC assay could facilitate mining of
spatial relationship between the two markers for evaluation of tumor
microenvironment.
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Background
With multiple approved immunotherapies for metastatic melanoma
(MM), tests that enable optimal treatment selection are needed.
BDX008 is a serum protein-based test that identifies patients with
better (BDX008+) or worse (BDX008-) survival (OS) on nivolumab [1].
Using similar methods and samples from the IL-2 Select trial, a test
for prediction of progression-free survival (PFS) after HDIL-2 treat-
ment has been developed that divides patients into two groups, A
and B (better and worse PFS, respectively). Performance of these
tests is compared in two cohorts of MM patients treated with either
HDIL-2 or nivolumab.
Methods
MALDI mass spectra were generated for pre-treatment samples from
114 pts in the IL-2 Select trial and 119 patients from a trial of nivolumab
with or without a peptide vaccine. (The IL-2 trial was used for develop-
ment of the IL-2 test, the nivolumab/peptide trial for development of
BDX008.) Both the IL-2 test and BDX008 were applied to all spectra
generated from these trial samples. Outcomes included PFS (HDIL-2),
time to progression (TTP; nivolumab/peptide), and OS (both), depend-
ing on the test and the trial agent (Fig. 47 and results).
Results
Of the 112 patients treated with HDIL-2 (2 failed BDX008 QC), 39
(35%) were classified as group A, and 89 (79%) as BDX008+. All
group A samples were BDX008+. PFS was strongly correlated with IL-
2 test classification: IL-2 test group B had inferior PFS compared with
Fig. 46 (Abstract P104). Comparative single and dual staining of
PD-L1 and CD8 in lung tumor tissue
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IL-2 test group A, but no difference whether BDX008+ or not. In con-
trast, OS was favorable with BDX008+ regardless of IL-2 test group.
Hence, patients classified as IL-2 test group B and BDX008+ had a
similar OS to group A patients despite an inferior PFS, possibly due
to subsequent checkpoint inhibitor therapy or to pre-IL-2 factors with
prognostic importance but not predictive for PFS after IL-2. In the
nivolumab patients, 72 (61%) samples were BDX008+ and 37 (31%)
fell into IL-2 test group A; all 37 were BDX008+. Both TTP and OS cor-
related closely with BDX008: BDX008+ had better outcomes than
BDX008-; also, BDX008- outcomes were independent of IL-2 test
status.
Conclusions
Patients classified into poor outcome categories by both BDX008 and
the IL-2 test have poor outcomes on both immunotherapeutic regi-
mens. For the remaining patients, the two tests perform differently,
identifying partially overlapping groups of patients likely to have
good outcomes with one or the other therapy.
Trial Registration
ClinicalTrials.gov identifier NCT01288963 and NCT01176461.
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Background
Multiple immunotherapeutic regimens for the treatment of meta-
static melanoma (MM) are now approved and can provide long term
benefit to a proportion of patients. Blood-based assays that can assist
treatment selection are of significant clinical relevance. Using serum
mass spectrometry, a test has been developed to predict good out-
comes on anti-PD-1 therapy. We present results on the development
and validation of this test.
Methods
MALDI mass spectra were generated for pretreatment serum samples
from 119 patients treated with nivolumab at Moffitt Cancer Center.
Using a classifier development platform optimized for creation of multi-
variate molecular diagnostic tests which can generalize well to inde-
pendent datasets, a test was created to identify patients with
particularly good outcomes. This test classifies samples into two groups:
group 1 (very good outcome) and group 2 (inferior outcome). This test
was validated in two independent cohorts of MM patients receiving
anti-PD-1 agents: 30 patients from Yale University (YU) and 25
patients, most treated with pembrolizumab, from Massachusetts
General Hospital (MGH). The test was also applied to pretreatment
samples collected from 21 patients from YU receiving combination
PD-1/CTLA-4 blockade. Difference in outcomes between patients
classified as group 1 and group 2 within each cohort were assessed
using log-rank p values and Cox proportional hazard ratios (HRs).
Results
Of the 119 patients used in test development, 34 (29%) were classified
as group 1. Group 1 had better survival (OS) and time-to-progression
(p=0.002 and p=0.014, respectively), with two-year survival of 67%. In
the YU cohort receiving an anti-PD-1 agent, 13 (43%) classified as
Group 1, which had better OS than Group 2 (p<0.001) and two-year
survival above 80%. Eleven (44%) patients from the MGH cohort were
classified as Group 1. There was a trend to improved OS for Group 1
compared to Group 2 (p=0.062, HR= 0.17). Within the cohort of patients
receiving combination PD-1/CTLA-4 blockade, 13 (62%) classified as
Group 1. Two-year survival was 83% in Group 1 and 63% in Group 2.
Conclusions
The test identifies a subgroup of patients with extremely good out-
comes on anti-PD-1 therapy. High two-year survival in the Group 1
cohorts may indicate that the test has potential utility in identifying
patients who derive significant benefit from anti-PD-1 monotherapy
and might gain little benefit from the addition of an anti-CTLA-4
agent. As follow-up was only 2 years for OS, and the numbers are
small, further validation is necessary.
Trial Registration
ClinicalTrials.gov identifier NCT01176461.
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Background
Multiplexed immunohistochemistry has become increasingly im-
portant as cancer immunologists seek understanding of specific
cell-to-cell interactions within tumor and its microenviroment. To
support this need, we have developed staining approaches that le-
verage the properties of tyramide signal amplification (TSA) to in-
crease signals above background and to provide photostable
balanced signals. However, automation is needed before broad
adoption occurs in research and eventually in clinical practice. We
present two methods for automation, one fully automated on a
Leica Bond Rx and the other semi-automated on a Biocare Intelli-
path. The fully automated approach uses sodium dodecyl sulfate
(SDS) to denature endogenous myeloperoxidase (MPO) and elimin-
ate cross reactivity among antibodies without affecting previously
applied fluorescence labels. The semi-automated on the Intellipath
automates all staining steps, except for antibody stripping which
occurs off-line using microwave. In this presentation, we present
detailed protocols and assess analytical performance.
Fig. 47 (Abstract P105).
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Methods
Previously, we demonstrated reproducible immunofluorescence la-
beling with a manual protocol utilizing microwave exposure to re-
move antibodies between each marker (Methods 70 (2014) 46–58).
In the fully automated approach using the Bond Rx, we replace the
microwave step with a 7-minute exposure to 5% SDS at 50C. Tonsil
and breast cancer sections were stained with a 6-plex, 7-color panel
for PD-1, PD-L1, CD8, CD68, Foxp3, cytokeratin, plus DAPI counter-
stain. Serial sections were used to assess reproducibility, cross talk,
interference, and signal-to-background ratio. Slides were scanned
and analyzed using multispectral imaging (VectraTM) to isolate fluor-
escence signals for accurate measurement.
Results
Balanced specific staining was achieved with both methods. Crosstalk
was below the limit of detection. Signal-to-background was above 10:1
for each label, as measured by looking at signal strength on and off
cells positive for the marker of interest. Coefficient of variation of mea-
sured signals was generally less than 20% for the semi-automated ap-
proach and less than 15% for the fully automated approach.
Conclusions
This is the first demonstration of reproducible and independent fully-
automated TSA-based automated multiplexed immunofluorescence
using SDS to perform antibody denaturation. It is also a demonstra-
tion of a semi-automated approach that performs antibody stripping
off of the autostaining instrument and is compatible with a broad
range of mid-range and conventional autostaining platforms.
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Background
Although checkpoint blockade immunotherapies are successful in
some cancer patients, the majority of patients still do not benefit
from these therapies. The advances of digital pathology and the
availability of quantitative whole slide image analysis allows for a sys-
tematic search for novel tissue-based biomarkers to predict therapy
response and overall survival. Here, we present a Tissue Phenomics
case study to discover a potential companion diagnostic test for ipili-
mumab (IPI) in malignant melanoma.
Methods
The patient cohort is a subset of the MISIPI study [1], comprising 30
melanoma patients. Consecutive sections from FFPE tissue were
immunohistochemically stained with CD3, CD8, and FoxP3. The sec-
tions were digitized and automatically aligned using an advanced
staining-independent image registration algorithm. Tumor regions
were manually annotated by a pathologist, excluding artifacts and
necrotic regions. A novel parameter-free cell segmentation approach
was used to automatically detect and classify cells with respect to
their protein expression profile [2] and to the spatial distance to the
annotated tumor border. We computed for each of the CD3+, CD8+
and FoxP3+ cell populations the average cell density in the tumor in
a border region within the tumor and in a border region just outside
the tumor. By computing a potentially predictive score for each ratio
of the measured cell densities, we identified the most promising pa-
tient stratification algorithm in terms of predictive values for therapy
response and the Kaplan-Meier statistics p-value for overall survival.
Results
We identified a promising scoring algorithm which is based on the
ratio of the CD8+ cell density at the inner tumor border to the CD8+
cell density in the tumor. It enables patient stratification into IPI re-
sponders and non-responders with high predictive values (positive
predictive value 68%, negative predictive value 79%, prevalence
39%) and at the same time, excellent prediction of overall survival
(p-value < 0.0015).
Conclusions
A novel companion diagnostic algorithm for ipilimumab in malignant
melanoma was discovered by Tissue Phenomics. It provides high
predictive power and enables considerably improved treatment deci-
sions. However, the results are still preliminary and need to be fur-
ther validated.
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Background
Tumor-associated macrophages (TAMs) and tumor infiltrating T-cells
(TILs) have been associated with tumor progression in various tumor
entities. In this study, we applied the Tissue Phenomics technology
to discover new TAM-related prognostic factors to predict prostate
cancer progression. This technology correlates clinical outcome data
with image analysis results from (virtually) multiplexed tissue slides.
Multiplexing enables the co-analysis of multiple immunohistochemi-
cally (IHC) stained tissue sections. Using this method, we investigated
the prognostic relevance of M1/M2 TAMs (CD68/CD163) and TILs
(CD3/CD8) within prostate cancer (PCa) resection specimens from
low-risk and intermediate-risk patients with respect to Prostate Spe-
cific Antigen (PSA) recurrence after radical prostatectomy (RP).
Methods
Analysis and quantification were performed on three consecutive du-
plex stained FFPE tissue sections from 89 patients (on which 40 with
PSA recurrence) with low- to intermediate-risk PCa after RP with a
Gleason-Score ≤ 7a. M1- and M2-type macrophages were character-
ized by CD68 and CD163, T-cells by CD3 and CD8, tumor and non-
tumor epithelial tissue regions by CK18 and p63. CK18 positive
glands without any p63-stained basal cell nuclei are considered as
tumor glands. The three duplex stained slides were analyzed and
converted into one virtual tissue slide through image co-registration.
TAMs and TILs were quantified separately in the distinct tumor re-
gions and the tumor microenvironment. Both, the overall number of
TILs and TAMs and the ratio of M1- and M2-positive macrophages
were analyzed using the Tissue Phenomics technology. The correl-
ation between various TIL and TAM cell densities within the different
regions of interest (tumor and tumor microenvironment), the tumor
grading and tumor stage, and clinical parameters (PSA recurrence,
overall and disease-free survival) were performed.
Results
Prostate cancer patients without PSA recurrence show a significantly
higher ratio of CD8 to CD163 positive cell densities in the tumor
microenvironment. The PSA recurrence prediction accuracy is 76.8%
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with a Kaplan-Meier log-rank test p-value of 2.7e-5 for the disease
free survival time.
Conclusions
These first results indicate a considerable prognostic potential of
TAMs to predict PSA recurrence in PCa. The application shows that
the Tissue Phenomics Technology enables the investigation and the
evaluation of the prognostic relevance of certain immune cell popu-
lations. The analysis of the relation of TILs to TAMs is an excellent ex-
ample for such kind of applications with a potentially high impact for
prostate cancer patient treatment decisions.
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Background
Several immune checkpoint inhibitors have been approved to treat
multiple solid tumor types. Immune responses could be modulated
by targeted therapies as well as cytotoxic agents. The opportunity
to combine immunotherapies with agents against targetable prote-
omic and genomic biomarkers may lead to improved outcomes
and reduced toxicities; however, analysis of multiple biomarkers
creates an increased demand for tissue. Using a multi-omic ap-
proach that incorporates mass spectrometry based proteomic ana-
lysis and NGS, we were able to objectively detect the expression of
multiple therapeutically-relevant proteins and genomic alterations
from a minimum two FFPE sections. Here, we report on patient
samples that express the PD-L1 protein and either co-express
therapeutically-relevant proteins (EGFR, HER2, MET, ROS1, TOPO1,
etc.) or gene mutations (MET, KIT, BRAF, JAK3, etc.).
Methods
Formalin-fixed, paraffin-embedded (FFPE) sections of tumor tissue
from patients with different cancer indications were obtained. For
proteomics analysis, tumor area of 8 mm2 was marked by a board-
certified pathologist. Following laser microdissection of the marked
areas, tumor cell proteins were extracted using the Liquid Tissue®
process and subjected to selected reaction monitoring mass spec-
trometry to quantify 27 targeted proteins in each patient sample.
For genomics analysis, genomic content was isolated from the FFPE
tumor tissue sections as well as from corresponding normal sam-
ples and subjected to NGS for whole genome sequencing (tumor
and normal) and whole transcriptome sequencing (tumor only)
analysis.
Results
Quantitative proteomic analyses of 1710 cancer patient samples
across multiple indications revealed a wide range (144 – 1025
amol/mg) of PD-L1 protein expression. Several actionable protein
targets were co-expressed with PD-L1, including targeted therapy
markers (EGFR (80%), HER2 (29%), MET (56%), ROS1 (22%)) and
chemotherapy markers (TOPO1 (100%), etc.). PD-L1 protein express-
ing tumors were also found to harbor therapeutically-relevant gen-
omic mutations, including MET (N375S and T1010I), JAK3 (V722I),
KIT (M541L), BRAF (V600E), CDKN2A (D84H), etc.
Conclusions
Tumor molecular profiling by both proteomic and genomic analysis
revealed co-expression of targetable proteins (EGFR, HER2, MET,
TOPO1, etc.) and genomic alterations (MET, KIT, BRAF, etc.) in pa-
tients that express the PD-L1 protein. From minimal amounts of tis-
sue, we were able to assess multiple therapeutically-associated
biomarkers using mass spectrometry based targeted quantitative
proteomics and NGS based comprehensive genomic (DNA and
RNA) analysis. Ongoing clinical trials involving immunotherapy and
chemo/targeted therapies could benefit from molecularly stratifying
patients by proteomic and genomic testing to increase efficacy and
reduce toxicity.
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Background
Colorectal cancer is the second leading cause of cancer death world-
wide. This high mortality is because almost half of colorectal cancers
are detected at an advanced stage of disease, and the currently used
prognostic factors are not always accurate. Recently, the prognostic
impact of the body’s immune response to cancer has been demon-
strated. Immunoscore (in situ immune cell infiltrate in tumours) has
been shown to be a very powerful prognositc indicator in patients
with clinically localized colorectal cancer. These patients are usually
treated with only surgical removal of the tumour; however, approxi-
mately 25% of these patients will have recurrence of their disease, in-
dicating that occult metastases were already present at the time of
curative surgery. No tumour-associated marker predicts the recur-
rence of this subgroup of patients that could benefit from adjuvant
therapy. These days are investigated other parameters of the im-
mune response – mostly cellular immunity and the production of im-
munosuppressive and neoangiogenic markers. VEGF is the factor
responsible for neoangiogenesis and it is being considered as a pos-
sible prognostic marker of disease progression. Transforming growth
factor-beta (TGF-beta) is also neoangiogenic and a highly immuno-
suppressive factor, as it suppresses the body’s natural immunity
against tumours. TGF-beta is also being considered as another pos-
sible prognostic marker of disease progression. The purpose of this
study was to monitor the immune response in patients with stage II
colorectal cancer, with a focus on cellular as well as humoral immun-
ity. TGF-beta and VEGF levels were followed.
Methods
22 patients with stage II colon cancer included in the research project
received routine cancer teratment. Basic parameters – histological type
and grade, proliferative markers – were established at baseline. Patients
were evaluated by a clinical immunooncolgist to exclude any immune
disorders of allergic or autoimmune origin. TGF-beta and VEGF were
measured using ELISA, and anti-tumour cellular immunity (CD4, CD8, T-
reg, B cells) were measured via flow cytometry.
Results
In patients with stage II colorectal cancer, predominantly a depres-
sion in cellular immunity was seen. Plasma levels of immunglobulins
were also reduced, particularly the IgG4 subtype. Most patients
showed some clinical symptoms of immunodeficiency, such as fre-
quent respiratory tract infections and/or herpetic infections. TGF-beta
and VEGF plasma levels were increased.
Conclusions
The correlation of these neoangiogenic and immunosuppressive fac-
tors, as well as the state of anticancer immunity, could help in the fu-
ture as a prognostic marker and contribute to the selection of
targeted immune therapy in patients with colorectal cancer.
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Background
Therapeutic strategies in non-small cell lung cancer (NSCLC) are
based on the histopathological evaluation of the tumor tissue which,
in conjunction with the TNM staging system, remains the gold stand-
ard for prognostic assessment. Nevertheless, histopathology and
stage-specific clinical outcomes vary significantly, indicating that
there is a need for additional prognosticators. A previous study re-
ported that intense lymphocytic infiltrates were found in 6-11% of
NSCLC and were associated with a significant increase in disease-free
and overall survival [1]. The aim of our study was to use multispectral
imaging and digital quantification to assess relationships between T
cells and FoxP3+ or PD-L1+ cells in tissue microarrays (TMAs) cored
from “hot spots” of dense infiltrates at the invasive margin and cen-
ter of the NSCLC.
Methods
Tissue microarrays (TMA) were generated from formalin-fixed
paraffin-embedded tissue of 98 curatively resected patients with
stage IA-IIIA NSCLC. TMAs included 3 cores for tumor center and 3
cores for invasive margin selected from the areas with the most
dense (hot spot) lymphocytic infiltrate. TMAs were immunolabeled
with mIHC technique for the following antibodies: PD-L1, CD8, CD3,
FoxP3, CD163, cytokeratin and DAPI and quantified with InForm soft-
ware. Results were compared between groups of patients with squa-
mous and non-squamous cell carcinoma and correlated with the
course of the disease, overall/progression-free survival, metastases or
relapse and clinicopathological parameters.
Results
In contrast to reports evaluating whole sections, analysis of “hot
spots” in this cohort of patients failed to provide a prognostic bio-
marker for survival. Current studies are evaluating how an evaluation
of the whole section correlates with results of this “hot-spot” analysis.
Our preliminary data suggests that the “hot-spot” analysis of CD8,
FoxP3 and PD-L1 does not allow us to identify outcome in NSCLC.
Conclusions
Multispectral assessment of CD8, FoxP3, and PD-L1 performed on
“hot-spots” of stage I-III NSCLC did not provide a prognostic bio-
marker. Given other reports that immune infiltrates are associated
with improved outcome, this suggests it may be important to evalu-
ate a larger percentage of the tumor. These findings appear to con-
trast with the colon immunoscore project which identified a
correlation with an enumeration of CD3+ and CD8+ T cell numbers
in hot-spots and disease-free and overall survival.
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Background
As the predominant lymphocyte subset in the liver, nature killer (NK)
cells have been shown to be highly associated with the outcomes of
patients with chronic hepatitis B virus infection (CHB) and hepatocel-
lular carcinoma (HCC). Previously, we reported that NKG2A, a check-
point candidate, mediates human and murine NK cell dysfunction in
CHB. However, NK cell exhaustion and, particularly, the level of
NKG2A expression within liver tumours have not been reported.
Methods
In this study, we analysed NKG2A expression and the related dys-
function of NK cells located in intra- or peritumour regions of liver
tissue samples from 207 HCC patients, in addition to analysing dis-
ease outcomes.
Results
The expression of NKG2A in NK cells and the NKG2A ligand, HLA-E,
in intratumour HCC tissues was observed to be increased. These NK
cells, and particularly CD56dim NK cells, with higher NKG2A expres-
sion showed features of functional exhaustion and were associated
with a poor prognosis. The increase in NKG2A expression might be
induced by IL-10, which was present at a high level in the plasma of
HCC patients. Blocking IL-10 could specifically inhibit NKG2A expres-
sion in NK cells.
Conclusions
These findings indicate that NKG2A expression is influenced by fac-
tors from cancer nests and contributes to NK cell exhaustion, sug-
gesting that NKG2A blockade has the potential to restore immunity
against liver tumours by reversing NK cell exhaustion.
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Background
Colorectal cancer (CRC) is the third most common type of cancer in the
United States. There have been exciting responses to immunotherapy
in CRC, but the ability to predict which patients would benefit from
these drugs remains elusive. Recent work has demonstrated the aber-
rant expression of non-coding repeat RNAs across cancers including
colon cancer [1, 2]. These repeats appear to trigger elements of the in-
nate immune response that may have implications for response to im-
munotherapy [1]. To determine if repeat RNAs are linked to the tumor
immune microenvironment, we developed a novel combined repeat
RNA in situ hybridization (RNA-ISH) with T cell immunohistochemistry
(IHC) on fixed formalin paraffin embedded (FFPE) tissues. We assessed
two different repeat types (HSATII and HERV-H) that have been well
documented in human cancers and reported to have an association
with innate immune responses [2]. To investigate correlation of host
immune T cells with these repeats a pilot study of seventy-five patients
of CRC was performed.
Methods
FFPE tissue sections of 75 patients were stained by RNA-ISH and
IHC on the Leica Bond RX. HSATII and HERV-H repeat RNA-ISH
and CD8 (cytotoxic) and FOXP3 (regulatory) T cell marker IHC
was performed on each case. Repeat RNA scores were deter-
mined as HIGH or LOW based on relative cancer cell expression
to normal adjacent tissues. T cell density was determined by
counting the number of positive cells in a 400 x 200 μm area. T
cell density differences were calculated by t-test.
Results
We found HSATII was HIGH in 47 (63%) and HERV-H was HIGH in 36
(48%) of CRC cases with a concordance between repeats of 51%.
Analysis with T cell subsets revealed lower CD8+ T cells in HSATII
HIGH tumors (306 vs 686 CD8+ T cells/mm2; p2; p=0.03).
Conclusions
Repeat RNAs are expressed across malignancies with varying levels
that correlate with different immune infiltrates. Cancer expression of
HSATII and HERV-H repeats offers a novel surrogate biomarker of
cytotoxic and regulatory T cell tumor infiltration. The mechanistic
effects of these repeats on immune cell function merits further
investigation.
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Fig. 49 (Abstract P113). Shorter survival of patients with higher
densities of HLA-E+ cells within tumours. (A, B) Correlations between
DFS or OS and the density of HLA-E+ cells in the IT regions of HCC
patients (N=177). Pearson’s correlation coefficients (R) and P values
are shown. (C, D) Kaplan–Meier survival curves for the duration of
DFS (C) and OS (D) in months, according to the HLA-E+ cells density
in IT (low densities, Red line; high densities, Black line) (log-rank test)
Fig. 48 (Abstract P113). The frequency of intratumour NKG2A+ NK
cells is increased in HCC. (A, B) The percentage of NKG2A-expressing
NK cells in healthy livers (N=17) and IT (N=28) and PT (N=25) from HCC
patients. The differences in the cumulative data were calculated using
a two-tailed paired Student’s t test. (C) NKG2A expression in NK cells
from the paired central tumour and PT from each HCC patient (N=23).
(D) The correlation between NKG2A expression in hepatic NK cells
from IT and the serum AFP and ALT levels and tumour diameters of
HCC patients. Spearman’s correlation coefficients are shown.
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Background
PD-1 antibodies have shown significant clinical activity against ad-
vanced melanoma, but ORR with PD-1 monotherapy remains less than
50%. We previously reported and validated a clinical scoring model to
predict response to anti-PD-1, and in our logistic regression analysis,
female sex was found to be associated with lower response rate (OR
0.36, 95% CI 0.19-0.67). We report further on outcomes in
immunotherapy-treated patients by sex and correlate this with results
of T cell profiling of an exhausted, antigen-experienced phenotype (%
PD-1highCTLA-4high CD8 cells) from pre-treatment biopsy samples.
Methods
336 patients (118 women, 218 men) with advanced cutaneous mel-
anoma were treated with pembrolizumab or nivolumab at 4 aca-
demic cancer centers between December 2011 and October 2013.
Baseline demographics and clinical characteristics were collected
from electronic health records. Tumor response was assessed using
RECIST v1.1 criteria. Pre-treatment flow cytometry data from 122 pa-
tients (45 women, 77 men) treated with both PD-1 monotherapy and
PD-1/CTLA-4 combination therapy were analyzed by sex for correla-
tive data.
Results
In the PD-1 monotherapy cohort, median ORR was 33.1% (95% CI 24.4-
41.2) in females and 54.6% (95% CI 47.9-61.3) in males (p=0.0001). Me-
dian PFS was 5.5 months (95% CI 3.4-7.1) in females and 18 months
(95% CI 11.3-23.8) in males (p=0.0004) (Fig. 51). Flow cytometry analysis
of pre-treatment tumor biopsies revealed a statistically significant re-
duced proportion of exhausted PD-1high/CTLA-4high CD8 T cells that
persisted across age groups (Fig. 52).
Conclusions
There is a significant discrepancy between response to PD-1 mono-
therapy between men and women with advanced melanoma. The
mechanisms of this may have immunologic basis given the differ-
ence in pre-treatment T cell profiles between men and women.
Trial Registration
ClinicalTrials.gov identifier NCT01295827, NCT01704287, NCT01721746,
and NCT02156804.
Fig. 50 (Abstract P114). Colon adenocarcinoma FFPE tissue stained
with dual color RNA-ISH (Red) for HERVH, HSATII and IHC (Brown) for
FOXP3 & CD8. 400X magnification a High HervH and Low FOXP3 b
Low HERVH and High FOXP3 c High HSATII and Low CD8 d Low
HSATII and High CD8
Fig. 51 (Abstract P115). Progression-free survival estimates by sex
in advanced melanoma patients receiving anti-PD-1 monotherapy
Fig. 52 (Abstract P115). Pre-treatment of PD-1high/CTLA-4high
CD8 T cells by sex
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Background
Contextual detection of multiple biomarkers on single formalin-fixed,
paraffin-embedded (FFPE) slides for clinical applications remains an
unmet need. Current multiplex immunohistochemistry (IHC) proce-
dures entail successive rounds of antibody application and fluoro-
phore attachment followed by antibody inactivation. We developed
a parallel multiplex IHC approach using series of epitope-tagged
antibodies and anti-epitope antibodies conjugated to fluorophores,
haptens, or enzymes, and demonstrated feasibility by 5-plex fluores-
cent and duplex brightfield assays of markers relevant for immuno-
oncology.
Methods
DNA sequences corresponding to peptide epitope tags were
fused in-frame to rabbit monoclonal antibody cDNAs for expres-
sion in mammalian cells. Recombinant tagging bypasses the po-
tential antibody inactivation associated with chemical-based
tagging. Conjugation of fluorophores or haptens to antibodies
was performed using NHS ester precursors. Horseradish peroxidase
(HRP) and alkaline phosphatase (AP) were conjugated to reduced anti-
bodies via NHS-maleimide linkers. Affinity of anti-epitope anti-
bodies to peptides was assessed using biolayer interferometry. IHC
of FFPE tissue sections was performed on VENTANA BenchMark
ULTRA platform.
Results
Rabbit monoclonal antibodies against CD3, CD8, CD68, FoxP3,
and PD-L1 were each engineered with a unique epitope tag.
Epitope-tagged primary antibodies produced identical diamino-
benzidine (DAB) staining intensity and pattern as untagged native
antibodies. Multiple clones of recombinant rabbit monoclonal
antibodies against each of the five epitope tags were conjugated
and screened for retention of affinity, stability, and appropriate
staining intensity and pattern in validated tissue microarrays. At
least one clone of each anti-epitope antibody met the functional
requirements and these were used to stain FFPE lung and tonsil
tissue sections in conjunction with cocktailed epitope-tagged
antibodies. Epitope-tagged antibodies were detected using one of
three detection configurations in order of sensitivity: 1) fluor-
conjugated anti-epitope antibodies, 2) hapten-conjugated anti-tag
antibodies and fluor-conjugated anti-hapten antibodies, and 3)
attachment of tyramide- or quinone methide-fluors to tissue
specimens with HRP- or AP-conjugated anti-epitope antibodies.
Titration of antibodies and assay optimization enabled pairings of
particular biomarkers with detection configurations to generate
specific fluorescence patterns and relative intensities similar to
those produced by DAB stains using untagged antibodies and
HRP-conjugated anti-species antibodies. Two-color brightfield
stains were generated using enzyme-conjugated anti-tag anti-
bodies and HRP- and AP-activated chromogens.
Conclusions
We have demonstrated feasibility of parallel multiplex IHC using a
series of epitope-tagged antibodies and fluor-, hapten-, or enzyme-
conjugated anti-epitope antibodies. Applying tagged antibodies and
anti-tag antibody probes as cocktails streamlines multiplex detection
and avoids the inactivation of antibodies that is necessary in multi-
plex approaches based on serially applied antibodies.
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Background
While immune therapies targeting select checkpoint molecules have
revolutionized cancer medicine, the fact that many patients fail to re-
spond underscores the need for improved patient stratification and
application of multi-nodal biomarkers reflecting in situ status of the
tumor immune microenvironment.
Methods
We developed a multiplexed immunohistochemical (IHC) imaging
approach based on sequential IHC with iterative labeling, digital scan-
ning and subsequent stripping of sections. To elucidate contextual in-
formation on leukocyte presence, complexity and functional
phenotype in situ, we investigated these parameters in head and neck
squamous cell carcinoma (HNSCC) utilizing multiplex IHC analyses in
de-identified tissue microarray sections reflecting human papilloma
virus (HPV)-positive and negative oropharyngeal HNSCC and normal
pharynx. Quantitative multiparameter image cytometry was developed
to enable quantification of cell density, composition and location of 16-
immune cell lineages, along with monitoring of programed cell death-1
(PD-1) receptor and ligand (PD-L1) expression.
Results
Intratumoral immune cell densities were comprehensively evaluated
by multiplex IHC/image cytometry via unsupervised clustering ana-
lysis and revealed presence of lymphoid, myeloid, and hypo-inflamed
profiles correlating with HPV-status. Myeloid-inflamed profiles with
low ratios of CD163–/CD163+ of CD68+ CSF1R+ macrophages and
CD8+ T cell/CD68+ ratios was significantly associated with poor prog-
nosis in both HPV-positive and negative HNSCC. Neoplastic cell nest
vs. stroma region analyses revealed distinct distribution patterns for
TH1 and TH2 lymphocytes, showing intratumoral TH1 orientation in
HNSCC. Intratumoral CD66b+ granulocyte infiltration was associated
with unfavorable prognosis. Further analysis for spatial characteristics
of immune complexity revealed high TH1/TH2 ratios and CD8
+ T cell
infiltration within a distance of 20 μm to PD-L1+ cells, indicating an
association between PD-L1 expression and regional characteristics of
immune complexity.
Conclusions
These results demonstrate the capability of multiplex IHC-based
image cytometry analysis toward improved understanding of hetero-
geneous tumor microenvironments.
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Background
We have previously shown that human leukocyte antigen (HLA)-
A*02, a common allele in the Scandinavian population, is a negative
prognostic factor in epithelial ovarian cancer [1]. It is a strong pre-
dictor of patient outcome, only inferior to clinical staging. We have
also shown that this prognostic trait in epithelial ovarian cancer is
stronger by the presence of the gene compared with the expression
of its protein, MHC class I [2]. Finally, we have shown that HLA-G ex-
pression in ovarian cancer is a negative prognostic marker [3]. Our
aim was to analyse the prognostic markers HLA-A*02 genotype, MHC
class I and HLA-G expression on tumour cells and the CD8+ lympho-
cyte infiltration in colon cancer.
Methods
Clinical information and primary tumours were collected from 520
colon cancer patients and followed for overall survival for 120
months. HLA-A*02 genotype was determined by conventional PCR.
MHC class I expression and CD8+ lymphocyte infiltration were deter-
mined by immunohistochemistry.
Results
Patients with a stage III tumour and HLA-A*02 genotype had a
better outcome if randomized to adjuvant chemotherapy versus
surgery alone (P=0.03). There was an indication that patients with
complete absence of MHC class I expression had a better overall
survival compared to patients with a decreased or increased ex-
pression. Expression of HLA-G was a negative prognostic marker
for the male patients (P=0.002). Also a high infiltration of CD8+
lymphocytes was important in the male patients, where a high
frequency of infiltration correlated with a good prognosis
(P=0.002). These factors were not, however, significant in the fe-
male population. The superior negative prognostic marker in the
female patients was HLA-A*02 genotype.
Conclusions
HLA-A*02 positivity may be an important marker to determine which
colon cancer patients should receive adjuvant chemotherapy. It also
seems to determine the outcome of the female patients, which raises
new questions as to why this gene, which most likely has the same
function in both genders, can be devastating to one gender and not
the other.
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Table 8 (Abstract P118).
N:o %
Cohort 520 100
Genus Women 249 47.8
Men 271 52.2
Localisation Colon dx 241 46.3
Transversum 47 9
Colon sin 41 8
Sgmoideum 182 35
Undertermined 9 1.7
Stage Duke B 230 44.2
Duke C 290 55.8
Treatment Surgery 275 52.9
Surgery + adj chemotherapy 245 47.1
Cohort descrition
Fig. 53 (Abstract P118). HLA-genotype and treatment
Fig. 54 (Abstract P118). MHC class I expression
Fig. 55 (Abstract P118). HLA G expression
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Background
One of the biggest challenges facing the field of immuno-oncology
is development of a comprehensive understanding of how the im-
mune system responds to a tumor. Multi-analyte profiling (DNA, RNA,
and protein) from limited sample is crucial to furthering our under-
standing of tumor immunity. NanoString’s nCounter® technology has
become an important platform for quantification of transcriptional
responses by enabling direct digital quantification of up to 800 RNA
targets from a single sample.
Methods
Now the nCounter technology can simultaneously quantify 770 RNA
transcripts plus 30 proteins from as few as 20,000 cells (up to 50,000
primary cells such as PBMCs). NanoString has developed content and
methods to allow digital quantification of both cell surface and intra-
cellular protein targets that are essential to immuno-oncology re-
search. These key targets include immune cell population markers,
immune checkpoint proteins, transcription factors, chemokines, and
cytokines. Protein detection is enabled via primary antibodies, which
are covalently linked to single stranded DNA indexing oligos. Cells
are stained with a multiplexed cocktail of labeled antibodies, and
DNA oligos are subsequently released via cell lysis for hybridization
to optical barcodes in the standard NanoString workflow. This tech-
nique enables quantitative, multiplexed protein detection over 5 logs
of dynamic range.
Results
As proof of concept, RNA and protein were measured simultaneously
from just 50,000 PBMCs treated with phorbol 12-myristate 13-acetate
(PMA) and ionomycin, TNFα, IFNγ, or anti-CD3/CD28. NanoString’s
multiplex RNA and protein detection provides a thorough evaluation
of the immunological response in these experiments and demon-
strates the value of multi-analyte profiling from the same sample by
characterizing the breadth of the response (via 770 RNA measure-
ments) and providing depth to the analysis (via tandem measurements
of RNA and protein for key targets). As independent confirmation, the
findings were validated with flow cytometry.
Conclusions
This advance in multi-analyte, multiplexed digital molecular profiling
with low sample input will accelerate immuno-oncology research
and may enable the discovery and development of novel immuno-
therapies and their associated companion diagnostics.
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Background
Characterization of the abundance, distribution, and colocalization of
key immunoregulatory proteins within the tumor microenvironment is
necessary for a thorough understanding of tumor immune responses.
Historically, immunohistochemistry and immunofluorescence have
been used to assess spatial heterogeneity of proteins and nucleic acids
in tissue slices, but these techniques are of limited utility due to the
challenge of measuring multiple targets in parallel. We have developed
a platform to enable spatially-resolved protein and RNA detection with
the potential to simultaneously quantify up to 800 targets with greater
than 5 logs of dynamic range from a single formalin-fixed paraffin-
embedded (FFPE) slide.
Methods
The technology uses DNA oligo tags covalently linked to detection
reagents (primary antibodies or mRNA-binding probes) via a UV
photocleavable linker to identify targets in situ and enable quantita-
tion via the standard nCounter® technology. A slide-mounted FFPE
tissue section is incubated with a cocktail of oligo-labeled primary
antibodies or mRNA binding probes, and a serial section is stained
with low-plex visible/fluorescent probes (e.g., nuclear staining probes,
or select antibody pairs such as anti-CD3 and anti-CD8) to generate
an image of the FFPE tissue slice morphology. Regions of interest
(ROI) in the tumor are then identified and sequentially illuminated
with UV light to release the DNA-oligos. Following UV illumination,
the photocleaved oligos are released into the aqueous layer above
the tissue slice, collected via microcapillary aspiration, and stored in
an individual well of a microtiter plate. Oligos are then hybridized to
nCounter optical barcodes to permit ex situ digital counting of as
many as 800 different analytes localized within a single ROI in the
tumor, which can be referenced using image capture software.
Results
We demonstrate validation of this technology by characterization of
a panel of immune proteins on FFPE tumor biopsies and tissue mi-
croarrays. We extend this technology to spatially-resolved multi-
plexed detection of RNA on a number of important immune targets
(e.g., CD3, CD45). We further demonstrate that this approach enables
protein detection at single cell resolution and enables simultaneous
Fig. 57 (Abstract P118). CD8+ infiltration and HLA-genotype
Fig. 56 (Abstract P118). CD8+ infiltration
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multiplexed detection of CD3, CD4, CD8, CD45, CD45R0, PD-1, PD-L1,
Vista, TIM-3, B7-H3, Ki67 and additional key immuno-oncology-(IO)
targets. Finally, we demonstrate detection of key IO RNA targets
using direct hybridization of oligo-labeled probes.
Conclusions
The ability to measure DNA, RNA, and protein at up-to 800-plex from
single slices of FFPE tissue may enable the discovery of key immune
biomarkers in tumors and accelerate the development immunother-
apy and their associated companion diagnostics.
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Background
CD19-targeting chimeric antigen receptor (CAR) T cell therapy
achieved remarkable results in patients with acute lymphoblastic
leukemia. However, few studies have shown promising results in pa-
tients with other CD19+ B cell malignancies, including lymphomas.
We have completed a trial treating 15 patients with various B cell
malignancies with third generation CD19-targeting (CD28/4-1BB) CAR
T cells with or without preconditioning using a moderate dose of
cyclophosphamide (500mg/m2) and fludarabine (25mg/m2). Herein,
we report the results of a biomarker screening pre and post CAR T
cell treatment using the trial biobank.
Methods
A biobank consisting of plasma and peripheral blood mononuclear
cells obtained from CAR T cell treated patients with relapsed or re-
fractory CD19+ B cell malignancy was analyzed for immunological
biomarkers. Samples were analyzed for immunosuppressive cells by
flow cytometry and for systemic biomarkers using a 233-analyte
proteomic analysis (ProSeek). Of the 15 treated patients, 11 patients
had lymphoma and 6 had leukemia. During CAR T cell manufacture,
lymphoma patients received standard treatment to control tumor
burden. All patients were treated with one infusion of CAR T cells
with dose ranges from 2x107 to 2x108 cells/m2. The two last patients
received anti-PD-1 antibody therapy post CAR infusion. Correlation of
biomarkers with survival was assessed by Spearman correlation.
Results
The patients were grouped into initial complete responders (6/15) and
long-term survivors (4/15). In patient blood, CAR mRNA peaked at 1
week post infusion and could still be detected with varying levels over
time up to 12 months post infusion. Baseline levels of monocytic
myeloid-derived suppressor cells were negatively correlated with sur-
vival (P=0.0231) and M2-like macrophages tended to be increased at
the time of relapse compared to the time of complete response (Mean
%HLA-DR+CD80-CD163+ of CD11b+cells: 15.4% vs. 8.3%). The proteomic
analysis is ongoing. So far, several chemokines (CXCL16, CCL16, CCL15)
as well as Th2 response and macrophage-associated molecules (IL8,
IL10, IL33R, GDF-15) are correlated negatively with survival, whereas
IL12, 41BB, TRAIL and transferrin receptor show a positive correlation.
Conclusions
In summary, we analyzed immunological biomarkers in 15 patients
treated with CAR T cells in Sweden. An increase of M2-like macro-
phages was seen prior to relapse and molecules connected with sup-
pressive responses were correlated negatively to survival including
angiogenic drivers such as IL8 and CCL16 warranting a trial combining
CAR T cells with angiogenic inhibitors. Instead, Th1-related IL12 and
41BB correlated with a longer survival time.
Trial Registration
ClinicalTrials.gov identifier NCT02132624.
Bispecific Antibodies
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Background
Combination checkpoint blockade has demonstrated increased clin-
ical responses relative to single checkpoint blockade. However, the
combination of nivolumab plus ipilimumab has also exhibited in-
creased immune-related adverse events. We reasoned that dual
checkpoint blockade could be accomplished using a bispecific anti-
body format, with the potential benefits of reduced cost and more
selective targeting of tumor-reactive lymphocytes to improve safety.
Numerous checkpoint receptors exist, including PD-1, CTLA-4, LAG-3,
BTLA, and others, encouraging the exploration of multiple bispecific
combinations.
Methods
Antibodies specific to PD-1, CTLA-4, LAG-3, and BTLA were assem-
bled into a bispecific antibody format in select combinations and op-
timized for stability and affinity. In vitro T cell stimulation activity of
these bispecific antibodies was measured in a SEB stimulation assay.
IL-2 and IFNγ production was measured by ELISA. In vivo activity was
evaluated by engrafting human PBMCs into NSG mice (huPBMC-NSG)
and measuring the extent of T cell engraftment by flow cytometry
after weekly treatment. An anti-tumor model was also developed
with the huPBMC-NSG system, in which KG1a AML cells were first in-
oculated and allowed to establish tumors, followed by engraftment
of huPBMC and treatment with antibody.
Results
We produced PD-1 x CTLA-4, PD-1 x LAG-3, CTLA-4 x LAG-3, and PD-1 x
BTLA bispecific antibodies. All of the bispecifics enhanced IL-2 produc-
tion in an in vitro SEB stimulation assay relative to control, indicating
functional checkpoint blockade. In most cases, IL-2 production was
similar or superior to that of anti-PD-1 alone. Treatment of huPBMC-
NSG mice with checkpoint bispecifics promoted enhanced T cell en-
graftment relative to control. Engraftment levels promoted by bispeci-
fics were generally superior to those found for anti-PD-1 treatment
alone, and in some cases comparable to a combination of anti-PD-1
and anti-CTLA-4 antibodies. In one run of the model, while anti-PD-1
treatment alone promoted a 7-fold increase in human CD45+ cells, a
PD-1 x CTLA-4 bispecific antibody induced a 22-fold increase, and a
CTLA-4 x LAG-3 bispecific promoted a 12-fold increase. Combining
CTLA-4 x LAG-3 with anti-PD-1 to achieve triple checkpoint blockade
promoted a 67-fold increase in human CD45+ cells, leading to severe
graft versus host disease. The bispecific antibodies also exhibited com-
pelling anti-tumor activity in a mouse AML model.
Conclusions
Dual checkpoint blockade with bispecific antibodies is feasible and
promotes strong T cell activation in vitro and in vivo. Multiple combi-
nations display compelling activity, suggesting clinical development
is warranted for the treatment of human malignancies.
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Background
Treatment of melanoma patients with nivolumab plus ipilimumab in-
creases progression-free-survival compared to each monotherapy.
The increase in efficacy of the combination regimen is accompanied by
an increase in adverse events. Since PD-1+CTLA-4+ tumor-infiltrating-
lymphocytes are dysfunctional in the tumor microenvironment, we
attempted to specifically target PD-1+CTLA-4+ double-positive T cells
with a PD-1 x CTLA-4 bispecific antibody in an effort to recapitulate effi-
cacy of the combination regimen while reducing toxicity.
Methods
Antibodies binding to PD-1 and CTLA-4 with favorable stability and func-
tional properties were assembled in a bispecific antibody platform with
substitutions in the Fc domain to suppress effector function. PD-1 x
CTLA-4 bispecific antibodies were evaluated in vitro by measuring anti-
body binding and de-repression of super-antigen stimulated peripheral
blood lymphocytes (PBMCs) and in vivo by monitoring the engraftment
of human PBMCs in NSG mice (huPBMC-NSG) by flow cytometry. To
evaluate anti-tumor efficacy we monitored the growth of established
KG1a AML cancer cells in huPBMC-NSG following treatment.
Results
Optimized candidate single-chain Fvs were confirmed to bind PD-1
and functionally block PD-L1 and PD-L2 binding to PD-1. We also
generated optimized anti-CTLA-4 Fabs. Anti-PD-1 and anti-CTLA-4 tar-
geting components were assembled into a bispecific format and dis-
played favorable biophysical and manufacturing properties. PD-1 x
CTLA-4 bispecific antibodies enhanced IL-2 secretion 5-fold relative
to control (p<0.001, n=18 donors) in response to antigenic challenge
of previously stimulated T cells, with 2-fold superior activity com-
pared to anti-PD1 bivalent antibody (p<0.001, n=18 donors). PD-1 x
CTLA-4 bispecific antibodies significantly enhanced T cell engraft-
ment in huPBMC-NSG mice compared to vehicle controls (p<0.001,
n=10/group). PD-1 x CTLA-4 bispecific antibodies promoted higher T
cell engraftment than anti-PD-1 alone (p<0.01, n=10/group) and simi-
lar engraftment to a combination of anti-PD-1 and anti-CTLA-4 bi-
valent antibodies. PD-1 x CTLA-4 bispecific antibodies also exhibited
compelling anti-tumor activity in a mouse AML model.
Conclusions
Dual blockade of PD-1 and CTLA-4 with a bispecific antibody re-
sults in T cell activation that is comparable to a combination of
bivalent antibodies targeting PD-1 and CTLA-4. Specific target-
ing of human lymphocytes positive for both PD-1 and CTLA-4
with a bispecific antibody may promote similar efficacy com-
pared to a combination of bivalent antibodies while reducing
adverse events. These data suggest that clinical development of
a PD-1 x CTLA-4 bispecific antibody is warranted for the treat-
ment of human malignancies.
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Background
Lymphocyte activation gene-3 (LAG-3) is a member of the immuno-
globulin superfamily expressed on activated T cells, NK cells, pDCs,
B cells, and γδ T cells, and participates in immune suppression, par-
ticularly through persistent strong expression in a percentage of
regulatory T cells (Tregs). Programmed cell death receptor (PD-1)
binds to its ligand PD-L1, expressed not only on activated immune
cells to inhibit cellular immune responses but also on tumor cells.
Expression of LAG-3 and PD-1 leads to T cell exhaustion, allowing
tumor escape from immune surveillance. Combining inhibitory anti-
bodies to PD-1 and LAG-3 reactivates T cells leading to efficacy in
murine models over single treatment [1] and prompted interest in
combining these two in the development of a LAG-3 and PD-L1
bispecific antibody for inhibiting tumor growth. This format may
additionally result in novel mechanisms of action that are impos-
sible to attain with combinations.
Methods
A murine-specific anti-LAG-3 and PD-L1 bispecific antibody was engi-
neered and analyzed for binding, blocking, and preventing LAG-3
and PD-L1-mediated T cell suppression in vitro. In addition, the LAG-
3/PD-L1 bispecific antibody was tested in 2 syngeneic murine tumor
models for its ability to suppress tumor growth.
Results
Not only is the bispecific anti-LAG-3/PD-L1 antibody (mAb2 TM) able
to bind both antigens simultaneously and with nanomolar affinities,
but it also demonstrates functional activity against both targets
in vitro. This potency translates into in vivo efficacy,where the anti-
LAG-3/PD-L1 mAb2 decreased tumor burden in the MC38 colon car-
cinoma tumor model, both in early-established or well-established
tumors. At the end of the study tumor-free animals were more nu-
merous in the LAG-3/PD-L1 bispecific group than in the group given
a combination of individual anti-LAG-3 and PD-L1 antibodies. The re-
sults were recapitulated in the CT26 murine colon cancer model, where
the LAG-3/PD-L1 mAb2 showed an increase of anti-tumor activity as
compared to the combination of anti-LAG-3 and anti-PD-L1 antibodies.
Conclusions
The promising preclinical results from this anti-mouse LAG-3/PD-L1
bispecific antibody supports continuing to progress with the devel-
opment of an anti-human LAG-3/PD-L1 mAb2 for use in the treat-
ment of cancer patients.
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Background
We describe a novel therapeutic molecule that simultaneously in-
hibits two important targets which control pathways that are hall-
marks of tumorigenesis. Epidermal growth factor receptor (EGFR) is
important for the growth and survival of tumor cells, and transform-
ing growth factor beta (TGFb) is a pleiotropic cytokine expressed in
the tumor microenvironment that regulates important processes
such as epithelial-to-mesenchymal cell transition (EMT), migration, in-
vasion, and tumor-specific immunosuppression. To date, therapies
have targeted these pathways individually; monoclonal antibodies
(mAbs) and small molecule inhibitors of EGFR are in clinical use, and
modulators of TGFb pathway are in late-stage clinical development.
Methods
FmAb2 is a recombinant fusion mAb consisting of the TGFb receptor
II extracellular domain (T-ECD) fused to cetuximab, an anti-EGFR
mAb. We hypothesized that using FmAb2 to block the EGFR and
TGFb pathways simultaneously would have a synergistic effect on in-
hibition of tumor growth and EMT, and also induce a tumor-specific
immune response. Furthermore, this agent would neutralize TGFb
preferentially in the tumor microenvironment, thereby improving ef-
ficacy while reducing systemic toxicity.
Results
FmAb2 was expressed in Chinese hamster ovary (CHO) cells, purified
using standard methodology and tested using in vitro and in vivo models.
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FmAb2 is secreted as an intact fusion protein and simultaneously binds
both targets in in vitro binding assays. In surface plasmon reson-
ance kinetic binding assays (Biacore), FmAb2 binds EGFR with a KD
of ~2.5 nM and TGFb1 with a KD of ~60 nM. FmAb2 binds EGFR on
the cell surface, neutralizes tumor cell-secreted TGFb1, inhibits pro-
liferation of sensitive tumor cell lines and activates NK cell-
mediated antibody-dependent cellular cytotoxicity (ADCC). Using
fluorescently labeled FmAb2, we demonstrate that systemically
administered FmAb2 in mice preferentially localizes to tumors
and is 10-fold more effective in neutralizing tumor TGFb1 com-
pared to T-ECD fused to IgG-Fc (T-ECD-Fc). Consistent with this,
we also observe significantly better inhibition of tissue inhibitor
of metalloproteinase-1 (TIMP-1) in FmAb2-treated tumors com-
pared to T-ECD at equivalent doses. In a head-and-neck mouse
xenograft model, FmAb2 administration is significantly superior to
cetuximab or T-ECD-Fc alone at equivalent doses. Furthermore,
FmAb2 treatment is more efficacious than the co-administration
of cetuximab + T-ECD-Fc at equivalent doses, most likely due to
better neutralization of tumor TGFb1.
Conclusions
FmAb2 is currently in preclinical development and is expected to
enter clinical testing soon.
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Background
Patients with acute myeloid leukemia (AML) have a dismal prognosis
despite improvements in chemotherapy and supportive care. Novel,
more effective therapies are needed for these patients. We report
the characterization of MCLA-117, a novel T cell redirecting antibody
for the treatment of AML that targets CLEC12A on leukemic cells and
CD3 on T cells. CLEC12A is a myeloid differentiation antigen that is
expressed on 90-95% of newly diagnosed and relapsed AML.
Moreover, CLEC12A is selectively expressed on leukemic stem cells
(LSCs) but not on normal early hematopoietic progenitors, including
hematopoietic stem cells (HSCs).
Methods
MCLA-117 is a human common light chain CLEC12AxCD3 full length
IgG1 bispecific antibody. Heterodimerization of the bispecific IgG is
facilitated by amino acid residues introduced at the CH3 interface.
MCLA-117 lacks Fc effector function following amino acid substitu-
tions in the CH2 region.
Results
MCLA-117 specifically binds to CLEC12A expressing myeloid cells and
CD3 expressing T cells, as evaluated using healthy donor samples. In
line with the CLEC12A expression MCLA-117 did not bind the HSCs,
nor the common myeloid progenitor cells. The potency of MCLA-117
to induce T cell mediated lysis of CLEC12APOS tumor cells was evalu-
ated in cytotoxicity assays. In co-cultures with resting healthy donor
T cells and AML tumor cells, MCLA-117 efficiently induced CLEC12A
antigen dependent T cell activation (EC50 of 44 ng/mL), T cell prolif-
eration and tumor target cell lysis (EC50 of 66±37 ng/mL). The effi-
cacy of MCLA-117 to induce lysis of AML blasts by autologous T cells
in primary AML samples with low T cell to AML blast ratios was exam-
ined in an ex vivo culture system. We demonstrated robust eradication
of AML blasts by MCLA-117, even at low E:T ratios (Fig. 58). In 9/11 AML
patient samples taken at diagnosis, MCLA-117 induced expansion of
autologous T cells (7-226-fold) and killing (31-99%) of AML blasts at low
E:T ratios (E:T 1:3–1:97).
Conclusions
MCLA-117 efficiently induced CLEC12A-mediated lysis of AML blasts
by T cells present in AML samples, even at very low E:T ratios, and
it provoked robust T cell proliferation. Based on its binding profile
within the hematopoietic compartment, MCLA-117 is expected to
specifically target myeloid blasts and LSCs while sparing the normal
HSCs. A phase I clinical study (MCLA-117-CL01) is ongoing to evalu-
ate the preliminary safety and efficacy of MCLA-117 in adult AML
patients.
Clinical Trials in Progress
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Background
Cisplatin-based combination chemotherapy is standard first-line
treatment for patients with advanced bladder cancer. The median
survival with these regimens is 13-15 months, and only 5-15% of
patients attain long-term survival. Programmed death ligand 1 (PD-L1)
is expressed in select urothelial cancer lesions. In the phase Ib
KEYNOTE-012 study, monotherapy with the anti–programmed death 1
antibody pembrolizumab demonstrated antitumor activity (objective
response rate, 28 %; 95 % CI, 13 %-47 %) and acceptable safety in
patients with chemotherapy-refractory metastatic PD-L1–positive
urothelial carcinoma, and higher tumor PD-L1 expression was asso-
ciated with higher response rates. KEYNOTE-361 is a randomized,
open-label, phase III study of pembrolizumab with or without chemo-
therapy versus chemotherapy alone in patients with advanced urothe-
lial carcinoma.
Methods
Key eligibility criteria include age ≥18 years; histologically or cyto-
logically confirmed diagnosis of advanced/unresectable or metastatic
urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra;
measurable disease based on RECIST v1.1 as determined by the local
site investigator/radiology assessment; no prior systemic chemother-
apy for advanced/metastatic urothelial carcinoma (with the exception
of neoadjuvant platinum-based chemotherapy with recurrence >12
months after completion of therapy; or adjuvant platinum-based
Fig. 58 (Abstract P126). MCLA-117 efficiently induced T cell
expansion and redirected lysis of AML blast in primary AML
samples even at a low E:T ratio. Primary AML blast sample taken at
diagnosis was incubated with MCLA-117 and a control Biclonics
(binding CD3 and an irelevant antigen). CLEC12A expression, T cell
proliferation and primary AML blast lysis was quantified using
flow cytometry
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chemotherapy following radical cystectomy with recurrence >12
months after completion of therapy); ECOG performance status 0-2;
and provision of a fresh tissue sample for biomarker analysis. Ap-
proximately 990 patients will be randomized 1:1:1 to receive: pem-
brolizumab 200 mg on day 1 of each 3-week cycle (Q3W) alone or in
combination with investigator’s choice of chemotherapy (gemcita-
bine [1000 mg/m2 on days 1 and 8 of each 3-week cycle] plus
cisplatin [70 mg/m2 Q3W] or gemcitabine plus carboplatin [AUC 5
Q3W] for cisplatin-ineligible patients), or investigator’s choice of
chemotherapy alone. Patients will be stratified based on chemother-
apy regimen (cisplatin or carboplatin, chosen before randomization)
and tumor PD-L1 expression (positive or negative). Treatments will
continue until progressive disease, unacceptable adverse events
(AEs), investigator decision, or 35 doses of pembrolizumab (pembroli-
zumab arms only). Response will be assessed per RECIST v1.1 by
blinded independent central review (BICR) every 9 weeks until week
54, then every 12 weeks thereafter. AEs will be evaluated throughout
treatment and for 30 days thereafter (90 days for serious AEs) and
graded per National Cancer Institute Common Terminology Criteria
for Adverse Events, version 4.0. The primary end points are PFS per
RECIST v1.1 as assessed by BICR and OS; key secondary end points
include objective response rate and safety and tolerability. Enroll-
ment in KEYNOTE-361 is ongoing.
Trial Registration
ClinicalTrials.gov identifier NCT02853305.
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Background
Treatment for patients with metastatic castration-resistant prostate can-
cer (mCRPC) has focused on suppression of testosterone and androgen
receptor signaling, palliative radiation therapy, and chemotherapy. As
expression of the programmed death-1 (PD-1) receptor and its ligand
PD-L1 is present in mCRPC lesions, particularly after initial treatment
with antiandrogen and/or chemotherapy, targeting this pathway may
be an attractive treatment option. Pembrolizumab, an anti-PD-1 anti-
body that blocks interaction between PD-1 and its ligands, PD-L1 and
PD-L2, produced durable responses in patients with heavily pretreated
PD-L1-positive prostate cancer in the KEYNOTE-028 study. KEYNOTE-
199 is a nonrandomized, multinational, open-label phase II study to
evaluate pembrolizumab monotherapy in patients with mCRPC previ-
ously treated with chemotherapy.
Methods
Eligible patients must be ≥18 years old with histologically or cyto-
logically confirmed adenocarcinoma of the prostate without small-
cell histology, measurable disease per RECIST v1.1 or detectable
bone metastases by whole-body bone scintigraphy and no RECIST
v1.1 measurable tumors, supplied tumor sample for PD-L1 expres-
sion (new or archived), progression of disease within 6 months be-
fore screening, and ECOG performance status 0-2. Patients must
have been treated with ≥1 targeted endocrine therapy (abiraterone
or enzalutamide) and ≤2 chemotherapy regimens, 1 of which must
have contained docetaxel. Patients also must have ongoing andro-
gen deprivation with serum testosterone <50 ng/dL. Patients will
be enrolled into 1 of 3 cohorts based on PD-L1 status and RECIST
v1.1 measurability: patients with PD-L1-positive, RECIST v1.1 meas-
urable disease (cohort 1, n=100), patients with PD-L1-negative,
RECIST v1.1 measurable disease (cohort 2, n=100), and patients with
bone metastases and RECIST v1.1 nonmeasurable disease (cohort 3,
n=50). Patients will receive pembrolizumab 200 mg every 3 weeks
until documented confirmed disease progression, unacceptable
adverse events (AEs), or illness that prevents further treatment.
Imaging response will be assessed every 9 weeks for approximately 1
year and every 12 weeks thereafter, per central imaging vendor review
using RECIST v1.1 criteria and the Prostate Cancer Clinical Trials
Working Group 3 guidelines. AEs will be monitored throughout the
study and graded per Common Terminology Criteria for Adverse
Events, version 4.0. Primary end points are the objective response
rate and duration of response for cohorts 1 and 2 combined and by
each cohort. Key secondary end points include safety and tolerabil-
ity, disease control rate, radiographic progression-free survival, and
overall survival for each cohort and all 3 combined. Exploratory
translational analyses and expression of other immune checkpoints
will also be evaluated.
Trial Registration
ClinicalTrials.gov identifier NCT02787005.
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Background
Pembrolizumab, a PD-1 immune checkpoint inhibitor, and dinaci-
clib, a cyclin-dependent kinase inhibitor, have demonstrated anti-
tumor activity as monotherapies in various tumor types, including
hematologic malignancies. In a preclinical study using a solid-
tumor syngeneic model (MC38), enhanced antitumor activity was
observed with the combination of pembrolizumab and dinaciclib,
with no significant toxicities. KEYNOTE-155 is a phase Ib study
designed to evaluate the safety and efficacy of the combination
of pembrolizumab and dinaciclib in patients with relapsed or re-
fractory chronic lymphocytic leukemia (CLL), multiple myeloma
(MM), or diffuse large B cell lymphoma (DLBCL).
Methods
Key eligibility criteria include ≥18 years, ECOG performance status 0-1,
and confirmed diagnosis of one of the following: CLL as defined by
2008 iwCLL criteria with ≥1 prior therapy; active MM with measurable
disease and ≥2 prior therapies including an IMiD and proteasome in-
hibitor; or DLBCL with progression following ≥2 prior therapies includ-
ing autologous stem cell transplantation (ASCT; or ineligible for ASCT).
An initial cohort of 12 patients (≥3 with each disease type) will be en-
rolled in the dose-evaluation phase (two 21-day cycles) to determine
dose-limiting toxicities (DLTs). In cycle 1, patients will receive pembroli-
zumab 200 mg on day 1, dinaciclib 7 mg/m2 on day 1, and dinaciclib
10 mg/m2 on day 8. In cycle 2 and beyond, patients will receive pem-
brolizumab 200 mg on day 1 and dinaciclib 14 mg/m2 on days 1 and 8.
If ≤4 patients experience DLTs in the first 2 cycles, expansion cohorts
(~30 patients each) will be opened for signal detection. If ≥5 DLTs
occur in the first 2 cycles, a lower dose of dinaciclib will be studied in
up to 24 patients. Treatment will continue until disease progression,
unacceptable toxicity, or 35 cycles. Response will be assessed every 3
cycles for CLL and DLBCL, and at the start of each cycle for MM. Primary
end points are safety and tolerability in both phases and objective re-
sponse rate within each disease type per investigator assessment in
the signal-detection phase. Secondary end points include duration
of response, progression-free survival, and overall survival within
each disease type in the signal-detection phase. Exploratory
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objectives include assessment of treatment effect on CD4, CD8, and
quantitative immunoglobulins; the relationship between candidate
biomarkers and antitumor activity; and the relationship between
genomic variation and response to treatment. KEYNOTE-155 will en-
roll up to 138 patients from multiple sites.
Trial Registration
ClinicalTrials.gov identifier NCT02684617.
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Background
Checkpoint inhibitors and tyrosine kinase inhibitors may have com-
plementary mechanisms of action in advanced renal cell carcinoma
(aRCC), providing a rationale for investigating combination treatment.
Inhibition of the programmed death-1 receptor ligand (PD-L1) pathway
leads to reactivation of an effective antitumor immune response
against multiple cancers, including RCC. Avelumab (MSB0010718C) is a
fully human IgG1 anti-PD-L1 antibody that has shown clinical activity in
patients with several tumor types. Axitinib is an anti-VEGF receptor
tyrosine kinase inhibitor approved for treatment of aRCC after failure of
1 prior systemic therapy. In an ongoing phase Ib study, avelumab plus
axitinib administered at standard monotherapy doses showed encour-
aging safety and antitumor activity in treatment-naïve patients with
aRCC. JAVELIN Renal 101 is a global phase III trial comparing avelumab
plus axitinib versus sunitinib as first-line treatment for patients with
aRCC.
Methods
The primary objective of this randomized, multicenter trial is to demon-
strate superiority of first-line avelumab plus axitinib versus sunitinib
monotherapy in prolonging progression-free survival (PFS). Eligibility
criteria include: aRCC with a clear cell component, availability of archival
or fresh tumor biopsy, ECOG PS ≤1, no prior systemic therapy for
advanced disease or prior immunotherapy, and measurable disease
per RECIST v1.1. Approximately 583 patients will be randomized 1:1
to receive either: Arm A, avelumab intravenously over 1 hour every
2 weeks plus axitinib orally twice daily continuously (cycle length 6
weeks); or Arm B, sunitinib orally once daily for 4 weeks followed
by 2 weeks off. Stratification factors are: ECOG PS (0 vs 1) and region
(US vs Canada/Europe vs rest of world). Treatment is discontinued for
unacceptable toxicity or if any criteria for withdrawal are met. Patients
may continue treatment beyond progression if investigator-assessed
clinical benefit is achieved and treatment is well tolerated. The primary
endpoint is PFS per RECIST v1.1 by blinded independent central review.
Secondary endpoints include overall survival, PFS by investigator as-
sessment, objective response, duration of response, time to response,
safety, and patient-reported outcomes. Pharmacokinetics, immunogen-
icity, and tumor tissue biomarkers will also be assessed. Enrollment in
this pivotal trial began in March 2016.
Trial Registration
ClinicalTrials.gov identifier NCT02684006.
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Background
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes
(TIL) has proven to be a powerful treatment option for patients with
metastatic melanoma with response rates of approximately 50% and
durable complete responses in about 15%. However, there is still a
need for improving TIL efficacy and a promising strategy is combin-
ation with immunomodulating agents. One such agent is vemurafe-
nib (vem), a selective BRAF inhibitor, which induces objective
responses in about 50% of melanoma patients with tumors express-
ing BRAFV600E/K. In addition to the direct anti-cancer effect, vem has
been shown to increase T cell infiltration into tumors, upregu-
late melanoma antigen expression and increase the frequency
of TIL recognizing autologous melanoma cells. This trial was
previously presented at the Society for Immunotherapy of Can-
cer annual meeting [1]. In this abstract an update on clinical re-
sponses is provided.
Methods
A total of 12 patients will be included in this open phase II non-
randomized trial primarily to investigate safety when combining ACT
and vem. Secondarily, clinical responses will be evaluated according to
RECIST and extensive immune monitoring will be performed. Patients
are treated with vem orally 960 mg BID one week prior to excision of
tumor material for T cell generation and continue vem until hospital ad-
mission (4-7 weeks). During hospitalization patients will receive a pre-
parative lymphodepleting regimen consisting of cyclophosphamide 60
mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days. TIL infusion con-
sists of 5-10 x 1010 T cells and patients are subsequently treated with
continuous interleukin-2 infusion following the decrescendo regimen for
5 days. Patients are evaluated for up to 5 years or until progression.
Results
So far 5 patients have been treated. No unexpected toxicity has been
observed. Three patients achieved confirmed ongoing partial re-
sponse (9+ months, 5+, and 4+) and 2 patients had progressive
disease at evaluation after TIL. Immune analyses are pending.
Conclusions
So far treatment combining vem and ACT using TILs has been safe
with no unexpected toxicity and encouraging clinical benefit with
durable responses has been observed.
Trial Registration
ClinicalTrials.gov identifier NCT02354690.
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Background
B7-H3 is part of the B7 superfamily of immune checkpoint molecules.
While its regulation and mechanism of action are not completely
understood, B7-H3 expression correlates with adverse pathology and
clinical outcomes in men with prostate cancer. B7-H3 expression ap-
pears to be associated with biochemical and clinical progression fol-
lowing treatment. The correlation between B7-H3 overexpression
and poor prognosis suggests a role in tumor immune escape. In
addition, B7-H3 levels remain high in the presence of androgen
deprivation. These results suggest a potential role for B7-H3 in pros-
tate cancer progression and support its use as a therapeutic target.
Enoblituzumab is an anti-B7-H3 humanized monoclonal antibody
with a proposed mechanism of action of antibody directed cellular
cytotoxicity. We propose a neoadjuvant study to determine the anti-
tumor, immunological and biological effects of enoblituzumab in
men with localized prostate cancer. We hypothesize that administra-
tion of enoblituzumab will be safe and feasible in the neoadjuvant
setting for men with localized intermediate and high-risk prostate
cancer. We also hypothesize that enoblituzumab will produce meas-
urable tumor cell death and antitumor immune responses in har-
vested prostate glands.
Methods
This is a single-center, single-arm, open-label pilot study of enobli-
tuzumab 15mg/kg IV weekly for 6 doses beginning 50 days prior
to radical prostatectomy. The target population (N=16) is men with
localized, intermediate or high-risk prostate adenocarcinoma
(Gleason sum ≥7), with adequate organ function, no adverse indi-
cations for standard radical prostatectomy, and no previous local
treatment to the prostate, anti-androgen exposure, or immuno-
therapy. The primary endpoint will be frequency/severity of ad-
verse events from time of first administration of enoblituzumab
until the 90th post-op day. Prostate glands will be harvested at
time of radical prostatectomy and prostate tissue will be examined
for the secondary endpoints and compared to pre-treatment biop-
sies. The secondary biological endpoint is tumor cell death, which
will be quantified by caspase 3 staining and post-treatment apop-
totic index. The trial will meet its biological endpoint if tumor cell
apoptosis is two-fold higher after treatment, which we will be able
to detect with an 80% power based on a one-sided t-test with a
significance level of 0.05, with 16 subjects. Other secondary end-
points will include CD8+ T cell infiltration, CD8/Treg ratio, TCR rep-
ertoire, and B7-H3 expression, and will be exploratory in nature. If
this study shows preliminary evidence of clinical activity and rea-
sonable safety, our future goal will be to use enoblituzumab in the
adjuvant and salvage settings.
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Background
We have previously shown that radiotherapy (RT) increases natural
killer (NK) cytotoxicity and homing in diverse pre-clinical models of
human solid malignancies, including sarcomas. Since sarcomas com-
monly afflict dogs, we hypothesized that dog PBMC-derived NK cells
would be effective in canine models of sarcoma, including adoptive
transfer in a canine RT/NK clinical trial.
Methods
Canine NK cells were isolated from 15 mls whole blood using Ficoll
separation and CD5 depletion. Isolated NK cells were expanded in
co-culture with irradiated K562c9IL21 for 2-3 weeks. Using 6-month
metastasis-free survival as the primary endpoint, a canine clinical trial
is underway evaluating RT and adoptive intratumoral NK immuno-
therapy. For this trial, treatment consists of palliative RT weekly for
one month followed by two intra-lesional injections of autologous
canine NK cells. In correlative studies, including dog patient-derived
xenografts (PDX), we assessed NK homing using eFluor 670 cell pro-
liferation dye and NK function by expression of activation markers in-
cluding IFNγ, granzyme B, and perforin.
Results
We have treated 7 of planned 14 dogs with osteosarcoma on
protocol. Of 3 evaluable dogs who have reached the 6- month
primary endpoint, we have observed 1 partial response and 2 are
metastasis-free, including 1 dog with complete resolution of a
suspicious 3 mm pulmonary nodule. In dog patients on trial, phe-
notyping of expanded NK cells from all patients showed > 90%
granzyme B and IFNγ expression prior to adoptive transfer. Tag-
ging experiments 1 week after intratumoral injection revealed
that 11 – 60% of CD45+ cells are eFluor 670 positive, confirming
persistence of injected NK cells post injection. Analysis of unacti-
vated circulating PBMCs post-injection demonstrated a significant
increase in granzyme B expression (2.25X ± 0.42, P < 0.01). Dog
PDX studies demonstrate that focal RT increases NK homing to
sarcomas on average 3.8X± 0.3 (P < 0.001) compared to unirradi-
ated controls. Immunohistochemical analysis of irradiated dog sar-
comas (historical controls) shows a significant increase in CD3+
tumor-infiltrating lymphocytes post RT (P < 0.04, see figure). Co-
culture experiments of dog PDX sarcomas ex vivo with allogeneic
NK cells showed RT-induced sensitization to NK killing at doses
of 10 - 20 Gy (P < 0.01).
Conclusions
RT and NK immunotherapy appear synergistic in dog models of
sarcoma, and preliminary results from a canine clinical trial of
palliative RT and autologous NK transfer for osteosarcoma are
promising, including possible abscopal effects. Further evalu-
ation of this novel radio-immunotherapy approach is warranted.
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Fig. 59 (Abstract P133). Canine Sarcomars Show Increased CD3+
Lymphocytes after Radiotherapy. a High power view of normal
dog lymph node in the absence of mouse anti-dog CD3
antibody. b High power view of normal dog lymph node shows
diffuse expression of CD3+ lymphocytes. c High power view
shows absence of CD3+ lymphocytes following amputation of distal
tibia dog osteosarcoma. d High power view positive increased CD3+
cells in dog osteosarcoma following palliative RT (scale bars 100 μm)
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Background
Uveal melanoma (UM) is a rare tumor variant with no established
treatments once metastases develop. Although a variety of immune
based therapies have demonstrated anti-tumor activity in metastatic
cutaneous melanoma, their use in UM has been disappointing. Re-
cently, adoptive T cell therapy has shown salvage responses in mul-
tiple refractory solid tumors. Based upon our identification from UM
liver metastases of tumor infiltrating lymphocytes (TIL) with strong
autologous reactivity, we sought to determine if clinical adoptive
transfer of such TIL could mediate regression in patients with meta-
static UM. Here we present an interim analysis of the ongoing clinical
trial, NCT01814046.
Methods
In the main arm of this phase II study, patients with metastatic mel-
anoma of ocular origin received nonmyeloablative lymphodepleting
conditioning chemotherapy consisting of intravenous cyclophospha-
mide (60 mg/kg/daily) for 2 days and fludarabine (25 mg/m2/daily)
for 5 days followed by an intravenous infusion of autologous TIL
and high-dose interleukin-2 (720,000 IU/kg). Clinical responses
were evaluated using Response to Evaluation Criteria in Solid
Tumors (RECIST), version 1.0. The study was designed to initially
enroll 19 patients and if 4 or more patients achieved an objective
clinical response, accrual would expand in a second phase to a
total of 33 patients.
Results
At the current time, 17 patients with metastatic UM have com-
pleted TIL treatment; 16 of these patients are evaluable for re-
sponse assessment. Five of 16 (31%) UM patients demonstrated
objective tumor regression. Among the responders, four patients
demonstrated partial tumor regression lasting between 4 and 10
months. One patient achieved complete tumor regression, ongoing
15 months after TIL infusion. In the year prior to TIL therapy, this
patient demonstrated marked progression of multiple liver metasta-
ses after anti-CTLA-4 and anti-PD-1 checkpoint therapy. However,
after a single infusion of TIL, we observed rapid and complete
tumor regression. Circulating serum tumor DNA specific for the pa-
tient’s GNAQ driver mutation demonstrated complete clearance by
10 days following cell therapy consistent with the patient’s clinical re-
sponse. Overall in the trial, the frequency of tumor-reactive T cells
within the administered infusion and the levels of IFN-γ released after
autologous tumor stimulation were positively associated with clinical
response (P=0.04, respectively).
Conclusions
To our knowledge, these clinical findings represent the first demonstra-
tion that autologous T cell transfer is capable of inducing complete and
durable tumor regression of metastatic UM. Refinement of this cell ther-
apy is aimed at identifying the antigenic targets associated with clinical
response.
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Background
CAVATAKTM is a bio-selected oncolytic and immunotherapeutic
strain of coxsackievirus A21 (CVA21). In a phase II study, intratu-
moral (i.t.) CVA21 injection of advanced melanoma lesions resulted
in regression in 28.1% of patients including non-injected lesions, in-
creases in tumor immune-cell infiltration, up-regulation of IFNγ re-
sponse and immune-checkpoint genes, including CD122 which
may be a marker for enhanced anti-tumor activity by anti-CTLA-4
blockade. Preclinical models using B16 ICAM confirmed enhanced
antitumor effects when CVA21 was combined with anti-CTLA-4 or
anti-PD-1. The preliminary data are presented from the open-label,
phase Ib MITCI (Melanoma Intra-Tumoral Cavatak and Ipilimumab)
in patients (pts) with advanced melanoma.
Methods
Pts received up to 3 x 108 TCID50 CVA21 i.t. on study days 1, 3, 5, 8
and 22, and then q3w for up to 14 additional i.t. injections. Ipilimu-
mab (3 mg/kg) was administered q3w for 4 doses starting at Day
22. The first response assessment (irRC) occurred on Day 106. The
primary endpoint was to assess safety of CVA21 in combination
with ipilimumab treatment (tx). Immune monitoring samples were
obtained to analyze T cells with regulatory, memory, and effector
phenotypes. Biopsies of injected lesions have been obtained in
some patients.
Results
No DLT’s have been reported in the 18 patients enrolled. Combin-
ation tx has been well-tolerated with only one grade 3 or higher
treatment-related AE being ipilimumab-related fatigue. Colitis or
other immune related toxicities have been grade 1 or 2. The study
met its primary statistical futility endpoint of achieving ≥ 4 confirmed
objective responses (CR or PR) in the first 12 pts enrolled. Of the first
11 pts eligible for investigator response assessment, ORR for the ITT
population is 57.1% (4/7), with the ORR for ipilimumab-naïve pts
being 67% (4/6). The DCR (CR+PR+SD) on the ITT population is
currently 86% (6/7). All responses were observed by 3.5 months
with complete tumor responses being observed in individual
injected and non-injected lesions. One three-fold increase in per-
ipheral blood CD4+ and CD8+ T cells with central and effector
memory phenotypes were observed comparing baseline to day
85 in most of the patients analyzed thus far.
Conclusions
CVA21 + ipilimumab tx of pts with advanced melanoma has been
well tolerated. This combination immunotherapy induced anti-tumor
activity in local, visceral and non-visceral lesions in a number of pa-
tients that have failed previous immunotherapies. Increases in T cell
effector and memory subsets were also observed.
Trial Registration
ClinicalTrial.gov identifier NCT01636882.
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Background
A subset of colorectal carcinomas (CRCs) have deficiencies in the
mismatch repair (MMR) system, resulting in microsatellite instability
(MSI). MSI-high tumors contain high levels of lymphocyte infiltrates
and strong expression of the programmed death 1 (PD-1) immune
checkpoint receptor and its ligand, PD-L1. Pembrolizumab is an
anti–PD-1 monoclonal antibody that blocks the interaction between
PD-1 and its ligands, thereby enabling an antitumor immune re-
sponse. In the phase II KEYNOTE-016 study, pembrolizumab showed
promising antitumor activity against MMR-deficient tumors in pa-
tients with treatment-refractory metastatic CRC, with an objective
response rate of 47% (95% CI, 23%-72%). KEYNOTE-177 (Clinical-
Trials.gov, NCT02563002) is an international, randomized, open-
label phase III study designed to evaluate the efficacy and safety of
pembrolizumab compared with standard-of-care chemotherapy as
a first-line treatment for MMR-deficient or MSI-high metastatic CRC.
Methods
Key eligibility criteria include age ≥18 years, confirmed MSI-high or
MMR-deficient stage IV CRC, measurable disease per RECIST v1.1 by
local site assessment, Eastern Cooperative Oncology Group per-
formance status 0-1, no active autoimmune disease or brain metas-
tases, and no prior therapy for metastatic disease. Patients are to
be randomized 1:1 to receive either pembrolizumab 200 mg every
3 weeks (Q3W) or investigator’s choice of standard-of-care chemo-
therapy. Chemotherapy must be chosen prior to randomization; op-
tions include mFOLFOX6 or FOLFIRI alone or in combination with
bevacizumab or cetuximab. Treatment is to continue until progres-
sive disease, unacceptable toxicity, patient/investigator decision, or
completion of 35 cycles (pembrolizumab only). Response is to be
evaluated by CT or MRI every 9 weeks per RECIST v1.1 by central
imaging vendor review and per RECIST adapted for immunotherapy
response patterns. Eligible patients may continue pembrolizumab
beyond initial RECIST-defined progression. Patients in the standard-of-
care arm who have progressive disease and meet crossover criteria
may be eligible to receive pembrolizumab for up to 17 treatment cy-
cles. Adverse events (AEs) are to be assessed throughout treatment
and for 30 days thereafter (90 days for serious AEs) and graded per
NCI CTCAE v4.0. Patients are to be followed for survival every 9
weeks. The primary end point is progression-free survival per
RECIST v1.1; secondary end points are overall survival, objective re-
sponse rate per RECIST v1.1, and safety and tolerability. Exploratory
end points include duration of response and health-related quality
of life. Enrollment in KEYNOTE-177 is ongoing, with 270 patients
planned to be enrolled.
Trial Registration
ClinicalTrials.gov identifier NCT02563002.
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Background
Checkpoint inhibitors of programmed cell death-1 protein (PD-1)/
programmed cell death-ligand 1 (PD-L1) and cytotoxic T lymphocyte
associated protein 4 (CTLA-4) pathways have demonstrated clinically
meaningful improvement in survival for patients with various tumor
types. Preclinical data demonstrate significant interplay between in-
nate and adaptive immune systems. Targeting colony-stimulating
factor 1 receptor (CSF-1R) may lead to disruption of the immunosup-
pressive effects of innate immune cells expressing CSF-1R. Treatment
with an anti-CSF-1R monoclonal antibody (mAb) induces anti-tumor
responses in multiple murine tumor models when combined with
CTLA-4 blockade [1], suggesting that combining a checkpoint inhibi-
tor with a CSF-1 pathway inhibitor may potentiate the anti-tumor re-
sponse. Study I5F-MC-JSCC will evaluate the effects of CSF-1R
inhibition using LY3022855 (anti-CSF-1R mAb) in combination with
durvalumab (MEDI4736; anti-PD-L1 mAb) or tremelimumab (anti-CTLA-
4 mAb) in participants with advanced solid malignancies.
Methods
JSCC is a phase Ia/Ib open-label, 3+3 dose-escalation (Part A), followed
by dose-expansion (Part B) study of LY3022855 in combination with ei-
ther durvalumab or tremelimumab. Eligible patients have confirmed
solid malignancies (regardless of PD-L1 status) and ECOG PS 0-1. Pa-
tients must not have received small molecule therapy, chemotherapy,
radiation therapy, monoclonal antibody treatment, or immunosuppres-
sive medication within 14-28 days of start of study treatment, but
prior immune checkpoint therapy is permitted. Pretreatment and
on-treatment biopsies will be obtained (Part A all patients, Part B
ovarian cohort). In the LY3022855+durvalumab regimen, LY3022855
(IV) will be administered at increasing dose levels as tolerated; dur-
valumab (IV) will be administered at a fixed dose. In the LY3022855
+tremelimumab regimen, both LY3022855 and tremelimumab (IV)
will be administered at increasing dose levels as tolerated. Once a
maximum tolerated dose has been identified for each combination,
enrollment to Part B (5 disease-specific expansion cohorts of 20 pa-
tients per cohort: LY3022855+durvalumab- non-small cell lung can-
cer, ovarian, melanoma; LY3022855+tremelimumab- mesothelioma,
melanoma) will begin. The primary objective is to characterize the
safety and tolerability of each combination in treatment of patients
with advanced solid malignancies, as well as define a recommended
phase II dose. Secondary objectives include assessment of antitumor
activity of each combination, immunogenicity, and pharmacokinetics.
Exploratory objectives are to assess immunomodulatory effects of the
combinations. Approximately 178 patients are planned.
Trial Registration
ClinicalTrials.gov identifier NCT02718911.
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Background
Chemotherapy with a platinum doublet has traditionally been the
standard of care for most patients with treatment-naive non–
small cell lung carcinoma (NSCLC). Preliminary data from the
phase I/II KEYNOTE-021 (ClinicalTrials.gov, NCT02039674) study
suggest manageable toxicity and encouraging efficacy of carbo-
platin and paclitaxel chemotherapy plus the anti–PD-1 antibody
pembrolizumab in treatment-naive NSCLC. KEYNOTE-407 (Clinical-
Trials.gov, NCT02775435) is a randomized, double-blind, placebo-
controlled phase III study to compare the efficacy and safety of
paclitaxel or nab-paclitaxel plus carboplatin with or without pem-
brolizumab as first-line treatment in advanced squamous NSCLC.
Methods
Eligible patients are aged ≥18 years and have stage IV squamous
NSCLC, an ECOG PS 0-1, and no prior systemic chemotherapy. Pa-
tients with mixed histology (e.g., adenosquamous) are allowed if
there is a squamous component in the specimen; small cell histology
is excluded. Approximately 560 patients will be randomly assigned
(1:1) to pembrolizumab 200 mg every 3 weeks (Q3W) plus carbopla-
tin area under the curve (AUC) 6 Q3W and paclitaxel 200 mg/m2
Q3W or nab-paclitaxel 100 mg/m2 day 1, day 8, and day 15 Q3W for
4 cycles followed by pembrolizumab 200 mg Q3W or to the same
regimen in which pembrolizumab is replaced by a normal saline pla-
cebo. Patients are to be stratified by choice of taxane (paclitaxel vs
nab-paclitaxel), PD-L1 status (tumor proportion score [TPS] ≥1% vs <
1%; and geographic region of the enrolling site (East Asia vs non–
East Asia) before randomization. Pembrolizumab/placebo will con-
tinue for 35 cycles or until disease progression, intolerable toxicity, or
investigator or patient decision to withdraw. Patients who received
placebo may be able to cross over to pembrolizumab at the time of
documented progression. Adverse events (AEs) will be monitored
throughout the study and for 30 days (90 days for serious AEs) after
treatment completion and graded per NCI CTCAE v4.0. Response will
be assessed by RECIST v1.1 by independent central radiologic review
at weeks 6, 12, and 18, then every 9 weeks until week 45, and every
12 weeks thereafter. The primary end points are progression-free sur-
vival (PFS) by independent radiologic review and overall survival; sec-
ondary end points are objective response rate, duration of response,
and safety. Exploratory objectives include PFS by PD-L1 TPS status
(≥1% vs < 1%) and choice of taxane (paclitaxel or nab-paclitaxel),
patient-reported outcomes (EORTC QLQ-C30 and LC13 and EuroQoL-
5D), pharmacokinetics, and biomarkers.
Trial Registration
ClinicalTrials.gov identifier NCT02775435.
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Background
Clinical responses to dendritic cell (DC) vaccines for brain tumors have
been demonstrably inconsistent. Several factors, including tumor and
treatment related immunosuppression, poor DC maturation, and subopti-
mal antigen sources, likely contribute to this phenomenon. We report
preliminary data from a clinical trial for patients with newly diagnosed
glioblastoma (GBM) that combines current standard of care treatment
with an autologous DC vaccine using mature DCs pulsed with allogeneic
cultured GBM lysates.
Methods
Twenty adult patients with resected newly diagnosed GBM who had
completed radiation/concurrent temozolomide were enrolled. DCs were
manufactured in vitro from CD14+ monocytes purified from patient leu-
kapheresis products and cultured to produce highly pure CD83+ mature
DCs. The mature autologous DCs were pulsed with allogeneic tumor ly-
sates with defined tumor-associated antigen expression. Patients received
temozolomide plus intradermal injections of the vaccine (10-20 x106 DCs)
for up to 6 cycles followed by vaccine alone for up to 6 cycles. In some
cases, patients received injections using a novel intradermal delivery de-
vice (3M human microstructured transdermal system).
Results
Allogeneic cultured GBM lysate pulsed DCs were manufactured suc-
cessfully to produce 15 doses of at least 10x106 DCs/injection in
100% (19/19) of patients to date. Vaccines were manufactured con-
sistently as DCs collectively averaged 91.4% CD83+ and 98.1% CD80-
positive for these maturation markers. Patients on trial have received
a median of 8 injections and three patients have received all 15
doses. Of the toxicities potentially related to the vaccine, only grade
1 and 2 toxicities (fever, rash, fatigue) have been observed. Mean
follow-up to date is 0.98 years (range 0.19 – 1.77 years); 15/20 pa-
tients are still alive. In the first 8 patients, median survival has not
been reached with median follow-up 1.56 years. To assess immune
responses to the vaccine, patients were monitored for over 120
immunophenotypes and circulating tumor antigen specific T cells by
flow cytometry with up to 8 longitudinal samples for some patients.
Conclusions
The combination of adjuvant temozolomide with an autologous ma-
ture DC pulsed with allogeneic tumor lysate vaccine was shown to
be safe, feasible, and able to produce tumor antigen-specific immune
responses in newly diagnosed GBM patients. This successful strategy
is well suited for continuing into later stage clinical trials.
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Background
Patients with HRLACC experience a 50% chance of disease recur-
rence/death following cisplatin-based chemoradiation (CCRT) plus
brachytherapy, and represent a group with a significant unmet need
for new treatments. Persistent infection with oncogenic strains of
human papillomavirus (HPV) is the most common cause of CC, and
provides rationale for therapeutic targeting of HPV. Axalimogene
filolisbac (AXAL/ADXS11-001) is an irreversibly attenuated Listeria
monocytogenes-listeriolysin O immunotherapy that secretes a HPV E7
fusion protein that induces HPV-specific cytotoxic T cell generation
and reduces immune tolerance in the tumor microenvironment. Pre-
vious studies demonstrated AXAL was well tolerated and associated
with objective tumor response and survival benefits in patients with
recurrent/metastatic CC. AXAL has received FDA Fast Track Designa-
tion for the treatment of HRLACC.
Methods
This double-blind, placebo-controlled, multinational, multicenter ran-
domized phase III trial is being conducted under a Special Protocol
Assessment agreement with the FDA. The study will evaluate
adjuvant AXAL in patients with HRLACC, defined as histologically
confirmed squamous cell, adenocarcinoma, or adenosquamous
carcinoma of the cervix and ≥1 of the following: 1) FIGO stage IB2,
IIA2, IIB with biopsy-proven pelvic nodes, or ≥2 positive nodes by
MRI/CT ≥1.5-cm diameter, or ≥2 positive pelvic nodes by PET; 2) all
FIGO stage IIIA, IIIB, IVA; 3) any FIGO stage with para-aortic lymph
node metastases criteria, defined by biopsy-proven para-aortic
node(s), or ≥1 positive para-aortic node(s) by MRI/CT >1.5-cm shortest
dimension, or ≥1 positive para-aortic node(s) by PET with SUV >2.5.
Eligible patients must be disease free per RECIST 1.1 following com-
pletion of CCRT with curative intent and aged ≥18 with GOG perform-
ance status 0–1. Patients will be randomized 2:1 to AXAL (1×109
colony-forming units) or placebo and receive a 60-minute infusion of
treatment every 3 weeks for 3 doses (weeks 1, 4, and 7) for the first 3
months (Induction Phase). Thereafter, patients will receive treatment
every 8 weeks for 5 doses or until disease recurrence (Maintenance
Phase); patients will receive a 7-day course of oral antibiotics/placebo
72 hours after completion of each treatment in both phases. Primary
objective is to compare disease-free survival (DFS) of AXAL with pla-
cebo; secondary objectives are safety and overall survival (OS). Ex-
ploratory objectives will determine if there is an association between
HPV subtypes and DFS/OS, and patient-reported outcomes. The de-
sign provides 85% power for a sample size of 450 to demonstrate a
reduction in the hazard of recurrence by 38%.
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Background
A large percentage of patients with NMIBC experience disease recur-
rence/progression after standard-of-care therapy with transurethral re-
section of bladder tumor (TURBT) and intravesical BCG instillation. The
programmed death-1/programmed death ligand 1 (PD-1/PD-L1) path-
way is frequently altered in cancer, leading to inhibition of active T cell-
mediated immune surveillance of tumors. PD-L1 is widely expressed in
urothelial tumors, providing a therapeutic rationale for targeting this
pathway in NMIBC. KEYNOTE-057 is an open-label, phase II study de-
signed to evaluate the efficacy and safety of the anti-PD-1 antibody
pembrolizumab in patients with high-risk, BCG-unresponsive NMIBC.
Methods
Eligibility criteria include age ≥18 years, histologically confirmed diag-
nosis of high-risk, BCG-unresponsive NMIBC (high-grade Ta, T1, and/or
carcinoma in situ [CIS] despite adequate BCG treatment), ineligible for
or declined radical cystectomy, and ECOG performance status 0-2. Eli-
gible patients must have undergone ≥2 cystoscopic procedures with
the most recent ≤8 weeks before study start, including complete TURBT
(tissue sample must be available). Patients will receive pembrolizumab
200 mg every 3 weeks for 24 months or until disease recurrence, pro-
gression, or unacceptable toxicity. Patients will be placed into cohorts
based on presence (cohort A) or absence (cohort B) of CIS as deter-
mined by tissue pathology at screening. Response will be assessed
using cystoscopy and urine cytology every 12 weeks for the first 2
years, every 24 weeks for the next 2 years, and every 52 weeks there-
after. CT imaging will be used to assess for metastatic or nodal disease.
At 18 months, patients with no evidence of disease may discontinue
treatment. Low-grade Ta recurrence will not be considered treatment
failure; these patients may undergo repeat TURBT and remain on treat-
ment. Adverse events (AEs) will be monitored throughout the study
and for 30 days after end of treatment (90 days for serious AEs and
events of clinical interest) and graded per Common Terminology Cri-
teria for Adverse Events, version 4.0. Primary end points are complete
response (cohort A) and disease-free survival (cohort B); secondary end
points include progression-free survival, overall survival, duration of re-
sponse, and the relationship between PD-L1 expression and response
to treatment. Enrollment will continue until approximately 260 patients
have enrolled.
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82 Page 82 of 221
Trial Registration
ClinicalTrials.gov identifier NCT02625961.
P142
KEYNOTE-013: an open-label, multicohort phase Ib trial of
pembrolizumab in patients with advanced hematologic
malignancies
Justin Kline1, Philippe Armand2, John Kuruvilla3, Craig Moskowitz4, Mehdi
Hamadani5, Vincent Ribrag6, Pier Luigi Zinzani7, Sabine Chlosta8, Seth
Thompson8, Arun Balakumaran8, Nancy Bartlett9
1Committee on Immunology and Department of Medicine, University of
Chicago, Chicago, IL, USA; 2Dana-Farber Cancer Institute, Boston, MA,
USA; 3Princess Margaret Cancer Centre and University of Toronto,
Toronto, ON, Canada; 4Memorial Sloan Kettering Cancer Center, New
York, NY, USA; 5Medical College of Wisconsin, Milwaukee, WI, USA;
6Institut Gustave Roussy, Villejuif, Ile-de-France, France; 7Institute of
Hematology “L. e A. Seràgnoli,” Università di Bologna, Bologna, Emilia-
Romagna, Italy; 8Merck & Co., Inc., Kenilworth, NJ, USA; 9Washington
University School of Medicine in St. Louis, St Louis, MO, USA
Correspondence: Justin Kline (jkline@medicine.bsd.uchicago.edu)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P142
Background
Pembrolizumab, a humanized monoclonal antibody that blocks inter-
action between PD-1 and its ligands, has demonstrated robust antitu-
mor activity and a manageable toxicity profile in advanced solid
tumors. KEYNOTE-013 is a multicenter, open-label, multicohort phase Ib
trial designed to assess the safety and efficacy of single-agent pembro-
lizumab in patients with hematologic malignancies. The KEYNOTE-013
trial design has been updated to include a cohort evaluating combin-
ation therapy of pembrolizumab and lenalidomide in patients with
relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who
have failed, are ineligible for, or refused stem cell transplantation (SCT).
Combination therapy of pembrolizumab, lenalidomide, and dexa-
methasone in R/R multiple myeloma (MM) in KEYNOTE-023 has demon-
strated synergistic efficacy and manageable toxicity [1].
Methods
Cohorts include patients with: (1) intermediate 1, intermediate 2,
or high-risk myelodysplastic syndrome (MDS) that failed ≥4 cycles
of prior treatment with a hypomethylating agent; (2) R/R MM that
failed ≥2 lines of prior therapy, including a proteasome inhibitor
and IMiD; (3) R/R nodular sclerosing or mixed cellularity Hodgkin
lymphoma (HL) (cohort 3); (4) R/R non-Hodgkin lymphoma (NHL)
who failed, were ineligible for, or refused SCT, including: (4a) R/R
primary mediastinal large B cell lymphoma (PMBCL), (4b) any
other R/R PD-L1–positive NHL, (4c) R/R follicular lymphoma (FL),
(4d) R/R DLBCL; and (5) R/R DLBCL. Key eligibility criteria for all
cohorts are age ≥18 years, ECOG performance status 0/1, measur-
able disease, and adequate hematologic, renal, and hepatic func-
tion. Patients in cohorts 1-4 enrolled under amendments 1-3 will
be treated with pembrolizumab intravenously (IV) 10 mg/kg every
2 weeks; those enrolled under amendments 4-6 will be treated
with pembrolizumab IV 200 mg every 3 weeks (Q3W) because of
updated program-wide PK/PD information. Patients enrolled in
cohort 5 will be treated with pembrolizumab IV 200 mg Q3W in
combination with lenalidomide taken orally once daily for 21
days of each 28-day cycle. Treatment will continue until disease
progression, intolerable toxicity, or up to 35 doses of pembrolizu-
mab (~2 years). The primary end points are objective response
rate and safety. Secondary objectives include duration of re-
sponse, progression-free survival, overall survival, and association
between PD-L1 expression and response. Enrollment is open for
MM (cohort 2), PMBCL (cohort 4a), and FL (cohort 4c), evaluating
single-agent pembrolizumab; and for DLBCL (cohort 5), evaluating
pembrolizumab in combination with lenalidomide. Approximately
222 patients will be enrolled.
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Background
Poly-ICLC, a double-stranded RNA complex, can directly activate den-
dritic cells and trigger NK cells to kill tumor cells. It can be given
intramuscularly (IM) to induce systemic inflammation and intratumo-
rally (IT) to induce immune infiltration of tumors.
Methods
In this phase II study, eligible subjects are head and neck, skin (mel-
anoma and non-melanoma), and sarcoma patients with recurrent or
metastatic disease who have failed prior systemic therapy. In each
treatment cycle, one accessible tumor site was targeted for IT injec-
tion of 1 mg of Poly-ICLC 3 times a week for 2 weeks followed by IM
boosters biweekly for 6 weeks and then a 2 week rest period. This
10-week cycle was repeated in cycle 2, followed by a 6 week no-
treatment period. Tumor biopsies were performed at baseline, week
3, and week 26. Pre- and post-vaccination tumors were evaluated by
quantitative multiplex immunohistochemistry (IHC) and RNA sequen-
cing. Blood samples were collected at baseline and prior to each
cycle for immune response evaluations.
Results
A phase I pilot portion of this study showed 1 patient who achieved
clinical benefit with stable disease (progression-free survival of 6
months). Poly-ICLC was well tolerated with principal side effects of
fatigue and inflammation at injection site (< grade 2). One case of
grade 3 tumor necrosis was observed. In the patient with clinical
benefit, IHC analysis of tumor showed increased CD4(60x), CD8(10x),
PD-1(20x) and PD-L1(3x) compared to patients with progressive
disease whose tumor biopsies showed unchanged/decreased CD4,
CD8, PD-1, and PD-L1 levels over treatment period. Furthermore,
RNASeq analysis of the same patient’s tumor and peripheral blood
mononuclear cells (PBMC) showed dramatic changes such as upregu-
lation of interferon-stimulated genes, chemokines, and genes associ-
ated with T cell activation and antigen presentation indicative of
local and systemic immune activation in response to Poly-ICLC
treatment.
Conclusions
Preliminary findings show that Poly-ICLC is well tolerated in
advanced solid cancer patients, and generates local immune re-
sponse in tumor microenvironment and systemic immune re-
sponse as evident in the patient achieving clinical benefit. These
results warrant further investigation, and are currently being
explored in this ongoing larger multicenter adaptive phase II clin-
ical trial.
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Background
Adenosine is elevated within the tumor microenvironment and sig-
naling through the A2aR is immunosuppressive. CPI-444 is an oral,
selective A2aR antagonist that inhibits A2aR and demonstrates anti-
tumor efficacy in mouse models alone and combined with PD-1/PD-
L1 blockade. CPI-444 was well-tolerated in previous clinical trials in
the non-oncology setting. This is the first report of adenosine block-
ade in cancer patients (pts).
Methods
This phase I/Ib, open label clinical trial uses a two-step adaptive
design to study CPI-444 alone and combined with atezo in pts
with selected advanced cancers. The objectives are to evaluate
safety and efficacy and to optimize dose/schedule. Eligible pts
have failed standard therapies with histologies: non-small cell
lung (NSCLC), melanoma (MEL), triple-negative breast (TNBC),
renal (RCC), prostate, head and neck (H&N), colorectal (CRC) or
bladder cancers. In step 1 of the trial, pts are randomized to
one of 4 cohorts (12 pts/cohort) including 3 single-agent cohorts
or combined with atezo. Step 2 contains multiple disease-
specific expansion cohorts to evaluate CPI-444 alone and com-
bined with atezo.
Results
Step 1 has enrolled 19 pts to date, median age 67 years (range, 36-84);
three pts each with NSCLC, TNBC, RCC and CRC, 2 pts each with MEL,
prostate and bladder cancer and one pt with H&N. Median number of
prior regimens was 3 (range, 1-5). Seven pts received prior anti PD-1/
PD-L1 therapy; 4 pts were resistant and 3 were refractory. Twelve pts
remain on study (range 1- 17 weeks) and 7 have discontinued due to
disease progression. Of 8 pts evaluable for response at 2 months, 3 had
stable disease (2 received CPI-444 alone); 11 pts have not reached the
first response assessment timepoint. A prostate cancer pt in the com-
bination cohort remains on treatment for >4 months with minimal re-
gression of nodal disease and a transient decrease in serum PSA. A
TNBC pt on CPI-444 alone showed 15% reduction in tumor burden. No
grade 3 or 4 adverse events or DLTs related to CPI-444 alone or
in combination with atezo were observed. Dose-dependent inhib-
ition of A2aR signaling was demonstrated in peripheral blood
mononuclear cells using a CREB phosphorylation assay. Evidence
of immune activation was observed in some pts treated with CPI-
444 alone as reflected by an increase in circulating activated PD-
1+/CD8+ T cells.
Conclusions
Early data demonstrate that CPI-444 is well-tolerated alone and com-
bined with atezo and demonstrates preliminary evidence of immune
activation and clinical activity. Enrollment is ongoing.
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Background
SEA-CD40 is a non-fucosylated, humanized IgG1 monoclonal anti-
body which binds CD40, an immune-activating TNF receptor. Binding
to CD40 on antigen-presenting cells (APCs) and enhanced crosslink-
ing via FcγRIIIa stimulates pro-inflammatory cytokine production and
induction of immune co-stimulatory receptors, leading to T cell acti-
vation and antitumor activity. Further, when CD40 is expressed on
malignant cells, SEA-CD40 induces antibody-dependent cellular cyto-
toxicity through enhanced NK cell binding.
Methods
This ongoing phase I dose-escalation study evaluates the safety,
tolerability, pharmacodynamic biomarkers, and antitumor activ-
ity of SEA-CD40 in adult patients with advanced metastatic solid
tumors (relapsed, refractory, or progressive disease after ≥1
prior systemic therapy). Antitumor activity is assessed after
every 4 cycles of treatment by immune-related response criteria
and RECIST v1.1.
Results
To date, 22 patients (median age 59 years; range, 28–76) with
solid tumors have received a median of 2.5 cycles (range, 1–16)
of SEA-CD40, 0.6–60 mcg/kg IV q3wk. Two dose-limiting toxicities
occurred at 60 mcg/kg (1 G3 and 1 G4 infusion-related reaction
[IRR]). AEs were primarily infusion-related toxicities. Treatment-
emergent AEs in ≥25% of patients were: chills (77%), nausea
(55%), fatigue (45%), vomiting (41%), dyspnea and headache
(32% each), and flushing and lymphopenia (27% each). Changes
in pharmacodynamic biomarkers consistent with CD40 and CD16
engagement were observed, including: dose-proportional in-
creases in inflammatory cytokine levels; B cell depletion with par-
tial recovery by next cycle; reduction in T regulatory cells;
transient margination of monocytes and NK cells with recovery
by Day 8; and upregulation of MHC class II on APCs. In 18
efficacy-evaluable patients, 4 had SD and 1 had PR by RECIST
(28% disease control rate [DCR]). Two patients had durable SD
(gastroesophageal junction tumor, 10 mcg/kg, PD after 12 cycles;
mesothelioma, 10 mcg/kg, PD after 8 cycles). The patient with PR
achieved PR after Cycle 4 (basal cell carcinoma, 60 mcg/kg, PD
following Cycle 8). Four patients remain on treatment.
Conclusions
SEA-CD40 is a biologically and clinically potent molecule in heavily
pre-treated patients with advanced solid tumors. Strategies to man-
age IRRs are being evaluated. Cytokine elevations correlate with pre-
clinical models and the proposed mechanism of action through
CD40 activation on APCs. Pharmacodynamic data and evidence of
clinical activity (28% DCR), along with preclinical evidence for
synergy when SEA-CD40 is combined with checkpoint inhibitors [1],
presents a compelling opportunity to enhance immunotherapy for
cancer.
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Background
While survival results with immune checkpoint blockade in the
second-line treatment setting of non-small cell lung cancer
(NSCLC) are impressive, many patients’ cancer progresses or be-
comes resistant to these therapies. Combinatorial approaches are
being investigated to improve response and outcomes with these
agents. Epigenetic therapy has been found to be effective com-
ponent of cancer treatment. Hypermethylation of DNA promoter
regions by DNA methyltransferases (DNMT) and histone deacety-
lation by histone deacetylases (HDAC) represent two of these crit-
ical epigenetic mechanisms of tumor-specific gene silencing.
Interestingly, 5 of 5 patients treated with combination epigenetic
therapy followed by PD-1/PD-L1 therapy achieved long-term clin-
ical benefit at our institution while on clinical trial. Preclinical
studies have also shown that combined HDAC/DNMT inhibition
can induce susceptibility to immune checkpoint therapy and in-
hibit tumor growth [1].
Methods
This is a multi-institution, open-label, randomized phase II study of
azacitidine and entinostat with concurrent nivolumab compared to
nivolumab alone in patients with recurrent, metastatic NSCLC. Pa-
tients with metastatic NSCLC who have received 1-2 prior therapies
and are Eastern Cooperative Group (ECOG) performance status (PS)
0-1 are stratified by histology and randomized to receive azacitidine
(40 mg/m2 subcutaneous (SQ) days 1-5, 8-10), entinostat (4 mg orally
days 3 and 10) and nivolumab (3 mg/kg intravenous (IV) days 1 and
15) for 6 28-day cycles, followed by nivolumab (3 mg/kg IV days 1
and 15) alone [Arm D] or nivolumab (3 mg/kg IV days 1 and 15) on a
28-day cycle alone [Arm C] until disease progression (Fig. 60). Statis-
tics: The primary endpoint of this trial is the percentage of patients
progression-free at 24 weeks. Using planned study enrollment of 60
patients on each Arm (n=120) and using the exact Mantel-Haenszel
test for analysis, this will provide 90% power to detect an odds ratio
of 3 for combination therapy over single-agent nivolumab with re-
spect to being progression-free at 24 weeks. Secondary endpoints in-
clude objective response rate, progression-free survival, time to
progression, overall survival and safety and tolerability. Correlative
Study: All patients are required to have pre- and post- treatment bi-
opsies; Arm D patients will also have biopsies while on combination
therapy. Plasma and peripheral blood mononuclear cells will also be
drawn for analysis.
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Background
Targeting the programmed death 1 (PD-1) pathway has been found
to be effective in patients with previously treated, advanced or clear
cell mRCC. Pembrolizumab is an anti–PD-1 antibody that blocks the
interaction between PD-1 and its ligands, enabling an increased anti-
tumor immune response. Most patients with mRCC progress within 1
year following the initiation of standard first-line treatment with anti-
angiogenic therapy, highlighting the need for therapies that provide
more durable benefit in mRCC.
Methods
KEYNOTE-427 (ClinicalTrials.gov, NCT02853344) is a phase II, open-
label study designed to evaluate the efficacy and safety of pembroli-
zumab monotherapy as a first-line treatment for advanced, recurrent
or metastatic clear cell or non–clear cell mRCC. Target enrollment in
KEYNOTE-427 is 105 patients in a clear cell cohort (cohort A) and 150
patients in a non–clear cell cohort (cohort B). Key eligibility criteria in-
clude locally advanced, metastatic or recurrent disease, measurable
disease per RECIST v1.1 assessed by blinded independent central re-
view (BICR), no prior systemic therapy for advanced RCC, provision of
a tumor tissue sample for biomarker analysis, and Karnofsky perform-
ance status ≥70%. Patients are to receive pembrolizumab intraven-
ously 200 mg once every 3 weeks until progressive disease, the
occurrence of unacceptable adverse events (AEs), or for up to 35
doses in patients without progressive disease. Patients who stop
pembrolizumab after 35 doses without progressive disease or who
stop treatment after a complete response will be allowed treatment
with an additional 17 doses of pembrolizumab upon progression. Re-
sponse will be assessed per RECIST v1.1 by BICR using CT and/or MRI.
Bone scans will be performed at baseline and throughout the study
for patients with a positive bone scan at baseline. AEs will be graded
per National Cancer Institute Common Terminology Criteria for
Fig. 60 (Abstract P146). Study Schema
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Adverse Events, version 4.0. The primary objective is estimation of
the objective response rate in each cohort per RECIST v1.1. An in-
terim analysis for response rate will be performed for the non–clear
cell RCC cohort when the 30th patient in this cohort has completed
the third scan. Secondary objectives include estimation of duration
of response, disease control rate, progression-free/overall survival,
and safety and tolerability of pembrolizumab treatment by cohort.
Trial Registration
ClinicalTrials.gov identifier NCT02853344.
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Background
The 9p24.1 locus is frequently amplified in rrPMBCL, leading to
overexpression of the PD-L1 and PD-L2 immune checkpoint li-
gands and providing a potential mechanism of immune evasion.
Pembrolizumab is an anti–PD-1 monoclonal antibody that blocks
the interaction between PD-1 and PD-L1 and PD-L2, thereby en-
abling an antitumor immune response. In the multicohort, phase
Ib KEYNOTE-013 study, pembrolizumab was associated with a tol-
erable safety profile and promising antitumor activity (overall re-
sponse rate [ORR] of 38% 6/16]) in patients with rrPMBCL. In the
phase II MC1485 study, pembrolizumab demonstrated promising
preliminary efficacy (ORR, 43% [3/7]) in patients with rrRS. The
multicenter, phase II KEYNOTE-170 study was designed to further
evaluate the safety and efficacy of pembrolizumab in patients
with rrPMBCL or rrRS.
Methods
Eligible patients must be at least 18 years of age and fit into 1 or 2
profiles: (1) diagnosis of rrPMBCL according to World Health
Organization 2008 criteria, failed to achieve a complete response
(CR) or relapsed after autologous stem cell transplantation (auto-
SCT), or are ineligible for auto-SCT and have failed to respond or re-
lapsed after ≥2 lines of prior treatment; or (2) pathologic diagnosis
per local institutional review of rrRS that transformed from under-
lying chronic lymphocytic leukemia (CLL), received at ≥1 prior ther-
apy for rrRS, and have relapsed or refractory disease. Patients are to
receive pembrolizumab 200 mg intravenously every 3 weeks for until
disease progression, unacceptable toxicity, or 35 cycles of treatment.
In patients with rrRS, additional standard therapies to treat the
underlying CLL may be added according to the physician’s discretion.
Eligible patients who attain a CR as determined by the independent
central imaging vendor may stop trial treatment and may be eligible
for retreatment upon disease progression. Response is to be assessed
every 12 weeks by independent central imaging vendor review
based on International Working Group (IWG) response criteria. Ad-
verse events (AEs) are to be assessed throughout treatment and for
30 days thereafter (90 days for serious AEs) and graded per NCI
CTCAE v4.0. Patients will be followed for survival every 12 weeks. The
primary end point is ORR by independent central imaging vendor re-
view according to IWG response criteria or IWG response criteria with
special considerations for rrRS; secondary end points include
progression-free survival, overall survival, and safety and tolerability.
Enrollment is ongoing and will continue until approximately 106 pa-
tients are enrolled.
Trial Registration
ClinicalTrials.gov identifier NCT02576990.
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Background
BRAF inhibitors induce antitumor responses in >50% of patients (pts)
with BRAF V600E/K mutant metastatic melanoma, but some patients do
not respond and most responders have only partial responses, the me-
dian duration of which is 7-9 months. BRAFi markedly increase tumor
infiltrating lymphocytes (TIL), although markers of T cell exhaustion and
PD-L1 are increased. We hypothesize that BRAFi will drive TIL into the
tumor parenchyma, and that by blocking PD-1/PD-L1 disinhibitory sig-
nals, pembrolizumab may improve the function and durability of TILs.
Methods
This study is an investigator-initiated phase I/II dose-seeking and efficacy
trial of P and V for pts with unresectable/metastatic BRAF mutant melan-
oma. Primary objectives are to determine safety and maximum tolerated
dose (MTD) of V combined with P in this population, and to assess ORR
with the combination, in comparison to historical benchmarks. Second-
ary objectives are to evaluate PFS and OS. Exploratory objectives are to
assess whether the combination favorably modulates the tumor micro-
environment and decreases T cell exhaustion in sequential biopsies of
tumor and blood samples. We aim to accrue up to 50 patients to this
study. Using the modified toxicity probability interval (mTPI) will allow ef-
ficient identification of the MTD; we expect at least 30 patients to be en-
rolled at the recommended phase II dose. Pts will receive P 200 mg q3
wks, and V 480 mg, 720 mg, or 960 mg BID, per mTPI. Treatment with
both V & P will start on day 1. The DLT monitoring period is 3 wks. Pts
will have CT scans at baseline and wk 9, then q12 wks. For pts with biop-
siable disease, biopsies at baseline and wk 3 are mandatory. Blood for
correlative studies will be drawn at baseline, wk 3, wk 9 and progression.
Pts will be treated until DLT or PD for up to 2 years.
Results
One patient has been started on therapy and is in wk 2 of the 3 wk
DLT monitoring period, with no significant toxicities thus far.
Conclusions
We anticipate that treatment with pembrolizumab and vemurafenib
will be safe and well tolerated. In addition to the primary efficacy
endpoint of ORR and secondary endpoints of PFS and OS, this study
includes extensive immune correlative analyses, including analysis of
PD-1/PD-L1 and levels of Treg, MDSC, and inhibitory cytokines in the
tumor parenchyma and peripheral blood. One patient on trial thus
far is tolerating treatment well, with no significant toxicities to date.
Trial Registration
ClinicalTrials.gov identifier NCT02818023.
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Background
T cells and natural killer (NK) cells require L-arginine for proliferation
and activation. Arginine depletion by arginase in the tumor micro-
environment induces immunosuppression and is associated with
tumor immune evasion, advanced disease stage and poor outcomes.
Arginase is secreted by granulocytic myeloid-derived suppressor cells
(G-MDSCs) and its pharmacological inhibition is expected to restore
arginine levels and relieve immunosuppression. CB-1158 is a potent,
selective, and orally-bioavailable small molecule inhibitor of arginase
(IC50=98 nM). CB-1158 reverses G-MDSC-mediated immunosuppres-
sion by blocking arginine depletion in an ex vivo human model. T
cells activated in the presence of G-MDSC-conditioned media dem-
onstrate reduced proliferation and suppressed production of Th1 cy-
tokines; this effect is reversed by the addition of CB-1158. In vivo,
twice daily dosing of CB-1158 causes dose-dependent increases in
plasma and tumor arginine levels and is associated with single agent
anti-tumor efficacy in multiple syngeneic models. CB-1158 also en-
hances the antitumor efficacy of checkpoint inhibitors.
Methods
CX-1158-101 is a phase I first-in-human study of CB-1158 in patients
with solid tumors. The primary objective is to evaluate the safety and
tolerability of CB-1158, as monotherapy and in combination with
nivolumab. Secondary objectives include selection of the recom-
mended phase II dose (RP2D), determination of CB-1158 pharmaco-
kinetics and evaluation the anti-tumor effect, for monotherapy and
nivolumab combination. Exploratory objectives include an evaluation
of pharmacodynamic biomarkers, including plasma arginine, plasma
arginase activity, and effects on immune function in the peripheral
blood and tumor biopsies. In Part 1a, safety/tolerability of escalating
doses of CB-1158 will be evaluated in patients with solid tumors of
any type. In Part 2, three expansion cohorts will open at the mono-
therapy RP2D. These cohorts include non-small cell lung cancer
(NSCLC, Cohort A), colorectal cancer (CRC, Cohort B), and Cohort C,
which will include patients with squamous cell carcinoma of the
head and neck (SCCHN), renal cell cancer (RCC), gastric or gastro-
esophageal junction (GEJ) cancer, urothelial cell cancer (UCC), and/or
melanoma. Upon demonstration of sufficient PK and/or PD effect of
CB-1158 in Part 1a, dose escalation of CB-1158 in combination with
full dose nivolumab will open in Part 1b. The dose escalation will en-
roll patients with NSCLC, RCC, and melanoma. In Part 3, two expan-
sion cohorts will enroll patients to the combination of CB-1158 and
nivolumab at the RP2D. These cohorts will enroll NSCLC and melan-
oma patients that have received prior anti-PD-1/PD-L1 therapy and
had progressive disease or prolonged (>24 weeks) stable disease.
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Background
Hu5F9-G4 is a humanized monoclonal antibody that targets CD47,
blocking its anti-phagocytic “don’t eat me” signal through macro-
phage receptor SIRPα, leading to tumor phagocytosis. CD47 is over-
expressed on human cancers and also on red blood cells (RBCs). In
primate toxicology studies, Hu5F9-G4 caused a transient anemia that
was improved with a single lower priming dose allowing higher
maintenance doses.
Methods
Relapsed/refractory solid tumors and lymphomas were included. This
dose escalation study included: Part A, to determine the priming
dose and Part B, to determine the maintenance dose. The maximum
tolerated dose (MTD) in part A was used for the single priming dose
in part B (Hu5F9-G4 dosed weekly). The primary objective is to deter-
mine safety and secondary objectives are to determine PK and PD.
Preliminary data reported from data cutoff of July 22, 2016.
Results
21 patients have enrolled. Part A included 0.1 (N=1), 0.3 (N=2), 1
(N=6), and 3 mg/kg (N=2). There were 2 dose-limiting toxicities
(DLTs) in Part A at the 3 mg/kg dose: grade (G) 3 abdominal pain
and G3 hemagglutination (H) (protocol-specific scale of 1+ H on per-
ipheral blood smear (PBS) and G2 headache). 1 mg/kg was selected
as the priming dose, with no >G2 anemia and almost 100% RBC re-
ceptor occupancy. Treatment-related adverse events (TRAE) in Part A
included: anemia (3 G1, 3 G2), hyperbilirubinemia (3 G1, 2 G2; uncon-
jugated), headache (6 G1, 1 G2), H on PBS (8 G1), and nausea (3 G1).
Part B included 3 (N=4), 10 (N=3), and 20 mg/kg (N=3, ongoing).
There have been no DLTs in 3 patients on 10 mg/kg (last fully eva-
luable cohort). Most toxicity was associated with the single prim-
ing dose and reversible. TRAE in Part B at 3 mg/kg included:
anemia (2 G1, 2 G2), hyperbilirubinemia (1 G1, 1 G3; unconju-
gated), headache (3 G1), H on PBS (1 G1), retinal toxicity (G2
protocol-specific scale, asymptomatic). TRAE at 10 mg/kg included:
anemia (3 G1), headache (2 G1), and nausea (1 G1). Target trough
levels associated with preclinical activity are being achieved at the
10 mg/kg dose, and half-life increases with repeated dosing. Two
patients with adenoid cystic carcinoma in Part A had stable dis-
ease for 16 and 8 months.
Conclusions
Hu5F9-G4 is well tolerated at 10 mg/kg weekly, with 1 mg/kg prim-
ing dose. Part B maintenance dose 20 mg/kg enrolling.
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Background
While sustained cytotoxic chemotherapy may be associated with
lymphopenia and immunosuppression, chemotherapy may also facili-
tate antigen release/presentation, adaptive expression of PD-L1, and
relative depletion of suppressive immune cell populations. Metastatic
triple-negative breast cancer (MTNBC) is an aggressive and incurable
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disease associated with high mutational load and tumor-infiltrating
lymphocytes, and is treated conventionally with sequential, sustained
cytotoxic chemotherapy. In heavily pre-treated patients, anti-PD-1/L1
monotherapy yielded modest response rates of 9-19% [1]. However,
we hypothesize that up-front treatment with 1st/2nd line chemother-
apy plus anti-PD-1/L1 might minimize immunosuppression (by treat-
ing patients before they are exposed to prolonged chemotherapy)
and maximize immunostimulation (by treating less chemo-resistant
disease and maximizing antigen release). In a preliminary cohort,
anti-PD-L1 plus chemotherapy (nab-paclitaxel) was safe, with favor-
able response rates compared to historical controls [2].
Methods
In a pilot/phase II investigator-initiated trial, we will evaluate the
safety and tolerability of anti-PD-1 (pembrolizumab 200mg IV every
three weeks) plus investigator-selected 1st/2nd line standard-of-care
chemotherapy with either weekly paclitaxel (80mg/m2 IV) or oral cap-
ecitabine (2,000mg twice daily, weekly 1 on/1 off). Secondarily, we
will evaluate efficacy of each combination employing a Simon 2-
stage design, as measured by week 12 radiographic response. Be-
cause chemotherapy-associated immunosuppression could poten-
tially influence immunotherapy efficacy, we will serially characterize
general immune status and T cell activation using a validated real-
time multi-parametric flow cytometry platform and peripheral blood
T cell receptor sequencing (to measure clonal repertoire diversity).
Via a companion biospecimen protocol, these data will be compared
with data from MTBNC subjects receiving paclitaxel or capecitabine
alone. Furthermore, baseline and post-treatment tumor-infiltrating
lymphocytes will be characterized using multi-spectral immunofluor-
escence (using a validated panel including CD3, CD8, CD163, FOXP3,
PD-L1, DAPI, and CK) and T cell receptor sequencing.
Results
As of 8/7/2016, five subjects have been registered for enrollment.
Conclusions
This investigator-initiated trial will provide important data, evaluating
the efficacy of commonly used chemotherapies (paclitaxel or capecit-
abine) plus anti-PD-1, as well as evaluating the effect of these regi-
mens on general immune status, peripheral T cell activation, and
tumor infiltrating lymphocytes. A registrational MTNBC trial of nab-
paclitaxel +/- anti-PD-L1 is ongoing.
Trial Registration
ClinicalTrials.gov identifier NCT02734290.
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Background
Adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TILs) is
based on infusion of activated and expanded cells isolated from autolo-
gous tumor tissue. The treatment has shown a clinical effect in approxi-
mately 50% of malignant melanoma patients with 20% obtaining a
complete response [1]. Recent studies suggest that TIL based ACT can
potentially be used with success in other cancers, including ovarian
cancer (OC). OC is the 5th leading cause of cancer death among
women. If inoperable, the treatment is a combination of chemotherapy.
Recurrent disease has a poor prognosis. The primary aim of this study
is to assess feasibility and tolerability of T cell therapy for OC. Secondar-
ily, to describe objective response using RECIST 1.1 and clarify if the
treatment can induce measurable immune responses against tumor
cells. This trial is presented at the European Society of Medical Oncol-
ogy (ESMO) 2016 conference. In this abstract an update on clinical re-
sponses is provided.
Methods
Six patients will be included. Patients with progressive/recurrent OC
and histologically verified serous adenocarcinoma are potential
candidates. Surgical removal of tumor tissue for T cell expansion is
performed. Stem cells are harvested for potential use if patients are
having difficulties recovering from lymphodepleting chemotherapy.
The treatment consists of lymphodepleting chemotherapy (60 mg/
kg cyclophosphamide for 2 days, 25 mg/m2 fludarabine for 5 days)
followed by T cell administration and high-dose decrescendo
interleukin-2 for up to 5 days. Patients are evaluated for up to 5
years/until progression.
Results
Five patients have received treatment. The first had a partial
metabolic response, stable disease (SD) with nearly 20% tumor re-
gression and >50% reduction in CA-125 at 6 weeks, but progres-
sive disease (PD) at 12 weeks. The second had SD at 6 weeks with
a small decrease in CA-125, but PD at 12 weeks. The third had SD
at 6 weeks with a 25% drop in CA-125, but PD at 12 weeks. The
fourth had SD at 6 weeks with stable CA-125 and awaits 12 weeks
evaluation. The fifth patient has not been evaluated yet. Only ex-
pected and manageable toxicities have been observed. All pa-
tients recovered without stem cell support. Immune analyses are
pending.
Conclusions
So far, T cell therapy for patients with advanced OC seems to be
manageable and tolerable.
Trial Registration
ClinicalTrials.gov identifier NCT02482090.
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Background
BGB-A317 is a humanized IgG4 anti-PD-1 mAb with high specificity
and affinity (KD=0.15 nM) for PD-1. It blocks PD-L1 and PD-L2 binding
and inhibits PD-1-mediated negative signaling in T cell lines and
tumor growth in a number of allogeneic xenograft models.
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Methods
A phase I, multicenter study was conducted to evaluate the safety, tol-
erability, PK and antitumor activity of BGB-A317 in patients with ad-
vanced solid tumors. A 3+3 dose escalation design was undertaken.
Patients received escalating doses of BGB-A317 intravenously at 0.5, 2,
5 and 10 mg/kg once every two weeks (Q2W). Additional patients were
treated at 2 and 5 mg/kg once every three weeks (Q3W).
Results
As of 27 July 2016, 103 patients were treated across 4 dose-escalating
cohorts of BGB-A317 Q2W (0.5 mg/kg, n=3; 2 mg/kg, n=6; 5 mg/kg,
n=6 and 10 mg/kg, n=7) and 4 dose-expansion cohorts (2 mg/kg,
Q2W, n=20; 2 mg/kg, Q3W, n=21; 5 mg/kg Q2W, n=20 and 5 mg/
kg, Q3W, n=20). One DLT (1/6) of grade 3 colitis was observed in
the 5 mg/kg Q2W dose-escalating cohort. Maximum tolerated dose
was not reached. Recommended phase II dose is 5 mg/kg Q3W.
The most common treatment-emergent adverse events (AEs) were
grade (G) 1-2 fatigue (42%), nausea (30%), diarrhea (25%), abdom-
inal pain (22%) and constipation (21%). Treatment–related G3 AEs
included fatigue (n=2), hypotension (n=2), back pain (n=1), colitis
(n=1), diabetes mellitus (n=1), diabetic ketoacidosis (n=1), dyspnea
(n=1), elevated ALT (n=1), hyperglycaemia (n=1), hypoxia (n=1) and
pneumonitis (n=1). Population PK analysis was conducted using
411 observed BGB-A317 serum concentrations from 31 patients
who received doses of 0.5, 2, 5 and 10 mg/kg Q2W and 13 patients
who received doses of 2 and 5 mg/kg Q3W. BGB-A317 PK is linear
and the terminal elimination half-life is 16 days. Patients’ body
weight is not a significant covariate on the clearance of A317.
Among 99 evaluable patients, preliminary evidence of anti-tumor
activities included 16 patients have partial responses (5 to be con-
firmed) and 20 patients exhibit stable disease. 13 responding pa-
tients remain on treatment, ranging from 18 to 38 weeks.
Conclusions
BGB-A317 demonstrates a favorable safety profile with AEs in keep-
ing with the class effect. Early promising anti-tumor activity has been
observed. BGB-A317 PK is linear and systemic clearance is not af-
fected by body weight, which supports fixed dosing. The expanded
phase IB study in selected cancer types is ongoing.
Trial Registration
ClinicalTrials.gov identifier NCT02407990.
P155
Preliminary safety data from a randomized multicenter phase Ib/II
study of neoadjuvant chemoradiation therapy (CRT) alone or in
combination with pembrolizumab in patients with resectable or
borderline resectable pancreatic cancer
Matthew H G Katz1, Todd W Bauer2, Gauri R Varadhachary3, Nicolas
Acquavella4, Nipun Merchant4, Gina Petroni5, Craig L Slingluff Jr.6, Osama
E. Rahma7
1Department of Surgical Oncology, Division of Surgery, The University of
Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of
Surgery, University of Virginia, Charlottesville, VA, USA; 3Department of
Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The
University of Texas MD Anderson Cancer Center, Houston, TX, USA;
4Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL,
USA; 5University of Virginia, Charlottesville, VA, USA; 6Division of Surgical
Oncology, University of Virginia, Charlottesville, VA, USA; 7Dana-Farber
Cancer Institute, Harvard University, Boston, MA, USA
Correspondence: Osama E. Rahma (osamae_rahma@dfci.harvard.edu)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P155
Background
Tumor-infiltrating lymphocytes (TILs) do not reach the pancreatic
cancer (PC) cells in significant numbers due to the presence of
stroma and a suppressive microenvironment [1]. Neoadjuvant che-
moradiation (CRT) can increase the presence of TILs in the PC micro-
environment (PCME) [2]. We tested the combination of CRT and
pembrolizumab for the first time in patients with pancreatic cancer
in the neoadjuvant setting.
Methods
Patients with resectable or borderline resectable pancreatic cancer
are randomized 2:1 to receive pembrolizumab intervenously every 3
weeks during concurrent CRT with capecitabine (825 mg/m2 orally
twice daily, 5 days/week, on days of radiation only) and radiation
(50.4 Gy in 28 fractions over 28 days) or Arm B to receive only con-
current CRT with capecitabine.
Results
As of July 5, 2016 a total of 13 patients have been enrolled on
the study (9 on Arm A and 4 on Arm B). Six patients had resect-
able disease (4 on arm A and 2 on arm B) while 7 patients had
bordeline resectable disease (5 on Arm A and 2 on arm B). Post-
neoadjuvant therapy, 2 patients were determined to have unre-
sectable disease (both on arm B) and 4 patients underwent sur-
gery (2 on each arm). Seven patients remain on neoadjuvant
treatment. All grade toxicities related to treatment are summa-
rized in Fig. 62. There were five grade 3 toxicities reported in
Arm A: 2 patients had diarrhea attributed to CRT and resolved
after holding the treatment; 2 patients had lymphopenia attrib-
uted to pembrolizumab or the combination; and one patient had
elevated alkaline phosphatase related to the combination that
met the definition of DLT and resolved after holding the treat-
ment and receiving steroids. There was only one grade 3 toxicity
reported on Arm B: lymphopenia attributed to CRT. There were
no surgical complications reported within 30 days post-surgery in
all patients who underwent surgery.
Conclusions
The study safety stopping boundaries have not been met and the
study will continue enrolling patients.
Trial Registration
ClinicalTrials.gov identifier NCT02305186.
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Fig. 61 (Abstract P154). Sixteen patients demonstrated partial
response (confirmed and unconfirmed), including 3 PRs in 5
urothelial carcinoma patients, 3 PRs in 9 RCC patients, 2 PRs in 4
gastric cancer patients, 2 PRs in 2 Merkel cell carcinoma patients, 1
PR in 1 colorectal cancer (CRC) patient with microsatellite instability
high (MSI-h) status, among 12 CRC patients, 1 PR in 1 pancreatic
cancer patient with MSI-h status, between 2 pancreatic cancer
patients, 1 PR in 1 penis squamous cell carcinoma patient, 1 PR in
1 duodenal carcinoma patient, 1 PR in 22 ovarian cancer patients,
and 1 PR in 7 mesothelioma patients
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Background
Standard first-line treatments for mRCC include antiangiogenic agents
sunitinib, pazopanib, and bevacizumab plus interferon, which yield
a median progression-free survival (PFS) of approximately 10-11
months and median survival of 23-29 months. 5-year survival in
mRCC remains low. Pembrolizumab, a programmed death 1 im-
mune checkpoint inhibitor, has been tested in combination with
axitinib, a vascular endothelial growth factor receptor inhibitor, in
patients with treatment-naive mRCC. This combination has demon-
strated manageable toxicity and promising clinical efficacy. The
combination of pembrolizumab plus axitinib is being further tested
for efficacy and safety in this open-label randomized phase III
study, KEYNOTE-426 (ClinicalTrials.gov, NCT02853331), versus suniti-
nib monotherapy in patients with treatment-naive mRCC.
Methods
Key eligibility criteria include age ≥18 years, treatment-naive ad-
vanced/metastatic renal cell carcinoma with clear cell histology,
measurable disease per RECIST v1.1, adequate organ function, and
Karnofsky performance status ≥70%. Patients will be stratified per
International Metastatic RCC Database Consortium risk category and
geographic region, and then randomly assigned 1:1 to receive pem-
brolizumab 200 mg once every 3 weeks plus axitinib 5 mg twice
daily or sunitinib 50 mg once daily for 4 weeks, then 2 weeks off.
Treatment will continue until progressive disease, unacceptable ad-
verse events, death, or withdrawal of consent. The primary end
points are PFS per RECIST v1.1, as assessed by blinded independent
central review, and overall survival. Secondary end points include ob-
jective response rate, duration of response, disease control rate,
safety, and patient-reported outcomes. Approximately 840 patients
will be enrolled globally.
Trial Registration
ClinicalTrials.gov identifier NCT02853331.
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Background
ICOS (Inducible CO-Stimulator molecule) is a co-stimulatory mol-
ecule expressed primarily on T lymphocytes. Clinical data identified
ICOS as a potentially key molecule in providing optimal anti-tumor
benefit following anti-CTLA-4 therapy. JTX-2011 is an ICOS agonist
antibody that will be entering early phase clinical development for
the treatment of advanced solid tumors. JTX-2011 has a dual mechan-
ism of action whereby it amplifies an immune response in T effector
(Teff) cells while preferentially reducing the number of T regulatory
cells (Treg).
Methods
An mRNA based gene-expression signature for ICOS expression and
an IHC assay for ICOS and for T cell markers were developed. ICOS
expression on intra-tumoral T cells and PD-L1 were analyzed in a
cohort of 126 HNSCC patients collected at University of Chicago
and in RNA sequencing data collected from The Cancer Genome
Atlas (TCGA). ICOS expression was correlated with other immune
signatures associated with response or resistance to anti-PD-1
therapy.
Results
Preclinical studies show that tumor models with the highest
levels of intra-tumoral ICOS are most responsive to treatment
with an ICOS agonist antibody. We hypothesize that tumors ex-
pressing high levels of ICOS would be expected to benefit from
JTX-2011 treatment, we analyzed ICOS mRNA expression in
~10000 solid tumors across 30 indications. Highest levels of ICOS
mRNA were observed in HPV+ and HPV- HNSCC. Flow cytometry
showed highest expression of ICOS on intra-tumoral CD4+ Tregs,
followed by CD4+ Teff and CD8+ T cells. We confirmed these re-
sults in a large set of clinical samples using a multiplex immuno-
fluorescence (IF) assay. A wide range of ICOS cell density was
observed in this dataset suggesting that identification of an ICOS
“high” group may enrich for patients most likely to benefit from
anti-ICOS targeted therapy. We further correlated ICOS expression
to expression of PD-L1, a marker associated with response to
anti-PD-1 therapy. Using IHC and gene-expression analyses, we
identified a subset of patients that is less likely to respond to
PD-1 therapy and more likely to respond to ICOS agonist therapy.
In preclinical studies, treatment with anti-PD-1 therapy increased
ICOS expression, suggesting that administration of JTX-2011 to-
gether with PD-1 blockade may provide an effective combination
strategy.
Fig. 62 (Abstract P155). Maximum Grade Toxicities Related
to Treatment
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Conclusions
These results support development of JTX-2011 in HNSCC patients ex-
pressing high levels of ICOS and suggest that combination of JTX-2011
with an anti-PD-1 agent may be an effective treatment paradigm.
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Background
Response rates remain low for refractory or relapsed/refractory
multiple myeloma (rrMM) treated with currently approved therap-
ies, including proteasome inhibitors and immunomodulatory drugs
(IMiDs). Lenalidomide reduces PD-L1 and PD-1 expression on MM
cells and enhances checkpoint blockade–induced cytotoxicity; PD-
1 blockade with pembrolizumab may thus act synergistically with
IMiDs to enhance tumor suppression. In the phase I KEYNOTE-023
study, the combination of pembrolizumab + lenalidomide and
low-dose dexamethasone was associated with an acceptable
safety profile and a promising overall response rate (ORR) of 50%
(20/40) in patients with rrMM, supporting further evaluation of
pembrolizumab in combination with immunomodulatory agents.
The randomized, open-label, multicenter, phase III KEYNOTE-183
study (ClinicalTrials.gov, NCT02576977) was designed to compare
the efficacy and safety of pomalidomide and low-dose dexametha-
sone with or without pembrolizumab in patients with rrMM.
Methods
Key eligibility criteria include age ≥18 years, Eastern Cooperative
Oncology Group performance status 0-1, confirmed diagnosis of
rrMM with measurable disease, ≥2 lines of prior treatment, and
documented progression on the last line of therapy. Prior therap-
ies must have included an IMiD, such as lenalidomide or thalido-
mide, and a proteasome inhibitor, such as bortezomib, ixazomib,
or carfilzomib. Patients are randomly assigned 1:1 to receive
pomalidomide 4 mg daily on days 1-21 and low-dose dexametha-
sone 40 mg (20 mg for patients aged >75 years) daily on days 1, 8,
15, and 22 of repeated 28-day cycles, with or without pembrolizu-
mab 200 mg every 3 weeks. Stratification is based on prior lines of
treatment (2 vs ≥3) and disease status (refractory vs. sensitive to
lenalidomide). Patients receiving pomalidomide must receive ap-
propriate anticoagulation prophylaxis therapy. Treatment will con-
tinue until disease progression or unacceptable toxicity. Response
will be assessed every 28 days by Clinical Adjudication Committee
blinded central review and investigator review based on Inter-
national Myeloma Working Group (IMWG) 2011 response criteria.
Adverse events (AEs) will be assessed throughout treatment and
for 30 days thereafter (90 days for serious AEs) and graded per NCI
CTCAE v4.0. Patients will be followed for survival every 12 weeks.
The primary endpoint is progression-free survival (PFS) based on
IMWG criteria and overall survival; secondary endpoints are ORR,
safety and tolerability, disease control rate, duration of response,
and second PFS. Enrollment is ongoing and will continue until
approximately 300 patients are enrolled.
Trial Registration
ClinicalTrials.gov identifier NCT02576977.
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Background
Lenalidomide in combination with low-dose dexamethasone is one of
the standard-of-care treatments for MM. Preclinical and experimental
data has shown that lenalidomide reduces PD-L1 and PD-1 expression
on MM cells and enhances checkpoint blockade-induced cytotoxicity;
thus, PD-1 blockade with pembrolizumab may act synergistically with
lenalidomide to enhance tumor suppression. In the phase I KEYNOTE-
023 study, the combination of pembrolizumab + lenalidomide and
low-dose dexamethasone was associated with an acceptable safety
profile and a promising overall response rate (ORR) of 50% (20/40) in
patients with relapsed/refractory MM, supporting further evaluation of
pembrolizumab in combination with lenalidomide. The randomized,
open-label, phase III KEYNOTE-185 study was designed to compare the
efficacy and safety of lenalidomide and low-dose dexamethasone with
or without pembrolizumab in patients with newly diagnosed and
treatment-naïve MM not eligible for transplantation.
Methods
Key eligibility criteria include age ≥18 years; newly diagnosed,
treatment-naive, active MM with measurable disease; ineligibility
for autologous stem cell transplantation; and Eastern Cooperative
Oncology Group performance status 0-1. Patients are randomized
1:1 to receive lenalidomide 25 mg daily on days 1-21 and low-dose
dexamethasone 40 mg (20 mg for patients aged >75 years) on days
1, 8, 15, and 22 of repeated 28-day cycles, with or without pembro-
lizumab 200 mg every 3 weeks. Stratification is based on age (<75
vs ≥75 years) and International Staging System (ISS) stage (ISS I or II
vs ISS III). Treatment will continue until disease progression or un-
acceptable toxicity. Response will be assessed every 28 days by
Clinical Adjudication Committee blinded central review and by in-
vestigator review based on International Myeloma Working Group
(IMWG) 2011 response criteria. Adverse events will be assessed
throughout treatment and for 30 days thereafter (90 days for
events of clinical interest) and graded per NCI CTCAE v4.0. Patients
will be followed for survival every 12 weeks. The primary end point
is progression-free survival (PFS) as assessed by central review ac-
cording to IMWG criteria; secondary end points are overall survival,
overall response rate, duration of response, second PFS, and safety
and tolerability. Enrollment is ongoing and will continue until ap-
proximately 640 patients are enrolled.
Trial Registration
ClinicalTrials.gov identifier NCT02579863.
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82 Page 91 of 221
P160
KEYNOTE-122: phase II study of pembrolizumab versus standard-
of-care chemotherapy in platinum-pretreated, recurrent or
metastatic nasopharyngeal carcinoma
Anna Spreafico1, Victor Lee2, Roger K C Ngan3, Ka Fai To4, Myung Ju
Ahn5, Quan Sing Ng6, Ruey-Long Hong7, Jin-Ching Lin8, Ramona F
Swaby9, Christine Gause9, Sanatan Saraf9, Anthony T C Chan4
1Princess Margaret Cancer Centre, Toronto, ON, Canada; 2Li Ka Shing
Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong
Kong, People’s Republic of China; 3Queen Elizabeth Hospital, Hong
Kong, People’s Republic of China; 4The Chinese University of Hong
Kong, Hong Kong, People’s Republic of China; 5Samsung Medical Center,
Sungkyunkwan University, Seoul, Republic of Korea; 6National Cancer
Centre Singapore, Singapore, Singapore; 7National Taiwan University
Hospital, Taipei City, Taiwan, People’s Republic of China; 8Taichung
Veterans General Hospital, Taichung City, Taiwan, People’s Republic of
China; 9Merck & Co., Inc., Kenilworth, NJ, USA
Correspondence: Anna Spreafico (anna.spreafico@uhn.ca)
Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):P160
Background
Current treatment for recurrent/metastatic nasopharyngeal carcinoma
(NPC) that progresses on a platinum-based regimen includes mono-
therapy with gemcitabine, capecitabine, or docetaxel. Although these
treatments are used in clinical practice, they have not been formally ap-
proved for second-line NPC. Prolonged exposure to Epstein-Barr virus
(EBV) in NPC leads to increased expression of programmed death-1
(PD-1), resulting in suppressed T cell immunity and tumor surveillance.
Pembrolizumab is a monoclonal anti-PD-1 antibody designed to block
the interaction between PD-1 and its ligands, PD-L1 and PD-L2. In the
phase Ib KEYNOTE-028 study, pembrolizumab was associated with an
overall response rate of 22% (6/27) in mostly heavily pretreated (≥3
lines) patients with NPC. KEYNOTE-122 is a multicenter, open-label, ran-
domized phase II study designed to evaluate the efficacy and safety of
pembrolizumab monotherapy versus chemotherapy in patients with
platinum-pretreated, recurrent or metastatic NPC.
Methods
Key eligibility criteria include age ≥18 years, histologically confirmed
nonkeratinizing differentiated NPC (WHO Class II) or undifferentiated
NPC (WHO Class III), metastatic or recurrent disease, EBV positivity de-
termined locally or centrally by EBV-encoded small RNA in situ
hybridization, previous treatment with platinum-containing regimen,
ECOG performance status 0-1, and measurable disease per RECIST v1.1.
Patients will be randomly assigned 1:1 to receive pembrolizumab 200
mg every 3 weeks (Q3W) or investigator’s choice of chemotherapy (cap-
ecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle,
gemcitabine 1250 mg/m2 once per week on days 1 and 8 of each 3-
week cycle, or docetaxel 75 mg/m2 Q3W). Treatment will continue until
disease progression, unacceptable toxicity, investigator decision, or 35
cycles of pembrolizumab. Patients who complete 35 pembrolizumab
cycles or discontinue pembrolizumab following a complete response
may receive an additional 17 pembrolizumab cycles upon disease pro-
gression. Response will be evaluated every 6 weeks for the first year of
treatment and every 9 weeks thereafter per RECIST v1.1 by central im-
aging assessment. Adverse events (AEs) will be assessed throughout
treatment and for 30 days thereafter (90 days for serious AEs) and
graded per National Cancer Institute Common Terminology Criteria for
Adverse Events, version 4.0. Upon disease progression, patients will be
followed for survival every 12 weeks. Primary end points are overall sur-
vival and progression-free survival per RECIST v1.1 by central imaging
assessment; secondary end points include objective response rate and
duration of response per RECIST v1.1 by central imaging assessment.
Enrollment is ongoing and will continue until approximately 160 pa-
tients have enrolled.
Trial Registration
ClinicalTrials.gov identifier NCT02611960.
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Background
T cells require glucose and glutamine for activation and prolifera-
tion. Tumor consumption of nutrients within the tumor microenvir-
onment may contribute to localized immune suppression, termed a
“metabolic checkpoint,” and selective inhibition of tumor metabol-
ism may reverse this immunosuppression. CB-839 is a potent, first-
in-class, oral inhibitor of glutaminase 1 that inhibits the tumor TCA
cycle by blocking glutaminase 1-mediated conversion of glutamine
to glutamate. In vitro studies of CB-839 demonstrated that blocking
glutaminolysis in tumor cells increased extracellular glutamine and
stimulated proliferation of T cells. In the CT26 syngeneic colon car-
cinoma model, combining CB-839 with a PD-1/PD-L1 inhibitor dou-
bled the rate of complete regressions over the checkpoint inhibitor
alone. Safety and preliminary evidence of activity of CB-839 as
monotherapy and in combination with everolimus and paclitaxel
were reported previously.
Methods
CX-839-004 is a phase I/II trial evaluating CB-839 + nivolumab in
patients with clear cell RCC (ccRCC), melanoma (mel), and NSCLC. The
primary objectives are to evaluate (i) safety and tolerability and (ii) anti-
tumor effect of the combination. Secondary objectives include deter-
mining the MTD/RP2D of CB-839 in combination with standard dose
nivolumab. Exploratory objectives include characterization of the
pharmacodynamics of the combination and evaluation of biomarkers
that may predict anti-tumor effect. Eligibility criteria include incurable
metastatic or locally advanced ccRCC, mel or NSCLC previously treated
with standard of care therapy, ECOG 0-1, and measurable disease by
RECIST 1.1. In the phase I portion, a minimum of 6-9 patients will re-
ceive escalating doses of CB-839 orally BID and nivolumab 3 mg/kg IV
on Days 1 and 15 every 28 days. Subsequent to determining the MTD
or RP2D, patients will be enrolled into phase II cohorts as follows:
Cohort 1 ccRCC checkpoint inhibitor naïve; Cohort 2 ccRCC with docu-
mented progressive disease (PD) or stable disease (SD) > 6 mo on nivo-
lumab in most recent line of therapy; Cohort 3 ccRCC with no better
than SD before documented PD on any checkpoint inhibitor in any
prior line of therapy; Cohort 4 melanoma with documented PD on a
PD-1/PD-L1 inhibitor in most recent line of therapy; Cohort 5 NSCLC
with documented PD or SD > 6 mo on PD-1/PD-L1 inhibitor in most re-
cent line of therapy. Tumor burden will be assessed approximately
every 8 weeks by RECIST 1.1 and irRECIST. Adverse events will be
graded per NCI CTCAE. Samples obtained for pharmacodynamic and
biomarker analyses will include pre-treatment and on-treatment tumor
biopsies, blood and plasma.
Trial Registration
ClinicalTrials.gov identifier NCT02771626.
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Background
Approved treatments for mCRPC include second-generation endocrine
therapies (abiraterone and enzalutamide) and taxanes (docetaxel and
cabazitaxel). These agents may increase programmed death ligand 1
(PD-L1) expression and/or facilitate release of neoantigens. Additionally,
the PARP inhibitor, olaparib, has activity in patients with mCRPC who
have DNA-repair defects. Pembrolizumab is an anti–programmed death
1 (PD-1) antibody that blocks the interaction between the immune
checkpoint receptor PD-1 and its ligands. KEYNOTE-365 (ClinicalTrials.-
gov, NCT02861573) is an international, nonrandomized, multicohort,
open-label phase Ib/II study evaluating the safety and response rate of
pembrolizumab in combination with olaparib (cohort A), docetaxel +
prednisone (cohort B), or enzalutamide (cohort C) in patients with
mCRPC.
Methods
Key eligibility criteria include: histologically or cytologically confirmed
adenocarcinoma of the prostate without small-cell histology, docu-
mented prostate cancer progression within 6 months preceding screen-
ing, and ongoing androgen deprivation with serum testosterone < 50
ng/dL. Cohort A will include patients previously treated with docetaxel
(prior treatment with 1 other chemotherapy is allowed, as well as ≤2
second-generation hormonal manipulations); cohort B will include pa-
tients previously treated with either abiraterone acetate or enzalutamide
(but not both) before chemotherapy; and cohort C will include patients
previously treated with abiraterone acetate before chemotherapy. Pa-
tients will receive pembrolizumab 200 mg once every 3 weeks (Q3W) (all
cohorts) and either olaparib 400 mg twice daily (cohort A), docetaxel 75
mg/m2 Q3W + prednisone 5 mg twice daily (cohort B), or enzalutamide
160 mg every day (cohort C). Treatments will continue until disease pro-
gression or unacceptable adverse events (AEs). There will be a maximum
of 35 cycles of pembrolizumab (all cohorts) and 10 cycles of docetaxel +
prednisone (cohort B). Patients who must discontinue a combination
component may continue with the other drug until progression/un-
acceptable AEs. Response will be assessed by evaluating prostate-specific
antigen (PSA) levels Q3W, and with radiologic imaging every 9 weeks for
the first year and every 12 weeks thereafter. Primary endpoints are
safety/tolerability and PSA response rate (decline of ≥50% from baseline
measured twice at least 3 weeks apart). Secondary end points include
time to PSA progression, radiographic progression-free survival based
on investigator-assessed RECIST v1.1 per the Prostate Cancer Working
Group 3 guidelines, and overall survival. Approximately 70 patients will
be enrolled in each cohort.
Trial Registration
ClinicalTrials.gov identifier NCT02861573.
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Background
Phase I testing of the hu14.18-IL2 immunocytokine (IC), a mAb reactive
with GD2 disialoganglioside, linked to IL2, in patients (pts) with melan-
oma showed immune activation, reversible toxicities, and a maximal
tolerated dose of 7.5 mg/m2/day. Preclinical data in IC-treated tumor
bearing mice with low tumor burden documented striking antitumor
effects. The main goal of this study was to obtain pilot data with
hu14.18-IL2 in subjects with advanced melanoma who achieved a
complete response (CR) through surgery.
Methods
Pts with completely resectable recurrent stage III or stage IV melanoma
were scheduled to receive 3 cycles of IC at 6 mg/m2/d IV over 4 hours
on days 1, 2 and 3 of each 28-day cycle. Pts were randomized to
surgical resection of all sites of disease either following (Group A)
or prior to (Group B) IC cycle 1. Primary objectives were 1) to evaluate
histological evidence of anti-tumor activity in terms of apoptosis/necro-
sis of hu14.18-IL2 and 2) to evaluate recurrence-free survival (RFS) and
overall survival (OS). The secondary objectives were 1) to evaluate
adverse events associated with treatment and 2) to evaluate biological
endpoints.
Results
Twenty melanoma pts (11 recurrent stage III, 8 stage IV, one un-
known primary) were randomized to Group A (11 pts) or B (9 pts).
Two Group B pts did not receive IC due to persistent disease fol-
lowing surgery. Six of 18 IC-treated patients remained free of recur-
rence, with a median recurrence-free survival of 5.7 months (95%
CI: 1.8-not reached). The 24-month RFS rate was 38.9% (95% CI:
17.5-60.0%). The median follow-up of surviving patients was 50.0
months (range: 31.8-70.4). The 24-month OS rate was 65.0% (95%
CI: 40.3-81.5%). Twelve pts had evaluable tumor samples for GD2
analysis and 6/12 showed expression of GD2 on melanoma cells.
There was no significant difference in RFS (p=0.791) or OS
(p=0.567) based on GD2 expression. There was a significant
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difference in the change in C-reactive protein values from baseline
to cycle 1, day 3 (p < 0.02). There were significant differences in the
change in lymphocyte counts from baseline to post-baseline time
points. Toxicities were similar to those previously reported for IC.
Immunohistologic evaluations of resected tumors showed variable
inflammation and tumor necrosis between pts and no clear differ-
ences between Groups A and B.
Conclusions
Prolonged tumor-free survival was seen in some melanoma pts at
high risk for recurrence who were treated with IC.
Trial Registration
ClinicalTrials.gov identifier NCT00590824.
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Background
Activated, autologous dendritic cells (aaDC) can be used to induce
anti-tumor immune responses. A unique method of applying aaDC is
through intratumoral injection, where the tumor cells serve as the
source of antigen required for an adaptive anti-tumor response. A
local effect may also occur as a result of cytokine production by the
injected DC which makes the tumor more susceptible to a pre-existing
or an induced immune attack.
Methods
Forty patients with locally advanced or metastatic solid tissue can-
cers were treated in a dose escalation trial in which aaDC were
injected percutaneously under image guidance into a single tumor.
Subjects had a median of 3 tumors (range 1 – 5) and had received
an average of 3.1 prior treatments. To generate the aaDC, autolo-
gous monocytes were converted ex vivo into DC which were then
activated. All batches of DC were released based on pre-specified
criteria which included immunophenotyping and a T cell-stimulation
assay, as well as sterility and endotoxin levels. Cytokine levels produced
by the activated DC during manufacturing were measured and patient
outcomes were correlated to these expression levels.
Results
All three doses levels were well tolerated. The main adverse events
related to treatment were grade 1 and 2 fevers. Twenty-one patients
achieved stable disease (SD) 8 weeks after initiating treatment, and
this was found to correlate with survival (p=0.01). Levels of certain
cytokines, such as such IL-8 and IL-12 p40, and TNFα were substan-
tially elevated in vitro and IL-8 and IL-12 p40 production were pre-
dictive of survival (p=0.001 and p=0.008, respectively). TNFα levels
also correlated with SD at week 8 (p=0.01). More than 70% of pa-
tients tested were found to have significant T cell responses, and/or
de novo or significantly enhanced PD-L1 expression in the tumor
post treatment, with a trend towards improved survival (p=0.1).
Conclusions
Study outcomes such as stabilization of disease and survival correlated
with high DC cytokine levels, in the absence of meaningful toxicity. The
DCVax treatment may be mediated through direct cytotoxic effects, as
well as modulation of the tumor microenvironment to increase tumor
infiltration by T cells, and attraction of inflammatory cells to the tumor.
The development of PD-L1 expression likely reflects an induced im-
mune response.
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Background
Intratumoral (IT) infiltration by activated immune effector cells is
associated with a significantly better prognosis, however, tumor-
associated immune suppression commonly occurs in non-small cell lung
cancer (NSCLC). CD8+ T cell or dendritic cell (DC) infiltration is an inde-
pendent favorable prognostic indicator. CCL21 is a lymphoid chemokine
that chemoattracts both lymphocytes and DC. Our preclinical studies re-
vealed potent systemic antitumor immune responses following IT in situ
vaccination with DC overexpressing CCL21. In clinical evaluation of this
strategy, we investigated anti-tumor specific systemic immune responses
and tumor-infiltrating CD8+ T cells (CD8+ TIL) in NSCLC patients in re-
sponse to in situ vaccination via IT administration of autologous DC
transduced with a replication-deficient adenoviral (Ad) vector expressing
the secondary lymphoid chemokine (SLC/CCL21) gene.
Methods
In a phase I trial, sixteen stage IIIB/IV NSCLC subjects received two vac-
cinations (1 x 106, 5 x 106, 1 x 107, or 3 x 107 dendritic cells/injection)
by CT- or bronchoscopic-guided IT injection (days 0 and 7). Immune re-
sponses were assessed by tumor antigen-specific peripheral blood
lymphocyte induction of IFN-γ in ELISPOT assays. Tumor biopsies were
evaluated for CD8+ T cells and tumor PD-L1 by immunohistochemistry.
Results
Twenty-five percent (4/16) of patients had stable disease at day 56
follow-up by RECIST criteria. Four possible vaccine-related grade 1 ad-
verse events (AE) occurred in 3 patients with no clear association to
dose or schedule; the AE included flu-like symptoms, blood-tinged spu-
tum after each injection, nausea, and fatigue. ELISPOT assays revealed
38% (6/16) of patients had systemic responses against autologous
tumor associated antigens (TAA). Tumor CD8+ T cell infiltration was in-
duced in 54% of subjects (7/13; 3.4 fold average increase in the number
of CD8+ T cells per mm2). Patients with increased intratumoral CD8+ T
cells following vaccination showed significantly increased PD-L1 mRNA
expression (p=0.02).
Conclusions
Intratumoral vaccination with Ad-CCL21-DC was well-tolerated and
resulted in 1) induction of systemic tumor antigen-specific immune
responses and 2) enhanced tumor CD8+ T cell infiltration accompan-
ied by increased PD-L1 expression. DC-CCL21 in situ vaccination may
be an effective approach to induce tumor CD8+ T cell infiltration in
combination with checkpoint inhibitor therapy. This will be assessed
in combination with PD-1/PD-L1 checkpoint inhibition.
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Background
Patients with high-risk melanoma have a 20-60% recurrence rate
with 5-year OS between 45% and 70%. We evaluated vaccination
with CDX-1401, a fusion protein consisting of human monoclonal
IgG1 antibody targeting the dendritic cell (DC) receptor DEC-205
linked to the full-length NY-ESO-1 tumor antigen, with or without
pretreatment with CDX-301, a recombinant human Flt3 ligand
(Flt3L), in a phase II, randomized study of subjects with resected
Stage IIb-IV melanoma. The primary objective was to determine
whether the immune response to NY-ESO-1 elicited by vaccination
with CDX-1401 and Hiltonol® (Poly-ICLC, from Oncovir) is substan-
tially increased by prior expansion of circulating dendritic cells (DC)
with CDX-301 therapy. Prevention of disease recurrence was not a
clinical endpoint for this study.
Methods
60 pts with resected melanoma were randomized to two cohorts.
Cohort 1 (CH1) received CDX-301 pretreatment (25 mcg/kg SQ daily x
10 days) in the first 2 of 4 monthly cycles of vaccination with CDX-1401
(1 mg IC day 1) + poly-ICLC (2 mg SQ, days 1 and 2). Cohort 2 (CH2) re-
ceived 4 monthly cycles of vaccine with CDX-1401 and poly-ICLC w/o
prior CDX-301. Antigen-specific immune responses were measured by
Elispot and ELISA; flow cytometry and T cell assays were performed to
evaluate the effects on immune cell subsets.
Results
The combination regimens of Flt3L, DC targeted NY-ES0-1 and poly-
ICLC were well tolerated. Substantial increases in innate immune cells
(DCs, NK cells and monocytes) were elicited in Flt3L treated (CH1) pa-
tients and w Flt3L treatment was associated with significant increases
in activated T cells. T cell responses were elicited in both cohorts but
were elicited earlier in CH1 and the number of individual responders
to NY-ES0-1 in CH1 was significantly greater than in CH2. In addition,
anti-NY-ES0-1-specific T cell responses in CH1 were significantly more
robust. Significant increases in antibody titer were noted in both co-
horts, but the average peak titer was significantly higher in CH1 vs
CH2. Additional flow analyses, gene expression profiling and func-
tional phenotyping of antigen-specific T cells are in progress.
Conclusions
In melanoma patients, DC mobilization with Flt3L is safe and leads to
substantially enhanced B and T cell responses to DC targeted
vaccines.
Trial Registration
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Background
NHS-IL12 (MSB0010360N; M9241), a tumor-targeting immunocyto-
kine comprising 2 heterodimers of IL-12 fused to the H-chain of the
NHS76 antibody, has affinity for single- and double-stranded DNA
and is designed to target necrotic tissue and deliver IL-12 to tumor.
In previous trials with human recombinant IL-12, clinical activity was
limited by toxicity. The goal is to reduce toxicity associated with sys-
temic IL-12 through highly specific delivery to the tumor.
Methods
A 3+3 dose-escalation study in patients with advanced solid tumors
was designed to demonstrate the safety of NHS-IL12 while evaluat-
ing pharmacokinetic (PK) and pharmacodynamic (PD) effects. Dosing
started at 0.1 mcg/kg, with a planned maximum DL9 (21.8 mcg/kg).
Patients were admitted for PK/PD draws and 48-hour observation
after the first 2 doses. Restaging evaluations were performed every 8
weeks using standard RECIST 1.1 and immune-related response criteria.
An expansion cohort (n=10) was enrolled at the maximum-tolerated
dose (MTD) for further PK/PD analysis.
Fig. 63 (Abstract P166). Anti-NY-ES0-1 specific responses in Cohort
1 are more robust and detected earlier vs Cohort 2. Differences be-
tween Cohort 1 and Cohort 2 at each time point are shown for
Mean (of cohort) corrected SPW. Asterisks (*) indicate highly
significant differences
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Results
From 12/2011–05/2016, 58 patients enrolled in DLs 1–9. 22 patients en-
rolled in single-dose cohorts (SDC); 36 patients in multiple-dose cohorts
(MDC; q4wk). In SDC, all patients completed treatment; there was 1
death unrelated to study treatment. In MDC, 32 patients discontinued
due to: progression (20), adverse events (AEs, 4), alternative treatment
(3), treatment-schedule conflict or withdrawal (4), and 1 death unre-
lated to study treatment. Median administrations in the MDC was 2.5
doses (range 1–22). Treatment-related AEs occurred in 47/58 pa-
tients (81%). Dose-limiting toxicities were observed in 1/6 patients
on DL8 (16.8 mcg/kg, grade 3 alanine aminotransferase (ALT) eleva-
tion) and 2/6 patients in DL9 (21.8 mcg/kg, grade 3 aspartate ami-
notransferase (AST) and ALT elevation and lipase elevation), making
the MTD 16.8 mcg/kg. 10 patients were enrolled in expanded DL8
at 16.8 mcg/kg. Most common AEs in DL8 (n=16) were decreased
lymphocyte count (81.3%), increased AST (81.3%), decreased white
blood cell count (75%), increased ALT (75%), and fever (62.5%). Most
AEs were transient and resolved within 10 days. Most symptoms were
controlled with NSAIDs or acetaminophen. Serum cytokines showed
time- and dose-dependent changes for IFN-gamma, IL-10, IL-12P70,
and TNF-a. Best overall response was stable disease in 15/30 evaluable
subjects. Five patients stayed on study treatment ≥182 days.
Conclusions
NHS-IL12 administered s.c. q4wk was safe and well-tolerated with pre-
dictable adverse events. Analysis of paired tumor biopsies to determine
intratumoral effects are ongoing. Updated data will be presented at the
conference.
Trial Registration
ClinicalTrials.gov identifier NCT01417546.
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Background
A standardized definition of BCG-unresponsive disease has been re-
cently agreed upon to assess the efficacy of salvage treatments for
patients with bladder cancer recurrence despite intravesical BCG
therapy. Previously, we have reported the results from a single-arm
trial of intravesical MCNA treatment in patients who have previously
failed BCG [1]. We now report the results of a retrospective analysis,
looking at efficacy with attention paid to the specific category of
BCG-unresponsive patients.
Methods
High-risk NMIBC patients with either papillary and/or carcinoma in
situ (CIS) having failed intravesical BCG treatment were enrolled.
BCG treatment failure was defined as cancer recurrence after at
least 2 courses of BCG (at least 5 of 6 induction instillations and at
least 2 of 3 maintenance instillations, or 2 induction courses). Pa-
tients received induction treatment with 6 weekly doses of 8 mg
MCNA intravesically, followed up by maintenance treatment of 3
weekly instillations at months 3, 6, 12, 18 and 24. Treatment efficacy
was evaluated by cystoscopy, urine cytology and biopsy, with disease-
free status achieved when central review of biopsy reveals absent high
grade disease.
Results
Of the 129 patients originally enrolled, 94 fit the newly defined BCG
unresponsive criteria. The cohort consisted of 68 (72.3%) with CIS, with/
without papillary tumor, and 26 (27.7%) with exclusively papillary tumor
upon recurrence after BCG. In the CIS-containing group, the complete
response rate measured at months 6, 12, and 24 were 39.7% (28-
52.3%), 23.5% (14.1-35.4%), and 13.2% (6.2-23.6%), respectively. In
the group with only papillary tumors, the corresponding disease-
free survival rates were 61.2% (38.2-7.8%), 61.2 (38.2-77.8%), and
50.1% (27.5-69%).
Conclusions
Intravesical MCNA therapy is an alternative therapy to radical cystec-
tomy in the patients with recurring disease after intravesical BCG
treatment. It has the potential to offer 24% of patients with CIS and
60% of patients with papillary tumors a chance to safely preserve
their bladder.
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Background
4-1BB costimulation imprints long term changes in the behavior
of costimulated T cells [1]. There is not a satisfactory mechanis-
tic explanation yet.
Fig. 65 (Abstract P168). Disease Free Survival
Fig. 64 (Abstract P168). Study Design
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Methods
To determine the specific DNA methylation changes occurring upon 4-
1BB costimulation, purified human CD8+ T cells from three healthy do-
nors were activated in vitro for 5 days with anti-CD3 monoclonal antibody
(OKT3) and either with anti-4-1BB monoclonal antibody urelumab or its
corresponding isotype (huIgG4). Activated lymphocytes were left 5 days
in culture with huIL-7 without further stimulation. Such back-to-resting
CD8+ lymphocytes were reestimulated with OKT3 for 12, 24 and 36h to
validate the expression of the genes differentially methylated upon pri-
mary stimulation at mRNA and protein levels. DNA methylation profiles
of both activated and resting cell subsets were characterized with Infi-
nium 450K DNA methylation array (Illumina). To further confirm our ob-
servations, identical experimental procedure was performed with anti-4-
1BB 6B4 agonist antibody in a CD8+ T cell donor. Differentially methyl-
ated genes between OKT3+anti-4-1BB versus their corresponding control
counterparts were validated by pyrosequencing on activated and resting
CD8+ from independent group of healthy donors (n=8 for Urelumab and
n= 11 for 6B4). Expression changes were confirmed by qRT-PCR and flow
cytometry in activated, rested and reestimulated CD8+.
Results
853 genes were differentially methylated in urelumab-treated CD8+
T cells compared with their controls, 52 of which were shared with
6B4-costimulated CD8+ T lymphocytes. A number of differentially
methylated genes are involved in i) T cell migration, ii) T cell activa-
tion, survival and homeostasis and iii) regulation of gene expression
including key T cell transcription factors.
Conclusions
4-1BB costimulation induces CD8+ T lymphocytes that are poised to
respond more effectively to a second antigen exposure. These ac-
quired functions are imprinted in the genomic DNA of the CD8+ T
cells by DNA methylation during 4-1BB co-stimulation, and involve
key genes for CD8+ T cells.
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Background
Glucocorticoid-induced TNFR-related (GITR, TNFRSF18) is a member of
the TNFR superfamily with pleiotropic T cell modulatory activity. In the
mouse, GITR is expressed at high levels on regulatory T cells (Treg) and
has been reported to antagonize their suppressive capacity, whereas it
is expressed at moderate levels on conventional effector T cells (both
CD4+ and CD8+) for which where it exerts stimulatory activity. Studies
have indicated that GITR-targeting agents mediate anti-tumor control
via two mechanisms: depletion and possibly suppression of Treg and/or
direct agonism of effector T cells.
Methods
We have developed a novel anti-GITR antibody with enhanced agon-
ist activity using single-domain antibodies (sdAbs) in a multivalent
format. A tetravalent anti-GITR agonist antibody induces NF-kB acti-
vation and T cell stimulation in vitro that is superior to a conventional
bivalent antibody; multivalency confers agonist activity in the
absence of Fc-mediated crosslinking. Treg-depleting activity is ob-
tained with an Fc effector-competent format.
Results
The tetravalent antibody potently controls tumor growth in vivo fol-
lowing a single dose with activity as low as 0.08 mg/kg. Treatment
reduces Treg frequency, thereby altering the ratio to effector T cells
within the tumor to create a favorable environment for an effective
anti-tumor immune response. CD8+ T cell activation and proliferation
is observed in vivo, and treatment confers long-term immunity to
tumor re-challenge.
Conclusions
In summary, multivalent GITR agonist antibodies are a promising mo-
dality for the treatment of cancer and we are exploring candidates
for clinical development.
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Background
Glioblastoma (GBM) is one of the deadliest and most aggressive
forms of brain cancer with a median survival of ≤ two years. Previ-
ously, our lab has demonstrated that Interleukin-13 receptor (IL-13R)
alpha2 (α2) is a novel tumor antigen and is overexpressed in ~78%
of the GBM tumors. IL-13Rα2 can be targeted by cancer vaccines,
chimeric antigen receptor modified T cells (CAR-T) and a chimeric fu-
sion immunotoxin consisting of IL-13 and truncated Pseudomonas
exotoxin (IL-13-PE). However, the significance and regulation of the
IL-13/IL-13R axis is not completely understood in the context of can-
cer immunology and in particular IL-13 signaling through the IL-
13Rα2 chain.
Methods
We characterized and confirmed IL-13Rα2 expression in GBM tumor
cell lines and its biological function by performing RT-qPCR and test-
ing their sensitivity to the cytotoxic effect of IL-13-PE. We examined
the activation of AP-1 family of transcription factors after treating
GBM cell lines; U251, A172, U87MG (IL-13R+) and T98G (IL-13R-) with
IL-13. Five members of the AP-1 family (c-Jun, Jun-D, Jun-B, c-Fos
and Fra-1) were studied by immunocytochemistry (ICC) after treating
40,000 glioma tumor cells with IL-13 (20ng/ml) for 30 minutes in a
glass chamber slide. We used IL-2 treatment as a negative control,
since these cell lines did not express IL-2 receptors.
Results
We observed an overexpression of IL-13Rα2 mRNA in three of four
GBM cell lines (U251, A172 and U87MG), which also showed high
sensitivity to IL-13-PE immunotoxin. By ICC analysis of tumor cells,
we found that three members of AP-1 family (c-Jun, Jun-D and Fra-1)
were activated only in IL-13Rα2 positive glioma cells when treated
with IL-13. In contrast, IL-13Rα2 negative T98G cells did not show
activation of any of the AP-1 members. Two other members of the
AP-1 family, Jun-B and c-Fos, were not activated after treatment
with IL-13. We also observed that the extent of immunostaining and
percent positive cells for c-Jun and Fra-1 in IL-13Rα2 positive glioma
cells were significantly higher than IL-13R negative cells (P< 0.001).
Conclusions
Our results show that IL-13 mediates signaling in IL-13Rα2 positive
GBM cell lines through the AP-1 pathway by activating c-Jun, Jun-D
and Fra-1. IL-13 did not activate any of the AP-1 family members in a
receptor negative GBM cell line. These results indicate that IL-13Rα2
is a key player in the IL-13/IL-13Rα2 axis for initiating signal transduc-
tion through the AP-1 pathway in GBM tumor cells and may be a
good target for immunotherapy.
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Background
4-1BB agonist antibodies were the second T cell co-stimulatory
agents to enter the clinic after αCTLA-4. Despite impressive efficacy
against both hematologic and solid tumors and an ability to suppress
adverse events associated with checkpoint blockade, their develop-
ment has been stymied by poor understanding of their underlying
mechanism and the resulting inability to separate off-target liver tox-
icity from on-target anti-tumor immunity. We sought to uncover the
mechanisms by which 4-1BB agonist antibodies trigger hepatotox-
icity in hopes of discovering approaches by which the anti-tumor
and hepatotoxic effects could be separated.
Methods
C57BL6/J mice (Taconic) were treated every 3 days for 3 doses
with the 4-1BB antibody 3H3 (250ug), αPD-1 (RMP1-14, 250ug),
αCTLA-4 (9D9 or 9H10 100ug), or αCD40 (FGK4.5 100ug). For 4-
1BB knockout reconstitution experiments, mice were sublethally
irradiated and then transferred with 2x106 splenocytes as on d-1.
CCR5, CXCR3, CCR2, Ebi3, IL27Ra, MHCII, and B2m knockout mice
and FoxP3-DTR and OT-1 transgenics were purchased from Jack-
son. Serum liver enzymes were read on day 16 by the MDACC
mouse pathology core.
Results
We find that α4-1BB mediated liver damage initiates through stimu-
lation of myeloid cells, followed by subsequent recruitment and ac-
tivation of CD8 and CD4 T cells in the liver. Moreover, we show that
the inflammatory cytokine IL-27 is essential in myeloid conversion
of T cells into mediators of liver damage. Conversely, FoxP3+ regu-
latory T cells (Treg) act to suppress 4-1BB agonist induced liver in-
flammation, and liver pathology worsens significantly when they
are ablated. Further, we show that concomitant CTLA-4 blockade
ameliorates 4-1BB hepatotoxicity by expanding peripheral Tregs,
but that this effect is lost with addition of αPD-1. Additional differ-
ences exist between the tumor and liver microenvironments, which
may be exploited to selectively promote on target activation of 4-
1BB by agonist antibodies in the future.
Conclusions
4-1BB activation of liver-resident myeloid cells promotes the sub-
sequent recruitment and activation of T cells in an IL-27
dependent manner. These T cells mediate the liver pathology as-
sociated with 4-1BB antibodies unless their activity is suppressed
by Tregs. Our results support the use of 4-1BB agonists in ra-
tional combinations, in particular with CTLA-4 blockade, which
may expand Tregs in the liver to ameliorate α4-1BB mediated
toxicities.
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Background
Tumor immunotherapy is a unique therapeutic modality in our
fight against human cancers. The recent success of immune
checkpoint therapies highlights the value and potential of this
approach. Epigenetic regulation of tumor immunology is becom-
ing a key area of investigation. Experimental data have linked
HDAC-inhibition to the enhancement of tumor antigen expression
and presentation, the activation of effector T and NK cells, and
the suppression of T regulatory cells. These observations are con-
founded by the potential immune-inhibitory effects by HDAC-
inhibitors on DC and T cell activation. Here, we have examined
the immune modulatory effects of pan-HDAC-inhibitor, panobino-
stat (LBH589), and its interaction with a PD-1 antibody, in preclin-
ical settings.
Methods
Panobinostat was tested in vitro in human peripheral blood mono-
nuclear cell (hPBMC) cultures at concentrations from 5 nM to 500
nM. Next, panobinostat was examined in vivo as single agent and in
combination with the PD-1 antibody, 1D2, in MC38, a murine syn-
geneic tumor model.
Results
Panobinostat restored IL-2, IFNg, and TNFa expression that was
inhibited during T cell exhaustion. Elevation of tumor-infiltrating
lymphocytes (TIL) was observed by both flow cytometry and im-
munohistochemistry. Of note, the proportion of CD8+ effector-
memory cells was increased by panobinostat. Proteomic analysis
of the treated MC38 tumors revealed increases in IFNg levels
under panobinostat treatment. Molecular profiling of tumor
samples by NanoString indicated that panobinostat treatment
led to increases of MHC class I, II and invariant chain expres-
sion. This is coupled with inductions of chemokine and cytokine
expression and increases in effector T cell functions as mea-
sured by Granzyme A and B expression. Finally, while panobino-
stat and PD-1 antibody each achieved some level of anti-tumor
efficacy, the combination of panobinostat and PD-1 antibody
achieved complete responses in 10 out of 10 mice tested. The
tumor regression was durable as none of the treated mice had
any recurrence of tumors more than 60 days after the cessation
of treatment.
Conclusions
Our preclinical data point to a dichotomy of immune modulation by
panobinostat. While it may be immune-suppressive during priming,
panobinostat is immune-stimulatory under antigen-experienced,
immune-exhaustive environment. With the latter more reflective of
the tumor microenvironment, we saw evidence of panobinostat be-
ing immune-stimulatory on TIL in a preclinical setting, with induction
of both TIL percentages as well as activity. The positive effects on TIL
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and the promising combination efficacy with PD-1 antibody in vivo
support further testing of panobinostat as a possible immuno-
oncology agent both in preclinical and clinical settings.
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Background
Pathogen-associated molecular patterns (PAMPs) provide crucial ac-
tivating signals to the immune system. Importantly, due to their po-
tent ability to induce pro-inflammatory cytokines that can cause
systemic toxicity, most PAMPs are limited to local administration
such as subcutaneous or intratumoral injection. Imprime PGG (Imprime)
is a soluble yeast β-1,3/1,6 glucan that has been administered intraven-
ously (i.v) to >400 healthy volunteers and cancer patients with minimal
adverse effects. Imprime has shown promising efficacy when combined
with other therapeutic antibodies in multiple clinical trials. Imprime has
been previously shown to have promising efficacy in combination with
immune checkpoint inhibitors in pre-clinical mouse tumor models and
is currently being explored clinically in combination with anti-PD-1 ther-
apy. In data presented here, we sought to further understand how
Imprime functions to link the innate and adaptive immune systems via
dendritic cells (DCs) to induce T cell priming providing benefit to check-
point inhibitor therapy.
Methods
To examine in vivo effects of Imprime, C57BL/6 mice were injected
i.v. with 1.2 mg of Imprime. 16hr post treatment, lymph nodes (LNs)
were harvested and mRNA levels were determined using the Quanti-
Gene Plex platform (Affymetrix). To study Imprime’s effect on CD8 T
cell priming, 1x105 OT-I CD8 T cells were transferred into congenic
hosts and immunized with H-2Kb/OVA257-264 peptide +/- Imprime.
Separately, healthy human volunteers were infused with 4mg/kg
Imprime and serum cytokines/chemokines were examined using the
Luminex platform.
Results
Following i.v. administration of Imprime in non-tumor bearing mice,
Imprime rapidly bound resident and migratory DC subsets, caused
DC maturation, and increased DC recruitment into LNs. Transcrip-
tional profiling in LNs showed increased mRNA levels of chemokines
important in immune cell trafficking, pro-inflammatory cytokines,
and a strong type I interferon signature. Many of these chemokines
were also increased in the blood of healthy volunteers, as was detec-
tion of Imprime binding to DCs. In congenic mouse recipients that
were immunized with peptide +/- Imprime after transfer of OVA-
specific OT-I CD8 T cells, those primed in the presence of Imprime
demonstrated greater overall expansion and acquisition of effector
functions than peptide alone. Imprime’s transcriptional profile and
ability to enhance T cell priming was dependent on the C-type lectin
receptor Dectin-1.
Conclusions
Together, these data demonstrate that Imprime acts as a unique
i.v.-administered PAMP that primes the immune system and in-
spires a coordinated adaptive immune response. These qualities
make Imprime an attractive candidate to synergize with cancer
immunotherapies.
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Background
For the development of agonist antibodies that stimulate immune
responses, a balance is required between sufficiently strong im-
mune stimulation and the untoward effects of systemic immune ac-
tivation. This is particularly true for CD40, a molecule expressed by
antigen presenting cells, which is critical in the regulation of im-
mune responses. Agonist CD40 antibodies are highly effective in
preclinical tumor models either through direct interaction with
CD40-expressing lymphomas, or indirectly through the activation of
adaptive anti-tumor immunity. There are several agonist CD40 anti-
bodies in clinical development, but limited data are available with
regard to their clinical activity and safety profile. Data reported for
the agonist anti-CD40 mAb CP-870,893 (Roche/Pfizer) [1] demon-
strated clinical activity in cancer patients, but its low maximum tol-
erated dose (0.2 mg/kg) may impede the full potential of activating
this pathway. We set out to develop a CD40 agonist antibody with
strong immune stimulating properties and a safety profile that al-
lows for systemic dosing.
Methods
Anti-CD40 monoclonal antibodies (mAbs) were generated by
immunization of human Ig transgenic mice with recombinant and
cell surface expressed human CD40. We selected hybridomas that
produced human antibodies with an assay using a reporter cell line
engineered to express CD40 and NFκB-responsive luciferase. The
variable regions of lead antibodies that displayed differential activity
were cloned in human IgG1 or IgG2 constant domains and expressed
in CHO cells.
Results
From this panel, CDX-1140, a human IgG2 antibody, was selected
for further development. CDX-1140 is a potent inducer of human
B cell proliferation and activation, and similarly directly stimulates
dendritic cells to upregulate costimulatory molecules and secrete
cytokines. Importantly, CD40 stimulation with CDX-1140 is inde-
pendent of the Fc domain of the antibody. In vivo, CDX-1140 has
potent anti-lymphoma activity in xenograft models, and a pilot
study in non-human primates has shown good pharmacodynamic
and safety profiles. A summary of these functional activities will
be presented.
Conclusions
These data support CDX-1140 as a novel CD40 agonist with potential
for immunotherapy of cancer patients.
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Background
Blockade of immune checkpoint receptors (e.g., PD-1, CTLA-4) has
emerged as a promising new approach to enhance anti-tumor re-
sponses. While immunotherapies directed against PD-1 and CTLA-4
are showing unprecedented efficacy in the treatment of cancer,
some patients and tumor types remain refractory to these therap-
ies. This has resulted in a broadening of immunotherapy research
and development to include additional inhibitory receptors (e.g.,
LAG-3, TIGIT, Tim-3) targeted individually or in combination with
other immune checkpoint receptors. A major challenge in the de-
velopment of biologics is access to quantitative and reproducible
functional bioassays. Existing methods rely on primary cells and
measurement of complex functional endpoints. These assays are
cumbersome, highly variable, and fail to yield the data quality re-
quired for drug development. To address this need, we have devel-
oped a suite of immune cell line-based bioluminescent reporter
bioassays for individual and combination immune checkpoint im-
munotherapy targets including PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-
3, TIGIT, PD-1+TIGIT and more.
Methods
These reporter-based bioassays were rationally designed to reflect the
mechanism of action (MOA) of drug candidates targeting individual
and combination immune checkpoint receptors. Each assay consists of
an effector cell and an artificial antigen presenting cell (aAPC). Effector
cell lines were engineered on a T cell background to express inhibitory
receptor(s) and a luciferase reporter driven by specific response ele-
ments under the precise control of intracellular signals mediated by the
T cell receptor (TCR) and inhibitory receptor target(s). The aAPCs were
specially engineered to be able to activate the TCR in an antigen-
independent manner and also stably express the ligand(s) of check-
point receptor(s). These cell lines were developed in Thaw-and-Use
format and can be used in assays without cell culture.
Results
Upon co-culture of effector cells with aAPCs, TCR activation in ef-
fector cells is suppressed by signaling from immune checkpoint re-
ceptor(s), which can then be specifically reversed by blocking
antibodies targeting the inhibitory receptor(s) and/or their ligand(s).
The bioassays were demonstrated to be specific to research-grade
antibodies with known blocking activity as well as FDA-approved
drugs (e.g., nivolumab, ipilimumab). In addition, the bioassays are
pre-qualified according to ICH guidelines and demonstrate the per-
formance required for use in antibody screening, potency testing
and stability studies.
Conclusions
We have developed a suite of MOA-based bioassays for immune
checkpoint receptors. These assays are easy to use and demonstrate
high assay specificity, sensitivity and reproducibility. They are suitable
for drug development in a quality-controlled environment.
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Background
CD137 (4-1BB) is a key costimulatory immunoreceptor and a highly
promising therapeutic target in cancer. To overcome limitations of
current mAb-based approaches which monospecifically target
CD137, we generated PRS-343, a CD137/HER2 bispecific designed to
promote CD137 clustering by bridging CD137-positive T cells with
HER2-positive tumor cells, thereby providing a potent costimulatory
signal to tumor antigen-specific T cells.
Methods
We have previously described the generation of PRS-343 as a fusion
of a CD137-specific Anticalin® protein to a variant of the HER2-
targeting monoclonal antibody trastuzumab with an engineered
IgG4 backbone. PRS-343 was found to efficiently activate T cells
ex vivo in the presence of HER2-positive cells. Here, in vivo proof of
concept data is presented utilizing a humanized mouse model in im-
munocompromised mice and the SK-OV-3 cell line as a HER2-positive
xenograft. Tumor-bearing mice received human PBMC and weekly in-
jections of PRS-343 for three weeks. An IgG4 isotype antibody served
as the negative control, while a CD137-targeting benchmark anti-
body and trastuzumab with an engineered IgG4 backbone (“tras-
IgG4”) served as controls for monospecific targeting of CD137 and
HER2, respectively.
Results
PRS-343 activity was investigated at four different weekly doses, ran-
ging from 4μg to 200μg. We found that PRS-343 dose-dependently
led to strong tumor growth inhibition compared to treatment with
the isotype control. Tumor response was accompanied by a signifi-
cantly higher frequency of hCD45(+) tumor infiltrating lymphocytes
(TIL) as determined by immunohistochemistry (IHC). Single IHC stain-
ings against the T cell markers hCD3, hCD4 and hCD8 indicated that
the rise in TIL frequency was due to an expansion of CD3+CD8+ T
cells, while CD4+ lymphocytes remained at a low frequency both in
the treatment and control groups. Interestingly, we observed neither
tumor growth inhibition nor an increase in human TIL frequency with
the anti-CD137 benchmark. The tras-IgG4 control was also devoid of
lymphocyte infiltration into the tumor, but displayed a tumor growth
inhibition comparable to PRS-343.
Conclusions
We report potent costimulatory T cell engagement of the immunore-
ceptor CD137 in a HER2-dependent manner, utilizing the CD137/
HER2 bispecific PRS-343. PRS-343 displays dual activity in vivo based
on monospecific HER2-targeting and bispecific, tumor-localized costi-
mulation of CD137. Compared to known CD137-targeting antibodies
in clinical development, PRS-343 has the potential to provide a more
localized activation of the immune system with higher efficacy and
reduced peripheral toxicity. The positive functional data of PRS-343
support investigation of its anti-cancer activity in clinical trials.
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Background
Antibodies against the PD-1/PD-L1 pathway have yielded impressive
clinical results; however, not all patients benefit from these treat-
ments, and many experience only partial responses. There is there-
fore a continued interest in developing new strategies to further
boost anti-tumor immune responses and maximize therapeutic effi-
cacy. CD8+ Tumor infiltrating lymphocytes (TIL) in both human and
mouse tumors have been shown to express the co-stimulatory mol-
ecule 4-1BB. In addition to PD-1, 4-1BB agonists can induce tumor re-
gression in pre-clinical models that is further boosted by anti-PD-L1
mAbs, but the detailed mechanism remains unclear.
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Methods
We utilized the murine melanoma cell line B16, expressing the model
antigen SIY, implanted subcutaneously into syngeneic C57BL/6 mice
for these experiments.
Results
To determine if TIL already present in the tumor were sufficient for
tumor regression, we utilized the S1P inhibitor FTY720. Therapeutic
efficacy was preserved when anti-41BB combination immunotherapy
was administered with FTY720, arguing it works directly on T cells in
the tumor microenvironment. A markedly augmented number of
antigen-specific CD8+ TIL occurred after combination immunotherapy
even with FTY720 administration, arguing that antigen-specific TIL
were expanded directly in the tumor microenvironment. To assess
the mechanism of TIL accumulation, we performed BrdU labeling to
measure proliferation, and detection of active caspase-3 to measure
apoptosis. Unexpectedly, we found that proliferation of CD8+ TIL was
not affected by combination immunotherapy. Instead, a significant
decrease of active caspase-3 levels occurred in CD8+ TIL after im-
munotherapy, arguing that the accumulation of antigen specific TIL
was due to decreased apoptosis. To further study the molecular
mechanism of intratumoral TIL accumulation, we performed a gene
expression profiling on untreated and immunotherapy-treated CD8+
TIL. Pathway analysis revealed that IL-2 and NF-kB were major hubs
of differentially regulated genes. Consistently, we found increased IL-
2 production in CD8+ TIL after immunotherapy. Therefore, we tested
if T cell-intrinsic IL-2 signaling within the tumor site was required for
successful immunotherapy. Intratumoral antibody-mediated blockade
of IL-2 did not decrease the efficacy of combination immunotherapy.
Mixed bone marrow chimeras of wild type (WT) and CD25-/- bone
marrow confirmed that there was no defect in CD25-/- CD8+ TIL accu-
mulation after immunotherapy.
Conclusions
These results suggest that restored IL-2 production by TIL is a marker
of successful immunotherapy but is not required for therapeutic effi-
cacy. Current studies are focusing on the role of T cell-intrinsic NF-kB
signaling in successful combination immunotherapies that utilize
agonist 4-1BB antibodies.
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Background
STAT3 transcription factor promotes prostate cancer progression and
sustains potently immunosuppressive tumor microenvironment.
STAT3 activity in both cancer cells and in tumor-associated immune
cells is likely responsible for resistance of metastatic prostate cancers
to current treatments, including immunotherapy.
Methods
We previously demonstrated that ligands for endosomal Toll-like
Receptor 9 (TLR9), CpG oligonucleotides, allow for cell-selective
delivery of therapeutics to TLR9+ myeloid immune cells and
tumor-propagating cells in prostate cancers. Here, we describe
new CpG-conjugated STAT3 antisense oligonucleotides (ASO),
chemically modified for improved nuclease resistance (T1/2 =
106 h in human serum).
Results
CpG-STAT3ASOs are quickly and efficiently internalized by human
(DU145, LN-TLR9) and mouse (Myc-CaP, Ras/Myc-driven RM9) prostate
cancer cells as well as by TLR9+ immune cells, including polymorpho-
nuclear myeloid-derived suppressor cells (PMN-MDCSs) derived from
blood of prostate cancer patients. In contrast to STAT3ASO alone, the
naked CpG-STAT3ASO was internalized by rapid scavenger receptor-
mediated mechanism even at low concentrations. Correspondingly,
CpG-STAT3ASOs showed improved potency of STAT3 knockdown at
mRNA and protein levels in target cells. As assessed by biodistribution
studies in mice, the intravenous (IV) injections of fluorescently-
labeled CpG-STAT3ASOCy3 effectively targeted TLR9+ myeloid cells
and cancer cells in organs, such as spleen and bone marrow. For
efficacy studies, we used syngeneic (RM9) and xenotransplanted
(LN-TLR9, DU145), castration-resistant prostate tumors implanted
intratibially in mice. Repeated IV injections of 5 mg/kg CpG-
STAT3ASO resulted in regression of bone-localized RM9 tumors
while treatments using STAT3ASO alone or CpG-scrambled ODN
failed to control tumor progression. Antitumor effects of CpG-
STAT3ASO depended on combination of direct and immune me-
diated cancer cell killing as suggested by reduced antitumor effi-
cacy in xenotransplanted tumor models in immunodeficient mice.
Both STAT3ASO and CpG-STAT3ASO reduced STAT3 activity in
tumor and tumor-associated immune cells, but only the latter re-
sulted in tumor infiltration by neutrophils and T cells. These ef-
fects were associated with reduced PD-L1 expression on MDSCs
and the reduced percentage of regulatory T cells. Our preliminary
results using blood samples from prostate cancer patients’ sug-
gest that CpG-STAT3ASO effectively alleviates tolerogenic effects
of human PMN-MDSCs on T cell activity.
Conclusions
Overall, our strategy allows for two-pronged targeting of metastatic,
castration-resistant prostate cancers using safer and more efficient
reagents based on TLR9-targeted oligonucleotide delivery.
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Background
Artificial antigen presenting cells (aAPCs) are platforms that
present the two necessary signals for T cell activation. Tradition-
ally, aAPCs have signaling molecules randomly dispersed on their
surface, although data has shown the importance of nanoscale
signal organization and co-stimulatory molecule choice on stimu-
lation [1]. Traditional aAPCs are thus inefficient for studying the
dynamics of T cell activation. Here, we have developed a novel
platform where signal 1 and 2 molecules are on distinct nanopar-
ticles that are co-clustered on the T cell surface within a mag-
netic field. By manipulating nanoparticle properties and the types
of co-stimulatory molecules, we show the benefit of this platform
as a tool to study T cell stimulation.
Methods
Iron-dextran or polystyrene particles where conjugated with sig-
nal 1 peptide-MHC and signal 2 anti-CD28 mAb either on the
same or separate 30-4500nm particles. Murine CD8+ cells were
stimulated with nanoparticles and a 0.2T magnetic field. Activa-
tion was measured by cell proliferation, cytokine secretion, and
cytotoxicity.
Results
We first showed that signal 1 and 2 can be separated onto dis-
tinct particles when these particles are clustered within a mag-
netic field (Fig. 66a). The resultant CD8+ T cells have equivalent
cytotoxicity as compared to cells stimulated with traditional
aAPCs (Fig. 66b). T cell activation is dependent on the co-
clustering of both signaling molecules – when either is presented
on a non-paramagnetic polystyrene particle, proliferation is de-
creased (Fig. 67a). The two signaling molecules also must be clus-
tered sufficiently close, at the scale of tens of nanometers, as
there was an inverse correlation between particle size and T cell
proliferation (Fig. 67b). Finally, signal separation allows for greater
enrichment of the clonal T cell subsets using signal 1 only
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particles, and thus greater activation over the same time period
after the addition of signal 2 particles and a magnetic field. Sig-
nal separation also allows for easy optimization of signal 2 type
and ratio (preliminary data not shown).
Conclusions
Here, we have demonstrated a novel T cell activation platform that
involves simpler aAPC synthesis without sacrificing activation poten-
tial. This platform enables the study of the clustering of signaling
molecules as well as easy manipulation of the types and ratios of dif-
ferent co-stimulatory signals.
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Background
Targeting immune checkpoint pathways, such as programmed death
ligand- 1 (PD-L1, also known as CD274 or B7-H1) or its receptor pro-
grammed cell death-1 (PD-1) have shown clinical benefit in patients
with many different types of tumors. While PD-L1 expression is not a
reliable biomarker for predicting response to therapy, the expression
of the coinhibitory molecule PD-L1 on the surface of tumor cells is
associated with worse prognosis in many tumors. This negative effect
of PD-L1 expression is seen even when only a small fraction of the
tumor expressed PD-L1 on the tumor cell surface. Here we describe a
splice variant (secPD-L1) that does not splice into the transmem-
brane domain, producing a secreted form of PD-L1.
Methods
Lymphoma, kidney and breast cancer cell lines were analyzed for full
length and secPD-L1 mRNA expression by qRT-PCR. RNASeq analysis
in the Cancer Cell Line Encyclopedia confirmed expression of secPD-
L1 in human tumor cell lines. RNASeq analysis of full-length PD-L1
and secPD-L1 was performed on The Cancer Genome Atlas, the GTEX
database of non-malignant human tissue and sorted immune cells
from healthy donors. Monocyte-derived dendritic cells were gen-
erated from healthy donors, stimulated with TNFa/PGE, polyIC, or
LPS and assayed for expression of full-length PD-L1 and secPD-
L1. Recombinant His-tagged secPD-L1 was produced to test
whether it functioned as an inhibitor of proliferation and IFNg
production in coactivation assays with T lymphocytes isolated
from healthy donors.
Results
The secPD-L1 variant is expressed by cancer cell lines that also ex-
press the full-length PD-L1, as well as non-malignant immune cells
particularly activated monocyte-derived dendritic cells. In The Cancer
Genome Atlas, expression of secPD-L1 is found in primary tumors
with higher expression of full-length PD-L1. Furthermore using re-
combinant secPD-L1 we found that secPD-L1 contains a unique 18
amino acid tail containing a cysteine and can dimerize, and inhibit T
cell proliferation and IFN-gamma production in vitro.
Conclusions
This is the first report that a secreted splice variant of PD-L1 is
expressed in a subset of many types of tumors, homodimerizes
and is functionally active. Since secPD-L1 does not require cell-to-
cell interaction to mediate its inhibitory effect, it may function as
a paracrine negative immune regulator within the tumor
microenvironment.
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Fig. 67 (Abstract P180). a Db-gp100 signal 1 and anti-CD28 signal
2 mAbs were conjugated to the surface of 100 nm iron dextran or
polystyrene nanoparticles. PMEL CD8+ T cells were stimulated with
different combinations of these particles in the presence or absence
of a magnetic field, and cell counts were taken after 7 days (*p<0.05
by two-way ANOVA). b PMEL CD8+ T cells were stimulated with
signal 1 and 2 on separate iron-dextran particles of increasing size
within a magnetic field. Cell counts were taken after 7 days (*p<0.05
by one-way ANOVA)
Fig. 66 (Abstract P180). a TCR transgenic PMEL CD8+ T cells were
stimulated for 7 days with Db-gp100 signal 1 only particles with
increasing molar doses of anti-CD28 signal 2 (s2) only particles (i.e.
2X = 2:1 molar excess signal 2). aAPC refers to traditional signal 1
and 2 aAPCs. Cells were incubated in the presence or absence of a
magnetic field for the first three days, and cell counts were taken on
day 7. b PMEL CD8+ T cells were stimulated for 7 days with signal 1
(s1) only particles, signal 1 and 2 on separate particles (s1 + s2), or
signal 1 and 2 on the same particle (s1/2 aAPC). After 7 days, T cell
mediated killing of target B16-F10 cells was measured (*p<0.05 by
two-way ANOVA)
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Background
The protective capability of tumor antigen specific T cells is regulated
by both co-stimulatory and inhibitory signals in the tumor microenvir-
onment. Current approaches in cancer immunotherapy seek to restore
the function of unresponsive T cells by blocking inhibitory pathways.
However, providing exogenous co-stimulatory signals are showing clin-
ical promise and provide novel approaches for combination therapy.
Methods
Multiple solid tumor mouse models in multiple different mouse
strains were used (MCA205/B6, CT26/Balb/C, d42m1T3/129) to deter-
mine the synergy of aOX40 (clone OX86) with aPD-L1 (clone
10F.9G2) in large, established tumors. Tumors were allowed to grow
until they were ~50-70mm2 before treatment began. Animals were
treated either alone or concurrently with 250μg aOX40 or 200ug
aPD-L1 for a total of 500μg aOX40 and 600μg aPD-L1. Animals were
euthanized and T cells isolated from secondary lymphoid organs and
tumors. T cells were sorted for TCRβ chain sequencing based on
Nur77GFP expression and or Foxp3RFP expression. TCRβ chain se-
quencing was performed by Adaptive Biotechnologies. T cell meta-
bolic function was assessed using 2NBDG and TMRE as well as a
Seahorse Analyzer. Phenotyping and functional assays were per-
formed using traditional methods of flow cytometry.
Results
We demonstrate for the first time that agonist OX40 monoclonal
antibodies metabolically reprogram CD4 Th1 skewed and CD8 ef-
fector T cells. In addition, using tetramers to track tumor-antigen
specific CD8 T cells, we observe a significant expansion of ef-
fector memory CD8 T cells with enhanced cytotoxic function.
Moreover, despite increased regulatory T cell (Treg) proliferation
in the periphery, the CD8/Treg and CD4/Treg ratio is significantly
increased in the blood and tumor of combination therapy treated
animals. Furthermore, using a TCR signal strength reporter system, we
observed the clonal expansion of a number of tumor infiltrating CD8 T
cells that were actively receiving strong TCR signals in situ. Unlike
aOX40 or aPD-L1 alone, combination immunotherapy focused the CD8
T cell repertoire response such that the 10 most frequent clones within
the tumor made up almost 40% of the total CD8 T cell response.
Conclusions
Our findings suggest that concurrently targeting both positive
(OX40) and negative (the PD-1/PD-L1 axis) T cell pathways can re-
store the function of failed tumor antigen specific T cells and pro-
mote tumor regression of well established tumors.
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Background
Prostate cancer (PC) is the second most common cancer type among
men worldwide. Other non-malignant conditions of the prostate,
such as benign prostatic hyperplasia (BPH), affect a majority of the
older male population. Furthermore, chronic prostatic inflammation
is common and is discussed to be a potential driver of benign and
malignant prostate conditions. We aimed to compare the phenotype
of lymphocytes present in prostates without pathologic changes with
those infiltrating PC or BPH lesions, focusing on characterization of
co-inhibitory receptor expression.
Methods
Lymphocytes were isolated from prostates of patients with PC (n=5),
BPH (n=31), and deceased transplantation donors (n=5). Two tissue
samples per PC patient were processed, one primary malignant and
one adjacent non-malignant. Prostate-infiltrating lymphocytes were
isolated using mechanical dissociation followed by density gradient
centrifugation and flow cytometric analysis.
Results
Analysis showed that the majority of prostate-infiltrating T cells in
all prostate conditions were CD8+ and had a CD45RO+CCR7- ef-
fector memory phenotype. The ratio of CD4+/CD8+ T cells was com-
parable in all conditions, except BPH, where it was slightly higher
than in healthy prostates. T cells expressing CD25 were more abun-
dant in prostate tissue of PC patients (median 13.7% at malignant
site, 15.1% at non-malignant site) and BPH (13.6%) compared to
healthy controls (3.3%). Analysis of co-inhibitory receptor expres-
sion revealed that PD-1 was expressed by a larger proportion of T
cells in PC specimens (71.0%, 60.0%) than in BPH (34.6%) and con-
trol prostates (47.2%). The opposite was found for LAG-3, which
was expressed by a larger proportion of T cells in BPH (18.1%) than
in PC (8.6%, 2.6%). Median frequency in control prostates was
13.1%. There were no differences between the sample types re-
garding frequencies of T cells expressing TIM-3 or CTLA-4, nor in
quantity of Tregs or ϒδ T cells. Compared to peripheral blood, the
frequency of Tregs was significantly higher in all prostate tissue
types; 17.0%, 16.6%, 16.5% and 20.5% in control, BPH, malignant
and non-malignant site compared to 7.2% and 5.4% in blood of
BPH and PC patients.
Conclusions
Many prostate-infiltrating T cells seem to express co-inhibitory recep-
tors LAG-3 and PD-1, regardless of prostate condition. Furthermore,
presence of Tregs does not seem to be unique to the PC environ-
ment. However, we did find an increased frequency of T cells ex-
pressing PD-1 in PC lesions. It is of great importance to elucidate
expression of co-inhibitory receptors for different solid cancers to
narrow down patient groups that might benefit from different
immunotherapies.
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Background
In stem cell transplant, few have studied the recipient lympho-
cytes’ recognition of mismatched donor antigens and MHC mole-
cules, and how these primed host T cells may then recognize
and kill leukemic cells. Previously, our group infused haploidenti-
cal, G-CSF mobilized, donor T cells into patients with refractory
hematological malignancies preconditioned with 100cGy total
body irradiation. Strong recipient immune responses, with some
durable remissions, were seen in hematologic malignancies. In a
second trial without G-CSF mobilization or recipient radiation, pa-
tients exhibited weaker inflammatory and anti-leukemic responses
[1]. We therefore decided to characterize the alloreactive antileu-
kemic response in a murine preclinical model with the AML
leukemic cell line, C1498.
Methods
B6D2F1 mice were injected with C1498 leukemic cells and subse-
quently on day 7 were injected with haploidentical spleen cells from
C57BL/6 mice. They were then monitored for signs of tumor progres-
sion and euthanized when they became moribund. T lymphocytes
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obtained from these euthanized mice were also tested for their abil-
ity to generate anti-C1498 responses when stimulated with haploi-
dentical stimulator cells. We performed vitro experiments whereby
healthy B6D2F1 splenocytes were stimulated with mitomycin-treated
haploidentical spleen cells from a C57BL/6 mouse, and grown in
mixed lymphocyte culture and tested on day 5 for their ability to lyse
Cr51-labeled syngeneic blasts and C1498 leukemic target cells.
Results
Results of the murine model demonstrated the ability of alloreactive
cytolytic T lymphocytes to lyse C1498 leukemic cells but not syngen-
eic blast cells. In addition, isolated CD3+ cells obtained from C1498
bearing mice were able to generate anti-C1498 lytic activity when
stimulated with haploidentical cells in vitro. These responses are be-
ing explored further in vivo.
Conclusions
In previous trials, increased PD-1 expression in recipients following
initial markers of T cell activation suggest that T cell exhaustion
mediates leukemic cell survival. Increased PD-L1 expression on
leukemic cells provides one explanation for their eluding the host
inflammatory response. Total body irradiation may be disrupting
the equilibrium of host-tumor tolerance. G-CSF mobilization of
donor lymphocytes increases donor antigens for host recognition
and subsequent alloreactivity. The murine model shows that allor-
eactive T cells can generate lysis specific to tumor but not self anti-
gens. This model of alloreactive tumor response can be explored as
a adjuvant therapy to other therapeutic approaches, including
checkpoint inhibition.
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Background
Immune checkpoint inhibitors have changed the landscape of cancer
therapy with the general acceptance that they will be the mainstay
of future therapies. This is evident from a large number of ongoing
clinical trials evaluating checkpoint inhibitors as a single agent or in
combination with other therapeutic modalities. While these
antibody-based therapies show impressive clinical activity, they suffer
from the shortcomings including the failure to show responses in a
majority of patients, immune-related adverse events (irAEs) due to
the breaking of immune self-tolerance and need to administer by
intravenous injection. The recent reports on severe demyelinating
polyradiculoneuropathy leading to death observed in two patients
with the anti-PD-1 immunotherapy also point to the need for short-
acting agents for the better management of irAEs. Towards address-
ing these shortcomings, we are developing small molecule agents
targeting one or more immune checkpoint pathways to increase the
response rate and dosing by oral route with relatively shorter phar-
macokinetic exposure.
Methods
We at Aurigene have devised a strategy to identify agents targeting
single or multiple immune checkpoint proteins by taking advantage
of the sequence/structural similarities among immune checkpoint
ligands and receptors. In this strategy, high affinity shortest
pharmacophore derived from the extracellular domain of checkpoint
proteins are first identified and transformed into therapeutic agents
with optimized drug-like properties. Our strategy has resulted in the
identification of agents targeting PD-L1 alone, VISTA alone, PD-L1
and VISTA, and PD-L1 and TIM-3. The first compound from this ap-
proach AUPM-170/CA-170, a first-in-class dual antagonist targeting
PD-L1 and VISTA, is undergoing clinical trials.
Results
Herein we report the pharmacological evaluation of another novel
small molecule antagonist dually antagonizing PD-L1 and TIM-3 path-
ways. Potent functional activity comparable to that obtained with an
anti-PD-1 or anti-TIM-3 antibody in rescuing T cell proliferation and
effector functions was observed with the lead compound, AUPM-327.
AUPM-327 showed selectivity against other immune checkpoint pro-
teins as well as in a broad panel of receptors and enzymes. In pre-
clinical models of melanoma, breast and colon cancers, AUPM-327
showed significant efficacy in inhibition of tumor growth upon oral
dosing with excellent tolerability.
Conclusions
These findings support further development of AUPM-327 in the clinic.
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Background
Tumor cells evade immune surveillance by expressing cell surface li-
gands such as PD-L1 that are known to disrupt normal T cell func-
tion. Inhibition of these immunologic checkpoints has led to durable
clinical remissions in metastatic melanoma, lung cancer, and bladder
cancer [1-3]. We have recently described a new checkpoint family
member HHLA2 that plays a significant role in inhibiting T cell activ-
ity [4]. We sought to characterize HHLA2 expression patterns in hu-
man urothelial carcinoma.
Methods
After obtaining IRB approval, we identified urothelial tumor cases
from our institutional database and obtained paraffin-embedded
tissue specimens originating from either transurethral resections
(TUR) or radical cystectomies. A validated immunohistochemistry
(IHC) protocol for HHLA2 staining has been previously described
by the authors [4]. Tumor slides were examined by a single path-
ologist with no prior knowledge of patient clinical characteristics.
Tumors were considered positive for HHLA2 expression (HHLA2+)
if the number of positively stained tumor cells exceeded 1/100.
Results
We identified 46 urothelial tumor specimens with adequate tissue for
staining (Fig. 68). 37/46 (80%) specimens were obtained from TUR
and 9/46 (20%) were obtained from radical cystectomy. Our cohort
was enriched with aggressive tumor characteristics, specifically 45/46
(98%) were high grade, 34/46 (76%) were stage pT2 or higher, and
15/46 (33%) had metastases to lymph nodes and/or distant organs.
HHLA2 was expressed in 28/46 (61%) tumors (Fig. 69).
Conclusions
This is the first study to demonstrate a robust expression pattern of
the newly discovered immune checkpoint ligand HHLA2 in human
urothelial tumors. Future studies will need to be conducted to further
characterize the functional role of HHLA2 in bladder cancer immune
evasion pathways and to develop therapeutic strategies to enhance
immune mediated tumor destruction.
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Background
The large number of immunoglobulin super family (IgSF) receptors
on immune cells and tumors are attractive targets for the develop-
ment of cancer immunotherapies. While nearly all commercial strat-
egies targeting this family are focused on antibody-based biologics,
we have developed a novel affinity ligand platform based upon yeast
affinity maturation of human IgSF family extracellular domains
(ECDs), which we term variant Ig Domains (vIgDs). vIgDs unique bio-
chemical properties, including small size, monomeric/single domain
structure, and capacity to interact with multiple counterstructures,
combined with the near universal expression of IgSF family members
and their counterstructures on immune cells and tumors, position
the vIgD platform as an exciting new option for development of
immuno-oncology biologics with first-in-class mechanisms of action.
Methods
IgSF domains of interest were mutagenized and cloned as yeast dis-
play libraries. Soluble counterstructure ligands were used to stain the
display libraries, and yeast clones exhibiting the highest binding
were isolated by flow cytometry sorting. vIgDs from the sorting out-
puts were subcloned into a mammalian Fc fusion expression vector,
and individual vIgD-Fc fusions were recombinantly expressed in
HEK293 cells. Purified preparations of vIgD-Fc fusions were used to
stain eukaryotic cells transfected to surface express the target coun-
terstructure. vIgD-Fc fusion proteins possessing desirable binding
properties were tested for functional activity using in vitro assays
with human primary T cells.
Results
Random and rationally designed mutant vIgD libraries were stained
with counterstructure ligands and successfully sorted to isolate vIgDs
with increased binding to the target counterstructures as demon-
strated by elevated binding curves of successive selection outputs.
vIgDs were expressed as recombinant Fc fusion protein constructs
and demonstrated superior binding of transfectants expressing coun-
terstructures compared to their parental wild-type IgSF domain Fc fu-
sion protein. The resulting variants also demonstrated superior
costimulatory activity when co-immobilized with anti-CD3 in human
primary T cells.
Conclusions
Receptors built from IgSF domains are critical orchestrators of cellular
communication in the immune system. However, IgSF receptors typ-
ically exhibit relatively low affinities for their target counterstructures,
prohibiting their use as oncology therapeutics. Engineering of IgSF
domains using yeast display affinity maturation allows the generation
of variant proteins possessing superior binding to single or multiple
native counterstructures. These binding improvements translate into
beneficial alterations of functional activity, including improved costi-
mulatory activity. The vIgD therapeutic platform is a new option for
both development of soluble recombinant therapeutics or improve-
ment of engineered cellular therapies.
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Background
Ibrutinib, a covalent inhibitor of BTK, is currently revolutionizing B
cell lymphoma treatment. Most solid tumors do not express BTK.
However, BTK has been identified as a critical pathway in syn-
thetic lethality assays in MYC dependent tumor cell lines. Interest-
ingly, BTK can also be expressed in myeloid cells downstream to
Fcg receptors. Also, ibrutinib inhibits interleukin-2-inducible T cell
kinase (ITK), with potential ability to shift the balance from Th2
to Th1 T cells. Therefore, ibrutinib might have immunomodulatory
Fig. 69 (Abstract P186). Example of a human urothelial tumor that
expresses HHLA2
Fig. 68 (Abstract P186). Clinicopathologic characteristics of patients
by HHLA2 staining status
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effects in addition to its direct effects on cancer cells. Interest-
ingly, aggressive MYCN amplified neuroblastoma (NB) are also
highly infiltrated by myeloid cells. In osteosarcoma (OS), osteo-
clasts are derived from myeloid lineage. Thus, BTK blockade could
be of double interest in NB and OS through both tumor- and
immune-targeted effects.
Methods
We analyzed BTK expression by quantitative RT-QPCR and FACS ana-
lysis in different NB or OS cell lines and tumors from patients. We
assessed the impact of ibrutinib on macrophage differentiation as-
says. In vivo anti-tumoral ibrutinib efficacy was evaluated in a mouse
transplantable NB and rat orthotopic OS syngeneic models.
Results
High levels of BTK expression in some neuroblastoma tumor samples
and variable levels of expression of BTK in patient tumor cell lines
were observed. Interestingly, ibrutinib therapy had a positive impact
on Neuro2A syngeneic NB models. No synergic effect of ibrutinib
and anti-PD-L1 therapy could be obtained. In the rat OS model, ibru-
tinib had also therapeutic activity with a positive impact on growth
of orthotopic bone tumors. However, we observed a negative impact
of ibrutinib therapy on the number of spontaneous OS lung metasta-
sis. Ibrutinib had no impact on the viability and differentiation of M1,
M2 or Mo-DCs. However, it impaired human M1 macrophages differ-
entiation towards a more immunosuppressive M2 phenotype with
lower CD86 and CD163 expression, but no variation of HLA-DR and
PD-L1. This negative effect was reversed by a TLR4 agonist.
Conclusions
Ibrutinib therapy has shown a positive therapeutic efficacy on the
growth of primary tumors of a mouse NB and rat OS syngeneic
models. However, in the OS model, ibrutinib therapy resulted in a
higher number of spontaneous lung metastasis. This effect could be
due to a negative impact of ibrutinib on anti-tumoral M1 macro-
phage differentiation. However this effect can be blocked by TLR4
stimulation suggesting that combinations of ibrutinib with TLR ago-
nists might be of interested in solid tumors.
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